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ABSTRACT 
Deborah Dawn Hutchinson Allen:  Exploring cognitive reserve and compensatory behaviors 
used to maintain executive control function in adults with primary brain tumors 
(Under the direction of Virginia J. Neelon, PhD, RN)       
Technological advances have improved survival in primary brain tumor (PBT) patients, 
bringing a need to understand the relationship between executive control function (ECF) and 
self-reported cognitive function (SRCF) in survivors.  Neuropsychological testing demonstrates 
few objective changes in some who report significant cognitive difficulties.  To date, little 
research has explored the discrepancy between objective cognitive performance (OCP) and 
SRCF.  This study describes the congruence of OCP to SRCF in 40 adult PBT survivors. 
Structured interviews with 7 exemplars describe compensatory behaviors.     
Neuropsychological test scores were converted to z-scores using age- and education-
specific norms.  A z-score of -1.3 determined cognitive impairment; Everyday Cognitions Scale 
scores determined SRCF.  Analyses include descriptive statistics, graphical plots, correlations, 
chi-square and t-tests. 
The study sample (n=40) averaged 50 years old (SD 9.7), had high-grade PBT (n=35), 
was at least 1 year beyond completion of treatment, 1.3-25 years since diagnosis, and included 
22 women.  ECF was impaired in 25% of subjects, memory in 35%, and attention in 27.5%.  
More than half of subjects self-reported changes in memory and attention.  Neither age, time 
since diagnosis, or tumor/treatment-specific variables were associated with OCP or SRCF scores.  
Dividing a scatterplot of OCP/SRCF scores into quadrants created four subject groupings.  
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Analyses focused on the two groups with normal OCP who had normal (congruent) or abnormal 
(incongruent) SCRF scores.  Both groups were mostly female, middle-aged, well-educated, and 
6-8 years removed from diagnosis of high-grade PBT.  Those with high cognitive reserve (CR) 
had congruent OCP/SRCF scores and less impact of PBT-specific symptoms on quality of life; 
those with low CR tended to have incongruent OCP/SRCF scores, more severe symptoms that 
impacted quality of life, and more depressive symptoms.  Low CR exemplars were socially 
isolated and had curtailed activities since diagnosis.  High CR exemplars continued cognitively-
engaging activities.  During testing, all subjects exhibited similar compensatory behaviors to 
maintain cognitive function.  Those with congruent scores tended to be less aware that they used 
compensatory strategies.  
This study shows that CR and use of compensatory behaviors may explain discrepant 
relationships between OCP and SRCF, and may lead to development of interventions to 
minimize cognitive decline and improve quality-of-life.  
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CHAPTER 1:  INTRODUCTION 
 
 Advancements in cancer treatments have improved survival for patients with primary 
brain tumors (PBT) (Jemal et al., 2009).  As a result, increasing emphasis has been placed on 
symptom recognition and on lessening symptom impact on the cancer survivor’s quality of life 
(Armstrong, Cohen, Eriksen, & Hickey, 2004; Dodd, Miaskowski, & Paul, 2001).  Survivors of 
PBT experience a variety of distressing symptoms, particularly cognitive impairment, across the 
trajectory of their illness (Edvardsson & Ahlstrom, 2005; Fox, Lyon, & Farace, 2007).  
Neuropsychological evaluations of PBT survivors have predominately focused on cognitive 
function during and immediately after treatment completion, and have demonstrated few changes 
in cognitive function (Taphoorn & Klein, 2004), but still survivors report significant difficulties 
in returning to work and other cognitive activities (Fox, Lyon, & Farace, 2007).  To date, 
however, little research has explored the discrepancy between cognitive performance on 
neuropsychological tests and self-reported cognitive function. A better understanding of this 
discrepancy may lead to development of cognitive interventions that might lessen or prevent 
cognitive decline after treatment, and improve quality of life of survivors with PBT.  
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Background and Significance 
 
Adult survivors of PBT report that dealing with the impact of symptoms presents 
challenges to their everyday life (Adelbratt & Strang, 2000), and that altered cognitive abilities, 
particularly regarding functions that require executive control, are the most distressing (Fox, 
Lyon, & Farace, 2007; Edvardsson & Ahlstrom, 2005; Moretti, Torre, Antonello, Cazzato, Bava, 
et al., 2005).  These cognitive difficulties hamper their ability to return to work or participate in 
social activities, and result in long-term changes in their daily lives (Correa, 2010; Godbout, 
Grenier, Braun, & Gagnon, 2005).  Survivors of PBT are usually between 45 to 55 years of age, 
in the prime of their lives, when they are diagnosed, so there is an expectation that they will 
resume their prior lives after completion of their cancer treatment (Edvardsson & Ahlstrom, 
2005; Godbout et al., 2005).  Some survivors of PBT may continue to work, but they have to 
make adaptations to accommodate the effects of illness and treatment (Davies, Hall, & Clarke, 
2003; Edvardsson & Ahlstrom, 2005).   
 
Objective findings of cognitive impairment. 
The neuropsychological effects of cancer treatment include deficits in memory, attention, 
concentration, organizational ability, motor skill, language skill, and multi-tasking ability 
(Anderson-Hanley, Sherman, Riggs, Agocha, & Compas, 2003).  Even when survivors of PBT 
report difficulties performing cognitive functions in everyday life, standardized cognitive 
assessment may not demonstrate significant cognitive impairments when compared standards for 
age and gender matched healthy individuals (Archibald et al., 1994; Steinbach et al., 2006; 
Taphoorn & Klein, 2004).   
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The functional decline related to memory, attention, and executive control function 
(ECF) is known to impact the quality of life for survivors of PBT (Wefel, et al., 2004).  These 
long-term neuropsychological effects are associated with depression, decreased quality of life, 
inability to perform normal activities of daily living, and failure to return to work (Anderson-
Hanley et al., 2003).    
 
Discrepancy between subjective and objective reports of cognitive impairment.  
Few studies have explored the discrepancy between cognitive performance on 
neuropsychological tests and self-reported cognitive function.  Raffa (2010) suggests that this 
discordance reflects survivor compensation to maintain cognitive performance.   
Compensatory strategies comprise techniques or behaviors that individuals use to help 
perform tasks and maintain function (Tomey & Sowers, 2009; Wilson, 2000).  Compensation 
may occur by adapting the physical environment to reduce the need for a function or by making 
residual function more effective using functional aids like canes, talking books and voice 
reminders, or using rehearsal strategies and mnemonics to enhance existing residual function 
(Tomey & Sowers, 2009; Wilson & Watson, 1997; Wilson, 2000).  Survivors with PBT describe 
their use of storytelling or of taking breaks during neuropsychological testing as typical of the 
changes they have employed in everyday activities since their diagnosis, even when they were 
not found to be cognitively impaired on neuropsychological evaluation.  The behaviors they used 
during the present study may have been compensatory means to optimize their performance or to 
maintain function through pacing themselves.  The observation of these behaviors raises 
questions about how much effort is required of these survivors to completed standardized 
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neuropsychological assessments, what compensatory behaviors positively and negatively affect 
their effort, and how these compensatory behaviors are incorporated into their activities.   
Similarly, breast cancer survivors with mild post-treatment cognitive decline reported 
having more difficulty performing work-related tasks (Wefel et al., 2008).  They described 
having to use an increased effort to maintain their functional abilities (Wefel et al., 2008).  A 
better understanding of the type of strategy used to maintain function, and the effort required will 
help guide future interventions.   
 
Compensation and cognitive reserve.  
Compensation after treatment of PBT may occur through recruitment of alternative 
neural paths or adaptations in existing neural pathways (Goh & Park, 2009). Functional MRI 
scanning has demonstrated that adaptive neural recruitment is one of the compensatory processes 
used by elderly subjects while performing cognitive tasks in.  
Cognitive reserve refers to resilience of cognitive function to brain damage; it is amassed 
through educational and occupational activities.  Cognitive reserve has been invoked to explain 
individual variability in cognitive function (Satz, 1993; Stern, 2002; 2003) by postulating that 
individuals with high cognitive reserve can maintain cognitive function in the face of 
neuropathology than can individuals with lower reserve.  Thus, individuals with high cognitive 
reserve may adapt more readily and without self-awareness to the cognitive demands after 
surviving a PBT.  Cognitive reserve may also explain the discrepancy between subjective and 
objective assessments of cognitive function in survivors with PBT. 
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Overview and Purpose of the Study 
 
The purpose of this study is to describe the relationship of ECF to self-reported cognitive 
function in 40 adult survivors of PBT.  In an exemplar subset of seven subjects who reported 
cognitive concerns, structured interviews were used to explore any compensatory strategies they 
use to maintain cognitive function.  It is hoped that the results of this study will provide insight 
into whether cognitive reserve and use of compensatory behaviors may explain the sometimes 
discordant relationship between measures of cognitive performance and self-reported cognitive 
function.  In addition, the results may provide insight into what components of ECF benefit from 
compensatory behaviors, how to screen for the use of behaviors in clinical situations, and how to 
encourage the types of behavior that may be useful in maintaining cognitive function.   
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CHAPTER 2:  REVIEW OF THE LITERATURE 
 
 
 This review of the literature describes the significance of cognitive impairment in adult 
survivors of PBT with a focus on subjective and objective research findings and the discrepancy 
between these findings.  The use of compensatory strategies and cognitive reserve to explain this 
discrepancy will be discussed.  
 
Significance of Cognitive Impairment  
 
Cognitive impairments related to cancer or its treatment has been described since the 
1980’s when the term chemobrain was coined by Shilberfarb (1983).  While originally proposed 
to describe the impairments observed during chemotherapy treatments, cognitive impairment 
may be due to the development of cancer or effects from treatment and can endure beyond 
treatment administration (Archibald et al, 1994; Wefel, Witgert, & Meyers, 2008).   
The cause of cognitive impairment in cancer patients is multifactorial and may be viewed 
as an interaction of the disease, treatment, and person. Thus the risk of developing cognitive 
impairment may be dependent on the type, grade, location, and extent of the cancer (Bosma et 
al., 2006; Kayl & Meyers, 2003; Surma-aho et al., 2001; Taphoorn & Klein, 2004).  Treatments 
that may add to the development of cognitive impairment from that already promoted by the 
cancer itself include surgery, chemotherapy, radiation therapy, and medications to control 
cancer-related symptoms (Ahles & Saykin, 2001; Armstrong et al., 2004; Taphoorn & Klein, 
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2004).  Factors pertaining to the person include age, gender, education, socioeconomic status, 
genetic susceptibility, and immune reactivity may protect or accelerate the development of 
cognitive impairment (Klein et al., 2003; Taphoorn & Klein, 2004).  
One meta-analysis, that included studies up to 2002, examined the neuropsychological 
effects of varying cancer treatments across different cancers in adult patients (Anderson-Hanley, 
et al., 2003).  The authors reported large effect sizes, d = -.89 to -.90, for impairment by at least 
one standard deviation in executive functioning and verbal memory.  However all domains were 
declined in cancer patients receiving systemic therapies by ⅓ to 1 SD below normative samples 
or control groups.  Most of these studies had small sample sizes and only examined cognitive 
function the first six months after completing treatment. These results substantiate the existence 
of cognitive decline during and after completion of cancer-related therapies for persons with 
non-central nervous system cancers.  Thus, the effect of treatment on cognitive function may be 
more severe or prevalent for those with the additional burden of neuropathology from a PBT. 
For those with PBT, all of these multifactorial variables have been demonstrated to 
impact on the development of cognitive impairment.  Adult survivors with PBT are usually 
diagnosed in their fifth or sixth decade of life (Jemal, Siegel, Ward, Hao, Xu, & Thun, 2009).  
Prior to the 1990’s and due to the low rate of incidence, high rate of mortality, and severity of 
neurological deficits associated with its invasive nature, cognitive impairment was an expected 
outcome with diagnosis but not well researched (Taphoorn & Klein, 2004).  However, with 
technological advances, five-year survival rates have increased and cancer is now viewed as a 
chronic disease.  Additionally, cognitive impairment in survivors of PBT at baseline and during 
the illness trajectory predict survival (Klein et al., 2003), recurrence (Bosma et al., 2006; Meyers 
& Hess, 2003; Taphoorn & Klein, 2004), and functional outcomes (Hahn et al., 2003, 2009; 
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Mukand, Blackinton, Crincoli, Lee, & Santos, 2001).   Our increased awareness, measurement, 
and knowledge of cognitive impairment in cancer survivors, particularly those with PBT, has led 
to improvements in the delivery or dose of therapeutic modalities to protect cognitive function 
(Ahles & Saykin, 2001; Armstrong et al., 2004; Surma-aho et al., 2001). 
 
Objective Findings of Cognitive Impairment 
 
 Cognitive impairment by neuropsychological evaluation has been found to be as high as 
89% in samples of survivors with PBT (Imperato, Paleologos, & Vick, 1990; Klein et al., 2001, 
2003).  Thus, several studies have explored whether tumor specific factors (tumor grade and 
location) influenced the development of cognitive impairment in survivors of PBT.  Klein and 
colleagues (2003) observed that poorer cognitive function before treatment in older survivors 
with WHO Grade IV tumors had the shorter survival times.  In high grade PBT survivors (WHO 
Grade III and IV tumors), poorer cognitive function at diagnosis was a predictor for tumor 
recurrence (Bosma et al., 2006).  In addition, they observed that survivors on antiepileptic 
medications had more impairment in the domains of attention and executive control function.  
However, Kayl and Meyers (2003) did not find any differences in cognitive function between 24 
newly diagnosed survivors with WHO Grade III and WHO Grade IV tumors after surgical 
resection.  Survivors with left hemispheric lesions that involved the survivor’s dominant 
hemisphere had more cognitive dysfunction after radiation therapy (Hahn et al., 2009).  
Survivors with frontal lesions were more likely to have better cognitive performances (Kaleita et 
al., 2004).  Additionally, Meyers and Hess (2003) observed in longitudinal follow-up with 56 
survivors of PBT that declines in cognitive function performances on neuropsychological 
evaluations preceded tumor progression observed on neurodiagnostic imaging scans.  Across all 
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of these studies, the cognitive domains predominately affected were those of memory, attention, 
and executive control function.   
 Treatments involving surgical resection, radiation therapy, and chemotherapy have been 
shown to have some effects on cognitive function or development of cognitive impairment.  The 
area that has received the most attention has been the short-term and long-term effects of 
radiation therapy.  Several studies have found that survivors of low grade PBT treated with 
radiotherapy had poorer cognitive function, particularly with memory and attention, than those 
survivors who did not receive radiation therapy (Douw et al., 2009; Goldstein, Armstrong, John, 
& Tallernt, 2003; Klein et al., 2002).  In addition, there were no differences on performances of 
memory three months after completion of radiation therapy only (Lilja, Portin, Hӓmӓlӓinen, & 
Salminen, 2001) or when combined with chemotherapy (Hilverda et al., 2010).  Laack and 
colleagues (2005) found that cognitive performances for attention, memory, and verbal fluency 
were improved 18 months after radiation therapy; however this was not sustained at the 3 year 
follow-up.   Long-term survivors of low grade PBT treated with radiation therapy 1 to 22 years 
earlier also demonstrated declines in those same domains (Moretti et al., 2005; Klein et al., 
2002).  Unlike findings with radiation therapy, surgical resection of the tumor has been found to 
improve cognitive performance (Duffau et al., 2003; Scheibel, Meyers, & Levin, 1996).   
 
Subjective Findings of Cognitive Impairment 
 
While this review has focused primarily on the objective findings of cognitive 
impairment in survivors of PBT through neuropsychological evaluations thus far, the subjective 
or patient’s perspective of their cognition function is also of importance (Taphoorn & Klein, 
2004; Meyers & Hess, 2006; Wefel, Witgert, & Meyers, 2008).  Cognitive impairment has been 
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associated with the presence of other self-reported symptoms in survivors of PBT (Armstrong et 
al., 2006; Fox, Lyon, & Farace, 2007).  Cognitive impairment, depression, fatigue, pain, and 
sleep disturbance were significantly correlated and were found to explain 62% of the variance in 
reported quality of life and functional status of long-term survivors with malignant PBT (Fox, 
Lyon, & Farace, 2007).   
There are several qualitative and quantitative studies that found cognitive impairment 
impacting everyday function in survivors of PBT (Davies, Hall, & Clarke, 2003; Edvardsson & 
Ahlstrom, 2005; Huang, Wartella, & Kreutzer, 2001; Tang, Rathbone, Park-Dorsay, Jiang, & 
Harvey, 2008; Wideheim, Edvardsson, Pahlson, & Ahlstrom, 2002).  Everyday functioning 
requires the activation and maintenance of executive control (Lezak, Howieson, & Loring, 2004; 
Valenzuela & Sachdev, 2006).  Executive control function (ECF) is vital to the coordination of 
activities, decision making, planning, sequencing, correcting error, inhibiting responses and 
behaviors (Lezak, Howieson, & Loring, 2004), and are necessary for the initiation and 
organization of goal-directed behaviors (Farias et al., 2008).  Everyday functions that include 
maintaining household functions, performing work-related activities, and engagement in hobbies, 
recreational, or social activities have been reported as those most affected after diagnosis and 
treatment for PBT (Davies, et al., 2003; Farias, Mungas, Reed, Harvey, Cahn-Weiner, & 
DeCarli, 2006; Hanna-Pladdy, 2007; Wideheim, et al., 2002).  Davies and colleagues explored 
the prevalence of disabilities in two year survivors and found that 50% of the participants 
reported moderate to severe disability in everyday life.  There was only one participant still 
working after completion of treatment.  Adults with PBT describing these cognitive impairments 
emphasize the impact on their everyday functioning and relate these deficits as most distressing 
(Fox, Lyon, & Farace, 2007; Edvardsson & Ahlstrom, 2005; Moretti, et al., 2005; Godbout, 
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Grenier, Braun, & Gagnon, 2005; Steinbach, Blaicher, Herrlinger, Wick, Nagele, et al., 2006; 
Meyers & Brown, 2006).  For survivors of PBT, specific cognitive impairments reported on self-
reported questionnaires include their forgetfulness, inability to concentrate or feeling distracted, 
slowed processing and reaction times, difficulty in prioritizing, inability to problem-solve, and 
lack of motivation (Dietrich, Monje, Wefel, & Meyers, 2008; Brown, Buckner, Uhm, & Shaw, 
2003).  All are common to ECF dysfunction.   
 
Discrepancy between Objective and Subjective Cognitive Impairment 
 
 There were several studies that performed both objective and subjective instruments to 
measure cognitive impairment in survivors of PBT.  Correa and colleagues (2008) found that 9 
survivors with low grade PBT who had radiation therapy and concurrent chemotherapy had mild 
declines in cognitive function as compared to their baseline measures; this was associated with 
self-reported measures of function.  In another study with 24 survivors of low grade PBT, 
significant changes in psychomotor function was found 4 to 5 years after completing radiation 
therapy yet self-reported function yielded few cognitive complaints.  In a large oncology 
rehabilitation study with 119 subjects, the researchers found that subjective and objective 
cognitive function scores were not associated (Poppelreuter et al., 2004).  Although 25% of the 
sample demonstrated some cognitive impairment by objective performance scores, up to 38.7% 
of the sample reported cognitive complaints of reductions in their ability to process quickly, 
maintain attention, and get motivated. 
 Excluding the previous 3 studies, an additional 22 studies exploring cognitive impairment 
in survivors of cancer from years 1998 to 2010 by cross-sectional or longitudinal designs, 15 
studies did not find any association between subjective report of cognitive function and objective 
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cognitive performance scores (Ahles et al., 2002; Debess, Riis, Engebjerg, & Ewertz, 2010; 
Castellon et al., 2004; Downie, Mar Fan, Houede-Tchen, Yi, & Tannock, 2006; Fliessback et al., 
2005; Harder et al., 2004; Hermelink et al., 2007, 2010; Jenkins et al., 2006; Mallinson, Cella, 
Cashy, & Holzner, 2006; Mehnert, et al., 2007; Reid-Arndt, Hsieh, & Perry, 2010; Schagen et 
al., 1999, 2002, 2008; Shilling & Jenkins, 2007; van Dam et al., 1998; Weis et al., 2009).  Most 
of the subjects for these studies were survivors of breast cancer (n=16) but sample size varied 
across study.  The two most commonly used self-report instruments for cognitive function were 
the European Organization for Research and Treatment of Cancer Quality of Life Questionniare 
and the Questionnaire for Self-perceived Deficits in Attention.  However, objective measures for 
cognitive performance varied greatly, as well as the definitions used for cognitive impairment (z 
score of 1, 1.5, or 2 SD below norm; 1 SD below sample mean; performance below 10th or  5th 
percentile; and number of impaired tests).   
 To explain the discrepancy between subjective and objective cognitive function, some 
have suggested that the instruments of objective cognitive function do not have high enough 
sensitivity or specificity (Kayl, Wefel, & Meyers, 2006; Middleton, Denney, Lynch, & 
Parmenter, 2006; Wefel, Witgert, & Meyers, 2008).  Others suggest that subjects underestimate 
their actual performance or tend to be overly sensitive to change in function (Klein et al., 2001; 
Rabbitt & Abson, 1991; van Gorp et al., 1991).  Additional symptoms or mood disorders may 
factor into the discrepancy between subjective and objective cognitive functions (Rabbitt & 
Abson, 1991; Sawrie et al., 1999).  Some offer that subjective reports of decline in cognitive 
function may precede that of objective findings in cancer survivors as they may be adapting to 
their functional demands through compensation (Kayl, Wefel, & Meyers, 2006; Wefel, Witgert, 
& Meyers, 2008).
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Compensatory Strategies 
 
 Compensatory strategies are techniques or behaviors that individuals use to perform tasks 
that are often difficult for them to perform otherwise (Tomey & Sowers, 2009; Wilson, 2000).  
Compensation may occur by adapting the physical environment to reduce the need for a function 
or to make residual function easier, using functional aids like canes, talking books and voice 
reminders, or using rehearsal strategies and mnemonics to enhance existing residual function 
(Tomey & Sowers, 2009; Wilson & Watson, 1997; Wilson, 2000).  Many individuals fail to 
recognize that they adopt strategies and incorporate behaviors to maintain their function as the 
compensation has been done subconsciously (Weiss, Hoenig, & Fried, 2007).   
 Survivors of PBT who have continued to be engaged and active reported fewer physical 
and cognitive problems (Davies, Hall, & Clarke, 2003).  Further, they indicated they had found 
ways to cope or adapt with their disabilities (Davies, Hall, & Clarke, 2003).  Rehabilitation 
programs focused on functional outcomes have described improvements in self-reported 
cognitive function in survivors of PBT.  Those who sustained cognitive improvements had 
longer survivorship, thus cognitive improvement predicted overall prognosis (Huang et al., 2001; 
Tang et al., 2008).  As most neurological rehabilitation centers foster engagement in mentally-
challenging activities, this latter study suggests that one may be able to restore and sustain 
function and live longer by active participation in daily activities early in their treatment phase.   
 Magnetic resonance imaging (MRI) studies of survivors with PBT demonstrate extensive 
structural neuropathology. Yet neither the presence nor the extent of structural neuropathology 
relate to the degree of cognitive impairment that exists (Moretti, et al., 2005; Meyers, 2008).  In 
fact, much variability in cognitive function exists for adult survivors of PBT (Gehing et al., 
2008).  Several functional imaging studies in aging populations have demonstrated activation of 
  
   
14 
 
cerebral areas that are normally not used for specific functions until damage has occurred 
(Ricker, Hillary, & DeLuca, 2001; Scheibel et al., 2007; Scarmeas et al., 2004; Cabeza, 
Anderson, Locantore, & McIntosh, 2002).   It has been suggested that the activation of alternate 
neural pathways to circumvent damaged areas to maintain function may explain some of the 
disparity between neuropathology and cognitive function (Wefel, Witgert, & Meyers, 2008).  
Further functional imaging research is needed to understand if these compensatory mechanisms 
are observed among survivors with PBT. 
 
Cognitive Reserve 
 
 Stern (2003) proposed compensation as the recruitment of alternate neural networks or 
use of cognitive strategies to maintain cognitive function when neuropathology disrupts normal 
processes. He further suggests that the efficiency of the brain to process cognitive tasks relates to 
the level of cognitive reserve one possesses.  Cognitive reserve is the accumulation of a lifetime 
of cognitive achievements and experiences that create the efficient neural networks for 
processing and compensation (Scarmeas & Stern, 2004).  Therefore, lifestyle factors including 
educational attainment, occupational position, premorbid intelligence, and types of engaging 
activities, serve to modify the level of cognitive reserve that an individual may have (Hultsch, et 
al.., 1999; Wilson, Mendes de Leon, Barnes, Schneider, Bienias, Evans, & Bennett, 2002; 
Wilson, Barnes, & Bennett, 2003; Valenzuela, Sachdev, Wen, Chen, & Brodaty, 2008). It has 
been observed that those engaged in cognitive activities across their lifespan maintained 
everyday function as compared to those who participate in few activities (Valenzuela, et al., 
2008; Wilson, Barnes, & Bennett, 2003).  Two studies demonstrate that the early life activities 
had a greater effect on maintaining late life cognitive function in aging populations (Dik, Deeg, 
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& Jonker, 2003; Fritsch, et al., 2007).  Engagement in activities in late life can also promote 
higher levels of cognitive reserve as demonstrated in differences of cognitive function (Wang, et 
al., 2002; Fratiglioni, et al., 2000) and cerebral blood flow (Scarmeas et al., 2003) in those with 
mild cognitive impairment or mild dementia.  Thus, the continued engagement in cognitive 
activities throughout the lifespan may protect against cognitive decline (Wilson et al., 2002). 
 There has been one study with cancer survivors exploring whether cognitive reserve may 
explain the variability in cognitive impairment (Ahles et al., 2010).  Using a longitudinal design, 
subjective and objective cognitive function was assessed prior to treatment, and 1 month, 6 
months, and 18 months after completion of treatment in 60 breast cancer survivors.  Survivors 
treated with chemotherapy who had lower premorbid intelligence had lower performance scores 
for processing speed as compared to those who did not receive chemotherapy.  The subjective 
and objective reports of cognitive function were not associated although those who received 
chemotherapy self-reported more cognitive symptoms.  Further, younger survivors with higher 
premorbid intelligence reported the persistence of cognitive symptoms but maintained a normal 
objective cognitive performance.  The authors suggested that they may be more aware of the 
changes in their cognitive capacity or using compensatory strategies to maintain performance. 
 
Study Purpose and Specific Aims 
 
 These results are fundamental to the conceptual framework that compensation and 
cognitive reserve may be useful for explaining the discrepancy between objective and subjective 
cognitive function in adults with primary brain tumors.  Compensatory strategies that adult 
survivors with PBT incorporate into everyday function have not been explored, particularly those 
used to maintain executive control function.  Identifying these strategies may help us to learn 
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what is useful, successful, or requires more effort to maintain cognitive function.  Thus, the 
exploration of compensation may aid in directing future research for the development of 
intervention and prevention strategies in which to preserve, restore, or diminish the decline of 
cognitive function.  It is hoped that this research will provide essential insights for teaching 
patients and families cues to discern early cognitive decline and strategies to manage cognitive 
changes or prevent decline.  
Therefore, the purpose of this study was to explore the relationship of ECF and self-
reported cognitive function in 40 adult survivors of PBT.  In a subset of 7 PBT subjects who 
reported concerns in ECF, the relationship of ECF and compensatory behaviors was explored 
through a structured interview using the FCAS.   The specific aims are: 
Aim 1:  To describe executive control function (ECF) and its components in adults following 
treatment for primary brain tumor (PBT).  This aim was addressed by examining subject 
scores on the following standardized tests of ECF.   
a. Memory was measured by Hopkins Verbal Learning Tests (HVLT) on Immediate 
Recall (IR), Delayed Recall (DR), and Recognition Discrimination Index (RDI),  
b. Attention was measured by Trails Making Test Parts A (Trails-A) and B (Trails-
B) and Symbol Digit Modalities (SDMT), 
c. Verbal Fluency (semantic memory) was measured by Controlled Oral Word 
Association (COWA), and 
d. ECF was measured by the Clinical Trials Battery (CTB) Composite score, Trails 
Making Test Parts B-A Difference score (TMT Difference), and Executive 
Interview-25 scores (EXIT-25). 
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Aim 2:  To describe self-reported cognitive function in adults following treatment for PBT.  
This aim was addressed by examining subject self-reported scores on the Everyday 
Cognitions Test (ECog). 
a. Self-reported cognitive function (ECog total scale score), 
b. Self-reported Memory (ECog memory subscale), 
c. Self-reported Attention (ECog attention subscale), 
d. Self-reported Verbal Fluency (ECog language subscale), and 
e. Self-reported PBT-specific symptom assessment by Functional Assessment of 
Cancer Therapy-Brain Tumor (FACT-BT) and MD Anderson Symptom 
Inventory-Brain Tumor (MDASI-BT). 
Aim 3:  To describe the relationship of ECF performance scores and subject self-report 
scores.  This aim was addressed by exploring the congruence/incongruence:  
a. CTB Composite score and ECog total score,  
b. TMT Difference score and ECog total score, and  
c. EXIT-25 score and ECog total score.  
Aim 4:  To explore whether cognitive reserve or compensatory behaviors explain the 
congruence or incongruence between ECF performance scores and subject self-report scores.  
This aim was addressed by two items:   
a. Cognitive reserve as measured by the Hollingshead Index, and  
b. Compensatory behaviors as measured by the Florida Cognitive Activities Scale.  
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CHAPTER 3:  REPORT ON FEASIBILITY STUDY  
 
 
 This chapter reports data from a pilot study to determine the feasibility of using a brief 
neuropsychological battery and self-report questionnaires to identify dysfunctional executive 
control in survivors of PBT (see Chapter 4, Methods, for descriptions for the instruments used 
and Appendix A-F for Study Protocol, IRB Approval, and Consents).  A secondary goal was to 
compare executive control function (ECF) in adults with PBT to healthy controls.  
Neuropsychological measures used were the Mini-Mental Status Exam (MMSE), Executive 
Interview (EXIT-25), Trails Making Test-Part B (Trails B), Symbol Digit Modalities Test 
(SDMT), North American Adult Reading Test (NAART), and the Controlled Oral Word 
Association Test (COWA).  Symptom assessments were derived from a demographic and health 
history form, Everyday Cognitions Scale (ECog), Everyday Memory Questionnaire (EMQ), 
Florida Cognitive Activities Scale (FCAS), Functional Assessment of Cancer Therapy-Brain 
Tumor (FACT-BT), MD Anderson Symptom Assessment-Brain Tumor (MDASI-BT). Scores 
from 3 survivors of PBT were compared to those from 11 healthy control subjects. 
Feedback from subjects was used to modify the instruments used, lessen subject burden, 
and reduce time for study completion.  Study protocols were adjusted to permit questionnaires to 
be completed at home, and to reduce the number of trials on a touch/vibration recognition and 
reaction time task.  All subjects who opted to take the symptom assessments at home returned 
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them.  Being able to answer the symptom assessments at home allowed the neuropsychological 
measures to be performed early in the study protocol, thereby reducing subject fatigue. 
   
Preliminary Report of Subject Scores  
 
 A total of 14 subjects participated: 3 men and 8 women in the healthy control (HC) 
group; 1 man and 2 women survivors of PBT.  The two female PBT subjects also participated in 
a structured interview that focused on describing their symptom experience trajectory.  Ages for 
all subjects (listed in Table 3.1) were similar, with healthy controls (HC) averaging 46.5 years 
[standard deviation (SD) 7.7 years]; PBT subjects averaged 46.0 years (SD 1.0 years).  
Education, while not matched, was slightly higher for HC group at 13.7 years (SD 2.4 years) 
compared to the PBT group at 12.3 years (SD 0.6 years).  Survivors of PBT all had malignant 
tumors, diagnosed 9 years (SD 1.4 years) before study enrollment; all three received similar 
therapies, consisting of gross total resection, radiation, and chemotherapy for at least one year.   
Both groups reported a similar global health status (Table 3.1). Several HC subjects were 
on blood pressure medications, but no subjects took medications for sleep, anxiety, or 
depression.  Protocol enrollment screening MMSE scores were similar: HC group scored 29.9 
(SD 0.3) and PBT group scored 29.1 (1.0).  Scores on the MMX, a variant of the MMSE global 
cognitive screening tool that  incorporates more ECF and delayed memory items, were slightly 
higher for the HC group at 49.8 (SD 0.4) than the PBT group at 47.7 (SD 2.5) out of a potential 
50 point total.  Neither group endorsed depressive symptoms (CESD-R).  However, premorbid 
intelligence as measured by the North American Adult reading Test (NAART) was greater in the 
HC group; HC subjects read 39.7 words (SD 20.5) compared 23.3 (SD 11.9) words in the PBT 
group. 
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EXIT-25=Executive Interview-25; COWA=Controlled Word Association Test; SDMT=Symbol Digit Modalities 
Test; OARS=Older Adults Resource Services Activities of Daily Living and Independent ADL; FCAS=Florida 
Cognitive Activities Scale; ECog=Everyday Cognitions Questionnaire 
 
   
On the EXIT-25, HC subjects averaged 0.9 (SD 1.4) points out of 50 while the PBT 
group averaged 4.3 points (SD 0.5).  Items that were consistently missed by the PBT group were 
design fluency (creating designs with 4 straight lines), a complex Luria hand sequence (three 
rapidly alternating hand movements), and a visual counting task (number of fish with a 
Table 3.1. 
Comparison of Executive Control Function by Subject Scores. 
 Normal 
Range 
PBT #1 
Scores 
PBT #2  
Scores 
PBT #3  
Scores 
   Healthy Controls (n=11) 
   Range           Mean        SD 
Subject Characteristics 
  Age  45 47 46 30-52 46.5 7.7 
  Education  12 12 13 8-16 13.7 2.4 
Global Health Characteristics 
  MMSE 0-30 29 28 30 29-30 29.9 0.3 
  NAART 0-61 18 37 15 10-60 39.7 20.5 
  CESD-R 0-60 35 27 26 20-33 23.4 3.9 
Executive Control Function 
  EXIT-25 0-50 4 4 5 0-4 0.91 1.4 
  COWA Total  
    Letter C 
    Letter F 
    Letter L 
Unlimite
d 
54 
22 
20 
12 
45 
14 
17 
14 
17 
13 
4 
0 
 48.5 
16.7 
15.7 
16.0 
3.9 
4.1 
3.1 
4.9 
  Trails B 0-300 112 120 80 45-109 73.9 21.5 
  SDMT 0-72 51 2 35 30-56 45.2 9.3 
Self-Reported Everyday Function 
  OARS: Total 
    ADL 
    IADL 
0-28 
0-14 
0-14 
26 
13 
13 
28 
14 
14 
28 
14 
14 
27-28 27.9 
14 
13.9 
0.3 
  FCAS: Current 
    10 years ago 
0-100 84 
91 
97 
120 
87 
73 
 94.7 
88.3 
 
  Everyday Memory 0-52 38 34 17 14-26 18 3.2 
  ECogTotal 
    Memory 
    Language 
    Visuospatial  
    Planning 
    Organization 
    Divided Attention 
0-4.0 
0-4.0 
0-4.0 
0-4.0 
0-4.0 
0-4.0 
0-4.0 
3.3 
4.0 
3.0 
2.4 
2.4 
3.5 
4.0 
1.9 
2.8 
2.0 
1.4 
1.2 
1.3 
2.0 
1.1 
1.1 
1.0 
1.0 
1.0 
1.2 
1.5 
1.0-1.3 1.3 
1.3 
 1.0 
 1.0 
 1.0 
 1.1 
 1.1 
3.9 
1.9 
1.9 
0.0 
0.4 
1.7 
1.0 
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distractor).  Subjects in both groups averaged the same number of words on COWA for letter C 
(HC 16.7, SD 4.1; PBT 16.3, SD 4.9); the second letter F showed more variation, with HC 
producing 15.7 words (SD 3.1) compared to 13.7 (SD 8.5) in the PBT group.  One subject with 
PBT opted not to continue with the third letter, L; HC group averaged 16.0 words (SD 4.9) and 
the two PBT subjects averaged 13.0 words (SD 1.4).  For the SDMT, the HC group substituted 
43.6 items correctly (SD 9.3), compared to PBT group’s 29.3 (SD 25.0).  One subject with PBT 
did not follow instructions resulting in a score of 2 although she did substitute 55 items correctly 
during the timed examination.  The HC subjects performed Trails-B in 73.4 seconds (SD 21.5), 
but subjects with PBT were delayed for an average of 104 seconds (SD 21.2).  One subject with 
PBT had errors and opted not to proceed after corrective instructions. 
 Assessments of everyday function on the OARS Activities of Daily Living Scale showed 
that both groups were similarly able to perform activities of daily living, with HC group scoring 
27.9 (SD 0.3) and the PBT group, 27.3 (SD 1.1).  However, on the Florida Cognitive Activities 
Scale, subjects with PBT reported performing an average of 7 (SD 1.4) cognitive activities 
compared to HC group’s 13.5 activities (SD 0.7).  The PBT group reported that they altered their 
lifestyles, eliminating an average of 14 activities (SD 2.8) since diagnosis; the HC group had 
altered 4 activities on average (SD 2.8) in the preceding 10 years. On the Everyday Cognitions 
Questionnaire, the PBT groups scored all items as consistently worse since diagnosis and the HC 
reported no change.  On the Everyday Memory Scale, subjects with PBT reported more concerns 
with their memory, averaging 7.5 issues (SD 0.7) compared to HC group averaging 2.5 issues 
(SD 0.7).
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Compensatory Strategies   
 
 The compensatory strategies subjects with PBT incorporated into their performance are 
shown in Table 3.2.  Field notes were recorded during study participation.  Using constant 
comparative analysis (Charmaz, 2006; Glaser & Strauss, 1967), the field notes and answers on 
the FCAS were reviewed to detect recurring behaviors.   
Behavioral observation:  These types of behaviors were observed during the feasibility study.   
1. The survivors of PBT took more time to complete the study battery, ranging of 1.5 to 3.5 
hours as compared to 45 minutes for the healthy control group.   
2. All 3 survivors of PBT took more breaks during the study.  During these breaks they told 
stories, talked about their families, and asked health-related questions.  All of the healthy 
control subjects attended to the study battery moving from test to test to complete the 
battery quickly.  They did not take any of the breaks offered.   
3. All 3 survivors with PBT stayed focused on the testing tasks, especially the timed 
instruments.  Thus, the stories and questionnaires tended to occur during times between 
tasks or while answering items on the questionnaires.  Then, the PI was required to 
redirect the subject’s attention back to the study battery for completion.   
4. One survivor with PBT focused on speed for two timed instruments rather than accuracy 
in completing the task according to directions; this resulted in more errors.   
5. Despite the breaks, all of the survivors with PBT reported feeling fatigued at study 
completion.     
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Table 3.2.   
Characteristics of behaviors exhibited by PBT subjects during testing procedures.   
Characteristics of Behaviors PBT #1 PBT #2 PBT #3 
    Time to complete in hours 1.5 1.7 3.5 
    Fatigue X X X 
    Pacing X X X 
    Repetition   X 
    Engagement X  X 
    Perfectionism  X X  
    Motivation X X  
    Effort X X X 
    Frustration X X  
    Early Termination  X X 
 
 
FCAS:  The FCAS provides an opportunity to explore the cognitive activities subjects perform 
currently, and what activities or behaviors have changed since diagnosis.  Using it in an 
interview format allowed the PI to probe for more information regarding why they changed the 
behaviors.  In general, the healthy control subjects stated they had not changed activities over the 
past 10 years.  The responses from the 3 survivors with PBT are as follows: 
 The most common reason that behaviors or activities were stopped was that the subjects 
did not enjoy it much anymore. Additional reasons included: the activity required too 
much time, it involved interaction with others, or it was more difficult to perform since 
their diagnosis.   
 Subjects engaged in fewer social activities than before their diagnosis, primarily because 
they felt others became frustrated with their slower performance.   
 Subjects continued to drive, but only to familiar places.  Using maps or global positioning 
devices, and learning new roads were difficult, and they were concerned about getting 
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lost.  Further, none of the survivors with PBT drove on highways because they felt unsafe 
and distracted by the other vehicles.   
 Subjects used lists to remember appointments, conversations, and shop.   
 Subjects did not recall when they had started altering behaviors or activities but believed 
the changes occurred predominately during their chemotherapy treatments. While they 
did not resume any activities they had stopped during treatment, they continued to reduce 
their activities over time.   
 
Symptom Experience for 2 Survivors of PBT 
 
 Two of the survivors with PBT participated in a structured interview to explore the 
symptom experience.  The questions were open-ended, promoting subject perception of 
symptoms experienced since diagnosis and the perception of impact on their lives.  In these 
interviews, symptoms of cognitive impairment, fatigue, and sleep disturbance were described as 
persistent, interfering with quality of life, and causing the most distress in the respective order of 
severity.  Furthermore, the subjects were unaware that these symptoms might persevere after 
treatment completion and during remission (both survivors had been diagnosed 10 years before 
the interview).  Using constant comparative analysis (Glaser & Strauss, 1967; Charmaz, 2006), 
differences in symptoms through their trajectory of illness are outlined on Table 3.3.   
Specific concerns regarding the progressive worsening of cognitive function and its 
impact on everyday function were foremost in their descriptions.  Particular issues regarding 
cognitive function were changes in executive control, specifically relating to memory, attention, 
motivation, ability to multitask (resulting in loss of work), inability to drive distances, and 
inability to learn new tasks. 
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Table 3.3.   
Matrix of survivorship issues over the illness trajectory in 2 survivors with PBT. 
 Issue   Diagnosis   Treatment   Survivorship 
  Health  
  Care  
  Process 
  Many doctors 
  Throwing fits 
  Demanding scan 
  Surgery 
  Radiation 
  Chemotherapy 
  “Fighter” with aggressive therapies 
   Balancing  scientific vs. spiritual 
   meaning in their lives 
 
  Symptoms   Intense headaches  
  Visual disturbances 
  Projectile vomiting  
  “Something is wrong” 
  Nausea, Constipation 
  Weak spells or fatigue 
  “Brain cancer is  
   different” 
  Anxiety, apprehension  
  Memory/cognitive 
  Getting lost, forgetting tasks 
  “Feeling dumb” 
 
  Support  Husband on phone,  
 Family flew in, 
 Intensive care 
 
  Husband, family, church  
  and community support 
 Husband, family, children  
  Helping other cancer patients 
  Life  
  Impact 
 Frustrating experience   Concern @ hair,  
  Loss of others  
  with cancer 
  Frustrating disability, loss of work,  
  near  bankruptcy, fear of driving,  
  loss of independence, concerns about  
  being safe 
 
 
 
 
 
 
Summary of Feasibility and Pilot Findings   
 
 Feasibility:  By adding measures of psychomotor control to standard measures of ECF 
and more clinically relevant evaluations of ECF, differences in the relationship of ECF to 
everyday function were observed in the adult survivors with PBT when compared to healthy 
control subjects.  Feedback from subjects was used to modify battery protocol, instruments used, 
subject burden, and reduce time for study completion. 
Pilot findings:  Subjects with PBT had lower performance scores than healthy control 
subjects. These analyses are consistent with patient and family reported concerns of cognitive 
dysfunction and its impact on their everyday lives.  Additionally, subjects with PBT exhibited 
several behaviors during testing that were not demonstrated in the healthy control group: 
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difficulties with shifting attention, eliminating distractions, and speed of processing.  These 
observations of compensatory behaviors used during cognitive performances most likely 
represent some of the compensatory behaviors PBT survivors incorporate into their everyday 
function and require further study.   
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CHAPTER 4:  METHODS 
 
 
The specific aims for this study were to: 1) describe executive control function (ECF) and 
its components in adult survivors of PBT; 2) describe self-reported cognitive function in those 
survivors; 3) describe the relationship of ECF performance scores to subject self-report scores, 
and 4) explore whether cognitive reserve or compensatory behaviors explain the agreement or 
disagreement between ECF performance scores and subject self-report scores. 
 
Study Design 
 
A cross-sectional, descriptive-exploratory design was used to address the study aims 
(Figure 4.1).  All subjects completed the study testing and questionnaire in one session.  Forty 
survivors of PBT completed a structured, 100-minute battery of neuropsychological and 
symptom assessment questionnaires.  Seven subjects agree to participate in an additional 30-
minute structured interview following the cognitive testing.  The study protocol was approved by 
UNC Hospitals and Duke University Health System Institutional Review Boards, and Lineberger 
and Duke Cancer Center Protocol Review Committees.   
   
28 
 
 
Figure 4.1.  Study Design       
Aims 1-3 
Cognitive Battery & 
Questionnaire only 
 
 
Aim 4 
Structured 
interview 
 
 
 
Sample   
 
Twenty-two female and 18 male subjects were recruited from UNC and Duke Cancer 
Centers; all were English-speaking, and between 30 and 65 years old.  All participants 
demonstrated adequate global cognitive function by scoring >30 on the Telephone Interview for 
Cognitive Status (TICS) (Brandt, Spencer, & Folstein, 1988) and accumulating >24 points (M 
28.6, SD 1.6) on the Mini-Mental State Examination (MMSE) (Folstein, Folstein, & McHugh, 
1975).  All subjects had received chemotherapy, radiation therapy, or both for treatment of their 
PBT, and had completed treatment at least 1 year before their participation in this study.  All 
subjects denied additional neurological, cardiovascular disorders, or psychiatric disorders that 
might mask treatment-related cognitive impairment.  All subjects were determined by their 
neuro-oncologist to have a stable tumor status within 15 days of study participation.  Subjects 
with epilepsy related to their PBT were medically stable, and had had no change in medications 
during the 6 months before participation.   
Exemplar subset. 
Subjects who reported 5 or more cognitive concerns on the Everyday Cognitions Scale 
(ECog) during telephone screening (described in Telephone Screening Procedures) were eligible 
to participate in a structured interview following the cognitive battery and questionnaire; 7 of the 
40 subjects with PBT 
 
Exemplar subset of 
7 subjects with PBT 
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40 subjects were eligible and completed the structured interview. This exemplar subset 
comprised 4 women and 3 men aged 52.3 years old (SD 6.6 years).  They had an average of 15 
years of education (SD 1.3) and scored an average of 28.3 on the MMSE (SD 0.9).  Six subjects 
were retired but one was still employed; 3 of the subjects lived alone.  
 
Setting and Recruitment 
 
Participants were recruited at two sites: 1) the Lineberger Neuro-Oncology Clinic of 
University Hospital (Lineberger), University of North Carolina in Chapel Hill, North Carolina, 
and 2) the Preston Robert Tisch Brain Tumor Center, Duke University Health System (Tisch), 
Durham, North Carolina.  Both clinics are NIH-designated Comprehensive Cancer Centers that 
provide care to people of varying socio-economic and cultural backgrounds from time of 
diagnosis through end-of-life.  Physician support was provided by Dr. Wu at UNC and Dr. 
Desjardins at Duke.  Recruitment began in December 2011 and was completed in September 
2012.   
The study was conducted in two locations at the subject’s convenience: Duke University 
Tisch Neuro-Oncology sites or the UNC School of Nursing (SON) Biobehavioral Lab (BBL).  
Both locations provided a comfortable setting with a convenient bathroom and an area for 
breaks.   
 
Eligibility and Scheduling 
 
Patients with primary brain tumors (PBT) scheduled for a neuro-oncology clinic visit 
were screened for recruitment between January and September 2012. Three hundred of 1266 
patients scheduled at the Preston Robert Tisch Brain Tumor Center and 2 of 60 patients 
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scheduled at the UNC Lineberger Neuro-Oncology clinic, met the criteria for study participation 
(Figure 4.2).  Three hundred opt-in recruitment letters were sent, and 60 individuals who 
expressed interest (a 20% response rate).  Another 2 subjects were identified during their clinic 
visit and referred to the PI for discussion.  Both met eligibility criteria and agreed to participate.  
Although recruiting took place at two sites, 61 of the 62 responders were patients at the Preston 
Robert Tisch Brain Tumor Center at Duke.  
The opt-in letter instructed all responders to leave a voice message on the PI’s private 
office line requesting more study information.  All responder phone numbers were correct and all 
responders were contacted within 24 hours of their initial call or at a time requested by the 
responder.  In 7 cases (11%) an additional call from the PI was needed to arrange the telephone 
screening.    
Of the 62 responders, 7 were not eligible for study due to neurological instability or 
recent illnesses.  Twelve of the remaining 55 had scheduling conflicts and opted not to 
participate.  The first 40 of the remaining 43 responders were scheduled for study participation, 
and 3 were placed on a wait list One scheduled subject withdrew prior to participation due to 
tumor recurrence requiring surgical intervention.  Two additional subjects who completed the 
study battery were excluded from analysis because of tumor recurrence detected by clinical 
evaluation and MRI review.  The three wait-listed individuals were therefore included to give a 
final sample size of 40 subjects. 
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Figure 4.2.  Flow diagram of study recruitment. 
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Screening and Scheduling Procedures  
 
Subjects were screened in two phases (a telephone screen and a laboratory screen), whose 
components are listed in Table 4.1. 
 
Table 4.1.   
Two Step Screening Procedures 
 Telephone 
Screen 
Laboratory 
Screen 
 
Time to Complete 
Phone Recruitment &  
Description of Study 
X  2 minutes 
Mini-Consent for Health  
Screening Questionnaire 
X  1 minute 
Health Questionnaire, Telephone 
Cognitive Screen, & Modified 
ECog Questionnaire 
X  8 minutes 
Subject Information Packet X  2 minutes 
Subject ID & Scheduling X  2 minutes 
Informed Consent  X 5-10 minutes 
Laboratory Health Screen  X 5 minutes 
Mini-Mental Status Examination  X 5 minutes 
Subject Eligibility Form  X 1 minute 
 
Telephone screening protocol.   
The telephone screen determined eligibility based on a few questions about health status, 
medications, and dementia status.  The telephone screen was performed by the PI because it 
involved medical information with which the research assistant had no experience.  On average, 
this screen took 15 minutes to complete.   
Study description & verbal mini-consent. 
  If responders opted to participate after the initial discussion with the PI about the purpose 
of the study and its general description, a verbal consent (scripted and IRB approved to assure a 
standardized approach for all responders) was obtained before assessing their enrollment 
eligibility.   
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Eligibility determination. 
A health history and medication tool was used to survey all subjects regarding their 
health history and current medication use. Subjects were excluded if they had neurological or 
cardiovascular disorders prior to their PBT diagnosis, were taking psychoactive medications, had 
a history of alcoholism or illegal substance abuse, or if there was a family history of dementia 
syndromes (Table 4.2).   
 
Table 4.2.   
Criteria for eligibility   
 
Eligibility Criteria  
Phone 
Screen 
Lab 
Screen 
Age 30 to 65 years old X  
Read and write English language X  
Primary Brain Tumor: 
  Treated with prior chemotherapy or radiation therapy   
  No signs of paresis or aphasia. 
  Has stable tumor status determined by neuro-oncologist 
X  
Stable seizure status for last six months with no antiepileptic 
medication changes in the last six months 
X  
TICS > 30 points X  
MMSE > 24 points  X 
Signed informed consent  X 
* Exclusion Criteria: Exclude subject if yes to any of these   
General anesthesia within the last six months X  
Paresis or Aphasia X  
Known neurologic or cardiovascular disorders listed in Health 
History Screen     (Example:  Parkinson’s disease, multiple 
sclerosis, Alzheimer’s disease, CVA, immune disorders, 
depression, sleep disorder) 
X  
Medications: 
   Dopaminergics (Pramipexole, Ropinirole, Carbidopa, 
Levodopa) 
   Major anticholinergics (Example: Phenothiazines, 
Antiparkinson meds) 
   Alzheimer’s medications (Aricept, Remeril, Exelon, 
Namenda) 
X  
Chemotherapy: Carmustine, Lomustine (CeeNU), 
Carboplatin, Temozolomide (Temodar), Etoposide 
(Vepesid, VP-16), Irinotecan (CPT-11, Camptosar), 
Procarbazine (Matulane) 
X  
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 The Telephone Interview for Cognitive Status (Brandt, Spencer, & Folstein, 1988) was 
administered to screen for dementia.  This screening tool uses 11 items to assess orientation, 
immediate and delayed recall, attention, language and verbal fluency, counting and calculating, 
and nonverbal praxis.  Scores range from 0 to 41, with higher scores indicating higher cognitive 
performance.  This screen has 94% sensitivity and 100% specificity for dementia with cutoff 
scores at 30.  Test-retest reliability is .965 and the intra-class correlation coefficient is .99 
(Brandt, Spencer, & Folstein, 1988).    
Exemplar subset screening. 
The Everyday Cognitions Scale (ECog) (Farias et al., 2008), was modified to screen 
potential subjects for ECF impairment. Individuals with mild, multiple-domain cognitive 
impairment report difficulties on a third or more items on the ECF subscales (Farias et al., 2008), 
so it was hypothesized that inability to complete one-third of the 15 items would identify PBT 
responders with ECF impairments who could be interviewed regarding use of compensatory 
behaviors and engagement in cognitive activities.  Seven subjects were thus identified and agreed 
to participate in the additional structured interview. 
Subject information packet. 
Subject information packets were sent to all eligible responders.  This packet provided 
directions to UNC SON Biobehavioral Laboratory or the Tisch neuro-oncology clinic laboratory 
room in Durham, the date and time they were scheduled, and specific information regarding 
instructions for the night prior to and morning of the study procedures.    
Subject ID assignment. 
All individuals who started the telephone screening procedures were assigned a 
respondent identification number.  A subject ID was assigned for those deemed eligible after 
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completion of the telephone screen.  These IDs were linked with data collection forms used 
during study procedures.    
Subject scheduling for study participation. 
Upon completion of the telephone screen, the PI completed the Scheduling Form, which 
listed subject study date and time preferences, and served to facilitate the scheduling time in the 
UNC SON BBL or the Tisch BTC clinic laboratory room. Because many of the subjects come 
from long distances for their neuro-oncology care, every attempt was made to schedule the study 
battery at their convenience.  Since neuro-oncology clinic visits may be long and stressful and 
long, and in order to obtain their best cognitive performance, study subjects were encouraged to 
participate the day before or after their clinic encounter. Responders living near the study sites 
were offered other scheduling opportunities To promote optimal cognitive performance, study 
participation was scheduled 10 am and 2 pm. 
Laboratory screening protocol. 
Laboratory site. 
Data collection took place in the same room as the laboratory consent and screening at 
either the Tisch neuro-oncology clinic or UNC SON BBL.  Each subject was escorted by the PI 
or research assistant to a comfortable room containing all essential study equipment.  The room 
temperature was kept between 70 to 72 degrees to promote a similar and comfortable atmosphere 
at both facilities.   
Laboratory consent. 
Upon arrival at the UNC School of Nursing BBL or the Tisch BTC clinic, subjects were 
made comfortable before beginning the laboratory consent.  The PI or research assistant provided 
the subject with an outline of the study procedures, and answered any questions regarding study 
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purpose and procedures. The subject was then allowed to read the consent, or to have the PI or 
research assistant read the consent to them if they preferred.  The study purpose, procedures, 
duration, risks, benefits were explained, as well as the subjects’ right to confidentiality and to 
withdraw from the study at any time without reprisal. Subjects were encouraged to discuss 
questions or concerns regarding participation in the study and were informed how to contact the 
PI should they wish to discuss issues after study completion.   
Laboratory screen. 
After obtaining consent, the research assistant inquired about health or medication 
changes that might affect eligibility status, and recorded their vital signs.  The study was 
rescheduled if the subject reported any of the following conditions that might interfere with 
cognitive function: use of “cold” medications within the past week; procedures requiring general 
anesthesia within the past two weeks; alcohol intake in the last 24 hours; smoking of tobacco 
products within four hours of testing procedures; use of sedative or hypnotic medications the 
night prior to study procedures unless routinely taken; or a fever or cold at the time of study 
procedures.  The health and medication answers and vital signs were recorded on the Health 
Information Survey form.   
 The Mini-Mental Status Examination (MMSE) (Folstein, Folstein, & McHugh, 1975) 
was administered upon completion of the health eligibility screen.  The MMSE takes 
approximately 10 minutes to complete and has been used extensively as a screening test for 
global cognitive impairment.  The test items assess orientation, short-term memory, attention and 
calculation, constructional abilities, and language abilities.  Total scores range from 0-30; higher 
scores indicate better cognitive performance.  The recommended criterion score of 24 as a 
threshold for cognitive impairment was used to determine eligibility for study enrollment.  The 
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calculated score and all papers used for drawing were kept with the subject data files.  If subjects 
were to fail to score above 24, data collection would cease and the PI or research assistant would 
conclude participation by thanking the subject for his or her interest.  The protocol also called for 
the PI to discuss their ineligibility with them due to the low score on the MMSE and urge them 
to contact a medical provider for appropriate follow-up. The data were not to be retained, but a 
log indicating that the subject was ineligible due to low MMSE score was developed.    
 
Protection of Human Subjects  
 
Risks to subjects were considered minimal, but include that subjects may perceive that 
they were either depressed or too cognitively impaired to complete the study. To minimize 
distress, the PI was available throughout testing procedures to respond to concerns about the 
procedures. The test batteries were assigned tolerable time intervals (<15 minutes each), 
performed in a private room, and subjects observed for signs and reports of fatigue.  All issues 
regarding subject responses to any component of the study protocol were discussed in weekly 
meetings with Dr. Carlson.   
 Subject numbers were placed on the data collection forms; names were not used.  Subject 
identification and consents are stored in a locked file cabinet separated from subject data.  All 
digitized data, video recordings, and computers are password protected and stored in a locked 
cabinet; data files will be destroyed after analyses are completed.  Backup electronic copies are 
archived at another site on campus.   
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Variables and their Measurement 
 
The variables analyzed in this study consist of: 1) executive control function (ECF) with 
components of attention and working memory; 2) self-reported ECF; 3) cognitive activities; and 
4) descriptive factors.   Table 4.3 outlines the variables and their measurement.  When subjects 
refused to participate in any measure, the total score was indicated as missing. 
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Table 4.3.   
Variables, their Measurement and Reliability. 
Variable Measurement Internal Consistency (α) Test-Retest Reliability (r) 
Executive Control 
Function & 
components:   
     ECF 
 
 
 
  Attention 
 
 
 
  Verbal Fluency 
 
 Working Memory 
 
 
 
 
EXIT-25 
CTB Composite 
TMT Difference 
 
Trail Making Tests, Parts A 
and B 
 
Symbol Digit Modalities 
Test  
Controlled Oral Word 
Association 
 
Hopkins Verbal Learning 
Test 
 
 
 
.83 (Royall et al., 1992) 
 
 
 
.96 (Lezak et al.,  2004) 
 
.70 (Smith, 1991) 
 
 
.83 (Ruff et al., 1996) 
 
 
.74 (Mitrushina et al., 2005) 
 
 
 
 
 
 
 
.95 (Lezak et al., 2004) 
 
.74 (Mitrushina et al., 2005) 
 
 
.74 (Ruff et al., 1996) 
 
 
.74 (Mitrushina et al., 2005) 
Observed 
Compensatory 
Behaviors (from field 
notes) 
Identified during cognitive 
testing, may include: 
     Taking a break 
      Corrections 
      Starting Over 
      Halting 
      Repeating      
 
 
 
 
Self-reported cognitive 
function 
Everyday Cognitive Scale .80 (Farias et al., 2008) .82 (Farias et al., 2008) 
 
Cognitive reserve Hollingshead Index  
NAART 
 
72 (Blair & Spreen, 1989) 
 
Self-reported 
Compensatory 
Behaviors * 
Florida Cognitive Activities 
Scale 
.65 (Schinka et al., 2005) .55 (Dotson et al., 2008) 
Descriptive Measures Demographics Survey 
Health Information Survey 
CESD-R 
MDASI-BT 
FACT-BT 
 
 
.90 (Burnam et al., 1988) 
.91 (Armstrong et al., 2006) 
.83 (Weitzner et al., 1995) 
 
 
.40 (Radloff, 1977) 
.80  (Armstrong et al., 2005) 
.78 (Weitzner et al., 1995) 
* Subset of 7 survivors with PBT participated in structured interview at end of study battery. 
CESD-R=Center for Epidemiologic Studies for Depression, Revised scale; EXIT-25=Executive Interview-25; CTB 
Composite=Clinical Trials Battery Composite; FACT-BT=Functional Assessment of Cancer Therapy-Brain; MDASI-BT=MD 
Anderson Symptom Inventory-Brain Tumor; NAART=North American Adult Reading Test; TMT Difference=Trails Making 
Test Parts B minus A Difference score 
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Executive control. 
Executive control is defined as the capacity to plan, organize, and monitor the 
performance of goal-directed activities from beginning to end of an activity (NIH, 2010).  
Executive control is an everyday function (Valenzuela & Sachdev, 2006). demonstrated by 
coordinating activities, making decisions, planning and sequencing actions, correcting errors or 
inhibiting behaviors through the initiation and organization of goal-directed activities (Farias et 
al., 2008).  Executive control dysfunction, defined as impairment in one or several components 
of function, such as attention or memory, is predictive of inability to perform activities of daily 
living ([ADL]; Royall, Palmer, Chiodo, & Polk, 2004). Executive control dysfunction was 
measured by the following instruments and composite scores: 
1. The Executive Interview-25 (EXIT-25) (Royall, Mahurin, & Gray, 1992) is a 25-item 
functional examination developed to elicit responses indicating global executive control 
function. EXIT-25 assesses verbal and design fluency, motor and impulse control, frontal 
release signs, imitation behaviors and clinical signs of frontal lobe dysfunction.  Each item is 
scored individually according to subject response: 0 = correct answer, 1 = partially correct 
(as determined by Royall and colleagues), or 2 = incorrect, failure to complete, or refusal to 
answer. Response items are summed, with total scores ranging from 0 to 50.  Scores of 15 or 
higher indicate ECF impairment, with higher scores indicating more severe impairment.  The 
EXIT-25 total score correlates well with Trails B (r=.64) test, and is predictive of ADL 
function (Royall et al., 2004).  This examination is completed in 30 minutes or less.    
2. Clinical Trials Battery Composite (CTB Composite) (Johnson, Sawyer, Meyers, O’Neill, & 
Wefel; 2012) is a composite score signifying performance on tests of memory, attention, and 
verbal fluency.  This composite score provides a comprehensive determinant of ECF, and is 
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used as a measure of cognitive function in clinical trials with PBT subjects.  In the present 
study, the difference between raw performance scores for each instrument and the age- and 
education-specific normed mean for that instrument was calculated.  This difference was 
divided by the normative SD to determine the z-score, and the z-scores for each instrument 
were averaged to derive the subject’s CTB Composite score.   
3. Trails Making Test Parts B minus A Difference score (TMT Difference) measures the 
difference in cognitive demand between the Trails Making Test Parts A and B by controlling 
for the motor, visual, and speed components required in both tests (Arbuthnott & Frank, 
2000; Sánchez-Cubillo et al., 2009).  The raw scores from Parts A and B are subtracted to 
calculate the subject’s difference score.  This is then subtracted from age- and education-
specific normed TMT Difference scores and subsequently divided by the normative SD to 
determine the TMT Difference z-score.   
 Components of Executive Control. 
As with many cognitive functions, measurement of the components of ECF often overlap, 
but are considered to have two main subcomponents: attention and working memory.   
Attention. 
  Attention refers to the cognitive capacity to handle environmental stimuli.  Attention is 
described as having three common components: 1) focused attention, also known as selective 
attention, is defined as the capacity to focus on one or two stimuli while suppressing competing 
distractions; 2) sustained attention, or vigilance, refers to the capacity to maintain attention over 
time; and 3) divided attention capacity refers to the ability to perform two tasks simultaneously, 
which requires the capacity to shift focus in attention (Baddeley, Baddeley, Bucks, & Wilcock, 
2001; Lezak, 2004).   These components of attention are measured by processing speed, 
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accuracy and error rates, scanning, set-shifting, and distraction.  Dysfunction in attention results 
in slowed processing, diminished performance accuracy and an increased error rate.  Thus this 
study assessed attention with the following tests: 1) processing speed, or the capacity to perform 
a function accurately within a specified timeframe, measured by the Trail-Making Test – Part A; 
2) set-shifting, the capacity to switch among multiple aspects of a strategy or task, is measured 
by the Trail-Making Test - Part B; 3) inhibition of automatic response tendencies that interfere 
with achieving a goal is measured by the Trails Making Tests and Symbol Digit Modalities Test.  
1.  The Trail Making Tests ([Trails A and B]; Partington & Leiter, 1949) are designed to measure 
attention, sequencing, and mental flexibility during motor control and visual search tasks 
(Lezak, 2004).  Trails A requires the subject to sequentially connect 25 encircled numbers, 
and Trails B requires the subject to alternate encircled numbers 1 through 13 with encircled 
letters A through L. In both tests, the encircled items are randomly distributed on an 8” x 11” 
page.  Subjects are asked to connect the numbers sequentially in Trails A, or the alternating 
sequence of numbers and letters in Trails B, as quickly and accurately as possible. Subjects 
are corrected if they make an error between numbers or numbers and letters; errors are not 
scored, but the mistake and correction prolongs performance time.  Total time in seconds to 
complete the task is the primary outcome, with faster times indicating more efficient visual 
searching and better selective attention.  Maximum time allowed for each test is 5 minutes; 
subjects were allowed to complete the task but the time score assigned was 5 minutes.  Trails 
A and B correlate only moderately with one another (r = 0.49), suggesting each measures 
slightly different visual search and cognitive set-shifting functions (Lezak, 2004).  Both tests 
correlate highly with caudate atrophy in patients with Huntington’s disease, rA = 0.72,         
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rB =.80 (Starkstein et al., 1988). The Trail Making Tests are a component of the preferred 
neuropsychology battery developed by Meyers and Brown (2006) for use in adults with PBT.   
2.  Symbol Digit Modalities Test (SDMT) (Smith, 1991) tests attention through visual search.  
The SDMT requires subjects to scan and track 9 symbols that are paired with 9 substitute 
numbers.  The SDMT presents 11 rows containing varying symbols with 110 total blank 
squares beneath paired responses.  The subject is instructed to enter the correct substitute 
number beneath the symbol, and complete the sequential rows within 90 seconds; accuracy is 
emphasized over speed.  The total number of correct items is counted, and scores range from 
0-110, with higher scores indicating better performance in attention.  The SDMT correlates 
highly with the Wechsler Adult Intelligence Scale Revised Digit Symbol test, r = 0.91 
(Morgan & Wheelock, 1992) in neurology clinic outpatients.  This measure is a component 
of the NIH Toolbox for use in brain-injured patients.   
Working memory. 
Working memory an updated construct for “short-term memory,” refers to a cognitive 
storage buffer with limited capacity (Baddley, 2010; Repovš & Baddeley, 2006) and no ability to 
process beyond the capacity.  Working memory is responsible for: 1) processing information 
across tasks and modalities, 2) storing this information in a short-term buffer, 3) manipulating 
the information for further cognitive processing, and 4) subsequently storing the outcomes or 
products (of #3) in the same short-term buffer (Baddley, 2010).  Working memory was assessed 
using the Hopkins Verbal Learning Test.   
The Hopkins Verbal Learning Test – Revised (HVLT) (Shapiro, Benedict, Schretlen, & 
Brandt, 1999) measures new learning, short- and long-term memory, and word recognition.  The 
subject is read 12 words in three successive trials with free recall recorded following each trial.  
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Total number of correct responses for short-term free recall (HVLT Recall) are recorded and 
summed to provide a maximum total score of 36.  The maximum time allowed for this portion of 
the test is 5 minutes;. at the end of 5 minutes, the total number of words successfully recalled 
constitutes the HVLT Recall score.  Following a delay, the subject is presented with a yes or no 
recognition test (HVLT Recognition).  The subject is read a list of 24 words; 12 of which were 
not formerly presented but are used as distracters because they are semantically related to the 
previous words.  The total HVLT Recognition score sums correct identifications minus 
misidentifications; this score may range from -12 to +12.  The final portion of this test is a 25-
minute delayed free recall (HVLT Delayed) in which the subject is asked to recall the original 12 
words; maximum score is 12.  The HVLT is a valid measure of memory that is highly correlated 
with the Brief Visuospatial Memory Test-Revised in patients with non-lateralized brain injuries 
or psychiatric illness, r = 0.80 (Benedict et al., 1996).  HVLT is a component of the preferred 
neuropsychology battery developed by Meyers and Brown (2006) for use in adults with PBT.   
Verbal fluency.  
Verbal fluency refers to the ability to use one or more strategies to rapidly generate 
specific exemplars of a response category (e.g., words that begin with specific letters or types of 
animals) while avoiding response repetition (working memory component).  Verbal fluency was 
measured by the Controlled Oral Word Association Test.   
The Multilingual Aphasia Examination - Controlled Oral Word Association (COWA) 
(Benton, Varney, & Hamsher, 1978) is based on word retrieval to assess verbal fluency. Over a 
60-second interval, subjects are instructed to say aloud as many words as they can that begin 
with a specific letters of the alphabet (either C-F-L or P-R-W, with both selections providing 
equal difficulty levels).  Proper names and multiple forms of the same word are not counted. The 
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letters are selected based on the known frequency of words in the English language and 
subsequent letters in each series are more difficult than the preceding letter.  The total words 
produced using all three letters, regardless of early cessation or refusal to continue, are summed 
for a total score.  Duplicate words, multiple word reiterations, and use of proper nouns are 
summed as errors. The COWA is a valid measure of ECF, particularly attention, and correlates 
moderately well with ability of individuals with Alzheimer’s disease to read a telephone book, r 
= 0.40, or balance a checkbook, r = 0.45ease (Loewenstein et al., 1992).  The COWA is not 
highly influenced by prior education, and correlates poorly with the Wechsler Adult Intelligence 
Scale Verbal IQ       (r =.14) used to measure premorbid intelligence (Yeudall et al., 1986).  The 
COWA is a component of the preferred neuropsychology battery developed by Meyers and 
Brown (2006) for use in adults with PBT.   
 
Self-reported cognitive function.  
Self-reported cognitive function was assessed by the Everyday Cognitive Scale (Ecog) 
(Farias et al., 2008).  The ECog Scale uses a 39-item questionnaire to assess subjects self-rating 
of current cognitive ability to perform everyday activities.  There are a total of 6 subscales: 
memory, language, visuospatial and perceptual ability, and three ECF subscales.  For each item, 
subjects are asked to compare their current ability to perform activities to their ability before 
their diagnosis, using the following choices:  1=better or no change, 2=questionable or 
occasional problems, 3=consistently a little worse, 4=consistently much worse, or 5=don’t know.  
Higher ECog scores indicate the perception of increased problems with cognitive activities.  
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Cognitive reserve.  
Cognitive reserve (CR) refers to the lifetime accumulation of cognitive achievement and 
experiences that create an efficient neural network that facilitates processing and compensation 
(Scarmeas & Stern, 2004).  Proxies of CR include quantification of premorbid intelligence, 
occupational, and educational attainment.  These were estimated with the North American Adult 
Reading Test (Blair & Spreen,, 1989) and the Hollingshead 2-Factor Index for Social Position. 
1.  The North American Adult Reading Test (NAART) (Blair & Spreen, 1989) was used as a 
secondary screen for dementia and has been used to estimate premorbid intelligence.  The 
NAART is a 61 item test that asks subjects to read aloud a list of words chosen because they 
are pronounced differently they are spelled, thus requiring the subject to be familiar with the 
word.  The total NAART score represents the number of correct responses, with higher 
scores indicating higher intelligence.  Subjects may stop reading words with which they have 
difficulty or are unfamiliar; however the PI or research assistant encouraged the subject to 
continue reading the list.  Skipped or missed words and early termination of the test results 
are counted as errors and listed as incorrect responses.  The NAART correlates moderately 
with the Wechsler Adult Intelligence Test Revised IQ subscale, r = 0.62, and Full Scale IQ, r 
= 0.61 (Blair & Spreen, 1989). 
2.  The Hollingshead 2-Factor Index of Social Position (Hollingshead Index) (Hollingshead, 
1957) uses educational and occupational attainment to derive a solitary score for CR.  
Categories of occupations and categories of educational achievements are scored, then 
weighted for a summation index. Hollingshead Index scores range from 11-77 points; lower 
scores indicate higher levels of education and occupational attainment, and thus reflect 
higher CR.   
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Compensatory behaviors:  Exemplar subset. 
Compensatory behaviors are actions, or reactions to stimuli, used to achieve an expected 
outcome when performing tasks outside the range of normal task execution (Tomey & Sowers, 
2009; Weiss, Hoenig, & Fried, 2007).  These behaviors result from internal or external stimuli, 
and thus may be conscious or subconscious and overt or covert when used in everyday function. 
It is assumed that compensatory behaviors are present prior to the determination of clinical 
disability (Fried et al., 1996), but this may not be the case in persons with neuropathology such 
as are present in patients with PBT. Persons incorporating compensatory behaviors into everyday 
function tend to require more effort for task completion, and most underreport their use of 
compensatory behaviors (Weiss, Hoenig, & Fried, 2007; Fried et al., 1996).  Thus, direct 
observation and structured interviews were used in the present study to detect behaviors used by 
survivors of PBT for task completion.   
 To identify compensatory behaviors used to perform daily cognitive activities, a 
structured interview was administered at the completion of study procedures.  This interview 
incorporated subject responses to the Florida Cognitive Activities Scale (FCAS) (Schinka et al., 
2005) and open-ended questions.  In addition, field notes recorded during the observation of 
subjects’ study participation were reviewed for identification of compensatory behaviors. 
1.  The FCAS is a 25-item questionnaire that asks subjects to recall their level of participation in 
cognitively engaging activities 10 years earlier, as well as their current level of involvement 
in the same activities.  Subjects are asked to rate the level of activities as follows: 1=never 
did this activity; 2=have not done this in the past year; 3=less than once a month, 4=1-4 times 
a month; 5=5 times or more a month.  “Is this a change?” is asked after every item to 
facilitate the subjects’ reflection on activities they performed prior to diagnosis.  Higher 
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ratings indicate greater participation in cognitively engaging activities. This questionnaire 
can be completed using pen and paper, but it was read to subjects out loud to prompt 
discussions regarding their participation in activities and to reflect on when and why changes 
may have occurred.  To facilitate this discussion, the PI described the activity, followed with 
these statements:  
(1) Tell me more about the activity you indicated a change in  
(2) Tell me when you noticed changes in the activity occurring? 
(3) Tell me what may have prompted the changes in the activity? 
(4) Tell me what have you tried in order to continue performing the activity?   
Do you think this worked? Tell me more about this.  How long did this work for you? 
Did you have to start doing it differently again? tell me more about this.   
The FCAS correlates with the HVLT, Stroop Color Word Association Test, and Trails B in 
healthy controls and subjects with neurologic disorders (r=.33). 
2.  The open-ended questions were designed to facilitate subject description of behaviors and 
included: 
 (1) Tell me what activities you found were easy (or difficult) to do? 
 (2) Tell me how you maintained your energy to complete the tests? 
 (3)  Tell me what you did to be more accurate on the tests?   
  Through a pilot study of the structured interviews, it was learned that subjects were 
willing to discuss their cognitive performance, strengths, and weaknesses.  Therefore, it was 
expected that these questions and structured interview format would facilitate the intended 
discussions. 
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3.  Field Notes were recorded during the study procedures and after the subject left.  These notes 
included observations of behaviors, thoughts for future consideration that were provoked 
during the study procedures, or statements to illuminate subject performances.   
  Descriptive data. 
Descriptive data were collected in order to match patients with healthy controls on key 
variables, to describe the level of depressive symptoms, functional status, and self-rating of 
cognitive function, and to describe disease-specific symptoms in subjects with PBT.  These 
measures included: 
1.  A Health Information Form designed by the PI to assess subject health status.  It includes 
questions about date of birth, handedness to establish cerebral dominance, primary health 
care information, medications, and specifics regarding the brain tumor diagnosis and 
treatment regimen.   
2.  The Older Adults Resource Services Activities of Daily Living Scale (OARS) (Fillenbaum, 
1978) is a 14-item questionnaire that elicits subjects’ perception of their ability to perform 
activities of everyday life.  Subjects were instructed to recall whether, over the last month, 
they could perform physical or independent activities without help, with some help, or not do 
them at all.  Items were scored as: 0=completely unable to perform the activity yourself, 
1=perform with some help, or 2=perform without help.  Scores range from 0-28, with higher 
scores indicating a greater ability to perform activities of daily living.   
3.  The Functional Assessment of Cancer Therapy-Brain Tumor (FACT-BT) is a 33-item 
questionnaire that assesses five domains of well-being (physical, social and family, 
relationship with physician, emotional, and functional) in survivors of PBT (Weitzner et al., 
1995).   Item responses range from: 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 
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and 4=very much. Subjects were instructed to answer each item based on how they felt over 
the preceding week.  Higher scores indicate more difficulties and lower quality of life.  The 
FACT-Br had a modest correlation (r =.47) with the Ferrans and Powers Quality of Life 
Index-Cancer Version of (Weitzner et al., 1995). 
4.  The Center for Epidemiological Studies Depression-Revised Scale ([CESD-R]; Burnam, 
Wells, Leake, & Landsverk, 1988; Radloff, 1977) is an 8-item questionnaire used to detect 
depressive symptoms.  Subjects were asked to rate symptoms over the preceding 7 days.  
Item responses range from: 0=rarely (< 1 day), 1=some of the time (1-2 days), 
2=occasionally (3-4 days), and 3=most of the time (5-7 days).  Higher ratings indicate the 
presence of depression.  CESD-R correlates moderately with Hamilton’s Rating Scale, r 
=.44, and Raskin Rating Scale, r =.54, for depressed adults admitted to a psychiatric hospital 
(Radloff, 1977). 
5.  The MD Anderson Symptom Inventory – Brain Tumor (MDASI-BT) (Armstrong, Cohen, 
Eriksen, & Cleeland, 2005) is a 22-item questionnaire that measures six domains spanning 
affective, cognitive, focal neurologic deficits, generalized symptoms, constitutional 
symptoms, and gastrointestinal symptoms. Subjects were instructed to rate symptom severity 
and interference they had experienced over the preceding 24 hours.  Item responses are based 
on 0=“Not present” to 10=”As bad as you can imagine” scale.  Higher scores indicate greater 
symptom severity and problems for the subject.   
 
Data Collection Procedures 
 
 All study procedures were performed by the principal investigator (PI) or a trained 
research assistant; study personnel responsibilities are described in study procedure components.
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Cognitive and functional measures. 
After obtaining consent and performing the laboratory screen procedures, subjects were 
asked if they need a bathroom or nourishment break.  Opportunities for food and bathroom 
breaks were offered every 15 minutes to promote subject comfort, ease with testing procedures, 
and lessen subject fatigue.   
 All test instructions were scripted to ensure the use of standardized language by the PI or 
research assistant.  All instructions, when appropriate, asked the subject to be as accurate as 
possible in their responses rather than seeing how fast they could complete the tests. In order to 
understand the effort required and the subject burden imposed, after each test the subject 
completed a visual analog scale (VAS; developed by the PI) to estimate the level of difficulty 
experienced with the test.   
 The order of administration of the instruments and questionnaires and their 
administration times were standardized in an attempt to ease subject burden and fatigue.  Strict 
adherence to testing procedures was emphasized and subjects were not permitted to proceed to 
the next test until the allotted time had elapsed.  The order of testing administration, expected 
times to completion, and transition times to start the next test are listed in Table 4.4.  
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Table 4.4.   
Standardized Schedule:  Study Procedures, their components, and time for completion. 
 
 
 
 
Procedure 
 
 
 
 
Components 
Recommended 
Time to Complete 
for normal 
subjects 
Protocol 
(including 
VAS 
completion 
time) 
 
 
 
Endpoint from 
Time 0 
Ready to administer    0 
EXIT-25 EXIT-25 10 minutes 20 minutes 20 
Rest Break  5 minutes 5 minutes 25 
Neuropsychological 
Battery 
HVLT  
NAART 
COWA 
4 minutes 
2 minutes 
3 minutes 
10 minutes 
5 minutes 
5 minutes 
35 
40 
45 
Rest Break  5 minutes 5 minutes 50 
Neuropsychological 
Battery continued 
30 min Delayed Recall 
HVLT 
Trail Making Part A 
Trail Making Part B 
SDMT 
5 minutes 
2 minutes 
4 minutes 
5 minutes 
5 minutes 
5 minutes 
5 minutes 
5 minutes 
10 minutes 
10 minutes 
55 
60 
65 
75 
85 
Rest Break & 
Refreshments 
 5 minutes 10 minutes 95 
Structured Interview Florida Cognitive 
Activities Scale 
Open-ended Questions 
15 minutes 30 minutes 125 
Total Time including 
breaks 
 80 minutes 125 minutes 125 minutes 
 
 
It was uncertain how the proposed structured battery might affect cognitive performance, 
so all subjects used the VAS to rate testing effort upon completion of the task.  The VAS for 
subject self-rating of effort was based on a 10 cm line with markers from 0= “No Effort” to 10= 
“Greatest Effort.”  After completion of each neuropsychology test (Trails A & B, COWA, 
HVLT, and SDMT) the subject was instructed to place a mark along the 10 cm line to indicate 
the perceived effort needed to complete the test.  These analyses identified tasks felt by the 
subject to require more or less effort, and provided guidance for questions posed during the 
structured interview. 
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Self-report questionnaires.  
All subjects were asked to complete a Subject Packet of self-report questionnaires 
(OARS, CESD-R, full ECog, MDASI-BT, and FACT-Br).  To minimize burden, subjects were 
allowed to complete the forms at home and return them by mail.  This option was used by 8 of 
11 healthy control subjects and 1 of 3 subjects with PBT in the pilot study, and there was a 100% 
return rate.   
Exemplar subset for structured interview participation.   
The observational room in the UNC SON BBL was used to interview the subsample of 7 
survivors with PBT.  The room setup was standardized such that subject chair and table positions 
were marked for room conformity.  A break was offered before the structured interview and after 
completion of the neuropsychological battery.   
Study conclusion and payment.   
Upon completion of the visit, the subject was thanked for their participation, provided 
$25 for completion of the study procedures, provided a paid parking voucher, and given contact 
information for the PI.  The subject was told to contact the PI with questions they may have 
arisen after completion of the testing.  The PI sent a thank you letter to study participants. 
  
Research Training & Fidelity Protocols 
 
 Research Assistant training.   
A research assistant with experience in administering cognitive tests was hired and 
trained for all study procedures.  While experience with adult survivors of PBT was not 
necessary, it was preferred that the research assistant have experience at administering tests to 
persons with cognitive issues.   
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Multiple training sessions were scheduled to assure consistency of study procedures and 
test battery administration the first session reviewed the purpose of the study and the reading 
aloud of study scripts: telephone screening, laboratory procedures, structured interview, and 
video-recording.  This overview also covered data management procedures and the research and 
ethics training required by both IRBs.  All procedures were detailed in a notebook developed by 
the PI.   
 Study procedure sessions focused on administration of the laboratory screens, obtaining 
informed consent, and test administration; these were rehearsed by the research assistant and PI 
in order to standardize administration procedures, consider ways to minimize subject burden and 
ease study procedure flow, and maintain consistency in testing procedures.  Three sessions 
devoted to study procedure administration were used for training.  Data management procedures 
were also rehearsed in these practice sessions to ensure that data transcription and maintenance 
was accurate.   
 The research assistant was introduced to both recruiting site physician sponsors and clinic 
staffs to enhance collaboration with the PI and facility staff in identifying, recruiting, and 
enrolling subjects.  The research assistant worked with the PI during staff in-service education 
regarding study rollout and updates on study recruitment.   
 Research Assistant fidelity.   
The PI monitored research assistant performance of study procedures for the first five 
subjects and every fifth subject thereafter.  All audio-recordings were reviewed for adherence to 
study scripts, test schedule, and timing adherence.  The PI and research assistant met after each 
review session to discuss procedure adherence, problems or issues encountered with study 
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procedure, subject concerns, and data management.  Drift or deviations from protocols and 
procedures were corrected and study protocols were reinforced when appropriate.   
Research fidelity.   
Monthly meetings were held with Dr. Carlson to discuss issues addressed with the RA 
and ongoing data management and analyses.  The PI also addressed any study procedure 
difficulties with Dr. Raynor in order to improve subject completion of the study battery, help RA 
performance, and promote subject engagement.  
 
Data Management Procedures 
 
Data were collected by the PI or research assistant and maintained by the PI.  At the end 
of each session or when received from the subject, the neurocognitive battery, EXIT-25, and 
Subject Packet questionnaires were scored and recorded on paper forms, with all subscales and 
full scales totaled by hand.  These data were entered by the PI twice into an SPSS database and 
backed up onto compact discs.  Data were then compared and any discrepancies resolved by 
verifying correct responses from original paper forms. The data entry software was programed to 
perform range checks as data were entered.  
  
Power Analysis 
 
Power analyses were determined by Power and Precision™ software (Biostat Inc., 
Englewood, NJ) and outlined below for each specific aim.  For all power analyses, Type 1 error 
was restricted to 5%, test-wise, in two-sided tests.  The sample size of 40 survivors is based on 
80% power necessary to address Aim 3.  A sample size of 40 subjects will be sufficient to detect 
a minimum correlation of 0.41 between neuropsychological measures and self-report of ECF.    
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For the structure interviews, it was expected that a small sample of PBT survivors would 
provide an initial exploration for compensatory behaviors.  Seven subjects were recruited.  While 
this does not result in saturation, this initial exploration provides a unique contribution to our 
knowledge of cognitive performance and everyday function in survivors with PBT.  This aim 
provides preliminary data which may warrant future study while also providing the PI essential 
experience in conducting this proposed study.     
 
Data Analysis  
 
The analyses for each specific aim are as outlined below: 
Specific Aim 1.  To describe ECF and its components (working memory and attention) in 
adults following treatment for PBT subjects. 
 
The distribution of subject scores for each neuropsychological measure of executive 
control, attention, and working memory, and the self-report of ECF function was examined using 
individual subject scores coded within box plots to visually observe where individual subject 
scores were positioned in regard to the mean and standard deviations.  The box plots and 
scatterplots served to identify influential cases or outliers.   
Analyses for this question were based on the subject’s raw performance scores on each 
instrument in the standardized neuropsychology battery.  These scores were compared to mean 
normative data scores according to age and education (Table 4.5).  The difference of the raw 
performance score and the normed mean was calculated and then divided by the norm SD for 
determination of a z-score.  Cutoff z-scores of -1.3 SD were used to indicate mild impairment 
and -3.0 SD, severe impairment.  For these analyses, impaired function was defined as a raw 
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score that was -1.3 SD below the age- and education-specific normative data for each instrument 
and its subscales.  The means of the z-scores of the battery instruments were combined into the 
Clinical Trials Battery (CTB) Composite score for each subject.  In addition, subject 
performance was examined by recording the number of instruments on which they scored -1.3 
SD or more below normed expectations.  Performance scores of -1.3 SD or more below normed 
data on more than one instrument indicate mild to severe impairment in that domain (Lezak, 
Howieson, & Loring, 2004; Johnson et al., 2012).  The scores of all 40 subjects were evaluated 
using age, gender, and when appropriate, education normative data.  All of these tests have 
normative scores which can be used to identify patients who are -1.3 standard deviations or more 
below normative mean (Lezak, Howieson, & Loring, 2004).   
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* N=number of subjects in each age group, N/N=number of subjects in each education category for each age group. 
** N=number of combined subjects for all education and age groups (i.e., n=477 for age 25-64 with < 12 years of education). 
HVLT=Hopkins Verbal Learning Test; IR=Immediate recall; DR=Delayed recall; RDI=Recognition discrimination index; Trails A & B=Trails Making Test Parts A & B; SDMT=Symbol Digit Modality 
Test; COWA=Controlled Oral Word Association test    
Table 4.5.   
Normative data by test and source, stratified for age and years of education levels. 
 
Cognitive Test 
 
Citation 
Age group 
(years) 
N* Age Only Norms 
Mean (SD) 
< 12 years 
Mean (SD) 
> 12 years 
Mean (SD) 
HVLT-IR Brandt & Benedict, 
2001 
25-34 
35-44 
45-54 
55-64 
54 
61 
66 
43 
28.71 (  4.57) 
28.22 (  4.05) 
27.86 (  3.95) 
27.71 (  4.26) 
Not Available Not Available 
HVLT-DR Brandt & Benedict, 
2001 
25-34 
35-44 
45-54 
55-64 
54 
61 
66 
43 
10.24 (  1.94)  
10.16 (  2.08) 
10.06 (  1.73)  
  9.87 (  1.93)  
Not Available Not Available 
HVLT-RDI Brandt & Benedict, 
2001 
25-34 
35-44 
45-54 
55-64 
54 
61 
66 
43 
10.84 (  1.39)  
11.15 (  1.06) 
10.74 (  1.61)  
10.70 (  1.42)  
Not Available Not Available 
Trails A Tombaugh, 2004 25-34 
35-44 
45-54 
33 
39 
41 
24.40 (  8.71) 
28.54 (10.09) 
31.78 (  9.93) 
 
  
55-59 
60-64 
58/37 
55/31 
35.10 (10.94) 
33.22 (  9.10) 
31.72 (10.14) 
31.32 (  6.96) 
Trails B Tombaugh, 2004 25-34 
35-44 
45-54 
33 
39 
41 
50.68 (12.36) 
58.46 (16.41) 
63.76 (14.42) 
  
55-59 
60-64 
58/37 
55/31 
78.84 (19.09) 
74.55 (19.55) 
68.74 (21.02) 
64.58 (18.59) 
SDMT Smith, 1982 25-34 
35-44 
45-54 
55-64 
477/830** 
 
Not Available 53.30 (  7.98) 
51.50 (  8.03) 
47.26 (  9.56) 
42.80 (  9.02) 
57.72 (  9.08) 
54.20 (11.17) 
52.27 (  8.48) 
47.60 (  8.31) 
COWA Tombaugh et al., 1999 16-59 
60-79 
268/242 
292/185 
Not Available 40.40 (10.70) 
35.60 (12.50) 
44.70 (11.20) 
42.00 (12.10) 
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Specific Aim 2.  To describe self-reported ECF and its components in adults following 
treatment for PBT.   
 
This aim was explored using three self-reported measures of cognitive function or the 
presence of brain tumor specific symptoms: the ECog, FACT-BT, and MDASI-BT.  The 
distribution of subject scores for each instrument was examined using box plots and scatterplots 
to look for influential cases or outliers.  To aid in the interpretation of data, ECog subscale scores 
of 2 or higher were used to identify subject perception of change in cognitive function from 
“occasional problems” to “consistently much worse.”  Subject characteristics, including 
demographic variables and cancer-related factors, were explored to explain any differences in 
perception of cognitive function.  As the ECog has not been used in this population, ECog scores 
were compared to PBT-specific symptom assessments (FACT-BT and MDASI-BT) with 
emphasis on the cognitive items that each scale contained. 
 
Specific Aim 3.  To describe the relationship of ECF and its components to self-reported 
ECF for survivors with PBT. 
 
 The relationships between the neuropsychological measures of executive control, 
attention, and working memory (Exit-25, Trails A and B, COWA, SDMT, HVLT and delayed 
HVLT) and self-reported ECF (Everyday Cognitive Questionnaire, Everyday Memory Scale) 
was examined using Pearson-product moment correlations.  Type 1 error was restricted to 5%, 
testwise, in two-sided tests that the correlation is different from zero.  Exploratory analyses using 
normative scores for age, gender, and education level, when available, were used to describe the 
relationships between neuropsychological measures and self-report in those with PBT compared 
 60 
 
to a healthy normative population.  The scores from the Clinical Trials Battery Composite (CTB 
Composite), Trails Making Tests Difference Composite (TMT Difference), and Executive 
Interview-25 (EXIT-25) were compared to self-reported cognitive function scores on the 
Everyday Cognitions Test (ECog).  Scatterplots of subject scores were used to examine the 
relationship of cognitive performance (x-axis) and self-reported cognitive function (y-axis).  To 
describe subject patterns observed on the scatterplots, four quadrants were established as shown 
on Figure 4.3:  
 1)  Group A subjects report that cognitive function is unchanged since diagnosis 
(defined as ECog score <2.0) and had ECF performance scores defined as normal 
(CTB Composite score >-1.3 SD, TMT Difference score >50, or EXIT-25 score<5). 
 2)  Group B subjects report that cognitive function has changed since diagnosis (defined 
as ECog score >2.0) but ECF performance was within normal limits (CTB Composite 
score >-1.3 SD, TMT Difference score >50, or EXIT-25 score<5),  
3)  Group C subjects report that cognitive function is unchanged since diagnosis (defined 
as ECog score<2.0) but have poor ECF performance scores (defined as CTB 
Composite score< -1.3 SD, TMT Difference score>50, or EXIT-25 score > 5).  
4)  Group D subjects report that cognitive function has changed since diagnosis (defined 
as ECog >2.0) and have poor ECF performance scores (CTB Composite score< -1.3 
SD, TMT Difference score>50, or EXIT-25 score > 5).   
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Figure 4.3  
 Categorization of behaviors according to cognitive function.    
                                            + NP scores                 - NP scores 
- SR ECF scores 
 
 
+ SR ECF scores 
 
 
SR=self-reported, ECF=executive control function, NP=neuropsychological performance, 
 + or – indicates cognitive performance 
 
  
Specific Aim 4.  To explore whether cognitive reserve or compensatory behaviors 
explain the congruence or incongruence between cognitive performance scores and 
subject self-reported change in cognitive function scores.   
 
 This specific aim explored whether cognitive reserve (CR) might explain the observed 
congruence or incongruence between self-reported cognitive function and test performance.  
Analyses for Specific Aim 4 involved examination of: 1) cognitive performance by CR, 2) self-
reported change in cognitive function by CR, and 3) congruence-incongruence between 
performance and self-reported change in cognitive function by CR.  Scatterplots, correlations, t-
tests and non-parametric statistics were used to explore differences between congruent scores, 
Group A and C, and incongruent scores, Group B and D, (as described in Specific Aim 3) by CR.    
The structured interviews from the exemplar subset of 7 subjects are used to describe 
changes in cognitive activities that might illustrate compensatory behaviors. Neuropsychological 
test scores and self-reported questionnaires are limited in the identification of compensatory 
behaviors used to maintain cognitive function. 
D: Congruent B: Incongruent 
C: Incongruent A: Congruent 
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CHAPTER 5:  RESULTS 
 
 
The first section of this chapter presents sample description with subject characteristics, 
PBT-specific characteristics, and key medical symptoms and medications.  The next four 
sections focus on the results pertinent to each specific aim.  
    
Sample Description 
 
The sample (Table 5.1) consisted of slightly more women than men, predominately 
Caucasian, and ranging in age from 30 to 64 years (mean 50.1, SD 9.7 years). These study 
demographics contrast with national brain tumor registry data (CBTRUS, 2012) showing a 1.1:1 
male to female incidence of PBT diagnoses (CBTRUS, 2012), represent.  All participants in the 
present study had at least a high school education; 30% had additional technical or skill 
education or an associate degree (n=12), and 55% held a bachelor’s degree or higher (n=22).  
The majority (n=29) were living with a spouse.   
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Table 5.1. 
Sample demographics of survivors with PBT (n=40). 
Demographics Frequency % 
Gender 
    Female  
    Male 
 
22  
18  
 
55.0 
45.0 
Race 
   Caucasian 
   African American 
 
37  
  3  
 
93.0 
 7.0 
Education, number of years 
   <12 years 
   12 years 
   Technical Skilled/Associates 
   Baccalaureate or greater 
 
  0 
  6 
12  
22 
 
 - 
15.0 
30.0 
55.0 
Living situation  
   With spouse/partner 
   With parents 
   Alone 
 
30 
  3 
  7 
 
75.0 
  7.5 
17.5 
 
 
Tumor and treatment factors. 
Only subjects who had received chemotherapy or radiation therapy for their PBT 
diagnosis were eligible to participate in this study; this limited participation to those in WHO-
PBT grades II to IV tumors.  The distribution of WHO-PBT grade at time of study participation 
was: Grade II (n=5, 12.5%), Grade III (n=25, 62.5%), or Grade IV (n=10, 20%).  These 
distributions conform to national PBT demographics (CBTRUS, 2012).    
Hemispheric location of the tumor was split evenly, with 20 on the right and on the left 
(Table 5.2).  No subject had tumors in multiple locations or in the contralateral hemisphere. The 
most common tumor locations were, as expected, in the frontal (n=19) and temporal lobes 
(n=10), accounting for 72.5% of this sample.  There was no difference in WHO-PBT grade of 
tumors in various locations, χ2(2)=3.7, p=.18.    
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Table 5.2. 
Primary brain tumor location at time of diagnosis (n=40). 
Location Frequency  % 
Hemispheric location 
  Right 
  Left 
 
20 
20 
 
50.0 
50.0 
Lobe location 
  Frontal 
  Temporal 
  Parietal 
  Occipital 
  Midbrain, including pons and  cerebellum 
 
19 
10 
  5 
  2 
  4 
 
47.5 
25.0 
12.5 
  5.0 
10.0 
 
Therapeutic interventions. 
Despite differences in tumor pathology, treatment regimens were similar for all three 
tumor grades with the goals being to control tumor growth by surgical, chemotherapy, and 
radiation interventions. Most subjects received a combination of treatments during their disease 
trajectory.   
Thirty-four subjects (85%) underwent surgical resection, but six (15%) had tumor 
locations prohibiting surgical resection, Table 5.3.  Thirty-four subjects (85%) received 
chemotherapy and radiation therapy, 5 (12.5%) received chemotherapy only, and 1 (2.5%) 
received radiation therapy only.  Of the 39 patients who received chemotherapy, 25 (64%) were 
given multiple agents for a duration of 1 to 3 years.   
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Table 5.3.   
Frequency and percentage of subjects by type of therapeutic intervention (n=40). 
Therapeutic Interventions Frequency  % 
  Surgery + chemo + radiation 
  Surgery + chemo 
  Surgery + radiation 
  Radiation + chemo 
  Chemotherapy only 
30 
  3 
  1 
  4 
  2 
75.0 
  7.5 
  2.5 
10.0 
  5.0 
 
 
Tumor stability. 
All subjects met study criteria of clinical and radiographic stability as determined by their 
neuro-oncologist, and no longer needed chemotherapy for tumor control.  Two thirds of the 
sample (n=27, 67.5%) never experienced recurrence of their tumor after completion of treatment, 
Table 5.4.  The remaining one third had at least one tumor recurrence following their original 
diagnosis: 5 subjects (12.5%) had tumor recurrence with transformation from WHO-PBT Grade 
II to III classification, and 8 subjects (20%) had tumor recurrence without a change in 
classification. 
  
Table 5.4.   
Tumor recurrence by WHO-PBT grade classification (n=40). 
 Frequency % 
Type of Recurrence Grade II Grade III Grade IV All Grades 
No Recurrence 
Recurrence without transformation 
Recurrence with transformation 
4 
1 
0 
14 
  6 
  5 
9 
1 
0 
67.5 
20.0 
12.5 
 
 
Time from diagnosis. 
Survival rates vary across and within tumor grades, according to histology and molecular 
pathology.  Time from original diagnosis ranged from 1.3 to 25 years (median 6.7 years) and 
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averaged 8.4 years (SD 6.0 years).  These times vary according to tumor type (Figure 5.1):  
Grade II tumors averaged 5.1 years (SD 2.4 years), Grade III tumors, 10.9 years (SD 7.0 years), 
and Grade IV tumors, 3.9 years (SD 4.1 years).  The greatest variability was seen with Grade III 
tumors.  Because of unequal variances and group sizes across the three tumor grades (Levene 
statistic F(2, 37)=4.92, p=.01), a Kruskal Wallis test was used to show a significant difference in 
survival times by tumor grade at time of study participation, H(2)=12.09, p=.002.   
 
Figure 5.1.  Time since diagnosis by current tumor grade (n=40). 
 
 
Because of active current treatment and study eligibility criteria, recruitment of subjects 
with Grade II tumors (n=5) was lower than with other tumor grades.  Thus, these 5 subjects 
tended to have a shorter time trajectory since diagnosis (range 2 to 7.4 years; Mean 5.1, SD 2.4 
years) than expected from national PBT registry data (CBTRUS, 2012).   
In contrast, more subjects (n=10) with Grade IV tumors were recruited than expected.  
Consistent with national registry data (CBTRUS, 2012), 8 of these subjects had been diagnosed 
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within 3 years of study participation.  The 2 outliers were long-term survivors of greater than 10 
years since diagnosis.  Thus the range was 1.3-11.8 years (Mean 3.9, SD 4.1). 
The majority of subjects had current diagnoses of Grade III PBT (n=25).  As this group 
had the greatest variability, three subsets were observed: 19 subjects with no tumor recurrence 
averaged 8.4 ± 5.7 (SD) years since diagnosis, 6 subjects with tumor recurrence averaged 12.7 ± 
9.1 years since diagnosis (SD 9.1 years), and 5 subjects with transformation of tumor from Grade 
II to Grade III pathology averaged 15.8 ± 4.8 years.  These differences in survivorship times 
approached significance, H(2)=4.6, p=.10.   
Since all of the subjects who experienced tumor transformation had an original diagnosis 
of Grade II, and since survivorship time may influence cognitive function (Lovely et al., 2013), a 
transformation tumor category was created and this confirmed significant differences in survival 
times by tumor categories, H(3)=15.05, p=.002. Figure 5.2, demonstrates this point using 
CBTRUS (2012) survival timeframes of < 5 years, 5-10 years, and > 10 years, χ2(6)= 21.27, 
p=.002.   
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Figure 5.2.  Time since original diagnosis in months by WHO-PBT  classification (n=40).   
 
  
 
 
Self-reported medications. 
 
While most subjects (n=36, 90%) reported taking daily medications, four (10%) denied 
regular use of any medications, vitamins, supplements, or over the counter medicines.  Table 5.5 
shows the five classes of medications used.  The subjects took 1 to 8 medications per day 
(average of 3.2 medications daily), the majority of which were used to control neurological 
symptoms resulting from the PBT or its treatment.  Medications used to manage comorbid, non-
neurologic conditions were those commonly prescribed for the general US population.  There 
were no significant differences in medication use by tumor grade, recurrence, or other 
characteristics, but there was a significant relationship between elapsed time since diagnosis and 
use of medication agents, χ2(2)= 8.52, p=.01.  Those diagnosed less than 5 year prior to study 
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participation tended to take fewer agents for co-morbid conditions than those diagnosed more 
than 10 years before.    
 
Table 5.5.   
Frequency of daily medications by classifications and tumor grade (n=40). 
 Frequency % 
Classification Grade II Grade II to 
III 
Grade III Grade IV All Grades 
Antiepileptics 4 4 14 3 25 62.5 
Psychotropic & 
hypnotic agents 
1 4 9 7 21 52.5 
Cardiovascular 
agents 
2 1 11 6 20 50.0 
Endocrine/hormone 
replacement agents 
0 1 8 3 12 30.0 
Other agents 5 0 9 8 22 55.0 
No medications 0 1 2 1 4 10.0 
Footnote:  Subjects may report medications in multiple categories. 
 
Self-report of health status. 
Five self-report surveys were used to assess current health status and to determine 
whether symptoms interfered with everyday function and quality of life.  These were:  (1) Key 
medical events survey, (2) Functional Assessment of Cancer Therapy-Brain Tumor Scale 
(FACT-BT), (3) the MD Anderson Symptom Inventory-Brain Tumor Scale (MDASI-BT), (4) 
Older Americans Resources Services Activities of Daily Living Scale (OARS), and (5) Center 
for Epidemiologic Studies Depression Scale-Revised (CESD-R).  If subjects left any items blank, 
the research assistant attempted to clarify them in order to eliminate missing items. 
 
Key medical events survey. 
Subjects reported that their current health status was “the same as” or “better than one 
month ago” on the Key Medical Events Survey.   An average of 2.9 events (SD 1.8) were 
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reported (Table 5.6); 23 subjects (58%) reported 3 or more total events (Table 5.6).  Those with 
lower grade tumors, Grade II or Grade II to III transformations, reported more events, but the 
rate was not significantly different from other tumor grades, F(3,36)=1.4, p=.26.   
 
 
Table 5.6.  
Key medical events occurring within last 3 months as reported by subjects with PBT (n=40). 
 Frequency % 
Symptom Grade II    Grade   
II-III 
Grade 
III 
Grade 
IV 
All Grades 
All symptoms, M(SD) 3.6 (1.8) 3.8 (1.6) 2.4 (1.8) 3.2 (1.8) 2.9 (1.8) 
Neurological M (SD) 2.8 (1.3) 3.4 (1.5) 1.8 (1.5) 2.4 (1.0) 2.3 (1.4) 
  Headaches 4 3 6 3 16 40.0 
  Joint pain 3 2 5 4 14 35.0 
  Dizziness 1 2 7 1 11 27.5 
  Numbness 0 2 6 3 10 25.0 
  Weakness 0 4 3 2 9 22.5 
  Leg swelling 2 0 3 3 8 20.0 
  Walking 2 0 1 4 7 17.5 
  Falls 0 2 2 2 6 15.0 
  Dexterity problems 1 2 2 1 6 15.0 
  Seizures 1 0 1 1 3   7.5 
Other Medical, M (SD) 0.8 (1.1) 0.4 (0.6) 0.6 (0.8) 0.8 (1.2) 0.6 (0.9) 
  Cough 2 1 4 4 11 25.0 
  Cold symptoms 1 0 3 1 5 15.0 
  Heart racing 1 1 1 2 5 12.5 
  Short of breath 0 0 2 1 3   7.5 
  Fever or chills 0 0 1 0 1   2.5 
  Fainting 0 0 0 0 0   0.0 
  Chest pain 0 0 0 0 0   0.0 
  Wheezing 0 0 0 0 0   0.0 
Footnote:  Subjects may experience more than 1 key event. 
 
 
Neurologic events, Table 5.7, were more frequent than other medical events; 35 subjects 
(88%) reported at least one neurologic event (range, 0-5 events; mean, 2.3 events).  Fifteen 
subjects reported general medical events (range, 0-3 events).  There were no significant 
differences across tumor grades in the number of neurologic events, F(3,36)=2.20, p=.10, or 
general medical events reported, F(3,36)=.30, p=.82. 
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Table 5.7.   
Summation of Key Medical Events (n=40). 
 Frequency 
Events Range No events 1-2 events >3 events 
All Key Medical Events 0-7 5 12 23 
Neurologic Events 0-5 5 17 18 
General Medical Events 0-3 25 13  2 
 
 
Functional Assessment of Cancer Therapy-Brain Tumor Scale (FACT-BT). 
Lower scores on the total and PBT-specific symptoms subscale of the FACT-BT indicate 
greater symptom impact on quality of life.  Five subjects (12.5%) provided no answers on 2-3 
items, resulting in a total of 12 missing items across all subjects (0.6%).  The FACT-BT total 
score averaged 139.62 (SD 22.99) and PBT symptom-specific subscale averaged 54.48 (SD 
11.42), reflecting a moderate impact on quality of life (Table 5.8).  These scores were slightly 
better than FACT-BT validation scores (total score: M 136.0, SD 26.0; symptom-specific 
subscale: M 49.0, SD 13.6) in a sample of 101 survivors of PBT (Weitzner et al., 1995).  Subject 
responses to 9 cognitive items pertaining to concentration, new memory, verbal fluency, 
organization, and planning ranged from 10-32 and averaged 21.05 (SD 6.04).  The average is in 
the upper third of scoring range, indicating a moderate impact on quality of life. 
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FACT-BT=Functional Assessment of Cancer Therapy-Brain Tumor scale; MDASI-BT=MD Anderson Symptom 
Inventory-Brain Tumor scale; OARS=Older Americans Resource and Services Instrumental Activities for Daily 
Living scale; CESD-R=Center for Epidemiology Studies Depression-Revised scale. 
 
 
 
 
MD Anderson Symptom Inventory-Brain Tumor Scale (MDASI-BT). 
Higher scores on the MDASI-BT subscales assessing symptom severity and interference 
indicate greater dysfunction (Armstrong et al., 2006).  There were no missing answers on any 
items.  Subjects with PBT reported mean severity scores of 1.25 (SD 1.20) and interference 
scores of 1.35 (SD 1.95), which reflect minimal symptom burden.  These scores may be 
influenced by the long-term survival and relatively stable health of many of the subjects.  These 
scores are slightly better than the mean severity score of 1.52 and interference score of 2.1 found 
in 151 survivors of PBT, (Armstrong et al., 2006).  The MDASI-BT contains four items 
assessing cognitive symptom severity (memory, comprehension, verbal fluency, and 
Table 5.8.   
Self-reported quality of life and symptom interference for survivors of PBT (n=40). 
Scale  Potential 
Range 
Min – Max Mean (SD) Median 
FACT-BT      
   Total Scale 0-184   85-183 139.62 (22.99)   143.5 
   Brain Tumor Subscale 0-76   31-76   54.58 (11.42)     54.0 
   Cognitive Items 0-36   10-36   21.05 (  6.04)     23.0 
MDASI-BT      
   Severity Subscale 
   Interference Subscale 
0-10 
0-10 
    0-5.73 
    0-8.67 
    1.25    (1.19) 
    1.35    (1.93) 
      0.8 
      0.6 
   Cognitive Items 0-10     0-8.75     1.83    (2.02)       1.3 
OARS  
   Total Scale 
   Physical Subscale 
   Independent Subscale 
 
0-28 
0-14 
0-14 
  
  23-28 
  12-14 
  11-14 
   
  27.08    (1.47) 
  13.85    (0.48) 
  13.23    (1.17) 
     
    28.0 
    14.0 
    14.0 
CESD-R   0-60     0-39   10.38    (8.41)       9.5 
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concentration).  Subjects reported mild cognitive symptom severity, with an average of 1.8 (SD 
2.0) and range of 0–8.75.  
 
Older Americans Resources and Services Activities of Daily Living Scale (OARS). 
Higher summation scores on the total scale, and on the physical and instrumental 
subscales, indicate better ability to perform functional activities of daily living.  There were no 
missing items.  Only 14 subjects (35%) reported even minimal limitations on the physical or 
instrumental subscales; total scale scores ranged from 23 to 28 and averaged 27.08 (SD 1.47), 
Table 5.8.   
 
Center for Epidemiologic Studies Depression –Revised Scale (CESD-R). 
Depressive symptoms may influence cognitive function (Johnson et al., 2012), and higher 
scores on the CESD-R suggest presence of depression.  There were no missing items from any 
subjects.  Subject scores averaged 10.38 (SD 8.41), but there was a wide range of scores (0 to 
39).  Nine subjects (23%) had scores > 16, but none reported symptoms consistent with 
depressive categories, and thus represent features consistent with subthreshold depression.  No 
CESD-R scores for subjects with PBT are available for comparison, so it is unclear whether 
these higher CESD-R scores reflect the presence of significant neuropathology.   
 
Associations between Self-Reported Surveys. 
Neurological-associated symptoms on the Key Medical Events Survey were significantly 
associated with lower scores on the OARS, r=-.45, p=.004.  Total scores on the FACT-BT were 
significantly associated with MDASI-BT symptom severity (r= -.62, p< .001), MDASI symptom 
interference (r= -.5, p< .001), and OARS (r=.34, p=.03).  CESD-R scores were significantly 
related to symptom severity (MDASI Severity: r=.55, p<.000), symptom interference (MDASI 
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Interference: r= .41, p=.008), and quality of life (FACT-BT: r= -.72, p< .001). There were no 
significant associations between self-reported surveys and tumor grade, recurrence, or time since 
diagnosis.  Subjects who reported greater symptom severity also reported more impact on their 
daily function and quality of life. 
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Specific Aim 1   
 
To describe executive control function (ECF) and its components in adults following 
treatment for primary brain tumor (PBT).  This aim will be addressed by examining 
subject scores on the following standardized tests of ECF:   
a. Memory was measured by Hopkins Verbal Learning Tests (HVLT) on Immediate 
Recall (IR), Delayed Recall (DR), and Recognition Discrimination Index (RDI)  
b. Attention was measured by Trails Making Test Parts A (Trails-A) and B (Trails-
B) and Symbol Digit Modalities (SDMT) 
c. Verbal Fluency (semantic fluency) was measured by Controlled Oral Word 
Association (COWA) 
d. ECF was measured by the Clinical Trials Battery (CTB) Composite score, Trails 
Making Tests Difference (TMT Difference) score, and Executive Interview-25 
scores (EXIT-25) 
 
Memory. 
Working memory, which is essential to ECF, was assessed using the Immediate Recall 
(IR), 25-minute Delayed Recall (DR), and Recognition Discrimination Index (RDI) subscales of 
the Hopkins Verbal Learning Test (HVLT).  Being brief and easily administered, the HVLT 
subscales allow assessment of new learning, verbal memory, learning efficiency and 
organization through recall and recognition (Brandt & Benedict, 2002).  Table 5.9 shows subject 
performance scores for the HVLT subscales. 
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Table 5.9.   
Subject scores on HVLT subscales for memory (n=40). 
HVLT-IR=Hopkins Verbal Learning Test -Immediate Recall; HVLT-DR=Hopkins Verbal Learning Test-Delayed 
Recall; HVLT-RDI=Hopkins Verbal Learning Test-Recognition Discrimination Index 
 
 
 
Immediate recall (IR). 
Immediate recall summation scores ranged from 6 to 34 words recalled over three 
consecutive trials (Table 5.9).  Subjects recalled an average of 23.78 words (SD 6.33), which 
lower than the recall for all normative age groups (Brandt & Benedict, 2002).  Most subjects 
improved their recall during the three trials; only one subject had the best performance on the 
first trial.  No subject scored “0” for any trial.  Nine subjects (22.5%) scored 1.3 SD or more 
below, and 6 (15%) scored 3 SD below means for age-specific normative groups.   
Delayed recall (DR). 
Possible scores range from 0 to 12.  Two subjects could not recall any words on this task.  
The average number of words recalled was 7.73 (SD 3.15), which is below normed averages 
across all age groups (Brandt & Benedict, 2002).  A total of 17 subjects (42.5%) had 
performance scores indicating impairment of delayed memory:  12 subjects (30%) scored 1.3 SD 
or more below normative data, indicating mild impairment; 5 (12.5%) scored 3 SD below, 
indicating severe impairment.  More impairment was seen on the DR task (42.5%) compared to 
the IR (35%) or RDI (32.5%) tasks (Table 5.9). 
 
 
Memory 
Test 
 
 
Possible 
Range  
 
 
Actual 
Range 
 
 
 
M (SD) 
 
 
 
Median 
 
 
Skewness 
/Kurtosis 
-1.3-2.9 SD 
Below 
Norm 
F (%) 
<-3.0 SD 
Below 
Norm 
F (%) 
HVLT-IR  0-36 6-34 23.78 (6.33) 24 -0.65/0.34   9 (22.5) 6 (15.0) 
HVLT-DR 0-12 0-12   7.73 (3.15)   8 -0.78/0.25 12 (30.0) 5 (12.5) 
HVLT-RDI 0-12 0-12   9.58 (2.31) 10 -1.19/0.73   9 (22.5) 4 (10.0) 
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Recognition discrimination index (RDI) 
The RDI is calculated by subtracting all incorrect answers from the total of correctly 
recognized nouns.  Subject RDI scores ranged from 4 to 12 (average of 9.58. SD 2.31), which 
was below norm for all ages (Brandt & Benedict, 2002).  Seven subjects (17.5%) achieved 
perfect “12” RDI scores (Table 5.9).  Nine subjects (22.5%) scored 1.3-2.9 SD below norm, 
indicating mild impairment; an additional 4 subjects (10%) scored 3 SD or more below normed 
data, indicating severe impairment for semantic memory.   
Summary of memory performance scores 
Seventeen subjects (42.5%) performed at or above normative means on all three HVLT 
subscales, indicating no impairment in the cognitive domain of memory (Table 5.10).  Fourteen 
subjects (35%) scored 1.3 SD or more below norm on two or more memory tests, indicating mild 
to severe impairment in the cognitive domain of memory.    
 
Table 5.10.    
Frequency of impairment (-1.3 SD or more below norm) on 3 tests of memory (n=40). 
 F % 
No impairment on any of 3 tests 17 42.5 
Impairment on 1 test  9 22.5 
Impairment on 2 tests  6 15.0 
Impairment on all 3 tests  8 20.0 
 
 
Attention. 
Selective and sustained attention was assessed by measuring information processing with 
the Trail Making Tests-Part A (Trails A) and Part B (Trails B), and the Symbol Digits Modalities 
Test (SDMT).  These are timed instruments, which rely on the subject’s cognitive flexibility to 
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(1) efficiently and rapidly scan the material, and (2) retrieve items from working memory when 
set shifting between items. 
Trail Making Test-Part A. 
 As shown in Table 5.11, subject performance times ranged from 20 to 185 seconds and 
averaged 41.08 seconds (SD 26.95), which is below time averages for all age and education level 
comparison groups.  Thirteen subjects (32.5%) performed at or above their comparison group.  
Three subjects (7.5%) required prompting to correct errors during the task, giving them 
prolonged performance times ranging from 78 to 185 seconds.  These three subjects also had 
cognitive performance impairments across all tests of attention and memory.  Eight subjects 
(20%) had time performances 1.3 SD or more below age and education-specific normed data and 
an additional 4 subjects (10%) had time performances more than 3 SD below norm.   
 
 
Table 5.11.   
Subject scores on measures of attention:  Trails A, Trails B, and SDMT (n=40). 
TRAILS A=Trail Making Test Part A; TRAILS B=Trail Making Test Part B; SDMT=Symbol Digits  
Modalities Test 
 
 
 
Trails Making Test-Part B. 
 Subject performance times ranged from 35 to 300 seconds (Table 5.11).  The average 
time was 98.15 seconds (SD 57.5), which is longer than performance time averages for 
normative age groups.  Nine subjects (22.5%) performed at or above their comparison group. 
Nearly half of the sample (n=18, 45%) required prompting to correct errors during the test.  Two 
 
 
Attention 
Tests 
 
 
Possible 
Range  
 
 
Actual 
Range 
 
 
 
M (SD) 
 
 
 
Median 
 
 
Skewness 
/Kurtosis 
-1.3-2.9 SD 
Below 
Norm 
F (%) 
<-3.0 SD 
Below 
Norm 
F (%) 
Trails A 0-300 20-185 41.1 (27.0) 35.00 4.18/21.39 8 (20.0)   4 (10.0) 
Trails B 0-300 35-300 98.2 (57.5) 75.50  2.29/6.16 7 (17.5) 12 (30.0) 
SDMT  0-110 44-61 43.9 (14.1) 46.00 -0.39/0.36 6 (15.0)    5 (12.5) 
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subjects (5%) could not complete the task in the maximum time allotment, so their times were 
capped at 300 seconds; these 2 subjects also had their times capped on the Trails A.   Seven 
subjects (17.5%) had performance times that were 1.3 SD or more below age and education-
specific normative comparisons, and a further 12 subjects (30%) were 3 SD or more below norm.   
Symbol Digits Modalities Test. 
Subject performance on the SDMT ranged from 11 to 73 correct substitutions, with an 
average of 43.9 (SD 14.1; Table 5.11).  Ten subjects (25.0%) performed at or above their 
comparison group .Eleven subjects (27.5%) had performance scores 1.5 SD or more below age 
and education-specific norms, and 5 of them (12.5%) had scores 3 SD or more below norm.  
 Summary for attention performance scores. 
As displayed in Table 5.11, more subjects had subnormal performance scores (1.3 SD or 
more below normative comparisons) on the Trails B (n=15, 37.5%) than on the SDMT (n=13, 
32.5%) and Trails A (n=9, 22.5%).    
Fifteen subjects (37.5%) scored within normed expectations on all three measures of 
attention (Table 5.12).  Eight subjects (20%) scored 1.3 SD or more below on one measure; 11 
subjects (27.5%) had performance scores 1.3 SD or more below on two or more measures of 
attention (signifying impairment in the cognitive domain of attention).  More subjects had 
difficulties on the Trails B (n=19, 47.5%) than on the other tests of attention.  Those who had 
difficulties on the SDMT tended to have difficulties on the Trails B.  The 3 subjects who 
exceeded time limits on Trails A had impaired cognitive performances on all tests of attention 
and memory.  Six subjects with impaired performances on tests of attention did not have 
impairments on tests of memory. 
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Table 5.12.    
Frequency of impairment (-1.3 SD or more below norm) on all 3 tests of attention (n=40). 
 F % 
No impairment on all 3 tests 21 52.5 
Impairment on 1 test   8 20.0 
Impairment on 2 tests   6 15.0 
Impairment on all 3 tests   5 12.5 
 
 
Verbal fluency.   
Controlled Oral Word Association Test (COWA). 
 Subject summation scores on the COWA ranged from 9 to 72 words for an average of 
38.07 words (SD 13.65; Table 5.13).  Fifteen subjects (37.5%) produced more words than the 
average of normative comparison groups.  Nine subjects (22.5%) had performance scores 1.3 SD 
or more below normative age and education-specific comparisons, indicating impairment in the 
domain of verbal fluency.   
 
Table 5.13.   
Subject scores on the COWA for verbal fluency (n=40). 
  COWA=Controlled Oral Word Association Test 
 
Summary of performance scores across all instruments.  
Global cognitive impairment may be determined by impaired performance scores on four 
or more tests on the neuropsychological battery (Lezak, Howieson, Bigler, & Tranel, 2012).   Six 
subjects (15%) performed at or above normed expected scores on all seven instruments.  Eleven 
subjects (22.5%) performed 1.3 SD or more below normative values on a single instrument 
(Table 5.14).  The performance scores for 17 subjects across all 7 instruments showed no 
 
Verbal 
Fluency 
Test 
 
 
Possible 
Range  
 
 
Actual 
Range 
 
 
 
Mean (SD) 
 
 
 
Median 
 
 
Skewness 
/Kurtosis 
-1.3-2.9 SD 
Below 
Norm 
F (%) 
<-3.0 SD 
Below 
Norm 
F (%) 
COWA Unlimited   9-72 38.1 (13.65) 40.50 0.03/0.03 8 (20%) 1 (2.5%) 
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evidence of global cognitive impairment.  The remaining 23 subjects scored 1.3 SD or more 
below norm on 2-3 instruments, n=13 or 4-7 instruments, n=10, indicating the presence of mild 
to severe cognitive impairment.  
 
 
Table 5.14.    
Frequency of subject performance impairment (1.3 SD or more below norm)  
across all seven tests (n=40). 
 F  % 
No impairment on all 7 tests    6 15.0 
Impairment on 1 test   11 22.5 
Impairment on 2-3 tests   13 32.5 
Impairment on 4-7 tests     10 25.0 
 
 
 
Shared Variance between ECF, Memory, and Attention.  
 Principal components analysis (PCA) was performed to assess the shared variance of the 
ECF construct and it’s components of memory and attention.  Subject performance scores on the 
EXIT-25 and standardized neuropsychological battery for memory (HVLT-IR and HVLT-DR), 
attention (TMT-A, TMT-B, and SDMT), and language (COWA) were used.   
Sampling adequacy to determine if data were likely to factor well was assessed by the 
Kaiser-Meyer-Olkin (KMO) and Bartlett’s test of sphericity (Pett, Lackey, & Sullivan, 2003).  
Adequate sampling is indicated by a KMO >.7 and significant Bartlett’s test.  The KMO for this 
sample was .80 and the Bartlett’s test was significant p>.001.   
An unrotated PCA maximizes the sum of squared factor loadings to explain all item 
variance and assumes there is: 1) no shared variance, 2) all items measure the latent variable, and 
3) there is no error (DeVellis, 2003).  Using the Kaiser criterion rule, only one factor had an 
eigenvalue >1.0 and explained 59.44% of the total variance.  Further, the Cattell scree plot test 
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suggested the presence of 2 or less factors.  Thus PCA extraction produced only one component 
to explain the variance in scores (Table 5.15).    
 
Table 5.15.  Component extraction matrix using PCA. 
Scale Component 
HVLT-IR    .81 
HVLT-DR  .82 
TMT-A -.74 
TMT-B -.84 
SDMT  .76 
COWA  .66 
EXIT-25 -.75 
 
Correlations between cognitive performance scores and subject characteristics. 
 
No significant associations were observed between age, education, gender, time since 
diagnosis, tumor characteristics (hemisphere, location, grade, or treatment type), self-reported 
physical functioning, depressive symptoms, or PBT-specific symptoms and performance scores 
for memory subscales(HVLT subscales) or verbal fluency (COWA).  The HVLT-DR subscale 
was associated with the MDASI Severity subscale, r=-.32, p=.04.  Thus, impairments in delayed 
recall were associated with more severe symptoms. 
Performance scores for tests of attention were significantly associated with subject self-
report of PBT-specific symptoms on the MDASI and FACT-BT.  The MDASI Symptom 
subscale was associated with the Trails A (r=.55, p>.001), Trails B (r=.47, p=.002), and SDMT 
(r=-.43, p=.005).  Thus, impaired performance on any of the three tests of attention was 
associated with severity of PBT-specific symptoms.  The FACT-BT Total scale score was 
associated with the Trails A (r=-.31, p=.05) and Trails B (r=-.39, p=.01).  Thus, impaired 
performance on either Trails test was associated with presence of more PBT-specific symptoms.  
 83 
 
Age was significantly associated with performance on the SDMT, r=-.52, p<.001, indicating that 
older subjects produced fewer correct substitutions than younger subjects; the association was 
limited to this single test of attention.  Education, time since diagnosis, tumor characteristics, 
self-reported physical function and depressive symptoms were not associated with attention 
performance scores.   
 
Executive control function. 
Executive control function was measured by calculating the Clinical Trials Battery 
Composite score (CTB Composite), the Trails Making Test Part B minus A Difference score 
(TMT Difference), and the Executive Interview-25 (EXIT-25).   
Clinical Trials Battery (CTB) Composite. 
The CTB is a z-score composite of performance scores for test of memory (HVLT 
subscales), attention (Trails A and B), and verbal fluency (COWA). It has been used as an index 
of global cognitive impairment (Johnson et al., 2012).  AS the PCA demonstrated only one factor 
for all tests in the neuropsychological battery, the CTB Composite scores may be used to indicate 
subject performance for ECF.  The CTB Composite score ranged from 0.8 to -8.1 and averaged -
1.2 (SD 1.6).  Since the CBT is derived from the z-scores on each neuropsychological 
instrument, scores > 0 indicate better cognitive function, and lower scores indicate cognitive 
impairment.  Five subjects (12.5%) had CTB Composite scores of 0 or higher 
 (Figure 5.3).  Twenty-five subjects (62.5%) had CTB Composite performance scores between -
0.1 and -1.4 SD.  Seven subjects (17.5%) had CTB Composite scores of -1.3 – 3.0, indicating 
mild to moderate impairment, and 3scored below –3, indicating severe impairment.  The bar 
graph in Figure 1 shows that most subject composite scores were below 0 (skewness -2.6 and 
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kurtosis 8.6).  Age, education, tumor characteristics, self-reported physical function, and PBT-
specific symptoms were not associated with CTB Composite scores.   
 
 
Figure 5.3.   
Distribution of CTB Composite scores (n=40). 
 
 
Trails Making Tests Difference score. 
The Trails Making Tests Difference z-score (TMT Difference) has been considered an 
indicator of impaired ECF because it controls for speed, motor control, and visual scanning.  The 
TMT Difference ranged from 0 to 222 seconds, with a median of 45 seconds and an average of 
57.1 seconds (SD 41.8).   Age and education specific normative scores for the Trails-A and 
Trails-B were used to calculate z-scores for the TMT Difference score, with z-scores > 0 
indicating better cognitive function and scores < 0 indicating cognitive impairment.  Fifteen 
subjects (37.5%) had TMT Difference scores > 0, indicating that their mean performance scores 
were at normed comparison levels or higher (Figure 5.4).   Six subjects (15%) had TMT 
Difference scores of -0.1 to -1.3.  Five subjects (12.5%) had CTB Composite scores between -1.3 
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to -3.0, indicating mild to moderate executive control dysfunction.  Fourteen subjects (30%) 
scored below -3 SD, indicating severe impairment. Figure 5.4 shows that the majority of TMT 
Difference scores were below 0 (skewness -1.10 and kurtosis 0.6).  Age, education, tumor 
characteristics, self-reported physical function, or PBT-specific symptoms were not associated 
with TMT Difference scores.   
 
Figure 5.4.  
 Distribution of TMT Difference Scores (n=40). 
 
 
 
Executive Interview-25. 
 Executive Interview-25 (EXIT-25) scores ranged from 1 to 17 with a median score of 5 
and a mean of 5.93 (SD 3.58).  No subject scored 0 indicating that every subject had at least one 
item error on the EXIT-25.  Eighteen subjects (45%) had performance scores of less than 5 
points, indicating no evidence of ECF impairment.  The majority of subjects accumulated 5 or 
more points (n=22, 55%), but only one subject (2.5%) had a performance score above 15.  The 
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scores for these 22 subjects indicate mild ECF impairment in 16 (40%) and severe in 6 (15%). 
Figure 5.5 shows the distribution of EXIT-25 scores with a skewness of 1.2 (kurtosis 1.3). 
 
 
Figure 5.5.   
Distribution of EXIT-25 scores  
 
 
 
Subject age correlated moderately with performance on the EXIT-25, r=.48, p=.002, with 
older subjects tending to have worse performance scores on the EXIT-25.  There were no 
significant relationships between education, time since diagnosis, tumor characteristics, self-
reported physical function, depression, or PBT-related symptoms with EXIT-25 performance.     
 
Comparison between CTB Composite and EXIT-25. 
To explore the EXIT-25 as a global measure for detecting impairments of ECF in adults 
with PBT, EXIT-25 performance scores were examined and compared to CTB Composite 
scores.  The EXIT-25 and CTB Composite scores were significantly associated, r=.60, p<.001.  
The EXIT-25 was also significantly associated with all of the standardized neuropsychological 
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tests for memory, attention, and verbal fluency, p<.005. Figure 5.6 demonstrates the relationship 
between the EXIT-25 and CTB Composite scores, R2=.36.  Eliminating the two outliers with 
CTB Composite scores >-5.0 did not improve the correlation (R2=.22).   
 
 
Figure 5.6.   
EXIT-25 performance scores by CTB Composite scores (n=40). 
 
 
 
Specific Aim 1 summary. 
Mild to severe impairment in the domain of memory impairment was found in more 
subjects (32.5%) than was found in the domain of attention (27.5%).  Impaired performance was 
found on the HVLT-DR for memory in 42.5% of subjects, and on the Trails B for attention in 
37.5%.  Verbal fluency was the least affected modality in these subjects, with only 22.5% 
demonstrating impairment. ECF integrates functions from multiple cognitive domains, and 
R2=0.36 
 88 
 
22.5% of subjects demonstrated mild-to-severe impairment as determined by the CTB 
Composite score.  The percentage of subjects rated as cognitively impaired varied greatly on the 
EXIT-25 depending on the cutoff score used (55% were rated as having mild-to-severe 
impairment using a cutoff score of 5, but only 15% using a  cutoff score of 10).  Because there is 
no established score indicating mild-to-moderate impairment on the EXIT-25, further research is 
indicated to establish its value as a cognitive screen in survivors of PBT. 
 89 
 
Specific Aim 2   
 
To describe self-reported ECF and its components in adults following treatment for PBT.  
This aim will be addressed by examining the following self-report instruments containing 
cognitive function items: 
a. Self-reported cognitive function  on the Everyday Cognitions Scale (ECog) by 
total scale scores and its six subscales 
b. Self-reported PBT-specific symptom assessment by total scale scores and 
cognitive item scores 
i. Functional Assessment of Cancer Therapy-Brain Tumor (FACT-BT) 
ii. MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) 
 
 
Aim 2 was explored using three self-reported instruments for cognitive function or 
presence of brain tumor specific symptoms:   
a) Everyday Cognitions Scale (ECog) uses a four-point scale to measure subject’s 
perception of change in their ability to perform everyday cognitive functions; lower 
scores indicate less change in cognitive function since diagnosis.   
b) Functional Assessment of Cancer Therapy – Brain Tumor Module (FACT-BT) uses a 
four-point scale to measure subject perception of symptoms and their impact on 
quality of life during the preceding week; higher scores indicate greater symptom 
presence and quality of life impact.  
c) MD Anderson Symptom Inventory – Brain Tumor Module (MDASI-BT) uses an 11-
point scale to measure subject perception of symptom severity and interference with 
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daily activities for their current health state at the time of subject report; lower scores 
indicate less symptom severity and interference in daily activities.   
 
Self-reported Executive Control Function: Everyday Cognitions Scale.  
Total scale scores for the Everyday Cognitions Scale (ECog) ranged from 1.00 to 3.29, as 
displayed on Table 5.16.  The average score of 1.87 (SD 0.64) represents a perceived change in 
everyday cognitive function since diagnosis graded as “occasionally worse.”  To aid in the 
interpretation of data, ECog subscale scores of 2 or higher were used to describe subject 
perception of change in cognitive function from “occasional problems” to “consistently much 
worse.”  Subject characteristics, including demographic variables and cancer-related factors, 
were explored to explain any differences observed in perceptions of cognitive function. The 
ECog has not been used before in PBT survivors, but it offers a more comprehensive assessment 
of self-reported cognitive function, so ECog scores were compared to PBT-specific symptom 
assessments, focusing on the cognitive items that each scale contains. 
Table 5.16 shows that subject scores varied across the subscales, with the greatest 
variability observed in tasks requiring attention, memory, and organizing.  The mean scores on 
the subscales ranged from 1.44 (SD 0.58) for the visuo-spatial subscale to 2.32 (SD 1.05) for the 
attention subscale.  Thus, most cognitive functions were perceived as being affected since their 
diagnosis.  Memory (M 2.28, SD 0.86) and attention (M 2.32, SD 1.05) functions were the most 
affected cognitive functions., and those requiring visuo-spatial (M 1.44, SD 0.58) and planning 
(M 1.49, SD 0.61) abilities were least affected.  The mean scores for ECog total and subscales 
are consistent with reference mean scores of elderly subjects with mild cognitive impairment 
(Farias et al., 2006, 2008).
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aPotential range of scores = 1-4; higher scores indicate more change in cognitive function since diagnosis. 
 
 
Seventeen subjects (42.5%) had ECog total scale scores of >2, indicating a change in 
their cognitive function” since diagnosis from “occasionally worse” to “much worse. Scores >2 
were most frequently reported for tasks requiring attention (n=24, 60%), memory (n=21, 52.5%), 
and language (n=18, 45%).  Less commonly reported were impairments of function related to 
organizing (n=13; 32.5%), planning (n=7, 17.5%), and visuo-spatial (n=6, 15%) domains.  
Correlations between self-reported ECF and subject characteristics. 
There were no significant associations between ECog total score or its subscales and 
subject characteristics for age, education, medications, tumor grade, or tumor location.  Time 
since diagnosis was significantly associated with ECog planning subscale, r=.36, p=.02, and 
approached significance with ECog organizing subscale, r=.26, p=.10.   Thus, subjects with 
longer survival times were more likely to report worsening cognitive functions involving 
planning and organizing.  Tumor hemisphere was significantly associated with the total ECog 
score (r=-.45, p<.05,) and subscales for memory (r=-.44), attention (r=-.31), visuospatial         
(r=-.37), planning (r=-.39), and organizing (r=-.51).  Thus, patients with right hemispheric 
lesions (n=20) were more likely to report more cognitive dysfunction since diagnosis than those 
with left hemispheric lesions. 
Table 5.16.   
Self-reported cognitive function on the Everyday Cognitions scale and 6 subscales (n=40). 
Domain Min – 
Maxa 
Mean SD Median Skewness Kurtosis 
Total 1-3.29 1.87 0.64 1.85 0.53 -0.28 
Memory 1-4.00 2.28 0.86 2.19 0.23 -1.05 
Language 1-3.50 1.93 0.71 1.81 0.57 -0.55 
Visuo-spatial 1-3.29 1.44 0.58 1.21 1.72 2.73 
Planning 1-3.20 1.49 0.61 1.30 1.52 1.77 
Organizing 1-4.00 1.75 0.86 1.33 0.97 -0.29 
Attention 1-4.00 2.32 1.05 2.13 0.24 -1.35 
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Several everyday cognitive functions were significantly associated with self-reported 
ability to perform activities of daily living.  Scores on the OARS total scale were significantly 
associated with cognitive functions reported on ECog total (r=-.41, p<.05), memory (r=-.34), 
language (r=-.32), visuo-perceptual (r=-.38), planning (r=-.33), and organizing (r=-.37) scales.  
In addition, scores on the OARS Instrumental subscale were significantly associated with 
cognitive functions reported on ECog total (r=-.45, p<.05), memory (r=-.38), attention (r=-.32), 
language (r=-.35), visuospatial (r=-042), planning (r=-.39), and organizing (r=-.40) scales.  
Subjects who reported needing more assistance with instrumental activities of daily living, such 
as driving or preparing meals, also reported worsening of everyday cognitive activities.   
The presence of depressive symptoms was significantly associated with the ECog total 
scale (r=.49, p<.05), memory (r=.43), attention (r=.47), language (r=.47), planning (r=.47), and 
organizing (r=.37) subscales.  Thus, subjects who reported the presence of depressive symptoms 
were more likely to report worsening of everyday cognitive function.   
 
Self-reported PBT-specific symptom assessment. 
The Functional Assessment of Cancer Therapy-Brain Tumor Scale (FACT-BT) and MD 
Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) were used for self-report of 
subject perception of symptom presence, severity, and interference in their current everyday 
health state.  Table 5.17 shows subject data for self-reported quality of life and symptom 
interference.  
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aFACT-BT=Functional Assessment of Cancer Therapy-Brain Tumor scale; lower scores indicate greater symptom 
impact on quality of life. 
bMDASI-BT=MD Anderson Symptom Inventory-Brain Tumor scale; higher scores indicate greater symptom 
severity/interference. 
 
 
Functional Assessment of Cancer Therapy-Brain Tumor Scale (FACT-BT). 
The range of scores on the FACT-BT was 85 to 183, with lower scores indicating greater 
impact of symptoms on quality of life.  The FACT-BT total score averaged 139.62 (SD 22.99), 
indicating subject perception that brain tumor related symptoms have a moderate impact on their 
quality of life (Table 5.17).  These scores are similar to the mean score of 136.0 (SD 26.0) found 
for the FACT-BT in 101 PBT survivors (Weitzner et al., 1995).  This reference sample was 
similar to the present study population in age (M 41.2 years), mixed tumor grade, education 
(14.7 years), and time since diagnosis of 0 to 247 months (M 32.1 months), and all had received 
surgery, chemotherapy, or radiation treatment.   
The FACT-BT contains 9 items that pertain to cognitive functions of concentration, 
memory, verbal fluency, organization, and planning.  Subject responses for these 9 cognitive 
items ranged from 10-32 and averaged 21.05 (SD 6.04).  Thus, subject responses reflect a 
perception that cognitive symptoms create a moderate impact on quality of life. 
 
 
Table 5.17.   
Self-reported quality of life and symptom interference for survivors of PBT (n=40). 
Scale  Potential 
Range 
Min – Max Mean (SD) Median 
FACT-BTa     
   Total Scale 0-184   85-183 139.62 (22.99)   143.5 
   Cognitive Items 0-36   10-36   21.05 (  6.04)     23.0 
MDASI-BTb     
   Severity Subscale 
   Interference Subscale 
0-10 
0-10 
    0-5.73 
    0-8.67 
    1.25    (1.19) 
    1.35    (1.93) 
      0.8 
      0.6 
   Cognitive Items 0-10     0-8.75     1.83    (2.02)       1.3 
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MD Anderson Symptom Inventory-Brain Tumor Scale (MDASI-BT). 
Scores on the MDASI-BT symptom severity subscale ranged from 0 to 5.73, and on the 
MDASI-BT symptom interference subscale, from 0 to 8.73; higher scores indicate greater 
symptom severity or interference.  Subjects reported average scores of 1.25 (SD 1.20) for 
symptom severity and 1.35 (SD 1.95) for symptom interference.  These scores indicate minimal 
symptom burden at time of study, and are slightly lower than mean reference scores of 1.52 for 
symptom severity and 2.1 for symptom interference in 151 PBT survivors (Armstrong et al., 
2006).  The reference sample was similar to the present study cohort in age (M 45.8 years), 
education (M 14.5 years), mixed tumor grade, and all had received surgery, chemotherapy, or 
radiation therapy. 
The MDASI-BT contains four items assessing cognitive symptom severity for memory, 
comprehension, verbal fluency, and concentration.  Subjects reported cognitive symptom scores 
ranging of 0 to 8.75, with an average of 1.8 (SD 2.0). This reflects mild cognitive symptom 
severity, but the average is slightly higher than the total symptom severity mean of 1.25, 
indicating slightly more symptom severity. 
Correlations between everyday cognitive function and cancer-related symptoms. 
The FACT-BT scores were significantly associated with scores for the ECog total        
(r=-.59, p<.05), memory (r=-.65), attention (r=-.47), language (r=-.51), visuospatial (r=-.38), 
planning (r=-.51), and organizing (r=-.36) subscales. Figure 5.7 plots subject scores on the ECog 
total against scores on the FACT-BT.  Similar significant associations were observed with the 
FACT-BT cognitive items and the ECog scores:  ECog total (r=-.69, p<.05), memory (r=-.68), 
attention (r=-.59), language (r=-.68), visuospatial (r=-.48), planning (r=-.62), and organizing   
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(r=-.41).  Thus, those who perceive greater symptom impact on their quality of life tend to report 
greater change in cognitive function since diagnosis.    
 
 
Figure 5.7.   
Self-reported symptom impact on quality of life versus cognitive function (n=40). 
 
Footnote:  Lower scores on the ECog reflect no change since diagnosis; lower scores on the FACT-BT reflect 
greater symptom impact on quality of life. 
 
 
The MDASI-BT symptom severity scores were significantly associated with the ECog 
total (r=.39, p<0.05), memory (r=.41), visuospatial (r=.37), planning (r=.33), and organizing 
(r=.33) scores.  Symptom interference scores on the MDASI-BT were also significantly 
associated with the ECog total (r=.38, p<.05), memory (r=.41), planning (r=.39), and attention 
(r=.34) scores.  Similar associations were observed for the MDASI-BT cognitive items and ECog 
 96 
 
total (r=.44), memory (r=.45), attention (r=.40), language (r=.35), and visuospatial (r=.40) scales.  
Thus, subjects who report greater symptom severity or symptom interference tend to report more 
change in cognitive function since diagnosis.  This is seen in Figure 5.8 with subject scores 
plotted for symptom severity versus cognitive function. 
 
 
Figure 5.8.   
Self-reported symptom severity versus cognitive function (n=40). 
 
Footnote:  Lower scores on ECog indicate no change since diagnosis; lower scores on MDASI-BT indicate less 
symptom severity. 
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Specific Aim 2 summary. 
 
Subjects tended to report “occasionally worse” cognitive function since their diagnosis.  
Tasks that required memory and attention were more frequently and more severely affected 
(“consistently worse” or “much worse”) since diagnosis.  Subjects who needed assistance with 
instrumental activities of daily living or who endorsed depressive symptoms were more likely to 
perceive changes in cognitive function as worse.  Subjects reported a moderate impact of 
symptom presence on their quality of life, yet these symptoms were not severe and did not 
interfere greatly with their daily activities.  This may reflect subjects’ adjustment to the impact of 
symptoms in their lives.   
Cognitive symptoms were similar across subjects, thus subjects who reported less change 
in cognitive function (ECog) also tended to report less cognitive symptom severity and less daily 
interference (MDASI-BT) or impact on their quality of life (FACT-BT).  This suggests that the 
ECog may be useful in this population because it provides a comprehensive assessment of 
perceived changes in cognitive function since diagnosis rather than the assessment of symptom 
presence during the preceding week (FACT-BT) or the severity of interference in their lives 
during the previous 24 hours (MDASI-BT).   
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Specific Aim 3  
 
To describe the relationship of ECF (executive control function) performance scores and 
subject self-report scores.  This aim will be addressed by exploring the congruence or 
incongruence of the following relationships:  
a. Clinical Trials Battery (CTB) Composite score and Everyday Cognitions Scale 
(ECog) total score  
b. Trails Making Tests Parts B-A Difference (TMT Difference) score and Everyday 
Cognitions Scale (ECog) total score 
c. Executive Interview-25 (EXIT-25) score and Everyday Cognitions Scale (ECog) 
total score  
 
 
 To describe how executive control function (ECF) performance relates to subject self-
report, scores on the Clinical Trials Battery Composite (CTB Composite), Trails Making Tests 
Difference Composite (TMT Difference), and Executive Interview-25 (EXIT-25) were compared 
to self-reported cognitive function scores on the Everyday Cognitions Test (ECog).  Scatterplots 
of subject scores were used to examine the relationship of cognitive performance (x-axis) and 
self-reported cognitive function (y-axis).  To describe subject patterns observed on the 
scatterplots, four quadrants were established using measurement cutpoints of –1.3 for CTB 
Composite score and -1.3 for TMT Difference score, 5 for EXIT-25 score, and 2 for ECog total 
score.  Each quadrant contains a group of subjects defined under Methods, Chapter 4, as: 
 1) Group A comprises subjects who report no change in cognitive function since 
diagnosis and whose ECF performance scores were within normal limits. 
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 2) Group B comprises subjects who report a change in cognitive function since 
diagnosis, but whose ECF performance was within normal limits. 
3) Group C comprises subjects who report no change in cognitive function since 
diagnosis, but who had poor ECF performance scores .  
4) Group D comprises subjects who report a change in cognitive function since 
diagnosis, and who had poor ECF performance scores  
 
The relationship of CTB Composite and ECog. 
 Inspection of the scatterplot of CTB Composite performance scores versus ECog Total 
scale scores (Figure 5.9) shows that the majority of subject scores (n=30, 75%) fell above the -
1.3 SD cutpoint line on the CTB Composite, indicating normal or acceptable cognitive function.  
Subject perception of change in cognitive function since diagnosis varied from “no change 
(ECog score of 1)” to “much worse (ECog score of 4)”; a score of 2 was set as the cutpoint for 
ECog.  The resulting assignment of subjects to quadrants A and D, represent congruence of 
cognitive performance with cognitive function perception, while quadrants B and C represent 
incongruence of measured to perceived function.  There was a low level of agreement between 
the CTB Composite and ECog Total scale scores (Overall Percent Agreement=.53; Kappa=.03), 
indicating that self-reported change in cognitive function is not reflected in measurement of 
impaired cognitive function. 
There were 21 subjects (52.5%) with congruence of self-report and performance scores 
(Groups A and D), and 19 subjects (47.5%) with incongruence of self-report and performance 
scores (Groups B and C).  Group A comprised 17 subjects (42.5%) who reported little or no 
change in cognitive function since diagnosis and had normal cognitive performance scores. 
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Group D comprised 4 subjects (10%) who reported a perception of cognitive function change 
since diagnosis and had poor cognitive performance. Group B comprised 13 subjects (32.5%) 
who reported a change in cognitive function since diagnosis but had normal cognitive 
performance scores. Group C comprised 6 subjects (15%) who reported little or no change in 
cognitive function yet performed poorly.   
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Figure 5.9.  Scatterplot of CTB Composite scores and ECog total scores (n=40). 
 
Group A=normal performance & self-report. Group B=normal performance but report change in cognitive function. 
Group C=poor performance but report no or little change in cognitive function. Group D=poor performance & 
report change in cognitive function. 
 
  
Table 5.18 looks at subject and tumor characteristics to explore differences across the 
four group categories.  Chi-square and Kruskal-Wallis tests were used to examine mean 
difference across groups.  Gender was significantly different across groups, χ2 (3)=8.7, p=.03; 
women formed a majority of Groups A and B while men were the majority in Groups C and D.  
Tumor location was significantly different between groups, χ2 (3)=12.6, p=.05, with tumors of 
the parieto-occipital or midbrain areas being more common than frontal or temporal lobe tumors 
in subjects in Group D.  Time since diagnosis was greater in Groups C and D with poorer 
performance, the differences between groups were not significant. No significant differences in 
age, education, tumor grade, medications, or treatment modalities were detected across groups.    
A C 
D B 
-1.3 SD 
cutpoint 
2.0 cutpoint 
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Table 5.18.   
CTB Composite and ECog Scores:  Subject and tumor-related characteristics by group 
categories (n=40). 
 Group Aa  
(n=17) 
Group Bb 
 (n=13) 
Group Cc 
 (n=6) 
Group Dd 
(n=4) 
Gender (F, %) 
     Male 
     Female 
 
  7 (41%) 
10 (59%) 
 
  3 (23%) 
10 (77%) 
 
4 (66%) 
2 (34%) 
 
4 (100%) 
0     
Age, in years (M, SD) 50.3 (9.7) 46.1 (9.7) 53.5 (8.7) 57.5 (6.5) 
Education, in years (M, SD) 15.3 (2.0) 14.6 (1.8) 14.7 (2.1) 16.5 (1.0) 
Time since diagnosis in months 
(M, SD) 
82.7 (75.3) 98.6 
(70.5) 
119.8 
(96.3) 
160.3 
(104.0) 
Tumor hemisphere (F, %) 
     Left 
     Right 
 
10 (59%) 
  7 (41%) 
 
  3 (23%) 
10 (77%) 
 
5 (83%) 
1 (17%) 
 
2 (50%) 
2 (50%) 
Tumor location (F, %) 
     Frontal 
     Temporal 
     Other 
 
9 (53%) 
5 (29%) 
3 (18%) 
 
7 (54%) 
4 (31%) 
2 (15%) 
 
3 (50%) 
1 (17%) 
2 (33%) 
 
0 
0 
4 (100%) 
Tumor Grade (F, %) 
     Low grade, grade 2 
     Transformed low grade 
     High grade, grade 3 
     High grade, grade 4 
 
4 (24%) 
1  (5%) 
8 (47%) 
4 (24%) 
 
1  (8%) 
2 (15%) 
6 (46%) 
4 (31%) 
 
0    
1 (17%) 
4 (66%) 
1 (17%) 
 
1 (25%) 
1 (25%) 
1 (25%) 
1 (25%) 
aGroup A=normal performance & self-report; bGroup B=normal performance but report change in cognitive 
function; cGroup C=poor performance but report normal cognitive function; dGroup D=poor performance & report 
change in cognitive function. 
 
 
Compared to other groups, subjects in Group A tended to report that cancer-related 
symptoms had less impact on their quality of life (FACT-BT), H(3)= 9.8, p=.02 Table 5.19.  
Group A also reported less impact of cognitive symptoms on quality of life FACT-BT cognitive 
items), H(3)= 14.6, p=.002, and less severe cognitive symptoms (MDASI-BT cognitive items), 
H(3)= 6.6, p=.09.  There was a significant difference in reported depressive symptoms     
(CESD-R), H(3)= 8.1, p=.04, across groups.  Group A reported fewer depressive symptoms and 
Group B, more.  Subjects in Group D reported needing more assistance with activities of daily 
living (OARS Physical subscale), H(3)= 7.9, p=.05.  While the difference was not significant, 
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Group D reported a greater impact of symptoms on their quality of life (FACT-BT, MDASI 
Interference).   
Table 5.19.   
CTB Composite and ECog Scores:  Self-reported symptom assessments by group categories 
(n=40). 
       Group Aa 
     (n=17) 
    M (SD) 
       Group Bb 
     (n=13) 
     M (SD) 
        Group Cc 
       (n=6) 
        M (SD) 
        Group Dd 
        (n=4) 
         M (SD) 
FACT-BT  
     Total 
     Cognitive Items 
 
152.4 (18.6) 
27.6 (5.1) 
 
128.2 (20.5) 
19.3 (5.7) 
 
136.8 (29.1) 
22.3 (7.7) 
 
126.8 (14.5) 
16.5 (4.4) 
MDASI-BT      
     Severity 0.8 (0.6) 1.5 (1.0) 1.8 (2.0) 1.7 (1.8) 
     Interference 0.6 (0.6) 1.5 (1.5) 1.3 (1.5) 4.1 (4.5) 
     Cognitive Items 0.9 (0.8) 2.3 (1.9) 2.5 (3.3) 3.4 (2.8) 
 
CESD-R  6.4 (5.7) 15.5 (10.7) 10.5 (6.3) 10.3 (4.4) 
OARS 
     Total 
     Physical 
     Instrumental 
 
 27.4 (1.4) 
13.9 (0.5) 
13.5 (1.0) 
 
26.8 (1.5) 
13.9 (0.3) 
12.9 (1.3) 
 
27.3 (1.0) 
14.0 (0.0) 
13.3 (1.0) 
 
26.0 (2.3) 
13.3 (1.0) 
12.8 (1.5) 
FACT-BT=Functional Assessment of Cancer Therapy-Brain Tumor; MDASI-BT=MD Anderson Symptom 
Assessment-Brain Tumor; CESD-R=Center for Epidemiologic Studies Depression Scale-Revised; OARS=Older 
Americans Resources and Services Activities of Daily Living Scale. 
aGroup A=normal performance & self-report; bGroup B=normal performance but report change in cognitive 
function; cGroup C=poor performance but report normal cognitive function; dGroup D=poor performance & report 
change in cognitive function. 
 
 
The relationship of TMT Difference and ECog. 
Figure 5.10 shows the TMT Difference scores for cognitive performance and the ECog 
scores for self-reported cognitive function.  There was more spread of subject scores on this 
scatterplot compared to Figure 5.10.  The majority of subjects (n=25, 62.5%) remained within 
their groupings of A through D derived from Figure 5.9, but15 subjects moved across groups: 7 
subjects moved from Group A to C, 2 subjects moved from Group C to A, 5 subjects moved 
from Group B to D, and 1 subject moved from Group D to B.  Thus, twelve subjects with 
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acceptable CTB Composite scores had TMT Difference scores consistent with mild to severe 
impairment.  Likewise, three subjects moved from impaired CTB Composite scores to an 
acceptable range on TMT Difference score. 
 
 
Figure 5.10.   
Scatterplot of TMT Difference scores and ECog total scores (n=40). 
 
Group A=normal performance & self-report. Group B=normal performance but report change in cognitive function.  
Group C=poor performance but report no or little change in cognitive function. Group D=poor performance & 
report change in cognitive function. 
 
 
The cutpoint scores of 2 on the ECog for self-reported cognitive function and -1.3 SD on 
the TMT Difference composite (z-score) for cognitive performance were used define groups of 
subjects with congruent and incongruent scoring patterns.  There was a low level of agreement 
B 
C 
D 
A 
-1.3 SD 
cutpoint 
2.0 cutpoint 
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between the TMT Difference and ECog Total scale scores (Overall Percent Agreement=.50; 
Kappa=.01). 
Twenty subjects (50%) had congruent TMT Difference performance scores and self-
reported cognitive function scores, and 20 subjects (50%) had incongruent scores.  The 
congruent groups comprised 12 subjects (30%) in Group A who indicated relatively no change in 
cognitive function since diagnosis and had acceptable cognitive performance, and 8 subjects 
(20%) in Group D who reported a change in cognitive function since diagnosis and had poor 
cognitive performance.  For incongruent scores, 9 subjects (22.5%) in Group B reported 
worsening of cognitive function since diagnosis but had acceptable cognitive performance, and 
11 subjects in Group C (27.5%) who reported relatively no change in cognitive function but had 
poor cognitive performance by TMT Difference score.   
Table 5.20 shows the gender, age, education, and tumor-specific characteristics across 
groups. No significant differences between groups were detected by Chi-square or Kruskal-
Wallis analyses.  There was a trend toward longer time since diagnosis in Group D, however this 
was not statistically significant.  This trend was similar to that observed with the CTB Composite 
groups.   
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Table 5.20.   
TMT Difference and ECog Scores:  Subject and tumor-related characteristics by group 
categories (n=40). 
 Group Aa 
(n=12) 
Group Bb 
(n=9) 
Group Cc 
(n=11) 
Group Dd 
(n=8) 
Gender (F, %) 
     Male 
     Female 
 
5 (42%) 
7 (58%) 
 
3 (33%) 
6 (67%) 
 
6 (55%) 
5 (45%) 
 
4 (50%) 
4 (50%) 
Age in years (M, SD) 50.9 (8.1) 47.9 (11.6) 51.4 (11.0) 49.8 (9.1) 
Education in years (M, SD0 15.3 (2.3) 15.3 (1.4) 14.9 (1.6) 14.8 (2.1) 
Time since diagnosis in months 
(M, SD) 
84.5 (83.6) 78.9 (64.7) 101.0 (80.5) 151.6 (82.6) 
Tumor hemisphere (F, %) 
     Left 
     Right 
 
9 (75%) 
3 (25%) 
 
2 (22%) 
7 (78%) 
 
6 (55%) 
5 (45%) 
 
3 (38%) 
5 (62%) 
Tumor location (F, %) 
     Frontal 
     Temporal 
     Other 
 
5 (42%) 
3 (25%) 
4 (33%) 
 
4 (45%) 
2 (22%) 
3 (33%) 
 
7 (64%) 
3 (27%) 
1 (  9%) 
 
3 (38%) 
2 (24%) 
3 (38%) 
Tumor Grade (F, %) 
     Low grade, grade 2 
     Transformed low grade 
     High grade, grade 3 
     High grade, grade 4 
 
2 (17%) 
1   (8%) 
5 (42%) 
4 (33%) 
 
0 
2 (22%) 
4 (45%) 
3 (33%) 
 
2 (18%) 
1 (  9%) 
7 (64%) 
1 (  9%) 
 
2 (24%) 
1 (14%) 
3 (38%) 
2 (24%) 
aGroup A=normal performance & self-report; bGroup B=normal performance but report change in cognitive 
function; cGroup C=poor performance but report normal cognitive function; dGroup D=poor performance & report 
change in cognitive function. 
 
 
Self-reported symptoms (Table 5.21) were similar to those observed with the CTB 
Composite groups.  Group A tended to report less impact of symptoms on their quality of life 
(FACT-BT), H(3)= 10.6, p=.01, and less severity of symptoms (MDASI-BT), H(3)= 7.3, p=.06.  
Group A also reported less impact of cognitive symptoms (FACT-BT cognitive items), H(3)= 
14.6, p=.002.  Group D tended to report the greatest impact of cognitive symptoms on quality of 
life.  There was a significant difference in depressive symptoms (CESD-R), H(3)= 6.7, p=.08, 
with Group A reporting fewer symptoms, and Group B reporting more .   
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Table 5.21.   
TMT Difference and ECog Scores:  Self-reported symptom assessments by group categories 
(n=40). 
 Group Aa  
(n=12) 
M (SD) 
Group Bb 
 (n=9) 
M (SD) 
Group Cc 
 (n=11) 
M (SD) 
Group Dd 
(n=8) 
M (SD) 
FACT-BT 
     Total 
     Cognitive Items 
 
154.5 (16.9) 
27.5 (  4.2) 
 
129.6 (19.9) 
20.2 (  5.8) 
 
140.3 (26.4) 
24.5 (  8.0) 
 
125.3 (184.) 
16.4 (  4.3) 
MDASI-BT     
     Severity 0.6 (0.5) 1.6 (1.0) 1.7 (1.6) 1.4 (1.5) 
     Interference 0.6 (0.6) 2.0 (2.7) 1.0 (1.2) 2.3 (2.7) 
     Cognitive Items 0.9 (0.9) 2.2 (1.7) 1.8 (2.6) 3.1 (2.6) 
 
CESD-R 6.5 (5.4) 14.7 (10.8) 8.8 (6.8) 13.7 (8.8) 
OARS 
     Total 
     Physical 
     Instrumental 
 
27.5 (1.0) 
14.0 (0.0) 
13.5 (1.0) 
 
27.0 (1.4) 
13.9 (0.3) 
13.1 (1.2) 
 
27.3 (1.6) 
13.8 (0.6) 
13.5 (1.0) 
 
26.3 (1.9) 
13.6 (0.7) 
12.6 (1.5) 
FACT-BT=Functional Assessment of Cancer Therapy-Brain Tumor; MDASI-BT=MD Anderson Symptom 
Assessment-Brain Tumor; CESD-R=Center for Epidemiologic Studies Depression Scale-Revised; OARS=Older 
Americans Resources and Services Activities of Daily Living Scale. 
aGroup A=normal performance & self-report; bGroup B=normal performance but report change in cognitive 
function; cGroup C=poor performance but report normal cognitive function; dGroup D=poor performance & report 
change in cognitive function. 
 
 
 
The relationship of EXIT-25 and ECog. 
Figure 5.11 shows an even greater dispersion of subject scores than the previous two 
scatterplots.  When comparing subject assignment to groups in Figure 5.10, there was substantial 
movement (n=18, 45%) across the groups.  Five subjects moved from Group B to D, 2 subjects 
moved from Group D to B, 9subjects moved from Group A to C, and 2 subjects moved from 
Group C to A.As a result, 14 subjects with acceptable CTB Composite scores had impaired 
EXIT-25 scores, and 4 subjects with impaired CTB Composite scores had normal EXIT-25 
scores.   
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Figure 5.11.   
Scatterplot of EXIT-25 performance scores and ECog total scores (n=40). 
 
Group A=normal performance & self-report. Group B=normal performance but report change in cognitive function. 
Group C=poor performance but report no or little change in cognitive function. Group D=poor performance & 
report change in cognitive function. 
 
 
 
The cutpoint scores of 2 on the ECog and 5 on the EXIT-25 were used define groups of 
subjects with congruent and incongruent scoring patterns.  There was a low level of agreement 
between the EXIT-25 and ECog Total scale scores (Overall Percent Agreement=.48; 
Kappa=.06). 
Nineteen subjects had congruent patterns in scores, and 21, incongruent patterns.  Group 
A contained 12 subjects (30%) with congruence between ECog Total scale scores and the EXIT-
25.  Group D, also congruent, had 7 subjects (17.5%).  The incongruent Group B had 10 subjects 
who performed well on the EXIT-25 but reported a change in cognitive function since diagnosis, 
A 
B D 
C 
* 
2.0 cutpoint 
cutpoint 
score of 5 
 109 
 
and Group C had 11 subjects (27.5%) who reported relatively little or no change in cognitive 
function since diagnosis yet performed poorly on the EXIT-25.    
Table 5.22 shows group similarities for subject and tumor-related characteristics; Chi-
square and Kruskal-Wallis analyses were used to determine significant differences across groups. 
Groups C and D, who performed poorly on the EXIT-25, tended to be older, H(3)=11.4, p=.01. 
Time since diagnosis was longer for those in Groups B and C, but not significantly different 
from Groups A and D.  Tumor location by hemisphere was the only tumor –related characteristic 
that was significant between groups, H(3)=8.5, p=.03, with more right hemispheric tumor 
locations in Group B.   
 
Table 5.22.   
EXIT-25 and ECog Scores:  Subject and tumor-related characteristics by group categories 
(n=40). 
 Group Aa 
(n=12) 
Group Bb 
(n=10) 
Group Cc 
(n=11) 
Group Dd 
(n=7) 
Gender (F, %) 
     Male 
     Female 
 
5 (42%) 
7 (58%) 
 
3 (30%) 
7 (70%) 
 
6 (55%) 
5 (45%) 
 
4 (57%) 
3 (43%) 
Age in years (M, SD) 47.2 (8.0) 43.9 (9.5) 55.5 (9.1) 55.7 (6.8) 
Education in years (M, SD) 15.0 (2.2) 15.2 (1.7) 15.3 (1.8) 14.9 (2.0) 
Time since diagnosis in months (M, 
SD) 
63.0 (50.9) 125.7 (79.8) 124.5 (96.5) 95.1 (84.1) 
Tumor hemisphere (F, %) 
     Left 
     Right 
 
8 (64%) 
4 (33%) 
 
1 (10%) 
9 (90%) 
 
7 (64%) 
 4 (36%) 
 
4 (57%) 
3 (43%) 
Tumor location (F, %) 
     Frontal 
     Temporal 
     Other 
 
5 (42%) 
3 (25%) 
4 (33%) 
 
6 (60%) 
1 (10%) 
3 (30%) 
 
7 (64%) 
3 (27%) 
1   (9%) 
 
1 (14%) 
3 (43%) 
3 (43%) 
Tumor Grade (F, %) 
     Low grade, grade 2 
     Transformed low grade 
     High grade, grade 3 
     High grade, grade 4 
 
3 (25%) 
1   (9%) 
4 (33%) 
4 (33%) 
 
2 (20%) 
2 (20%) 
5 (50%) 
1 (10%) 
 
1   (9%) 
1   (9%) 
8 (73%) 
1   (9%) 
 
0 
1 (14%) 
2 (29%) 
4 (57%) 
aGroup A=normal performance & self-report; bGroup B=normal performance but report change in cognitive 
function; cGroup C=poor performance but report normal cognitive function; dGroup D=poor performance & report 
change in cognitive function. 
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Self-reported symptoms (Table 5.23) were similar to those observed with the CTB 
Composite and TMT Difference groups.  Group A reported less impact of symptoms on their 
quality of life (FACT-BT), H(3)= 10.2, p=.02, and less symptom severity (MDASI-BT), H(3)= 
7.8, p=.05.  Subjects in Group A also reported less impact of cognitive symptoms on their quality 
of life (FACT-BT cognitive items), H(3)= 16.0, p=.001, and less cognitive symptom severity 
(MDASI-BT),  H(3)= 11.4, p=.01, while Group D subjects reported the greatest cognitive 
symptom severity (MDASI-BT). Depressive symptoms (CESD-R) were significantly different, 
H(3)= 6.3, p=.09, with Group A reporting fewer and Group B reporting more depressive 
symptoms.  Group B also reported requiring more physical assistance with activities of daily 
living (OARS Physical subscale), H(3)= 7.9, p=.05.    
 
Table 5.23.   
EXIT-25 and ECog Scores:  Self-reported symptom assessments by group categories (n=40). 
 Group Aa  
(n=12) 
M (SD) 
Group Bb 
 (n=10) 
M (SD) 
Group Cc 
 (n=11) 
M (SD) 
Group Dd 
(n=7) 
M (SD) 
FACT-BT 
     Total 
     Cognitive Items 
 
155.1 (20.9) 
28.9 (  4.8) 
 
127.3 (16.7) 
18.5 (  4.3) 
 
141.0 (22.1) 
23.3 (  6.2) 
 
128.6 (22.9) 
18.9 (  7.1) 
MDASI-BT     
     Severity 0.6 (0.5) 1.5 (1.3) 1.6 (1.5) 1.6 (0.9) 
     Interference 0.5 (0.6) 2.4 (2.3) 1.0 (1.1) 1.7 (3.1) 
     Cognitive Items 0.6 (0.7) 2.0 (2.2) 2.1 (2.4) 3.4 (1.8) 
 
CESD-R 7.0 (6.2) 16.0 (12.1) 8.0 (6.1) 11.9 (4.6) 
OARS 
     Total 
     Physical 
     Instrumental 
 
27.7 (0.9) 
14.0 (0.0) 
13.7 (0.9) 
 
26.8 (1.9) 
13.6 (0.7) 
13.2 (1.3) 
 
27.1 (1.6) 
13.8 (0.6) 
13.3 (1.1) 
 
26.4 (1.3) 
14.0 (0.0) 
12.4 (1.2) 
FACT-BT=Functional Assessment of Cancer Therapy-Brain Tumor; MDASI-BT=MD Anderson Symptom 
Assessment-Brain Tumor; CESD-R=Center for Epidemiologic Studies Depression Scale-Revised; OARS=Older 
Americans Resources and Services Activities of Daily Living Scale. 
aGroup A=normal performance & self-report; bGroup B=normal performance but report change in cognitive 
function; cGroup C=poor performance but report normal cognitive function; dGroup D=poor performance & report 
change in cognitive function. 
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Correlations: ECF performance and self-report. 
 Performance scores for the CTB composite and self-reported ECog scores were not 
correlated, r=.13, p=.41.  Performance scores for the TMT Difference z-scores and self-reported 
ECog scores were not correlated, r=-.20, p=.22.  Performance scores for the EXIT-25 and self-
reported ECog total scores were not correlated, r=.02, p=.91.   
The relationship between cognitive performance and self-reported cognitive function was 
explored by looking at the correlation of specific instruments measuring cognitive performance 
with self-reported cognitive function. Five significant correlations were found between 
measurements of ECF performance and self-reported cognitive function (ECog subscales).  The 
HVLT-IR subscale for working memory was associated with the ECog organizing subscale, 
r=.32 (p<.05).  The HVLT-RDI subscale for memory recognition was associated with the ECog 
total scale (r=.31, p<.05), planning subscale (r=.33, p<.05), organizing subscale (r=.38, p<.05), 
and attention subscale (r=.38, p<.05).  These associations reflect subjects’ perception of an 
increased demand on executive control functions for the performance of memory tasks. 
 
Specific Aim 3 summary. 
  
The three cognitive performance composites (CTB Composite, TMT Difference, and 
EXIT-25) were not significantly associated with self-reported cognitive function (ECog) scores, 
validating the discrepancy between self-report and actual performance.  Examination of the 
relationship of the three measures of ECF performance (CTB Composite, TMT Difference 
Composite, and EXIT-25 scores) with self-reported ECF (as measured by the ECog Total score) 
led to the construction of the 4 subject groups, A through D.  The majority of subjects fell into 
Groups A and B because they had better cognitive performance scores.    
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Group A included more female subjects between 40 to 60 years of age with college 
education.  They tended to participate in the study 6 years after diagnosis and most had high 
grade tumors with predominately a left frontal location.  This group of subjects tended to report 
fewer brain tumor-specific and depressive symptoms, less symptom severity, less impact of 
symptoms on their quality of life, and being able to perform most activities of daily living 
without needing assistance.  This group demonstrates adaptation to their diagnosis with the 
ability to maintain everyday function. 
Group B also had more female subjects with ages between 35 to 55 years of age and 
some college or technical training.  These subjects had a longer time since diagnosis (8 years), 
and more right frontal, high grade tumors.  Although they reported that their brain tumor specific 
symptoms were not severe, and that they did not need assistance with activities of daily living, 
they tended to report more depressive symptoms. 
Group C contained more men whose ages ranged from 45 to 62 years and who had 
completed some college or technical training.  Their time since diagnosis was longer (M 10 
years), and they predominately had left hemisphere, high grade tumors.  In addition to denying 
changes in cognitive function since diagnosis, they also reported few brain tumor specific or 
depressive symptoms that impacted their quality of life. 
Group D subjects were older men (ages 51 to 64 years) who had a college education.  
Time since diagnosis was generally the longest in this group, averaging 13 years.  They reported 
the most brain tumor specific symptoms, and required assistance with activities of daily living. 
While the scores for the CTB Composite and TMT Difference were similar across 
subjects, there was variability in the distribution self-reported cognitive function scores (ECog) 
and cognitive performance on the EXIT-25.  The EXIT-25 lacks accuracy in determining 
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presence of cognitive impairment when used with a cutpoint score of 5.  In addition, 10% of 
impaired performances as determined by the CTB Composite were not detected on the EXIT-25.  
Further exploration of item discrimination for executive control dysfunction and the appropriate 
cutpoint score for cognitive impairment in this population before the EXIT-25 can be 
recommended for use as a screen for cognitive function.  
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Specific Aim 4 
 
To explore whether cognitive reserve or compensatory behaviors explain the congruence 
or incongruence between cognitive performance scores and subject self-reported change 
in cognitive function scores.  This aim will be addressed by two items: 
a.  Cognitive reserve as measured by the Hollingshead Index 
b.  Compensatory behaviors as measured by the Florida Cognitive Activities Scale 
 
This specific aim explored whether cognitive reserve (CR) or lack of CR might explain 
the observed congruence or incongruence between subject self-reported cognitive function and 
actual performance.  Analyses for Specific Aim 4 involved the examining the relationship of: 1) 
cognitive performance to CR, 2) self-reported change in cognitive function to CR, and 3) 
congruence-incongruence between performance and self-reported change in cognitive function 
by CR.  Scatterplots, correlations, t-tests, and non-parametric statistics were used to explore 
differences between congruent scores, (Group A and D), and incongruent scores, Group B and C, 
(as described in Specific Aim 3) by CR. Changes in cognitive activities since diagnosis that 
might illustrate compensatory behaviors were derived from structured interviews using the 
Florida Cognitive Activities Scale in a subset of the sample.  
Cognitive reserve is the process of optimizing cognitive performance through recruitment 
of neural networks to cope with or compensate for the cognitive demands of maintaining 
function (Stern, 2009).  Cognitive reserve has been used to explain variations in cognitive 
function between individuals with similar neuropathology. Those with higher cognitive reserve 
have demonstrated greater efficiency and neural flexibility for coping or compensating with the 
cognitive effects from cancer and its treatment (Ahles et al., 2010).  The most commonly used 
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measures of cognitive reserve include premorbid intelligence, educational achievement, and 
occupational attainment (Jones, et al., 2011).   
Two instruments were used in the present study to examine the CR proxies: the North 
American Adult Reading Test (NAART); (Blair & Spreen, 1987, 1989) for estimating premorbid 
intelligence, and the Hollingshead 2-Factor Index of Social Classification (Hollingshead Index) 
(Hollingshead, 1957) for measuring educational and occupational attainment.  Spreen and 
Strauss (2006) recommend excluding NAART performance scores when they meet 2 criteria in 
subjects with neuropathology: correct scores < 28, and correct scores > 15 points below expected 
age and education normative data.  Twenty percent (n=9) of this study’s sample met these 
exclusion criteria (Appendix J).  Given these limitations, the Hollingshead Index was used as the 
primary measure for CR.  The Hollingshead Index is a measure of socioeconomic status based on 
educational and occupational attainment.  The Hollingshead Index scores ranges from 11 to 77, 
with higher scores indicating less educational and occupational attainment.  This sample had a 
mean Hollingshead Index of 31.75 (SD 11.6), which served as the cutpoint between high and low 
CR.   
 
Cognitive performance by high and low CR. 
Performance scores for each instrument in the neuropsychological battery and the CTB 
Composite were assessed by t-test for differences between high and low CR groups (Table 5.24).  
Those with high CR had better performance scores across all seven instruments for memory, 
attention, verbal fluency, and CTB Composite scores.  The COWA performance scores were 
significantly higher in those with high CR, t(38)=-2.01, p=.05.  No other significant differences 
were observed between high and low CR groups.
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Table 5.24. 
Cognitive performance scores by cognitive reserve group (n=40). 
 Potential Low CR High CR 
Instrument Range Min-Max Mean SD Min-Max Mean SD 
CTB Comp Unlimited -8.10-0.40 -1.56 2.09 -3.0-0.80 -0.82 0.97 
HVLT-IR 0-36 6-34 22.89 7.79 14-33 24.57 4.69 
HVLT-DR 0-12 0-12 7.11 3.53 2-12 8.29 2.72 
HVLT-RDI 0-12 4-12 9.37 2.36 4-10 9.76 2.30 
Trails A 0-300 20-185 44.21 36.36 20-80 38.24 14.46 
Trails B 0-300 35-300 112.63 73.18 40-180 85.05 35.46 
SDMT 0-110 12-65 41.16 14.59 11-73 44.95 14.30 
COWA* Unlimited 9-55 33.68 12.83 22-72 42.05 13.43 
*p<.05. 
CR=Cognitive Reserve; CTB Comp=Clinical Trials Battery Composite; HVLT-IR=Hopkins Verbal Learning Test-
Immediate Recall; HVLT-IR=Hopkins Verbal Learning Test-Delayed Recall; HVLT-RDI=Hopkins Verbal 
Learning Test-Recognition Discrimination Index; Trails A=Trails Making Test Part A; Trails B=Trails Making Test 
Part B; SDMT=Symbol Digit Modalities Test; COWA=Controlled Oral Word Association test. 
 
 
Table 5.25 displays the number of subjects with impaired cognitive performance scores 
on the CTB Composite and each instrument according to low or high CR.  The number of 
subjects with performance z-scores of 1.3 or more below normative comparison scores was 
similar in both CR groups.  Three subjects with high CR and 3 subjects with low CR had no 
observed impairment on any of the cognitive tests. The smallest number of subjects with 
impairment was noted for verbal fluency test (COWA scores) in both high and low CR groups.   
Compared to those with high CR, subjects with low CR had more severe impairment (scores 3 
SD or more below normed comparison groups). 
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Table 5.25.   
Number of subjects with mild to severe cognitive impairment by instrument for high and low 
cognitive reserve groups (n=40). 
  Frequency (%) 
 Low CR (n=19) High CR (n=21) 
Instrument Below -1.3 
SD 
Below -3 
SD 
Total Below -1.3 
SD 
Below -3 SD Total 
CTB Comp 3 (16) 3 (16)  6 (32) 3 (14)    1 (  5) 4 (19) 
HVLT-IR 2 (11) 5 (26)  7 (37) 7 (34)    1 (  5) 8 (39) 
HVLT-DR 6 (32) 3 (16)  9 (48) 6 (29)    2 (10) 8 (39) 
HVLT-RDI 5 (26) 1 (  5)  6 (32) 4 (19)     2 (10) 6 (29) 
Trails A 3 (16) 2 (11)  5 (26) 5 (24)     2 (10) 7 (34) 
Trails B 3 (16) 8 (42) 11 (58) 4 (19)     4 (20) 8 (39) 
SDMT 2 (11) 4 (22)  6 (33) 4 (19)     1 (  5) 5 (24) 
COWA 4 (21) 1 (  5)  5 (26) 4 (19)             0 4 (19) 
CR=Cognitive Reserve; CTB Comp=Clinical Trials Battery Composite; HVLT-IR=Hopkins Verbal Learning Test-
Immediate Recall; HVLT-IR=Hopkins Verbal Learning Test-Delayed Recall; HVLT-RDI=Hopkins Verbal 
Learning Test-Recognition Discrimination Index; Trails A=Trails Making Test Part A; Trails B=Trails Making Test 
Part B; SDMT=Symbol Digit Modalities Test; COWA=Controlled Oral Word Association test 
 
 
Self-reported cognitive function (ECog) by high and low CR. 
Table 5.26 displays subject self-reported change in cognitive function since diagnosis 
(ECog), classified by high or low CR.  Differences in performance were assessed by t-tests. 
Subjects with high CR reported less change in everyday function since diagnosis compared to 
those with low CR.  Subjects reported more change since diagnosis (higher scores) in memory 
and attention than in other subscales of the ECog.  Mean scores for attention, t(38)=2.46, p=.02, 
memory, t(38)=1.32, p=.008, and total score, t(38)=1.99, p=.05, were significantly lower for 
those with high CR, indicating they perceived less change in function since diagnosis.
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Table 5.26. 
Self-reported cognitive function on the ECog by high and low CR (n=40). 
 Low CR High CR 
Domain Min-Maxa Mean SD Min-Maxa Mean SD 
Total* 1.08-3.37 2.08 .72 1.00-2.63 1.69 .52 
Memory* 1.13-4.00 2.65 .87 1.00-2.63 1.95 .70 
Language 1.00-3.50 2.09 .82 1.00-3.13 1.79 .58 
Visuo-spatial 1.00-3.20 1.53 .69 1.00-2.43 1.35 .47 
Planning 1.00-3.29 1.64 .77 1.00-2.00 1.34 .39 
Organizing 1.00-3.40 1.83 .91 1.00-4.00 1.67 .84 
Attention* 1.00-4.00 2.72 1.14 1.00-3.75 1.92 .84 
*p<.05 
aPotential range of scores is 1- 4.   
CR=cognitive reserve; ECog=Everyday Cognition Scale. 
 
Table 5.27 shows the number (frequency) of subjects reporting changes in cognitive 
function, ECog score >2 by high and low CR.  Memory, attention, language, and global 
cognitive functions were changed since diagnosis for more subjects with low CR as compared to 
those with high CR.    
 
aScale mean score of 2 or greater to indicate impairment.   
ECog=Everyday Cognition Scale; CR=cognitive reserve. 
 
  
 
Table 5.27.    
Number of subjects reporting perceived change in function since diagnosisa on the 
ECog by high and low CR (n=40). 
 
 Low CR (N=19) High CR (N=21)  
Domain Freq % Freq %   
Total 10 53 7 33   
Memory 14 74 9 43   
Language 10 53 8 38   
Visuo-
Perceptual 
3 16 3 14   
Planning 4 21 3 14   
Organizing 7 37 5 24   
Attention 13 68 12 57   
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High and Low CR summary. 
In summary, the Hollingshead Index was used to categorize subjects into high and low 
cognitive reserve groups.  Across all subjects, cognitive performance scores and reported change 
in cognitive function predominantly affected the domains of memory and attention.  While an 
equal number of subjects with high and low CR had impaired performance scores, more of those 
with low CR had severe cognitive impairment (-3 SD or more).  Subjects with low CR also 
reported experiencing more change in cognitive function since diagnosis as compared to those 
with high CR. 
 
 
Congruence between cognitive performance and self-reported cognitive function by 
high and low CR. 
 
These analyses used CTB Composite scores for cognitive performance and ECog total 
scale scores for self-reported cognitive function to categorize congruence or incongruence in 
those with high or low CR.  Similar to the analyses in Specific Aim 3, scatterplots of subject 
scores were used to examine the relationship of cognitive performance (x-axis) and self-reported 
cognitive function (y-axis). The cutpoint for CTB Composite scores was set at -1.3 and for ECog 
scores, at 2.0. This created four quadrants, labeled as Groups A through D, to establish 
congruence or lack of congruence.     
Figure 5.12 displays the scores of high CR subjects by cognitive performance and self-
reported change in cognitive function.  Group A (n=12, 57%) shows the congruence and Group 
B (n=5), the incongruence of subjects with high cognitive performance (n=17, 81%).  Only 4 
subjects with high CR were found in Groups C and D (low cognitive performance).   
Figure 5.13 plots the scores of subjects with low CR by cognitive performance and self-
reported change in cognitive function.  Subject scores are spread out more evenly across the 
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scatterplot; Groups A and B show the congruence and incongruence of low CR subjects with 
high cognitive performance (n=13; 68%).  The majority of subjects with low CR were in Group 
B (n=8, 42%) with incongruent scores.  There were only 6 subjects with low CR in Groups C 
and D.
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Figure 5.12.   
Self-reported cognitive function and performance by subjects with high CR (n=21). 
 
 
 
Figure 5.13.   
Self-reported cognitive function and performance by subjects with low CR (n=19). 
 
 
D B 
A 
C 
B 
A C 
D 
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High Cognitive Reserve. 
Table 5.28 lists subject and tumor characteristics of subjects with high CR for Groups A 
through D. The t-test and Chi-square analyses found no significant differences between groups 
for subject or tumor-related characteristics.  Group A (congruent) tended to have recorded the 
shortest time since diagnosis.  Subjects in Groups C and D, with poor cognitive performance, 
were men and had longer times since diagnosis.  Those in Group B (incongruent scores) tended 
to be younger and reported more brain tumor specific symptoms, including depressive 
symptoms.   
 
Table 5.28.   
High Cognitive Reserve: Subject and tumor-related characteristics by group categories  
(n=21). 
 Group Aa  
(n=12) 
F 
Group Bb 
 (n=5) 
F 
Group Cc 
 (n=2) 
F 
Group Dd 
(n=2) 
F 
Gender  
     Male 
     Female 
 
6 
6 
 
2 
3 
 
2 
0 
 
2 
0 
Age, in years (M, SD) 51.6 (9.2) 46.0 (11.8) 59.5 (0.7) 60.5 (2.1) 
Education, in years (M, SD) 16.2 (1.6) 16.4 (0.9) 17.0 (1.4) 17.0 (1.4) 
Time since diagnosis,  
    in months (M, SD) 
70.0  
(79.3) 
89.8  
(74.8) 
138.0  
(164.1) 
187.0  
(77.8) 
Tumor hemisphere  
     Left 
     Right 
 
7 
5 
 
1 
4 
 
2 
0 
 
1 
1 
Tumor location  
     Frontal 
     Temporal 
     Other 
 
8 
1 
3 
 
3 
2 
0 
 
1 
0 
1 
 
0 
0 
2 
Tumor Grade  
     Low grade, grade 2 
     Transformed low grade 
     High grade, grade 3 
     High grade, grade 4 
 
3 
0 
6 
3 
 
0 
1 
2 
2 
 
0 
1 
0 
1 
 
1 
0 
1 
0 
aGroup A=normal performance & self-report; bGroup B=normal performance & reported change in function;  
cGroup C=poor performance but reported normal function; dGroup D=poor performance & reported change in 
function. 
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Low Cognitive Reserve. 
Table 5.29 lists subject and tumor characteristics of subjects with low CR for Groups A 
through D.  There were no significant differences in subject or tumor-related characteristics 
between groups by t-test or Chi-square analyses.  Group B tended to have recorded the least time 
since diagnosis, while Group D had the longest time since diagnosis.  Subjects in Groups C and 
D, with poor cognitive performance, were men; subjects in Groups A and B were primarily 
women.  Subjects in Group B (incongruent) tended to be younger and reported more depressive 
symptoms than the other groups.  However, Group D reported the greatest impact of symptoms 
on their quality of life (FACT-BT), severity and interference with daily lives (MDASI-BT).   
 
Table 5.29.   
Low Cognitive Reserve: Subject and tumor-related characteristics by group categories (n=19). 
 Group Aa  
(n=5) 
F 
Group Bb 
 (n=8) 
F 
Group Cc 
 (n=4) 
F 
Group Dd 
(n=2) 
F 
Gender  
     Male 
     Female 
 
1 
4 
 
1 
7 
 
4 
0 
 
2 
0 
Age, in years (M, SD) 47.2 (11.2) 46.1 (9.1) 50.5 (9.5) 54.5 (9.2) 
Education, in years (M, SD) 13.2 (1.1) 13.5 (0.9) 13.5 (0.9) 16.0  
Time since diagnosis,  
     in months (M, SD) 
113.2 
(61.1) 
104.1 
(72.3) 
110.8 (78.6) 133.5 
(153.4) 
Tumor hemisphere  
     Left 
     Right 
 
3 
2 
 
2 
6 
 
3 
1 
 
1 
1 
Tumor location  
     Frontal 
     Temporal 
     Other 
 
1 
4 
0 
 
4 
2 
2 
 
2 
1 
1 
 
0 
0 
2 
Tumor Grade  
     Low grade, grade 2 
     Transformed low grade 
     High grade, grade 3 
     High grade, grade 4 
 
1 
1 
2 
1 
 
1 
1 
4 
2 
 
0 
0 
4 
0 
 
0 
1 
0 
1 
aGroup A=normal performance & self-report; bGroup B=normal performance & reported change in function;  
cGroup C=poor performance but reported normal function; dGroup D=poor performance & reported change in 
function. 
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Congruence/Incongruence: Groups A and B. 
These analyses focus on Groups A (congruence) and B (incongruence) since these two 
groups contained a majority of subjects (n=30, 75%).  Table 5.30 shows subject characteristics 
by high and low CR for Groups A and B.    
 
Table 5.30.   
Subject and tumor-related characteristics by high and low CR (n=30). 
 Congruent Scores Incongruent Scores 
 Group Aa  Group Bb 
 High CR 
(n=12) 
Low CR 
(n=5) 
High CR 
(n=5) 
Low CR 
(n=8) 
 M (SD) M (SD) M (SD) M (SD) 
Gender, Frequency 
     Male 
     Female 
 
6 
6 
 
1 
4 
 
2 
3 
 
1 
7 
Age in years 51.6 (9.2) 47.2 (11.2) 46.0 (11.8) 46.1 (9.1) 
Employed, Frequency 6 2 1 1 
     
Time since diagnosis in months 70.0 (79.3) 113.2 (61.1) 89.8 (74.8) 104.1 (72.3) 
     
CTB Composite -0.5 (0.5) -0.8 (0.4) -0.3 (0.9) -0.4 (0.5) 
ECog Total 1.3 (0.3) 1.6 (0.4) 2.3 (0.3) 2.6 (0.5) 
NAART  116.7 (6.8) 105.3 (8.8) 114.4 (7.2) 109.4 (8.4) 
     
FACT-BT 
     Total 
     Cognitive Items 
 
156.5 (16.1) 
28.5 (5.1) 
 
142.5 (22.2) 
25.4 (5.0) 
 
141.6 (19.9) 
21.4 (4.0) 
 
119.8 (16.8) 
18.0 (6.5) 
MDASI-BT     
     Severity 0.6 (0.5) 1.1 (0.9) 0.7 (0.5) 2.0 (0.9) 
     Interference 0.5 (0.5) 0.7 (0.9) 1.0 (1.4) 1.9 (1.6) 
     Cognitive Items 0.8 (0.7) 1.2 (1.0) 0.9 (0.9) 3.2 (1.7) 
     
CESD-R 5.9 (4.4) 7.6 (8.7) 9.8 (9.5) 19.1 (10.3) 
OARS 
     Total 
     Physical 
     Instrumental 
 
 27.5 (1.5) 
    13.8 (0.6)     
13.7 (0.9) 
 
27.2 (1.3) 
     14.0       
13.2 (1.3) 
 
26.6 (2.0) 
13.8 (0.5) 
12.8 (1.6) 
 
27.0 (1.2) 
       14.0 
13.0 (1.2) 
aGroup A=normal performance & self-report; bGroup B=normal performance but report change in cognitive 
function. CR=Cognitive reserve; FACT-BT=Functional Assessment of Cancer Therapy-Brain Tumor; MDASI-
BT=MD Anderson Symptom Assessment-Brain Tumor; CESD-R=Center for Epidemiologic Studies Depression 
Scale-Revised; OARS=Older Americans Resources and Services Activities of Daily Living Scale. 
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Subjects in Group A (congruent) tended to be women. Subjects in Group A reported 
fewer symptoms and less impact on their quality of life (FACT-BT, MDASI-BT interference, 
CESD-R scores) than subjects in Group B (Table 5.29).  Group A subjects with high CR were 
more likely to have higher premorbid intelligence, to be employed at time of study participation, 
and to report fewer symptoms than those with low CR. 
Subjects in Group B (incongruent) tended to be women.  Low CR subjects in Group B 
had longer time since diagnosis and reported greater symptom impact on quality of life, 
symptom severity, and symptom interference (FACT-BT, MDASI-BT, CESD-R scores) 
compared to those with high CR.   
Using Kruskal-Wallis tests to compare mean differences in symptoms between subjects 
within groups, it was determined that subjects with low CR in Group B tended to report greater 
symptom severity, H(1)=4.82, p=.03, cognitive symptom severity, H(1)=5.88, p=.02, and impact 
on their quality of life, H(1)=3.62, p=.06, as compared to those with high CR in Group B.  There 
were no significant differences in subject or tumor characteristics for Group A between high and 
low CR.   
Summary on congruence and cognitive reserve in Groups A and B. 
 Cognitive reserve was used to categorize assess cognitive performance and self-reported 
change in cognitive function.  Thirty subjects (75%) were classified into Groups A (n=17) and B 
(n=13).  The majority of subjects in Group A had high CR (n=12, 71%).  Those with high CR in 
Group A reported the fewer symptoms and less symptom severity.   
The majority (n=8, 62%) of subjects in Group B had low CR.  Subjects who reported a 
perceived change in cognitive function tended to report greater symptom severity, greater impact 
on quality of life, and more depressive symptoms, particularly those with low CR.  Thus, CR 
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may help moderate the cognitive effects of cancer and cancer treatment as observed in Groups A 
and B.   
 
Exemplars.  
Observations considered for further exploration by a researcher are referred to as 
exemplars.  Four exemplars, 2 from Group A and 2 from Group B, were used to explore 
compensatory behaviors used to maintain cognitive function.  The exemplars were a subset of 7 
subjects (from the total sample of 40) who agreed to participate in structured interviews to 
explore their perception in changes in behavior since diagnosis and to identify their use of 
compensatory strategies to maintain everyday function. Using a list of 25 items on the Florida 
Cognitive Activities Scale, the subjects were asked to reflect on their everyday cognitive 
activities and preferences; to note whether a change had occurred, why the change might have 
occurred, what the nature of the change was, and whether the change was voluntary or forced 
due to limitations.  It was expected that these questions would engage the subject in discussing 
the strategies employed to perform activities, the degree to which the strategies worked, and any 
changes in strategy they may have used over time.   
Group A (congruence. 
High Cognitive Reserve. 
 A 51 year old woman with high CR in Group A reported very few changes in activities 
since her diagnosis 7.5 years earlier.  She stated that most of her activities were unchanged, “just 
less often” and she now allows more time for “get things done.”  She leaves memos around the 
house to keep her organized and writes all appointments down on her calendar.  She continues to 
play several musical instruments in a group, at church, and at home.  During her performance on 
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the cognitive test battery, she used the following techniques: she asked to have instructions 
repeated a couple of times, she counted numbers out loud, and closed her eyes “to memorize the 
words.”  She reported difficulty with her memory and difficulty participating in conversations, 
and less change in her ability to maintain attention or concentration.   
Low Cognitive Reserve.  
 A 64 year old woman with low CR in Group A was a 12 year survivor.  She reported 3 
activities that she had changed since diagnosis:  she did less sewing because she found it difficult 
to figure out where the pieces should go, less dancing, and less shopping because she required 
more rest on her days off.  She continued to work because her employer had adjusted her work 
duties after a seizure that led to her initial diagnosis (none subsequently).  She writes everything 
down in a composition notebook, from work activities to phone conversations and appointments.  
She integrates the notebook with her calendar or “it won’t get done.”  She says she uses “tricks 
to remember things,” including remembering people or events by telling stories to make things 
“personal,” writes parking space numbers on the parking ticket to prevent getting lost, and hooks 
her keys to her purse to prevent losing them.  During study participation, she read questionnaire 
items and the Symbol Digit Modalities Test numbers out loud.  She looked around the room to 
get ideas for words to say on the Controlled Oral Word Association test. 
Group B (incongruence). 
High Cognitive Reserve. 
 A 62 year old man is an 11 year survivor with high CR in Group B.  He reported that he 
had made changes in 6 activities, including reading, playing games and doing puzzles, social 
engagements, doing all the financial records, and making home repairs.  He had recently retired 
and moved with his wife to live near his children so they may help provide support in his care.  
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He felt that he was less attentive at work, that his concentration was lagging, and that it was 
“getting too hard to think and took too long.”  He was frustrated by his slow processing speed, 
which impacted his ability to make decisions and follow conversations.  These changes in his 
cognitive functioning led to his decision to retire and change his living situations because he was 
“withdrawing from the usual social activities” and was frustrated with his inability to follow 
along in conversations.  He and his wired organized the furniture and kitchen in their new home 
to resemble as closely as possible their previous home so he could remember where to find 
items.  He found that using memos or lists helped him improve memory, organization 
(prioritization), and attention.  He said that playing new games with his grandchildren helped his 
memory and communication skills, and that a new interest in photography was keeping him 
active.  He used a paper on top of paper questionnaires to keep himself on the correct reading 
line, which he also does when he reads technical journals.  He also repeated instructions and 
spoke out loud each next step for the Trails Making tests and the Symbol Digit Modalities Test.    
Low Cognitive Reserve.  
This exemplar is a 47 year old, 12 year survivor with low CR in Group B.  She reported 
changes in 18 activities that ranged from playing games or doing puzzles to reading, social 
engagements, and trying new activities.  There were 7 activities that she engaged in more often 
since her diagnosis (puzzles, crafts, walking), while the other 11 she participated in less often 
(going to social activities, driving to unfamiliar places, reading, and gardening). Her changes 
occurred due to a variety of reasons: she found it “hard to concentrate” while reading or 
following conversations in a room full of people; she felt “overwhelmed” when driving on 
highways to new locations, even with GPS; being in big stores; loud noises and conversations 
“get on my nerves.”  She realized that she increased activities that have led to more social 
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isolation, such as gardening, doing puzzles, and calling her friends because she could “control 
the timing and ability to handle” the activity.  During her performance on the cognitive test 
battery, she used the following techniques: she asked to have instructions repeated for several 
tests, she repeated words or instructions back to the examiner, she called out loud the next step in 
the test to keep on task, she used fingers to count numbers or words, and she closed her eyes “to 
concentrate.”  At the end of the interview, she reflected that she “protects herself” to keep from 
getting too frustrated or overwhelmed and tells herself that she is “still doing well overall.” 
Exemplars summary. 
 
These 4 subjects used some of the same techniques for their everyday cognitive function 
and performance as they did on the cognitive battery.  All four subjects had similar CTB 
Composite scores, ranging from -1.1 to -0.6.  However, the subject with low CR in Group B 
reported more cognitive difficulties and more changes in her activities since diagnosis.  These 
preliminary observations of changes in cognitive activities and incorporation of compensatory 
strategies to maintain function warrant further exploration. These individuals describe behaviors 
that were successfully implemented and those that were abandoned; it is hoped that such 
exemplars may help direct future study. 
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CHAPTER 6:  DISCUSSION 
 
This chapter first discusses objective cognitive performance, subjective (self-reported) 
change in cognitive function, and the discrepancy between objective and subjective findings in 
adult survivors of PBT.  Thereafter, the discussion focuses on whether cognitive reserve and 
compensatory strategies may explain some of the discrepancy between objective and subjective 
findings in survivors of PBT.  Finally, the chapter looks at limitations of the study and 
implications for future research.  
 
Objective Cognitive Performance 
 
Most (77.5%) of the subjects in this study did not have cognitive impairment based on the 
Clinical Trials Battery Composite score. Only 9 of 40 subjects were scored as impaired, a lower 
prevalence than that reported in the literature (>50%) for similar PBT survivors (Johnson et al., 
2012; Zuchella et al., 2013).  This discrepancy most likely reflects differences in time since 
diagnosis, tumor grade, tumor location, treatment type, and treatment duration, although 
variability in cognitive impairment may be due to differences in types of neuropsychological 
tests used to determine cognitive performance, the cutpoint z-score or sample median-split score 
used to define impairment (Caine, Mehta, Laack, & Gondi, 2012; Jones et al., 2011; Mandelblatt 
et al., 2013).   
Subjects in this study had more domain-specific impairment for memory (32.5%) than 
attention (27.5%).  While memory was more commonly impaired than attention in this sample, 
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impairment was more severe in the domain of attention.  These domain-specific impairments of 
attention and memory resemble those previously reported in survivors of PBT (Johnson et al., 
2012; Zucchella et al., 2013).  Because the domains of attention and memory are essential 
components of the Executive Control Function, a decline in one or both domains before an 
observable decline in ECF performance may help identify those at risk for eventual decline 
(Wefel, Witgert, & Meyers, 2008).   
No subject-, tumor-, or treatment-related factors were associated with cognitive 
impairment in this sample.  In contrast, subject and cancer-related characteristics have been 
associated with cognitive impairment in other studies of survivors (Hodgson et al., 2013; 
Lindner, Phillips, McCabe, Mayes, Wearden, et al., 2014).  Isolated studies have found that older 
age (Johnson et al,. 2012), longer time since diagnosis (Correa, 2008; Klein et al., 2002; Moretti 
et al., 2004; Scheibel, Meyers, & Levin, 1996), frontal tumor location (Satoer et al., 2012), left 
hemispheric tumor location (Hahn et al., 2009; Zucchella et al., 2013), high-grade PBT (Johnson 
et al., 2012), or PBT-specific treatment (Moretti et al., 2004; Zucchella et al., 2013) are 
associated with impaired cognitive function in PBT survivors.  Many of these studies are done 
soon after treatment cessation, which may increase the association of those factors with cognitive 
impairment.  However, the purpose of the present study was to describe cognitive impairment at 
least one year after completion of treatment, so subjects were further removed from treatment 
effects and may have had more time to recoup cognitive function or learn compensatory ways  to 
maintain function.  
 132 
 
Self-Reported Cognitive Function 
 
In contrast to objective neuropsychological testing, more than half of our subjects 
reported changes in performance of everyday activities requiring attention and memory.  In 
addition, subjects who reported greater change in cognitive function since diagnosis tended to 
report greater cognitive symptom severity and interference (MDASI-BT), and impact on their 
quality of life (FACT-BT).   
In support of the findings in the current study, Armstrong and colleagues (2006) had 201 
subjects report on 4 cognitive symptoms (remembering, understanding, speaking, thinking) while 
validating the MDASI-BT.  Symptom severity for the cognitive function items ranged from 0 to 
8, similar to the findings from the current study, and less than 10% of the sample reported the 
severe cognitive dysfunction.   
Cognitive symptoms are distressing. Changes in thinking, memory, multi-tasking, 
planning, slower processing, and attention impact the everyday lives of long-term PBT survivors 
(Godbout et al., 2005).  Fox and colleagues (2007) describe how a symptom cluster involving 
cognitive impairment, depression, fatigue, sleep disturbances, and pain impairs the functional 
status (Karnofsky Performance Status) of long-term PBT survivors.   
Given the above reports, most survivors of PBT report changes in cognitive function.  
Cognitive symptoms may vary in severity and impact on their quality of life, but it may be that 
these symptoms are precursors of a decline in objective cognitive performance (Ganz et al., 
2013) or that they reflect an aspect of cognitive function (or construct) that is not measured by 
objective cognitive performance tests in present use (Caine et al., 2012). 
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Self-reported associated depressive symptoms. 
Subjects in the present study who reported greater symptom severity (MDASI-BT 
severity subscale) and/or greater impact of symptoms on quality of life (FACT-BT) also tended 
to report more depressive symptoms (CESD-R).  Twenty-two percent of our sample reported the 
presence of depressive symptoms although none of the subjects carried a diagnosis of depression.  
Nevertheless, depressive symptoms have been associated with shorter survival times (Litofsky et 
al., 2003), greater cognitive impairment (Cook et al., 2013; Fuller et al., 2007), and functional 
decline (Tomey et al., 2010; Millán-Calenti et al., 2011). Fuller and colleagues (2007) observed 
that patients with PBT had more ECF impairment than did patients with other cancers, and they 
were more likely to have depressive symptoms.  The prevalence of depression is less than 25% 
in newly diagnosed survivors of PBT (Litofsky et al., 2003), but the presence of depressive 
symptoms is not unusual through the illness trajectory of PBT survivors.  Albeit the prevalence is 
low and somewhat expected, our results exemplify the need to perform depression screening 
with cognitive function studies.     
 
Discrepancy between Objective Cognitive Performance and Self-Reported Cognitive 
Function 
 
This study was able to identify a discrepancy between objective cognitive performance 
and self-reported cognitive function.  Dividing a scatterplot of objective and subjective cognitive 
function scores into quadrants provided the opportunity to describe four subject groupings. 
Because the majority of subjects (75%) were contained within two of these four groups that had 
normal cognitive performance scores, detailed analyses focused on those two groups – one with 
congruent scores and one with incongruent scores.   
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Seventeen subjects (42.5% of the total) had congruent scores (normal cognitive 
performance and no change in self-reported cognitive function since diagnosis).  This group was 
predominately female, aged between 40 to 60 years old, and well educated, with the majority 
completing college.  They had been diagnosed approximately 6 years earlier had predominately 
left frontal, high-grade tumors.  These subjects tended to report fewer brain-tumor-specific and 
depressive symptoms, less symptom severity, less impact of symptoms on their quality of life, 
and were able to perform most activities of daily living without assistance.   
There were 13 subjects (32.5% of the total) in the incongruent group (normal cognitive 
performance but self-reported a change in cognitive function); this group also had more female 
subjects, slightly younger (between 35 to 55 years of age), but fairly well educated, with some 
college or technical training.  These subjects had been diagnosed approximately 8 years earlier 
and had predominately right frontal, high-grade tumors.  Although they reported that their brain-
tumor-specific symptoms were not severe, and that they did not need assistance with activities of 
daily living, they tended to report more depressive symptoms. 
There are several similarities between these two groups: subjects had normal cognitive 
performance, were mostly female, middle-aged, well educated, and 6-8 years displaced from 
diagnosis of a high-grade, frontal tumor.  The major distinctions were that subjects with 
incongruent cognitive function scores were aware of or and sensitive to changes in cognitive 
function that had occurred since diagnosis, and that they reported more depressive symptoms. 
The discrepancy between objective and subjective measures of cognitive impairment may 
be related to instrumentation issues: use of varying cutpoints, different definitions of impairment, 
lack of a comprehensive measure, instrument construct, and instrument sensitivity and specificity 
(Gondi et al., 2013; Hurria, Somio, & Ahles, 2007; Hutchinson et al., 2012).  Therefore, some of 
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the cognitive symptoms that subjects report may be too subtle to detect on objective cognitive 
performance tests that are presently available; objective tests may underestimate the impact of 
mild cognitive impairments on everyday function, or subject reporting of cognitive symptoms 
may precede objective cognitive decline or impairment (Ganz et al., 2013; Meyers, 2013). While 
all of these issues may have some influence on the observed discrepancy, there have been 
suggestions that a subject’s ability to cope or adapt (a product of their lifetime of experiences, or 
cognitive reserve) may influence their everyday cognitive function (Wilson, Barnes, & Bennett, 
2003).   
 
Cognitive Reserve and the Discrepancy between Subjective and Objective Cognitive 
Impairment 
 
Cognitive impairment has been reported to compromise one’s ability to cope with the 
impact of illness (Higgins et al., 2012; Lovely et al., 2013; Paulson, Bowen, & Lichtenberg, 
2014).  The theory of cognitive reserve (CR) posits that those with higher CR are better prepared 
to cope with or compensate for illness by adapting their environment or invoking compensatory 
strategies (Suchy, Kraybill, & Franchow, 2011).   
In the present study, the majority of subjects with high cognitive reserve had congruent 
subjective and objective cognitive function scores.  Thus, they had good cognitive performance 
and self-reported fewer changes in cognitive function since diagnosis.  These subjects also 
reported fewer symptoms and less symptom severity.  In contrast, the majority of subjects with 
low CR tended to have incongruent cognitive function measures.  That is, they had good 
cognitive performance but reported a change in cognitive function since diagnosis.  These 
subjects also tended to report more symptom severity, greater impact on quality of life, and the 
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presence of depressive symptoms.  Tumor-specific factors, time since diagnosis, subject age, and 
treatment-related factors were not associated with these reported discrepancies.     
The exploration of CR is still relatively new, so only a few studies have explored the 
effect of CR on cognitive performance and self-reported function or well-being.  Ownsworth and 
colleagues (2013) observed that PBT survivors with higher CR reported less depression 
(Depression Anxiety Stress Scale), better emotional well-being (FACT-BT emotional subscale), 
and had fewer cognitive complaints while maintaining good cognitive function.  Thus, these 
survivors have congruent objective and subjective cognitive function like the subjects in the 
current study.  The congruence of self-report with objective performance may indicate that these 
subjects have indeed maintained function without the use of compensatory strategies or that their 
use of such strategies is subtle. 
To demonstrate the effects of CR during task performance, Steffener and colleagues 
(2011) used the functional MRI scanner to look at neural reserve and neural compensation in 
young and older healthy subjects.  Compared to those with low CR, older adults with high CR 
utilized neural networks with greater efficiency for task performance.  High and low CR was 
dichotomized by a composite of premorbid IQ and education.  Their high and low CR subjects 
had premorbid IQ and educational attainment similar to the high and low CR subjects in the 
current study.  The report by Steffener and colleagues implies that those with congruent good 
cognitive function may maintain their performance by efficient utilization of neural and 
cognitive compensation. 
Ahles et al. (2010) studied a group of younger breast cancer survivors with high CR who 
reported experiencing changes in cognitive function (Multiple Ability Self-Report 
Questionnaire) despite objectively good cognitive performances.  Incongruent cognitive function 
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scores were observed in a smaller number of high CR subjects in the current study.  The self-
report from this group could reflect a change in their cognitive awareness, an increase in effort to 
maintain cognitive function, or movement within their illness trajectory.      
As the theory of CR suggests, those with high CR are better prepared to compensate to 
maintain function when the need arises, and have an awareness of what they need to do to 
prevent functional decline (Stern, 2002).  Until cognitive demand is great, compensatory 
strategies can be used subconsciously to maintain function (Hampstead, Gillis, & Stringer, 2014; 
Weiss, Hoenig, & Fried, 2007).  When cognitive function is maintained, even with use of 
compensatory strategies, subjects are more likely to have congruent objective and subjective 
cognitive function measures (Sumowski, Wylie, DeLuca, & Chiaravalloti, 2009).  Once 
cognitive demand increases, subjects employ adaptive strategies to maintain function or they will 
have functional decline.  Those with high CR may be unaware of changes in their function for a 
longer period of time because they adapt using their accumulation of lifetime experiences 
(Foubert-Samier et al., 2012).  Because of their lifetime experiences, they tend to choose 
compensatory strategies that require the least amount of effort or change (Barulli et al., 2013).  
However, those with low CR may more readily recognize their need to compensate with external 
aids or environmental changes, and will tend to report greater severity in the changes that they 
experience.  Barulli and colleagues (2013) suggest that awareness of the compensations used to 
maintain cognitive function underlies the discrepancy between subjective, self-reported change 
in cognitive function and objective cognitive performance.   
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Compensatory Strategies 
 
Strategies used to compensate for cognitive dysfunction include changes in the physical 
or social environment, the use of memory or cognitive devices (external aids), or internal 
mnemonics (Hampstead, Gillis, & Stringer, 2014; Huckans et al., 2013; Tomey & Sowers, 2009; 
Wilson, 2000).  Hampsted et al. (2014) suggest that compensation may occur through several 
methods:  rehearsal based approaches (cognitive retraining through repetition), compensatory 
approaches using external aids (calendars, notes, social and physical environment changes), or 
internal aids (mnemonic strategies).  Curtailing social or leisure activities and social isolation are 
also examples of compensatory strategies individuals use to cope or adapt with cognitive decline 
(Fried et al., 1996; Schinka et al., 2005; Weiss et al., 2007; Wilson, 2000).   
The exemplars presented in this study illustrate some of the compensatory strategies they 
used since their diagnosis.  The low CR subjects tended to report a decreased frequency of 
activities, those with high CR continued to be cognitively engaged with some of the same 
activities they had been doing prior to diagnosis.  Those with low CR stopped more activities 
since diagnosis, and were more socially isolated, than those with high CR.  Regardless of CR, 
subjects used similar compensatory behaviors during study participation, and described 
incorporation of similar compensatory strategies to maintain cognitive function.  Despite CR, 
those with congruence between performance and self-report tended to be less aware of their 
compensatory strategies than those with incongruence.   
 The strategies noted by the exemplars in the current study are similar to those described 
by other cancer survivors (Lovely et al., 2013; Myers, 2013; Von Ah, Habermann, Carpenter, & 
Schneider, 2013).  Dyads of long-term PBT survivors and their caregivers describe the impact of 
cognitive changes in terms of loss of employment, friends and social activities, and diminution of 
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self-worth.  Von Ah and colleagues (2013) reported similar perceptions of cognitive loss, but 
they also noted that breast cancer survivors who were employed reported that they had to work 
harder and use compensatory strategies to maintain their work performance. Myers (2013) 
summarized 17 qualitative studies that reported survivor use of strategies to compensate for 
cognitive dysfunction that included consistency in performance to prevent cognitive failures 
(memo writing, doing things the same way, putting the keys in the same place), mitigating 
cognitive failures by changing the task (reading simpler books, doing more puzzles, getting 
enough rest, socializing when they felt best or not fatigued), avoidance of cognitive activities that 
created more demands than they could give, and self-permission to make mistakes or take more 
time.   
 In the present study, these compensatory strategies were used by subjects with both high 
and low CR, but others have found that those with high CR use a better strategy selection than 
those with low CR (Barulli et al., 2013).  Simply, those with high CR may use inherent 
strategies, earlier in their illness trajectory, to reduce effort required by cognitively demanding 
situations, and tend to choose the best strategies requiring the least effort.  Thus, those with low 
CR may need direction as to which strategies to use or which require the least effort.  Therefore, 
observing the compensatory strategies or behaviors used by PBT survivors may help identify 
which strategies are useful and which require too much effort; such observations can guide the 
design of future research into cognitive interventions.  
 
Study Strengths and Limitations    
 
A cross-sectional design was chosen for this study because the specific aims were 
descriptive and exploratory for directing future research.  All of the data were collected at time 
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of study participation, thus facilitating data completion and reducing missing data points.  All of 
the subjects participated at the time of their choosing when they came for an oncology clinic 
visit, thus reducing subject expense for travel and caregiver burden for time away from work or 
other obligations.  A solitary time point for study participation facilitated subject enrollment and 
subject burden.   
However, a cross-sectional design measuring cognitive performance and self-reported 
function limits the interpretation because there is no information about the subjects’ cognitive 
trajectory: what was their premorbid cognitive functioning, how has that changed over time, how 
will it continue to change over time?  This is particularly limiting regarding how those with high 
and low CR are affected over time.  The theory of CR postulates that those with high CR 
maintain function longer in the presence of neuropathology than those with low CR, so knowing 
where these survivors are in their cognitive trajectory would help identify when intervention 
would be useful.  In future research, a longitudinal design would permit tracking a subject’s 
change in cognitive function over time, thereby identifying those at risk of cognitive decline, and 
when to implement cognitive interventions (Shadish, Cook, & Campbell, 2002). 
Instrumentation. 
This study explored the use of several instruments that have not been previously studied 
in survivors of PBT: the EXIT-25 as a measure of cognitive function, specifically executive 
control function; the ECog as a measure of change in cognitive function since diagnosis; and the 
FCAS as a measure of compensation.  Lastly, the Hollingshead Index was used as a proxy for 
CR which has not been previously for use in survivors of PBT.  
Two composites of specific performance scores were explored for use as measures of 
ECF: the CTB Composite score and TMT Difference scores (Johnson et al., 2012).  While 
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composite scores compress the interpretation of many instruments into a solitary score, bias can 
result if one instrument score is greatly skewed, giving the composite score a value that does not 
accurately reflect cognitive function.  For instance, positive cognitive performances in one 
domain or on several tests may obscure significant impairment in other areas (Jones et al., 2011).   
The use of the EXIT-25 was exploratory in this sample.  The EXIT-25 was developed as 
a screen for dementia in elderly populations (Royall et al., 1992).  Since its development, there 
has been increasing emphasis in screening instruments to identify mild cognitive impairment in 
populations at risk for dementia (Malloy et al., 1997; Wefel et al., 2010).  This instrument has 
been used in a variety of medical populations including hospitalized medical patients (Royall, 
Chiodo, & Polk, 2000; Schillerstrom et al., 2005), subjects with schizophrenia and other 
psychiatric disorders (Scully et al., 1997; Schillerstrom et al., 2003), the neurologically injured 
(Larson, Leahy, Duff, & Wilde, 2008), and those who have undergone radiation therapy (Fuller 
et al., 2007).  There have been suggestions to change the standardized cutpoint of 15 for 
clinically significant cognitive impairment and use lower cutpoints to screen for mild cognitive 
impairment (Fuller et al., 2008; Larson et al., 2008; Larson & Heinemann, 2010).  This may be 
relevant to the present study because only one subject had a score above the cutpoint of 15.  
Cutpoints of 5 and 10 were explored in this study, but the EXIT-25 had a low level of agreement 
with the standardized neuropsychological battery, therefore limiting its usefulness as a screening 
instrument for ECF in this clinical population.   
The ECog was used to explore change in cognitive function since diagnosis.  The ECog is 
easily administered and offers a comprehensive assessment of everyday functions that reflects 
cognitive activities in specified domains (Farias et al., 2006; 2008).   This instrument had not 
been previously studied in survivors of PBT, and was validated in elderly populations (Farias et 
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al., 2006; 2008), so the items were compared to cognitive symptom items on 2 instruments 
validated for symptoms relevant to PBT, the FACT-BT and MDASI-BT.  The high level of 
agreement between tests suggests that the instruments tap into similar cognitive functions.  A 
strength of the ECog is that the subject must reflect whether and how much a comprehensive list 
of cognitive activities has changed over time rather than rate cognitive symptoms for severity, 
interference, or impact on their lives within the previous day (MDASI-BT) or week (FACT-BT) 
(Jones et al., 2011; Mandelblatt et al., 2013).    
One scale designed to examine the engagement in cognitive activities of community-
dwelling elders is the FCAS (Dotson, Schinka, Brown, Mortemer, & Borenstein, 2008; Schinka 
et al., 2005).  In the present study, the FCAS was used to explore the change in cognitive 
activities that subjects reported during a structured interview.  This instrument was helpful in 
facilitating conversations regarding the activity and how subjects had changed their engagement 
with the activity over time.  Their responses indicate that this instrument may be useful in 
determining how changes in cognitively-engaging activities may provide insight into 
compensatory strategies that survivors of PBT use to maintain function (Hampstead et al., 2014; 
Jones et al., 2011). 
This study used the Hollingshead Index as the measure of CR because it is an index for 
educational and occupational attainment.  Research proxies of CR have included premorbid 
intelligence and cognitively-engaging activities as lifetime measures (Foubert-Samier et al., 
2012; Reed, et al., 2011; Wilson, Barnes, & Bennett, 2003).  This study did not measure 
cognitively-engaging activities in all subjects, but premorbid intelligence was measured by 
performance scores on the NAART.  However, in 20% of the sample, neuropathology may have 
led to NAART scores that do not accurately reflect their premorbid intelligence, thereby limiting 
 143 
 
the use of premorbid intelligence as a proxy for CR (Strauss, Sherman, & Spreen, 2006).  Others 
have suggested the use of literacy instead of IQ (Ownsworth, Dwan, Chambers, Walker, & 
Shum, 2013; Puccioni & Vallesi, 2012).  Additionally, education has been cited to reflect the 
cognitively-engaging activities that one performs at early age, and offer that occupation may 
better reflect cognitive stimulation in adulthood by work-related activities and demands (Reed et 
al., 2011; Wilson, 2000; Wilson, Barnes, & Bennett, 2003).  What is needed is an index that 
takes into account educational, occupational, and cognitively-engaging activities as a lifetime 
measure for CR (Jones et al., 2011; Nucci, Mapelli, & Mondini, 2012).   
Subject heterogeneity. 
The present study sought to describe the discrepancy between cognitive performance and 
self-reported function in survivors of PBT who had undergone cancer treatment with 
chemotherapy or radiation therapy.  Several exclusion criteria were applied to control factors that 
might influence cognitive function, and to assure a healthy survivor for study participation.  
However, this sample is heterogeneous in regards to tumor grade, location, and treatment, and it 
is too small to control for or explore the effect of tumor location, grade, recurrence, and 
treatments on cognitive function and cognitive reserve (Davidson, Gao, Mason, Winocur, & 
Anderson, 2008; Hodgson et al., 2013; Mandelblatt et al., 2013; Nokia, Anderson, & Shors, 
2012; Robertson, 2013). 
Subjects in the sample ranged in age from 31 to 64 years old.  While not considered 
elderly, the age of the subject may affect cognitive abilities.  We cannot ascertain the risk that an 
individual might have for developing an age-related dementia, but aging has been associated 
with worsening cognitive performance (Gehring et al., 2011; Zucchella et al., 2013).   
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Consistent with tumor registry data (CBTRUS, 2012), our sample was comprised 
primarily of Caucasians (92.5%) and slightly more women (55%) than men.  The differences that 
culture, race, and gender may impose on cognitive functioning have become of interest (Dotson 
et al., 2008; Jones et al., 2011; Siedlecki et al., 2009; Tomey et al., 2010), but we have too few 
studies to fully understand the impact these characteristics on CR and survivors of PBT. 
Potential sources of bias. 
This study may have several sources for bias.  Study recruitment occurred at 2 academic 
tertiary medical centers with specialized neuro-oncology departments: one focused on care 
regionally and one with patients from across the nation.  Ninety-eight percent of this sample 
came from one site and represents a diverse geographical sample.  These participants may have 
higher socioeconomic status and higher education than survivors of PBT in regional care 
facilities.  This could be reflected in the Hollingshead Index scores for this sample, which ranged 
from 11 to 55, where the normal range extends to 77.  Thus, considering subjects to have a low 
CR as determined by the cutpoint of 31.75 (sample mean) on the Hollingshead Index may not 
accurately define a low CR group but rather a group intermediate between high and low CR.  
This could have led to the finding that subjects with low CR in Group B had insight that about a 
change in cognitive function while the literature suggests that those with lower CR tend not to 
have insight into changes in cognitive function (Jones et al., 2011).     
An additional potential source of bias regards those that choose to participate in research 
studies, particularly functional studies.  Study responders tend to maintain some ability to 
perform everyday functional activities and participate in informed consent procedures.  All of the 
subjects in this study also had to pass 2 cognitive screens before consenting and participating.  
 145 
 
Thus, the participants in this study may not reflect some survivors with lower cognitive abilities 
and limit generalizability. 
   
Implications for Future Research 
 
Decline in cognitive function is one of the most distressing symptoms for adult survivors 
of PBT.  However, many of the survivors in this study had maintained cognitive function despite 
neural damage from surgery, radiation, and chemotherapy.  The findings from this study suggest 
that cognitive reserve may play a role in maintaining cognitive function in survivors of PBT.  
This knowledge may help to identify those at more risk of developing cognitive decline so that 
early intervention may occur.   
Longitudinal measurement of cognitive function beginning at time of diagnosis is 
essential if we are to track changes in cognitive function over time. This will provide a 
framework for understanding the PBT survivor illness trajectory, when survivors are at risk, and 
when targeted interventions may be successfully implemented and sustained.  Self-reported 
everyday function must accompany objective cognitive performance measures to identify early 
changes in survivor perceptions because patient reports of change may precede objective changes 
in cognitive performance.  Learning to ask survivors about the effort needed to perform everyday 
activities may tell us whether compensation is occurring or changing, and may help with 
identifying their trajectory.  Furthermore, self-reported change in cognitive function may indicate 
a need for referral for more comprehensive, objective cognitive function evaluation.   
The theory of cognitive reserve provided a lens through which to view the discrepancy 
between subjective and objective cognitive function, as well as to explore compensation.  The 
findings of the present study illustrate several of the compensatory strategies used by PBT 
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survivors, with or without their awareness, and provide the foundation for further exploration of 
compensatory strategies that maintain cognitive function. Additionally, teaching PBT survivors 
and their families about cues to dysfunction, and how to look for help when concerned about 
cognitive failure may alleviate fear and provide opportunity for early intervention to prevent 
cognitive decline.    
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subject. You must notify the IRB of your action within five (5) working days of the event.
The Duke University Health System Institutional Review Board for Clinical Investigations (DUHS IRB), 
is duly constituted, fulfilling all requirements for diversity, and has written procedures for initial and 
continuing review of human research protocols. The DUHS IRB complies with all U.S. regulatory 
requirements related to the protection of human research participants. Specifically, the DUHS IRB 
complies with 45CFR46, 21CFR50, 21CFR56, 21CFR312, 21CFR812, and 45CFR164.508-514. In 
addition, the DUHS IRB complies with the Guidelines of the International Conference on 
Harmonization to the extent required by the U. S. Food and Drug Administration.
DUHS Institutional Review Board
2424 Erwin Rd | Suite 405 | Durham, NC | 919.668.5111
Federalwide Assurance No: FWA 00009025
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APPENDIX B: IRB CONSENT FORMS
University of North Carolina-Chapel Hill
Consent to Participate in a Research Study
Adult Participants
Consent Form Yersion Date: October 10, 2011
IRB Study # 11-1635
Title of Study: Exploring Compensatory Behaviors Used to Maintain Executive Control Function in
Adults with Primary Brain Tumors
Additional Study tnformation: Adult Participants with Primary Brain Tumors, Audio Recording
Principal Investigator:Deborah Allen, RN, MSN
Principal Investigator Department: Schoolof Nursing
Principal Investigator Phone number:9 1 9-8 83-7002
Principal Investigator Email Address: allendd@email.unc.edu
Co-Investigators: Barbara Waag Carlson RN, Ph.D. (Faculty Advisor)
Virginia J. Neelon RN, Ph.D.
MerleMishel, RN, Ph.D.
John Carlson, MA
Renee Raynor, PhD
Jing Wq MD
Funding Source: American Cancer Society Doctoral Scholarship in Nursing
Study Contact telephone number: 919-883-7002
Study Contact email: allendd@email.unc.edu
What are some general things you should know about research studies?
You are being asked to take part in a research study. To join the study is voluntary. You may refuse
to join, or you may withdraw your consent to be in the study, for any reason, without penalty.
Research studies are designed to obtain new knowledge. This new information may help people in
the future. You may not receive any direct benefit fiom being in the research study. There also
may be risks to being in research studies.
Details about this study are discussed below. It is important that you understand this information so
that you can make an infornred choice about being in this research study.
You will be given a copy of this consent form. You should ask the researchers named above, or
staff members who may assist them, any questions you have about this study at any time.
What is the+urpss€_oflh$-study?
The major purpose of this research study is to learn what problems persons who have undergone
treafinent for primary brain fumors report in their memory and thinking as compared to how they
perform on tests typically used to assess memory and thinking. While studies have shown that the
brain's ability to think and remember may be affected in persons following treatment for primary
brain fumor, studies have not been done to learn what everyday activities persons continue to use or
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may have difficulties with after treatment completion.  With this information, we may improve how
we detect changes in memory and thinking during treatment.
 
Are there any reasons you should not be in this study?
You should not be in this study if you cannot read or write English, younger than 30 years of age or
greater than 65 years of age, have any known neurodegenerative disorders or take medications
for Parkinson’s disease, Alzheimer’s Disease or other dementias, psychiatric disorders such as
schizophrenia, mania, depression, or bipolar disorder, seizure disorders that have required
medication changes in the past six months, general anesthesia in the past six months, problems with
numbness or tingling or moving your arms or legs, problems sleeping such as sleep apnea, pain
keeping you awake, or sleep walking, history of stroke or alcohol or drug abuse, or neuroimmune
disorders such as HIV, herpes, tuberculosis, syphilis, or hepatitis.  You should not participate today
and this study may be rescheduled if you took an over-the-counter cold medication last night, drank
alcoholic beverages or taken recreational drugs in the past 24 hours,  took sleeping medicines last
night which you do not routinely take every night, or if you have had recent procedures requiring
anesthetics in the past two weeks.  
 
How many people will take part in this study?
If you decide to be in this study, you will be one of approximately 40 adults with primary brain
tumors.
 
This study will take place at the University of North Carolina and Duke University.
 
How long will your part in this study last?
The study will take no more than 3 hours to complete. 
 
What will happen if you take part in the study?
After you review this consent form and have opportunity to ask questions about the testing
procedures, you will have your vital signs measured (heart rate, blood pressure, blood oxygen levels
in your finger).  Next you will be asked to complete a questionnaires about depression, your ability
to take care of yourself, and if you have noticed any problems with your ability to think or
remember.  This can take between 15 to 30 minutes to do.
 
Afterwards, you will be asked to take a brief neurological test and be asked to complete some tests
that measure your ability to think and remember.  This part of the study should take no more than
one hour to do.  Between tests, we will give you time to rest, get something to drink or eat or go to
the bathroom.  All together, this part of the study, should take no more than 90 minutes to complete. 
 
Audiorecording
The tests will be gven in a specific order and at a specific time.  We ask that you try to answer all
questions or perform tasks to the best of your ability. Therefore, we will be using a tape recorder in
order to make sure the person giving the test starts the test in the correct order, at the right time, and
writes down your answers correctly.  Only members of the research team will have access to these
recordings.  The recordings will be kept in a locked cabinet and will be destroyed after the study has
ended. 
 
___  OK to audiotape me.
___  Not OK to audiotape me.
 What are the possible benefits from being in this study?
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Research is designed to benefit society by gaining new knowledge.  You may not benefit personally
from being in this research study.
 
What are the possible risks or discomforts involved from being in this study?
There are no major risks to you as a subject in this study.  It is possible that you may feel
uncomfortable with some of the tasks that we ask you to do.  For example, the memory test may
make you feel anxious because some of the answers will be very easy and some will be very hard. 
We do not expect you to know all the answers.  Please do not hesitate to ask any member of the
research team any question, and we want you to tell us about any problems you may be having. 
 
Because we are taking many measurements, we may find people who may have a condition that
requires medical attention.  Examples of conditions that require medical attention include having a
high pulse rate, high or low blood pressure, or below normal measures on a memory or thinking
test.  If this is detected, we will talk with you and give you a form that tells you (1) what we found,
(2) what it may mean in terms of your health, and (3) where you can go to get some help.  Lastly,
there may be uncommon or previously unknown risks.  You should report any problems to the
researcher.
 
How will your privacy be protected?
Every effort will be taken to protect your identity.  Only Ms. Allen and the other study investigators,
and their research assistants will have access to your data.  As part of this study, your answers to
the questions that Ms. Allen and her research team ask you will not be included in your medical
record.  Study records that identify you will be kept confidential as required by law. You will be
assigned a unique code number in which the key to this code will be kept in a locked file in Ms.
Allen's office.  All data (paper forms, compact discs, audio and video recordings) will be kept under
lock and key at the School of Nursing.  After data analyses are completed, all data will be
destroyed. 
 
Participants will not be identified in any report or publication about this study. Although every effort
will be made to keep research records private, there may be times when federal or state law requires
the disclosure of such records, including personal information.  This is very unlikely, but if
disclosure is ever required, UNC-Chapel Hill will take steps allowable by law to protect the privacy
of personal information.  In some cases, your information in this research study could be reviewed
by representatives of the University, research sponsors, or government agencies for purposes such as
quality control or safety.
 
What will happen if you are injured by this research?
All research involves a chance that something bad might happen to you.  This may include the risk
of personal injury. In spite of all safety measures, you might develop a reaction or injury from being
in this study.  If such problems occur, the researchers will help you get medical care, but any costs
for the medical care will be billed to you and/or your insurance company. The University of North
Carolina at Chapel Hill has not set aside funds to pay you for any such reactions or injuries, or for
the related medical care. However, by signing this form, you do not give up any of your legal rights.
 
What if you want to stop before your part in the study is complete?
You can withdraw from this study at any time, without penalty.  The investigators also have the
right to stop your participation at any time.  This could be because you have had an unexpected
reaction, or have failed to follow instructions or unable to complete several of the tests. 
 
Will you receive anything for being in this study?
You will be receiving $25.00 for taking part and completing the procedures in this study.  You will
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You will be receiving $25.00 for taking part and completing the procedures in this study.  You will
also receive a parking voucher.  There will be no costs to you for being in this study.
 
What if you have questions about this study?
You have the right to ask, and have answered, any questions you may have about this research. If
you have questions, or concerns, you should contact the researchers listed on the first page of this
form.
 
What if you have questions about your rights as a research participant?
All research on human volunteers is reviewed by a committee that works to protect your rights and
welfare.  If you have questions or concerns about your rights as a research subject you may contact,
anonymously if you wish, the Institutional Review Board at 919-966-3113 or by email to
IRB_subjects@unc.edu.
 
 Participant’s Agreement:
I have read the information provided above.  I have asked all the questions I have at this time.  I
voluntarily agree to participate in this research study.
 
______________________________________________________
Signature of Research Participant
____________________
Date
______________________________________________________
Printed Name of Research Participant
 
[LAR]
______________________________________________________
Signature of Research Team Member Obtaining Consent
____________________
Date
______________________________________________________
Printed Name of Research Team Member Obtaining Consent
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University of North Carolina-Chapel Hill
Consent to Participate in a Research Study 
Adult Participants 
________________________________________________________________
 
Consent Form Version Date:  October 10, 2011
IRB Study # 11-1635
Title of Study: Exploring Compensatory Behaviors Used to Maintain Executive Control Function in
Adults with Primary Brain Tumors
Additional Study Information:  Adult Participants with Primary Brain Tumors, Video Recording
Principal Investigator:Deborah Allen, RN, MSN
Principal Investigator Department:  Schoolof Nursing
Principal Investigator Phone number:919-883-7002
Principal Investigator Email Address: allendd@email.unc.edu
Co-Investigators:         Barbara Waag Carlson RN, Ph.D. (Faculty Advisor)
     Virginia J. Neelon RN, Ph.D.
     Merle Mishel, RN, Ph.D.
     John Carlson, MA
     Renee Raynor, PhD
     Jing Wu, MD
 
Funding Source: American Cancer Society Doctoral Scholarship in Nursing
 
Study Contact telephone number: 919-883-7002
Study Contact email:  allendd@email.unc.edu
_________________________________________________________________
 
What are some general things you should know about research studies?
You are being asked to take part in a research study.  To join the study is voluntary.  You may refuse
to join, or you may withdraw your consent to be in the study, for any reason, without penalty.
 
Research studies are designed to obtain new knowledge. This new information may help people in
the future.  You may not receive any direct benefit from being in the research study.  There also
may be risks to being in research studies.
 
Details about this study are discussed below.  It is important that you understand this information so
that you can make an informed choice about being in this research study. 
 
You will be given a copy of this consent form.  You should ask the researchers named above, or
staff members who may assist them, any questions you have about this study at any time.
 
What is the purpose of this study?
The major purpose of this supplemental research study is to learn about strategies that persons who
have undergone treatment for primary brain tumors use for memory and thinking as compared to
persons who do not have primary brain tumors.  While studies have shown that the brain’s ability to
think and remember may be affected in persons following treatment for primary brain tumor, studies
have not been done to learn about the strategies persons use.  This additional information will assist
us in identifying ways to promote maintaining thinking and memory abilities.
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us in identifying ways to promote maintaining thinking and memory abilities.
 
Are there any reasons you should not be in this study?
You should not be in this study if you cannot read or write English, younger than 30 years of age or
greater than 65 years of age, have any known neurodegenerative disorders or take medications
for Parkinson’s disease, Alzheimer’s Disease or other dementias, psychiatric disorders such as
schizophrenia, mania, depression, or bipolar disorder, seizure disorders that have required
medication changes in the past six months, general anesthesia in the past six months, problems with
numbness or tingling or moving your arms or legs, problems sleeping such as sleep apnea, pain
keeping you awake, or sleep walking, history of stroke or alcohol or drug abuse, or neuroimmune
disorders such as HIV, herpes, tuberculosis, syphilis, or hepatitis.  You should not participate today
and this study may be rescheduled if you took an over-the-counter cold medication last night, drank
alcoholic beverages or taken recreational drugs in the past 24 hours,  took sleeping medicines last
night which you do not routinely take every night, or if you have had recent procedures requiring
anesthetics in the past two weeks  
 
How many people will take part in this study?
If you decide to be in this study, you will be one of approximately 10 adults with primary brain
tumors and 10 healthy adults in this research study.
 
This study will take place at the University of North Carolina and Duke University.
 
How long will your part in this study last?
This supplemental study will take 30 additional minutes to complete after the testing battery.  Both
studies will take no longer than 3 hours to complete.
 
What will happen if you take part in the study?
In this supplemental study, you will be video-recorded while you complete the tests for your
memory and thinking.  This will be done so that the researcher learn more about what you may do
that helps you to successfully complete the tests.  Often times, people move or do thing that while
they are not aware of it, helps them to do a task faster or more accurately.  The tapes will help us to
see these things.  The video camera will include your face as well as your upper portion of your
body.  The video recordings will be kept in a locked cabinet.  These tapes will be destroyed after the
researcher reviews the tapes. 
___  OK to audio/videotape me.
___  Not OK to audio/videotape me. 
At the end of the tests for your memory and thinking, you will be asked a few questions asking you
about what tests were more or less difficult and what strategies you may have used to complete the
tests.  This should take no more than 30 minutes to complete.
 
What are the possible benefits from being in this study?
Research is designed to benefit society by gaining new knowledge.  You may not benefit personally
from being in this research study.
 
What are the possible risks or discomforts involved from being in this study?
There are no major risks to you as a subject in this study.  It is possible that you may feel
uncomfortable with some of the tasks that we ask you to do.  For example, the memory test may
make you feel anxious because some of the answers will be very easy and some will be very hard. 
We do not expect you to know all the answers.  Please do not hesitate to ask any member of the
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research team any question, and we want you to tell us about any problems you may be having. 
 
Because we are taking many measurements, we may find people who may have a condition that
requires medical attention.  Examples of conditions that require medical attention include having a
high pulse rate, high or low blood pressure, or below normal measures on a memory or thinking
test.  If this is detected, we will talk with you and give you a form that tells you (1) what we found,
(2) what it may mean in terms of your health, and (3) where you can go to get some help.  Lastly,
there may be uncommon or previously unknown risks.  You should report any problems to the
researcher.
 
How will your privacy be protected?
Every effort will be taken to protect your identity.  Only Ms. Allen and the other study investigators,
and their research assistants will have access to your data.  As part of this study, your answers to
the questions that Ms. Allen and her research team ask you will not be included in your medical
record.  Study records that identify you will be kept confidential as required by law. You will be
assigned a unique code number in which the key to this code will be kept in a locked file in Ms.
Allen's office.  All data (paper forms, compact discs, audio and video recordings) will be kept under
lock and key at the School of Nursing.  After data analyses are completed, all data will be
destroyed. 
 
Participants will not be identified in any report or publication about this study. Although every effort
will be made to keep research records private, there may be times when federal or state law requires
the disclosure of such records, including personal information.  This is very unlikely, but if
disclosure is ever required, UNC-Chapel Hill will take steps allowable by law to protect the privacy
of personal information.  In some cases, your information in this research study could be reviewed
by representatives of the University, research sponsors, or government agencies for purposes such as
quality control or safety.
 
What will happen if you are injured by this research?
All research involves a chance that something bad might happen to you.  This may include the risk
of personal injury. In spite of all safety measures, you might develop a reaction or injury from being
in this study.  If such problems occur, the researchers will help you get medical care, but any costs
for the medical care will be billed to you and/or your insurance company. The University of North
Carolina at Chapel Hill has not set aside funds to pay you for any such reactions or injuries, or for
the related medical care. However, by signing this form, you do not give up any of your legal rights.
 
What if you want to stop before your part in the study is complete?
You can withdraw from this study at any time, without penalty.  The investigators also have the
right to stop your participation at any time.  This could be because you have had an unexpected
reaction, or have failed to follow instructions or unable to complete several of the tests. 
 
Will you receive anything for being in this study?
You will receive a total of $25.00 for taking part and completing the study procedures while being
video-recorded and interviewing.  You will also receive a parking voucher.  There will be no costs to
you for being in this study.
 
What if you have questions about this study?
You have the right to ask, and have answered, any questions you may have about this research. If
you have questions, or concerns, you should contact the researchers listed on the first page of this
form.
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What if you have questions about your rights as a research participant?
All research on human volunteers is reviewed by a committee that works to protect your rights and
welfare.  If you have questions or concerns about your rights as a research subject you may contact,
anonymously if you wish, the Institutional Review Board at 919-966-3113 or by email to 
IRB_subjects@unc.edu. 
Participant’s Agreement:
I have read the information provided above.  I have asked all the questions I have at this time.  I
voluntarily agree to participate in this research study. 
______________________________________________________
Signature of Research Participant
____________________
Date
______________________________________________________
Printed Name of Research Participant
 
[LAR]
______________________________________________________
Signature of Research Team Member Obtaining Consent
____________________
Date
______________________________________________________
Printed Name of Research Team Member Obtaining Consent
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You are being asked to take part in this research study because you have received treatment for your 
primary brain tumor.  Research studies include only people who choose to take part.  Please read this 
consent form carefully and take your time making your decision.  As your study staff discusses this 
consent form with you, please ask him/her to explain any words or information that you do not 
clearly understand.  The nature of the study, risks, inconveniences, discomforts, and other important 
information about the study are listed below.
Ms. Deborah Allen and Dr. Annick Desjardins will conduct the study. 
WHY IS THIS STUDY BEING DONE?
The major purpose of this research study is to learn what problems persons who have undergone 
treatment for primary brain tumors report in their memory and thinking as compared to how they 
perform on tests typically used to assess memory and thinking.  While studies have shown that the 
brain’s ability to think and remember may be affected in persons following treatment for primary 
brain tumor, studies have not been done to learn what everyday activities persons continue to perform 
or may have difficulties with after treatment completion.  With this information, we may improve 
how we detect changes in memory and thinking during treatment.
HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY?
If you decide to be in this study, you will be one of approximately 40 adults with primary brain 
tumors in this research study at Duke University.
WHAT IS INVOLVED IN THE STUDY?
After you review this consent form and have an opportunity to ask questions about the testing 
procedures, you will have your vital signs measured (heart rate, blood pressure, blood oxygen levels 
in your finger).  Next you will be asked to complete questionnaires about depression, your ability to 
take care of yourself, and if you have noticed any problems with your ability to think or remember.  
This can take between 15 to 30 minutes to do.
Afterwards, you will be asked to take a brief neurological test and be asked to complete some tests 
that measure your ability to think and remember.  This part of the study should take no more than one 
hour to do.  Between tests, we will give you time to rest, get something to drink or eat or go to the 
bathroom.  All together, this part of the study, should take no more than 90 minutes to complete.  
Audio-recording
The tests we will be using must be given in a specific order, at a specific time, and many require that 
you tell us the correct answer.  Therefore, we will use a tape recorder to make sure the person giving 
the test starts the test in the correct order, at the right time, and writes down your answers correctly.  
Only members of the research team will have access to these recordings.  The recordings will be kept 
in a locked cabinet and will be destroyed after the study has ended.  
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ARE THERE ANY REASONS NOT TO BE IN THIS STUDY?
You should not be in this study if you have had any seizures in the past six months requiring 
medication changes, any known neurodegenerative disorders or taking medications for a similar 
disorder such as Parkinson’s disease, multiple sclerosis, Alzheimer’s Disease or other dementias, 
psychiatric disorders such as schizophrenia, mania, or bipolar disorder, known problems holding a 
pen in your hand or moving your arms or legs, problems speaking clearly, problems with sleep such 
as sleep apnea, or history of stroke, HIV, herpes, tuberculosis, syphilis, or hepatitis.  You should not 
participate today if you have been treating a cold with over-the-counter medications in the past two 
weeks, drank alcoholic beverages or taken recreational drugs in the past 24 hours, or took sleeping 
medicines last night which you do not routinely take every night, or smoked tobacco products within 
four hours prior to testing procedures.  
HOW LONG WILL I BE IN THIS STUDY?
The study will take no more than 2 hours to complete. 
WHAT ABOUT MY RIGHTS TO DECLINE PARTICIPATION OR WITHDRAW FROM 
THE STUDY?
You may choose not to participate by telling the study staff and declining to sign the consent form.  If 
you begin the study, you can choose to stop participating at any time without penalty at any time.  
You may opt not to complete a survey or refuse to participate in a structured interview. 
WHAT ARE THE RISKS OF THE STUDY?
There are no major risks to you as a subject in this study.  It is possible that you may feel 
uncomfortable with some of the tasks that we ask you to do.  For example, the memory test may 
make you feel anxious because some of the answers will be very easy and some will be very hard.  
We do not expect you to know all the answers.  Please do not hesitate to ask any member of the 
research team any question, and we want you to tell us about any problems you may be having.  
Because we are taking many measurements, we may find people who may have a condition that 
requires medical attention.  Examples of conditions that require medical attention include having a 
high pulse rate, high or low blood pressure, or below normal measures on a memory or thinking test.  
If this is detected, we will talk with you and give you a form that tells you (1) what we found, (2) 
what it may mean in terms of your health, and (3) where you can go to get some help.  Lastly, there 
may be uncommon or previously unknown risks.  You should report any problems to the researcher.
ARE THERE BENEFITS TO TAKING PART IN THE STUDY?
Research is designed to benefit society by gaining new knowledge.  We hope that the information 
learned from this study will help identify successful strategies used for remembering and thinking 
that will benefit survivors of primary brain tumors. You may not benefit personally from being in this 
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research study.
WILL MY INFORMATION BE KEPT CONFIDENTIAL?
Study records that identify you will be kept confidential as required by law. Federal Privacy 
Regulations provide safeguards for privacy, security, and authorized access. Except when required by 
law, you will not be identified by name, social security number, address, telephone number, or any 
other direct personal identifier in study records disclosed outside of Duke University Health System 
(DUHS). For records disclosed outside of DUHS, you will be assigned a unique code number. The 
key to the code will be kept in a locked file in Ms. Allen’s office.
As part of this study, Ms. Allen and her study team will ask you to answer questions and complete 
memory tests.  Results of these tests and questionnaires will not be included in your medical record.  
The data collected at Duke University and University of North Carolina at Chapel Hill will be merged 
into one dataset for study analyses procedures after unique code numbers are assigned.  
Your records may be reviewed in order to meet federal or state regulations.  Reviewers may include 
representatives from the Duke University Health System Institutional Review Board. If this group 
reviews your research record, they may also need to review your entire medical record.
The study results will be retained in your research record for at least six years after the study is 
completed.  At that time either the research information not already in your medical record will be 
destroyed or information identifying you will be removed from such study results at DUHS.  Any 
research information in your medical record will be kept indefinitely.
If this information is disclosed to outside reviewers for audit purposes, it may be further disclosed by 
them and may not be covered by the federal privacy regulations.  
While the information and data resulting from this study may be presented at scientific meetings or 
published in a scientific journal, your identity will not be revealed.  
WHAT ABOUT COMPENSATION?
You will receive $25.00 for taking part and completing the procedures in this study.  You will also 
receive a parking voucher.  There will be no costs to you for being in this study.
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS?
For questions about the study or if you have problems, concerns, questions or suggestions about the 
research, contact Ms. Deborah Allen at 919-883-7002 at any time including after hours and on 
weekends and holidays.
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For questions about your rights as a research participant, or to discuss problems, concerns or 
suggestions related to the research, or to obtain information or offer input about the research, contact 
the Duke University Health System Institutional Review Board (IRB) Office at (919) 668-5111.
STATEMENT OF CONSENT
"The purpose of this study, procedures to be followed, risks and benefits have been explained to me.  
I have been allowed to ask questions, and my questions have been answered to my satisfaction.  I 
have been told whom to contact if I have questions, to discuss problems, concerns, or suggestions 
related to the research, or to obtain information or offer input about the research.  I have read this 
consent form and agree to be in this study, with the understanding that I may withdraw at any time.  I 
have been told that I will be given a signed and dated copy of this consent form."
__________________________________________ ___________
Signature of Subject Date
__________________________________________ ___________
Signature of Person Obtaining Consent Date
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You are being asked to take part in this research study because you have received treatment for your 
primary brain tumor.  Research studies include only people who choose to take part.  Please read this 
consent form carefully and take your time making your decision.  As your study staff discusses this 
consent form with you, please ask him/her to explain any words or information that you do not 
clearly understand.  The nature of the study, risks, inconveniences, discomforts, and other important 
information about the study are listed below.
Ms. Deborah Allen and Dr. Annick Desjardins will conduct the study..
WHY IS THIS STUDY BEING DONE?
The major purpose of this research study is to learn about strategies that persons who have undergone 
treatment for primary brain tumors use for memory and thinking as compared to persons who do not 
have primary brain tumors.  While studies have shown that the brain’s ability to think and remember 
may be affected in persons following treatment for primary brain tumor, studies have not been done 
to learn about the strategies persons use.  This additional information will assist us in identifying 
ways to promote maintaining thinking and memory abilities.
HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY?
If you decide to be in this part of the study, you will be one of approximately 10 adults with primary 
brain tumors and 10 healthy adults who will participate atDuke University.
WHAT IS INVOLVED IN THE STUDY?
In this supplemental study, you will be video-recorded while you complete the tests for your memory 
and thinking.  This will be done so that the researcher can learn more about what you may do that 
helps you to successfully complete the tests.  Often times, people move or do things that, while they 
are not aware of it, may help them to do a task faster or more accurately.  The tapes will help us to see 
these things.  The video camera will include your face as well as the upper portion of your body.  The 
video recordings will be kept in a locked cabinet.  These tapes will be destroyed after the researcher 
reviews the tapes.  
At the end of the tests for your memory and thinking, you will be asked a few questions asking you 
about what tests were more or less difficult and what strategies you may have used to complete the 
tests.  This should take no more than 30 minutes to complete.
ARE THERE ANY REASONS NOT TO BE IN THIS STUDY?
You should not be in this study if you have had any seizures in the past six months requiring 
medication changes, any known neurodegenerative disorders or taking medications for a similar 
disorder such as Parkinson’s disease, multiple sclerosis, Alzheimer’s Disease or other dementias, 
psychiatric disorders such as schizophrenia, mania, or bipolar disorder, known problems holding a 
pen in your hand or moving your arms or legs, problems speaking clearly, problems with sleep such 
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as sleep apnea, or history of stroke, HIV, herpes, tuberculosis, syphilis, or hepatitis.  You should not 
participate today if you have been treating a cold with over-the-counter medications in the past two 
weeks, drank alcoholic beverages or taken recreational drugs in the past 24 hours, or took sleeping 
medicines last night which you do not routinely take every night, or smoked tobacco products within 
four hours prior to testing procedures.  
HOW LONG WILL I BE IN THIS STUDY?
This supplemental study will take 30 additional minutes to complete after the first testing battery.
WHAT ABOUT MY RIGHTS TO DECLINE PARTICIPATION OR WITHDRAW FROM 
THE STUDY?
You may choose not to participate by telling the study staff and declining to sign the consent form.  If 
you begin the study, you can choose to stop participating at any time without penalty at any time in 
this study.  You may opt not to complete a survey or refuse to participate in a structured interview. 
WHAT ARE THE RISKS OF THE STUDY?
There are no major risks to you as a subject in this study.  It is possible that you may feel 
uncomfortable with some of the tasks that we ask you to do.  For example, the memory test may 
make you feel anxious because some of the answers will be very easy and some will be very hard.  
We do not expect you to know all the answers.  Please do not hesitate to ask any member of the 
research team any question, and we want you to tell us about any problems you may be having.  
Because we are taking many measurements, we may find people who may have a condition that 
requires medical attention.  Examples of conditions that require medical attention include having a 
high pulse rate, high or low blood pressure, or below normal measures on a memory or thinking test.  
If this is detected, we will talk with you and give you a form that tells you (1) what we found, (2) 
what it may mean in terms of your health, and (3) where you can go to get some help.  Lastly, there 
may be uncommon or previously unknown risks.  You should report any problems to the researcher.
ARE THERE BENEFITS TO TAKING PART IN THE STUDY?
Research is designed to benefit society by gaining new knowledge.  We hope that the information 
learned from this study will help identify successful strategies used for remembering and thinking 
that will benefit survivors of primary brain tumors.   You may not benefit personally from being in 
this research study.
WILL MY INFORMATION BE KEPT CONFIDENTIAL?
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Study records that identify you will be kept confidential as required by law. Federal Privacy 
Regulations provide safeguards for privacy, security, and authorized access. Except when required by 
law, you will not be identified by name, social security number, address, telephone number, or any 
other direct personal identifier in study records disclosed outside of Duke University Health System 
(DUHS). For records disclosed outside of DUHS, you will be assigned a unique code number. The 
key to the code will be kept in a locked file in Ms. Allen’s office.
As part of this study, Ms. Allen and her study team will ask you to answer questions and complete 
memory tests.  Results of these tests and questionnaires will not be included in your medical record.  
The data collected at Duke University and University of North Carolina at Chapel Hill will be merged 
into one dataset for study analyses procedures after unique code numbers are assigned.  
Your records may be reviewed in order to meet federal or state regulations.  Reviewers may include 
representatives from the Duke University Health System Institutional Review Board. If this group 
reviews your research record, they may also need to review your entire medical record.
The study results will be retained in your research record for at least six years after the study is 
completed.  At that time either the research information not already in your medical record will be 
destroyed or information identifying you will be removed from such study results at DUHS.  Any 
research information in your medical record will be kept indefinitely.
If this information is disclosed to outside reviewers for audit purposes, it may be further disclosed by 
them and may not be covered by the federal privacy regulations.  
While the information and data resulting from this study may be presented at scientific meetings or 
published in a scientific journal, your identity will not be revealed.  
WHAT ABOUT COMPENSATION?
You will be receiving $25.00 for taking part and completing the procedures in this study.  You will 
also receive a parking voucher.  There will be no costs to you for being in this study.
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS?
For questions about the study or if you have problems, concerns, questions or suggestions about the 
research, contact Ms. Deborah Allen at 919-883-7002 at any time including after hours and on 
weekends and holidays.
For questions about your rights as a research participant, or to discuss problems, concerns or 
suggestions related to the research, or to obtain information or offer input about the research, contact 
the Duke University Health System Institutional Review Board (IRB) Office at (919) 668-5111.
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STATEMENT OF CONSENT
"The purpose of this study, procedures to be followed, risks and benefits have been explained to me.  
I have been allowed to ask questions, and my questions have been answered to my satisfaction.  I 
have been told whom to contact if I have questions, to discuss problems, concerns, or suggestions 
related to the research, or to obtain information or offer input about the research.  I have read this 
consent form and agree to be in this study, with the understanding that I may withdraw at any time.  I 
have been told that I will be given a signed and dated copy of this consent form."
__________________________________________ ___________
Signature of Subject Date
__________________________________________ ___________
Signature of Person Obtaining Consent Date
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APPENDIX C: RECRIJITMENT STRATEGIES
@ lll-r{p*uRs,N(;
December 5,2071
<Title> <First> (MidI) <<Lasb>
<Street_1>
,, Cityrr, < State> <<Zip1>> <<Zip9>
Dear <Title> <Lash>:
The University of North Carolina School of Nursing is performing a research study
with adult survivors of primary brain tumors to explore how persons maintain
cognitive function after receiving cancer-related treatment.
The major purpose ofthis research study is to leam how persons u&o have
undergone treatment for primary brain tumors use memory and thinking for the
completion of everyday activities. While studies have shown that the brain's
abillty to think and remember may be affected in persons following treatment for
prima.ry brain tumor, studies have not been done to learn what everyday activities
persons continue to use or may have difficulties with after treatment completion.
With this information, we may be able to design better methods to detect these
changes during treafinent and design ways to promote maintaining thinking and
memory abilities.
You are being asked to consider participating in this research study. Your
participation in the study is voluntary. If you decide to be in this study, you will be
one of 40 adults with primary brain tumors to participate. This study will take
place at the University of North Carolina or Duke University in coordination with
your routine oncology clinic visit so you will not have additional travel. The study
will take no longer than 3 hours to complete.
After you review this consent form and have opportunity to ask questions about the
testing procedures, you will be asked to complete a questionnaire about depression,
your ability to take care of yourself, and if you have noticed any problems with
your ability to think or remember. Afterwards, you will be asked to take a brief
neurological test and be asked to cornplete some tests that measure your ability to
think and remember. This part of the study should take no more than two houts to
do. Between tests, we will give you time to rest, use the restroom, and will provide
you something to drink or eat. You will be cornpensated for your time and travel
with $25.00 cash.
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If participating in this study sounds like something you might be interested in 
please call Ms. Allen, the Principal Investigator of this research study, at the 
number below to discuss the study in further detail.  This will take no more than 15 
minutes of your time.  Thank you for your consideration.
The number to call Ms. Allen is:    
919-883-7002
Sincerely,
Deborah H. Allen, RN, MSN, FNP-BC, AOCNP
Predoctoral Student, School of Nursing
University of North Carolina at Chapel Hill
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 Date 
Name 
Address Street 
Address City, State  Zip 
 
Dear Name,  
 
I am a doctoral student at the University of North Carolina School of Nursing.  I 
am writing to you regarding a research study that I am conducting at the Neuro-
Oncology clinics at both UNC and Duke University.  This study is exploring how 
persons with primary brain tumors maintain cognitive function after receiving 
cancer-related treatment.  Based on your treatment records, you are eligible to 
consider participating in this research study.  
 
The major purpose of this research study is to learn how persons who have 
undergone treatment for primary brain tumors use memory and thinking for 
everyday activities.  While studies have shown that the brain’s ability to think and 
remember may be affected in persons following treatment for primary brain tumor, 
studies have not been done to learn what everyday activities persons continue to 
use or may have difficulties with after treatment completion.  With this 
information, we may be able to design better methods to detect these changes 
during treatment and design ways to promote maintaining thinking and memory 
abilities. 
 
You are being asked to consider participating in this research study.  Your 
participation in the study is voluntary.  If you decide to be in this study, you will be 
one of 40 adults with primary brain tumors to participate.  This study will take 
place at the University of North Carolina or Duke University in coordination with 
your routine oncology clinic visit so you will not have additional travel.  The study 
will take no longer than 2 hours to complete.   
 
The following information relates to the study procedures if you decide to 
participate.  When you present to the agreed upon time for study participation, you 
will have the opportunity to review the study consent form and ask questions about 
the testing procedures.  You will then be asked to complete a questionnaires about 
depression, your ability to take care of yourself, and if you have noticed any 
problems with your ability to think or remember.  Afterwards, you will be asked to 
 
175
take a brief neurological test and be asked to complete some tests that measure 
your ability to think and remember.  This part of the study should take no more 
than 2 hours to do.  Between tests, we will give you time to rest, use the restroom, 
and will provide you something to drink or eat.  You will be compensated for your 
time and travel with $25.00 cash and a parking garage voucher.   
 
If participating in this study sounds like something you might be interested in 
please call Ms. Allen, the Principal Investigator of this study, at the number below 
to discuss the study in further detail.  Thank you for your consideration. 
 
 
The number to call Ms. Allen is:    
919-883-7002 
 
 
Sincerely, 
 
 
 
Deborah H. Allen, RN, MSN, FNP-BC, AOCNP 
Predoctoral Student, School of Nursing 
University of North Carolina at Chapel Hill 
Clinical Associate, School of Nursing 
Duke University 
 
 
Annick Desjardins, MD, FRCPC 
Assistant Professor of Medicine 
Preston Robert Tisch Brain Tumor Center at Duke 
Duke Cancer Institute 
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ARE YOU A SURVIVOR OF A BRAIN TUMOR
and Interested in Participating in Research?
If you are between 30 & 65 years of age and have 
undergone treatment for a primary brain tumor, you may be 
eligible to participate in a research study that is examining 
cognitive function in survivors of primary brain tumors.
       
If you chose to participate, you will come to the 
School of Nursing in the morning to early 
afternoon.  While there, you will complete:
 Questionnaires about your health and ability to care 
for yourself,
 Heart rate, blood pressure, oxygen level measured,
 Tests that will measure your ability to think, 
connect numbers and letters, and memory skills.
We will provide you with free parking and $25 for your 
time upon completion of testing procedures.  
There are no needles or blood draws!!!!
For more information, please call…
Deborah Allen, RN, MSN at 919-883-7002
Supported by the Biobehavioral Laboratory at 
The School of Nursing, The University of North Carolina at Chapel Hill
This study has been reviewed and approved by the UNC-Chapel Hill IRB (IRB# 11- 1635)
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ARE YOU A HEALTHY ADULT 
and Interested in Participating in Research?
If you are between 30 & 65 years of age and have no 
neurological disorders, you may be eligible to participate in 
a research study that is examining cognitive function, 
particularly your thinking and memory.
       
If you chose to participate, you will come to the 
School of Nursing in the morning to early 
afternoon.  While there, you will complete:
 Questionnaires about your health and ability to care 
for yourself,
 Heart rate, blood pressure, oxygen level measured,
 Tests that will measure your ability to think, 
connect numbers and letters, and memory skills.
We will provide you with free parking and $25 for your 
time upon completion of testing procedures.
There are no needles or blood draws!!!!
For more information, please call…
Deborah Allen, RN, MSN at 919-883-7002
Supported by the Biobehavioral Laboratory at 
The School of Nursing, The University of North Carolina at Chapel Hill
This study has been reviewed and approved by the UNC-Chapel Hill IRB (IRB# 11- 1635)
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Are You Interested in Participating in a 
Research Study?
If you are 30-65 years of age and have undergone treatment 
for a primary brain tumor OR 30-65 years of age with no 
known neurological disorder and willing to serve as a 
healthy adult control, then you may be eligible to 
participate in a research study that is examining cognitive 
function, particularly your thinking and memory.       
If you chose to participate, you will come to the School of 
Nursing in the morning to early afternoon.  While there, 
you will complete:
 Questionnaires about your health and ability to 
care for yourself,
 Heart rate, blood pressure, oxygen level 
measured,
 Tests that will measure your ability to think, to 
connect numbers and letters, and memory 
skills.
We will provide you with free parking and $25 for your time
upon completion of the testing procedures.
There are no needles or blood draws!!!!
For more information, please call…
Deborah Allen, RN, MSN at 919-883-7002
This study has been reviewed and approved by the UNC-Chapel Hill IRB (IRB# 11-1635)
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APPENDIX D: TELEPHONE SCREENING
l)ate / I
Appendix A.l
TBLEPHONE SCREENING INSTRT]MENT
[. PHONE Re,cnurrrwrxt SCRIPT
A. lntroductory Remarks:
"Hello, this is Debbie Allen, from the Univetsity of North Carolina School of Nursing. I
understand that you would like to learn more about participating in a research study
involving how you think and remernber and any strategies you may use to maintain your
ability to think and remember. Is this a good time to talk?" If not, ask the potential
participant "when is a good time to call you?"
If we need to c'all again, date/time agreed upon:
B. Brief Description of the Study
"I thank you for yout call and your interest to discuss this study more. The purpose of
this research is to compare thinking and memory in persons who have undergone
fteatment fbr a primary brain tumor as to persons who have not had a brain tumor and to
learn u,hat strategies you may use to maintain your thinking and memory."
"We will ask you questions about your health, how well you think and remember, and
your daily activities, as well as measure your abililv to think and remember. It is our aim
to use this information to design better methods to detect early changes in cognition and
design inter-ventions to decrease the risk offurther decline. We ale testing this only in
adults with primary brain tumors and healthy adults. The total time to complete the study
will be no longer than three hours and we will compensate you for your time and travel
with $25.00 cash. Does this sound like something you might be interested in?"
Response: Yes No
If they say yes, go to the Mini-Consent for Telephone Screening.
If they say no, thank them for their time and interest in speaking with you"
ID:
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Date _____/_____/______  ID: ___________ 
 
C.  Mini-Consent for the Telephone Screen 
 
After the respondent tells you that they are interested in participating, ask them 
“Is it okay to ask you a few questions about your health and the medications you take?  It 
should take no more than 15 minutes.” 
 
  
   
If they say yes, go to Health Screening Questionnaire. 
 
If they need to reschedule, ask them for preference of contact phone numbers 
and a date/time to call.  
   Phone number 1:   (____) _____- ________ 
   Phone number 2:   (____) _____- ________ 
   Date & Time: _____________ , _________ AM/PM  
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Date _____/_____/______ ID: ___________
A.1-3
II.  RESPONDENT TELEPHONE SCREENING 
A.  Tracking Information
Date respondent called for information: ____/____/____
Date PI returned call: ____/____/____
B.  Group Assessment
1.  Have you had a brain tumor?
a.   Have you had surgery, chemotherapy, or radiation therapy as treatment for your   
brain tumor? Yes                No
i.    Date of surgery  _____/_____/_____   or     NA
ii.   Date of radiation therapy _____/_____/_____    or     NA
iii.  Date of chemotherapy   _____/_____/_____    or     NA
b.  Are you still on any chemotherapy?          Yes                No
If yes, what kind of chemotherapy are you taking? ________________________
If they do not remember the name, ask them if it is the following agents (circle the 
agent they indicate):
Carmustine, Lomustine (CeeNU), Carboplatin, Temozolomide (Temodar), 
Etoposide (Vepesid, VP-16), Irinotecan (CPT-11, Camptosar), Procarbazine 
(Matulane)
     
c.  Do you have any problems with holding a pen, writing, or speaking?     Yes        No
If they say yes, they are assigned to the brain tumor subject group.
Proceed to ask questions a and b below.
If they say no, they are assigned to the control group.
Proceed to question 2. 
If YES, stop interview here and go to NOT ELIGIBLE section on the last page
If any of the agents listed is an agent the responder is currently taking, 
stop interview and go to NOT ELIGIBLE section on the last page.
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Date _____/_____/______ ID: ___________
A.1-4
2.  Medications
Are you taking medications (including prescription & over-the-
counter)?
Yes      No
Record below:
Medication Name Reason for taking
1.     
2.     
3.     
4.     
5.     
6.     
7.     
8.   
9.
10.
11.
12.
Compare the list of medications to the Medication Exclusion Card.  Exclude the subject if 
she or he is taking any of the medications listed on the Medication Exclusion Card.  Put a 
check next to the name of any drug that excludes the subject from participating.  
MEDICATION EXCLUSION 
   Changes in seizure medications in the last six months YES NO
   Dopaminergics YES NO
   Major anticholinergics YES NO
   Alzheimer’s drugs YES NO
   Cold medications, sedative hypnotics in past 48 hours? YES NO
Medication Exclusion:
      Taking a medication on the Medication Exclusion Card? Yes No
If YES, STOP interview here.  
Go to Not Eligible section on last page.
If they say yes, ask “What medications are you taking?”
If they do not know, ask them to read all medication bottles to you that they 
have.
Proceed to questions 
183
Date _____/_____/______ ID: ___________
A.1-5
3.  Neurological Conditions
I’m now going to read a list to you. Please wait until I have read the entire list, and 
then say ‘yes’ if you have been diagnosed with any of these conditions, or say ‘no’ if 
you have not. 
a. Alzheimer’s Disease
b. Dementia
c. Parkinson’s Diseases
d. Schizophrenia
e. Mania
f. Bipolar Disorder
g. Unstable Seizure Disorder requiring antiepileptic changes in the last six months
h. Any problems with numbness or tingling in your arms or legs
i. Any problems moving your arms or legs
j. Had any surgery requiring general anesthesia in the last two weeks
Neurological Disease Exclusion:
Answer of “Yes” to any of the neurological conditions? Yes No
If YES, STOP interview here.  
Go to “Not-Eligible” section on last page.
4.  Other Neuroimmune Disorders
For this next list, again, please wait until I have read the entire list, and then say ‘yes’ 
if you have been diagnosed with any of these conditions, or say ‘no’ if you have not. 
a. Tuberculosis
b. Hepatitis
c. HIV or AIDS
d. Herpes
e. Syphilis
Neuroimmune Disorder Exclusion:
Answer of “Yes” to any of the neuroimmune disorders? Yes No
If YES, STOP interview here.  
Go to “Not-Eligible” section on last page.
5.  Cerebrovascular Events
For this next list, please wait until I have read the entire list, and then say ‘yes’ if you 
have had any of these conditions in the past 6 months or say ‘no’ if you have not. 
a. Stroke or Transient Ischemic Attack
b. Hit your head and lost consciousness 
Cerebrovascular Event Exclusion:
Answer of “Yes” to any of the cerebrovascular events? Yes No
If YES, STOP interview here.  
Go to “Not-Eligible” section on last page.
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A.1-6
6.  Sleep-Related Symptoms
After I have read the next list, please say ‘yes’ if you have had any of the following 
problems in the past month, or say ‘no’ if you have not.
a. Pain so bad it keeps you awake
b. Having to get up and urinate 3 or more times a night
c. Being easily awakened by sounds 
d. Having difficulty sleeping when away from home
e. Walking in your sleep
f. Falling out of bed
g. Waking from sleep violent or confused
Sleep-Related Exclusions:
Answer of “Yes” to any of the sleep-related symptoms  
questions?
Yes No
If YES, STOP interview here.  
Go to “Not-Eligible” section on last page.
7.  Alcohol & Drug Exclusions
These next questions are about alcohol and illegal drugs.  Please wait until I have read 
the entire list, and then just say ‘yes’ if you do any of the following or ‘no’ if you do 
not:
a. Have more than 3 cans of beer on more than 3 nights/week
b. Have more than 3 glasses of wine on more than 3 nights/week
c. Have more than 3 shots of distilled liquor on more than 3 nights/week
d. Currently smoke marijuana or use illegal drugs
Alcohol and Drug Exclusion:
Answer of “Yes” to any of the alcohol/drug questions? Yes No
If YES, STOP interview here.  
Go to “Not-Eligible” section on last page.
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A.1-7
8.   Age in Years
                    What is your date of birth? ____/_____/_____
9.  Years of Education 
         How many years of education have you completed?            _______ years
Born In Years Old Born in Years old
Before 1946 > 65 1964 47
1946 65 1965 46
1947 64 1966 45
1948 63 1967 44
1949 62 1968 43
1950 61 1969 42
1951 60 1970 41
1952 59 1971 40
1953 58 1972 39
1954 57 1973 38
1955 56 1974 37
1956 55 1975 36
1957 54 1976 35
1958 53 1977 34
1959 52 1978 33
1960 51 1979 32
1961 50 1980 31
1962 49 1981 30
1963 48 After 1981 < 30
Age exclusion:
      Age < 30 years     OR                Age > 65 years Yes No
If YES, STOP interview here.  
Go to “Not-Eligible” section below.
“That would mean that you are:  ________ years old.”
: ___/____/____ - ___/___/____
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A.1-8
10.  Mental Status Exam
The Telephone Interview for Cognitive Status
(Brandt, Spencer, & Folstein, 1988)
Instructions to Patient: “Now I’d like you to answer some questions and ask you to 
follow some instructions.  Do your best to respond to each question or instruction.  Some 
will seem very simple and some will be more difficult.”
Code in margin any question that patient refuses to answer (9) or is physically unable to answer (8).
Do not include the 8’s and 9’s in the total score, but do indicate reason code was used (where applicable).
Points
Avail.
Points
Earned
1. Ask “Please tell you full name?”
                      First Name 1   ______
                      Last Name 1   ______
2.  Ask “What is today’s date?”
Month 1   ______
                        Date 1   ______
Year 1   ______
Day of week 1 ______
Season 1   ______
If incomplete, ask specifics, such as ask  
“What is the month? “
                             “What season are we in?”
3. Ask:  “Where are you right now?”
                       House number 1   ______
                       Street 1   ______
                       City 1 ______
                       State 1   ______
                       Zip 1   ______
If incomplete, ask specifics, such as ask  
“What street are you on right now?”
4.  Ask “Count backwards from 20 to 1.”
                       2 points if completely correct on the first trial 2   ______
                       1 point is completely correct on second trial 1   ______
                       0 points for anything else 0 ______
Total Score for this Page 14 ______
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A.1-9
Points
Avail.
Points
Earned
5.   State “I am going to read you a list of 10 words.  Please listen 
carefully and try to remember them.  When I am done, tell me as 
many words as you can, in any order.  Ready?  
     The words are cabin, pipe, elephant, chest, silk, theatre, watch, 
whip, pillow, giant. Now tell me all the words you can remember.”
Cabin 1   ______
                        Pipe 1   ______
                        Elephant 1   ______
                        Chest 1   ______
                        Silk 1   ______
                        Theatre 1   ______
                        Watch 1   ______
                        Whip 1   ______
Pillow 1   ______
Giant 1 ______
There is no penalty for repetitions or intrusions.
6.  State “I want you to start with the number 100, subtract 7, and tell me 
your answer.  So 100 minus 7 equal what?”
     “And 7 from that?”
     “Keep subtracting seven until I tell you to stop.”
                        Stop after five answers; you may prompt after each answer.
                             1 point for each correct subtraction.
                             Do not inform the subject of incorrect responses, but allow subtractions 
                             to be made from the last response
                              (e.g. “93-85-78-71-65” would get 3 points)
Record responses:  _____   _____   _____   _____   _____
Correct Responses:    93        86          79           72            65 5   ______
7.  Ask the following questions:
    “What do people usually use to cut paper?”
                        1 point for “scissor” or “shears” only 1 ______
    “How many things are in a dozen?”
                        1 point for “12”              1 ______
    “What do you call the prickly green plant that lives in the desert?”
                        1 point for “cactus” only 1 ______
    “ What animal dose wool come from”
                        1 point for “sheep” or “lamb” only          1 ______
Total Score for this Page 19 ______
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A.1-10
Points
Avail.
Points
Earned
8.  Have the patient repeat these statements.
     “Say this: ‘No ifs, ands, or buts’.”
Stress s’s when you say it, s’s must be repeated back for a correct response.
              1 point for each complete repetition on the first trial.  
               Repeat only poorly presented.
1 ______
     “Say this:  ‘Methodist episcopal’.”
            1 point for each complete repetition on the first trial.  
               Repeat only poorly presented. 1 ______
9.  Ask these questions:
     “Who is the President of the United States right now?”
             1 point for correct first and last name. 1 ______
     “Who is the Vice-President?
             1 point for correct first and last name. 1   ______
10.  State:  
       “With your finger, tap 5 times on the part of the phone you speak into.”
              2 points if 5 taps are heard 2   ______
                1 point if subject taps more or less than 5 times 1   ______
11.  State:
       “I’m going to give you a word and I want you to give me its opposite.
         For example, the opposite of hot is cold.
         What is the opposite of ‘west’?”
               1 point for “east” 1   ______
          “What is the opposite of ‘generous’?”
                 1 point for “selfish,”  “greedy,”  “stingy,”  “tight,”  “cheap,”  “mean,” 
                                   “meager,”  “skimpy,” or other good antonym 1   ______
Total Score for this Page 8   ______
Total Score for Page 1 14   ______
Total Score for Page 2 19 ______
Total Score 41 ______
Mental Status Exclusion
       Score of 30 OR Less                                                     Yes              No
            If YES, STOP interview here.  
Go to “Not-Eligible” section.
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A.1-11
Modified Everyday Cognition Scale
(Farias, 2007; Allen 2009)
Instructions to Responder:
Read aloud:  “Now I will ask you to rate your ability to perform certain everyday tasks NOW, as 
compared to your ability to do these same tasks 10 years ago.   Try to remember how you were 
10 years ago and indicate any change you have seen.”  
Check the box that fits their responses to the following sentence:
    Compared to 10 years ago, I have noticed a change in…
No 
problems
Yes I have 
problems
1.   Planning the sequence of stops on a shopping trip. □ □
2.   The ability to anticipate weather changes and plan 
accordingly (i.e. bring a coat or umbrella).
□ □
3.   Developing a schedule in advance of anticipated events. □ □
4.   Thinking things through before acting. □ □
5.   Thinking ahead. □ □
6.   Keeping living and work space organized. □ □
7.   Balancing the checkbook without error. □ □
8.   Keeping financial records organized. □ □
9.   Prioritizing tasks by importance. □ □
10. Keeping mail and papers organized. □ □
11. Using an organized strategy to manage a medication 
schedule involving multiple medications.
□ □
12. The ability to do two things at once. □ □
13. Returning to a task after being interrupted. □ □
14. The ability to concentrate on a task without being distracted 
by external things in the environment.
□ □
15. Cooking or working and talking at the same time. □ □
Subsample Eligibility for Compensatory Behavior Observation (video-recording) in the 
UNC SON Biobehavioral Laboratory:
If the responder indicated difficulty by answering yes 5 or more items, ask the responder:
“A component of this study is looking at how you maintain your thinking and memory abilities.  
A way to do this is through video-recording in a laboraoty setting at the UNC School of 
Nursing.  Would you consider doing the study procedures in the UNC School of Nursing so that 
we may video-record your thinking and memory abilities.”     Yes       No
     IF yes, schedule with UNC SON BBL, otherwise schedule with neuro-oncology clinic.
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A.1-12
Not-Eligible Section
If the subject is deemed ineligible for study, state:
“Thank you for you time today.  We appreciate your interest.   However some health 
conditions or medications may interfere with the results with the study tests.  We are 
not able to enroll you in the study, but greatly appreciate your time and effort.”  
191
Date _____/_____/______ ID: ___________
A.1-13
COMPLETION OF TELEPHONE ELIGIBILITY
Script
Thank you for answering all of these questions.  You may enroll to participate in the 
study by completing more study questions that will be done at the UNC School of 
Nursing or Neuro-Oncology Clinic.  What upcoming date or days of the week are you 
able to come to the School of Nursing or Neuro-Oncology Clinic?
Instructions to the Participant
You will receive a subject information packet that provides a letter telling you the 
scheduled study date and time, instructions for transportation and parking with a map, an 
overview of the study and things you will need to do the night before the study.  I want 
you to read over all these instructions when you received them in the mail and call me if 
you have any questions.
It is expected that you will complete the study within three hours, depending on your 
needs.  While you are with us, you will be provided some nourishing refreshments.  
Please bring any medications that you need to take during those times with you.  
Would you like to have a reminder call the day before you come in for the research 
study?  
We thank you for your interest in this study and your willingness to participate.  I look 
forward to working with you in this research study at the UNC School of Nursing.
   Date 1:  ____/____/______  Time: ___:____
   Date 2: ____/____/______  Time: ___:____
Enter these dates to schedule the study procedures to check for availability 
with the UNC SON BBL calendar on the Scheduling Form, next page.
   Yes             No
If yes, ask them for two phone numbers of their choice to contact them.
Contact 1:  (_____) ______ - ________
Contact 2:  (_____) ______ - ________
What address would you like for us to mail this information packet to?
Street or Box:  ________________________________________
________________________________________
City:   ________________________________________
State: _____________ Zip:___________________
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SUBJECT INFORMATION PACKET 
 
 
Instructions for sending the Subject Information Packet 
 
1.  After consulting with the UNC SON Biobehavioral Laboratory calendar to schedule 
the subject, you will send the Subject Information Packet to the subject.   
 
This packet contains: 
1.  Letter to subject with their scheduled study date and time 
2.  Instructions labeled “Overview of the study” 
3.  Instructions labeled “What you should know before coming for the study” 
4.  Instruction sheet labeled “Directions” 
5.  Map of the UNC Campus 
 
 
2.  Be sure to address the letter to the subject. 
 
3.  Be sure to insert in the letter (Item #1) the scheduled date and time. 
 
4.  Make a copy of the letter to be retained in the subject file which will be kept in the 
locked cabinet. 
 
 
193
 March 22, 2014 
«Title» «First» «MidI»  «Last» 
«Street_1» 
«City», «State» «Zip5»«Zip9» 
 
 
Dear «Title» «Last»: 
 
Thank you for participating in our research study titled “Pilot Study of Sensory 
Information Processing and Motor Processing: Relationship to Executive Control 
in Adults with Primary Brain Tumors.”  We’re very excited that you called us 
about this important study and we’re looking forward to seeing you for your 
scheduled appointment in the University of North Carolina, School of Nursing 
Biobehavioral Laboratory.  We presently have you scheduled to come in as 
follows: 
 
 Date:  «BDay1», «BDate1», at 
 Time:  «BTime2» 
 Place:  «BPlace3» 
 
I have enclosed materials that provide more detailed information that I hope you 
will find helpful.  Please pay special attention to the page entitled, “What you 
should do now.” 
If you indicated that you prefer to receive a reminder call prior to the study, I will 
call you at the indicated number and date to make sure that you received this 
packet and to answer any questions you may have.  Please bring this packet with 
you when you come for your study, because you will be receiving other 
information that you may want to keep together.  In the meantime, please feel free 
to phone me (919-883-7002) with any questions or concerns you might have.  
We’ll look forward to seeing you then! 
 
Sincerely, 
 
 
Deborah H. Allen, RN, MSN, FNP-BC, AOCNP 
Predoctoral Student, School of Nursing 
University of North Carolina at Chapel Hill 
 
194
Date: _____/_____/______  ID: _________ 
 
OVERVIEW OF THE STUDY PROTOCOL 
 
The study will be conducted at: 
_____  the Biobehavioral Laboratory at the UNC School of Nursing, located 
in Carrington Hall.   
_____  the Neuro-Oncology Clinic at UNC Lineberger Cancer Center 
_____  the Tisch Brain Tumor Center at Duke Cancer Institute 
 
We will ask that you report to the lab at the scheduled time of _______ as 
indicated in your letter.  The study will take 3 hours.   
 
You will be given time for breaks, as well as snacks and drinks.  You may opt to 
bring in food, drinks, or items like pillows to make sitting more comfortable.  Let 
us know if you have any special needs that we should know; you may call us at 
919-883-7002.   
 
What You Should Do Now 
 
 
1.  Please let us know if you have any food allergies or other dietary requirements 
of which we might not already be aware.  You may call us at (919) 883-7002. 
 
 
2.  Please let us know if you plan to park in the hospital parking deck so that we 
may have a parking voucher prepared for you.  If you are scheduled to perform the 
study at the UNC School of Nursing, let us know if you plan to drive so that we 
can reserve a parking space for you (see directions on the following page).  You 
may reach us by telephone at (919) 883-7002.   
 
 
If you would prefer not to drive, you may ride one of the Chapel Hill Transit 
busses free of charge.  There is a bus stop located directly in front of the School 
of Nursing.  If you are having difficulty in arranging for transportation, please 
call so that we may help.  If you would like for us to do this, please call us as 
soon as possible (919-883-7002) so we may have enough time to make plans 
for your transportation. 
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What You Should Know Before Coming In For Your Study 
 
1.  On the day before the study, you should do the things that you would regularly 
do.  This includes going to bed and getting up at your usual times, eating what you 
usually eat, and taking your medications as prescribed by your doctor.  (The 
exceptions to this are listed below under the heading “What we ask you to avoid.”) 
 
2.  If you have been taking cold medicines the week before the study, please call us 
to discuss rescheduling the study procedures.   
 
3.  Do not to bring any valuables (large amounts of money or jewelry) that could 
be stolen.  Although this is unlikely to occur, it is better to be safe than sorry. 
 
4.  Your family or friends may come with you to see the laboratory.   
 
What We Ask You To Avoid 
 
We would ask that you avoid the following so we get the best recordings possible: 
 
a. Any alcoholic beverages after dinner (including wine and beer) on the 
night before coming in for your study, 
 
b. Medications that help you sleep or cold medications for 24 hours before 
coming in for your study, and 
 
c. Do not smoke any tobacco products for 4 hours before coming in for 
your study. 
On the day of your appointment: 
If you are going to be late or need to cancel your study,  
please call Deborah Allen directly   
at phone number 919-883-7002. 
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Directions to the UNC School of Nursing Biobehavioral Laboratory 
 
1. North on 15-501 Bypass (from Burlington/Carrboro): Take the Chapel Hill-
Pittsboro exit.  At the stoplight, make a left onto South Columbia Street.  Follow 
the road up the hill and go through the intersection of South Columbia and 
Manning Drive.  Start to get into the right lane and turn right at the stop light onto 
Medical Drive.   
 
2. South on 15-501 Bypass (from University Mall/Durham):  From University 
Mall, get ready to make a right turn at the Highway 54 exit (as you head into 
campus this becomes South Road).  At the first stoplight at the top of the hill you 
will see the Institute of Law to your left.  Continue going straight on South Road.  
At the second stoplight you will see Fetzer Gymnasium to your left and Raleigh 
Road to your right.  You’ll next see Student Stores on your right, and the Bell 
Tower on your left.  Continue straight, through another 2 stoplights past Manning 
Drive.  Make a left turn onto Pittsboro Road.  Get  in the left turn lane as this will 
bring you to South Columbia and Manning Drive.  Take a left onto Manning Drive 
at the stop light. Start to get into the right lane and turn right at the stop light onto 
Medical Drive.     
 
3. From Highway 54 (RTP or Raleigh): Take Highway 54 toward campus, go 
under the 15-501 bypass, and continue up the hill (as you head into campus, Hwy 
54 becomes South Road).  At the first stoplight at the top of the hill you will see 
the Institute of Law to your left.  Continue going straight on South Road.  At the 
second stoplight you will see Fetzer Gymnasium to your left and Raleigh Road to 
your right.  You’ll next see Student Stores on your right, and the Bell Tower on 
your left.  Continue straight, through another 2 stoplights past Manning Drive.  
Make a left turn onto Pittsboro Road.  Get  in the left turn lane as this will bring 
you to South Columbia and Manning Drive.  Take a left onto Manning Drive at the 
stop light. Start to get into the right lane and turn right at the stop light onto 
Medical Drive.     
 
4. From Downtown Chapel Hill (Coming from Franklin Street):  From the 
intersection of Franklin and South Columbia Streets (Spanky’s is on this corner), 
take South Columbia into campus.  At the second stop light, make a right onto 
Cameron Avenue and get into the left lane.  At the next stoplight, make a left onto 
Pittsboro Street.  Then make a left again at the next stop light, which will be at 
McCauley Street.  Cross South Columbia Street (at this point McCauley Street 
becomes South Road).  Make a right at the next stop light, which is Bell Tower 
Drive (which will take you into the Bell Tower parking area).   
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LABORATORY SCREENING
ID:
A.4 Laboratory Intake Screen & Mini-Consent
LABORATORY INTAKE SCREEN
Subject Preparation
For study procedures in the LINC School of Nursing: Give the subject a tour of the BBL
including the test areA bathroom, and nourishment station. Offer them something to drink and
have them seated in the testing interview area. Make sure the door is closed to the BBL and the
interuiew room prior to proceeding with the Laboratory Intake Screen.
For study procedures in the Neuro-Oncology Clinic: Make srue the subject has had an
opporhrnity to use the restroom and have some nourishment. Offer them something to drink and
have them seated in the provided clinic room. Make sure the door has.a sign "Do Not Disturb"
to prevent intemrptions.
Mini Consent
Ask the potential subject:
'Before we start I'd like to ask you a few questions and would like to perform a brief exam on
your ability to process and think. This is to make sure that you have had not changes in your
health status since we spoke on the telephone. There are some health corditions or problems
with thinking that may keep you from participating in the study. If you are not eligible to be
involved in the study, I will shred all of the information that you have given me over the phone
and what we have done today and you will not receive the $25 for your time and travel" Is it okay
to proceed with the questions and test now?'
If yes, proceed with the for:r questions below.
lfno, stop the interview and thank the subject for coming.
Escort the subject and ask ifthey need directions back to their parking area
Adiunct to Pre-Study Instrument
"Since we've last talked have you had any of the following:
1. Surgical procedures requiring general anesthesia?
2. Please tell me about any new medicine you are taking.
List the medications:
Yes
Yes
Yes
No
Are any ofthese drugs a sedative hypnotic or cold rnedication? Yes No
No
No
3. Have you had alcohol in the last 24 hours?
4. Have you smoked in the last 4 hours?
lf yes to any of the question, reschedule the resemch study time.
Date: I I Time:_:
lf no, proceed to the Mini-Mental Status Examination, next page.
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A.5  Mini-Mental Status Examination     
 
The Mini-Mental State Examination 
(Folstein et al., 1975) 
 
Instructions to Patient: “Now I’d like you to answer some questions and follow some 
Instructions.  Do your best to respond to each question or instruction.  Some will seem very 
simple and some will be more difficult.” 
 
Code in margin any question that patient refuses to answer (9) or is physically unable to answer (8). 
Do not include the 8’s and 9’s in the total score, but do indicate reason code was used (where applicable). 
   
 
Orientation 
Points 
Avail. 
Points 
Earned
1. Ask first:  “What is the day, date and season?” 
 If information is omitted, ask as needed: 
  
  Year 1   ______ 
  Season? 1   ______ 
  Date? 1 ______ 
  Day?   1   ______ 
  Month? 1   ______ 
   
  If patient can’t answer three of these correctly ask,  
  “What part of the day is this?” (morning, afternoon, evening, night).  
  Code response at end of MMSE total (see item #13) 
  
   
2. Ask:  “What is the name of this place and where is it located?” 
 If information is omitted, ask as needed: 
  
  State? 1   ______ 
  County? 1   ______ 
  Town or City? 1 ______ 
  Building? 1   ______ 
  Floor? 1   ______ 
   
   
Registration   
3. Name three objects, taking one second to say each.  
“I am going to give you a list of 3 words.  I want you to listen carefully then 
repeat them back to me. The words are book, house, candle. Please tell me 
the three words.” 
  
  Book 1   ______ 
  House 1   ______ 
  Candle 1 ______ 
  (Score responses on first try.  Then repeat objects until all are learned.)   
Tell patient, “Try to remember those objects because I’m going to ask you   
to repeat them from memory later.”   
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Attention and Calculation   
4. Serial Sevens.  Give one point for each correct answer.   
 “I want you to start with the number 100, subtract 7, and tell me 
 your answer.  So how much is 7 from 100?  _____  (93) 
 Now keep subtracting seven until I tell you to stop.” 
  (Stop after five answers; you may prompt after each answer.) 
  Record responses:   _____   _____   _____   _____   _____ 
  
  Correct Responses:    93        86          79           72             65 5   ______ 
   
 If patient missed any calculation, then ask the following:   
           “Now I am going to spell a word forward and I want you to spell  
 it backwards.  The word is ‘world,’ W-O-R-L-D.  Spell ‘world’  
 backwards.”  
  (Answer: D-L-R-O-W; repeat if necessary but not after spelling starts.   )
  Record responses:  _____   _____   _____   _____   _____ 
  
   
Recall   
5. Ask for the names of the three objects learned in Question 3.  
 (Give 1 point for each correct answer.) 
  
 (book, house, candle)  :  __________   __________   __________ 3 ______ 
   
Language   
6. Point to a pencil & a watch.  Have patient name them as you point.   
 “What do you call this?”   “What is this?” 2 ______ 
   
7. Have the patient repeat: “No ifs, ands, or buts.” 1 ______ 
 (Stress s’s when you say it, s’s must be repeated back for a correct response.)   
   
8. Have the patient follow a three-step command (using next page):   
 “Take this paper in your right hand, fold the paper in half with  
 both hands, and put the paper on the bed (floor, etc.).” 3 ______ 
   
9. Have the patient read and obey the following from the next page:   
      “CLOSE YOUR EYES.”   1 ______ 
   
10. Have the patient write a simple sentence of his or her choice. 1 ______ 
 (The sentence should contain a subject and a verb and should make sense. 
 Ignore spelling errors when scoring.). 
  
   
11. Put the Bender Gestalt design before patient and ask patient to,    
 “Copy this shape.” 1 ______ 
 (Give one point if all sides and angles are preserved and if the intersecting  
 sides form a quadrangle.). 
  
   
12. Total Score (sum 0’s & 1’s). 30 ______ 
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Close your eyes. 
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A.6   Subject Eligibility Form  
     
    SUBJECT ELIGIBILITY FORM 
Eligibility Criteria for Adult with Primary Brain Tumor TS / Lab 
Screen 
Yes No N/A 
Age 30 to 65 years old TS    
Read and write English language TS    
Primary Brain Tumor: 
1. Treated with prior chemotherapy or radiation therapy   
2. No signs of paresis or aphasia 
3. Has stable tumor status determined by neuro-oncologist 
TS    
Stable seizure status for last six months with no antiepileptic medication  
changes in the last six months 
TS    
TICS > 30 points TS    
MMSE > 24 points Lab    
Signed informed consent Lab    
     
Exclusion Criteria Exclude subject is yes to any of these     
General anesthesia within the last six months TS    
Paresis or Aphasia TS    
Known neurologic or cardiovascular disorders listed in Health History 
Screen     (Example:  Parkinson’s disease, multiple sclerosis, Alzheimer’s 
disease, CVA, immune disorders, depression, sleep disorder) 
TS    
Medications: 
Dopaminergics (Pramipexole, Ropinirole, Carbidopa, Levodopa) 
Major anticholinergics (Example: Phenothiazines, Antiparkinson meds) 
Alzheimer’s medications (Aracept, Remeril, Exelon, Namenda) 
TS    
Chemotherapy:  
Carmustine, Lomustine (CeeNU), Carboplatin, Temozolomide 
(Temodar), Etoposide (Vepesid, VP-16), Irinotecan (CPT-11, 
Camptosar), Procarbazine (Matulane) 
TS    
Sleep disorder/apnea or sedative hypnotic the night before TS & Lab    
Had cold meds, alcohol night before; tobacco 4 hr before Lab    
TS=telephone screen; N/A=not applicable 
 
Eligibility Criteria for Adult Healthy Control TS / Lab 
Screen 
Yes No N/A 
Age 30 to 65 years old TS    
Read and write English language TS    
TICS > 30 points TS    
MMSE > 24 points Lab    
Signed informed consent Lab    
     
Exclusion Criteria Exclude subject is yes to any of these     
General anesthesia within the last six months TS    
Paresis or Aphasia TS    
Known neurologic or cardiovascular disorders listed in Health History 
Screen     (Example:  Parkinson’s disease, multiple sclerosis, Alzheimer’s 
disease, CVA, immune disorders, depression, sleep disorder) 
TS    
Medications: 
Dopaminergics (Pramipexole, Ropinirole, Carbidopa, Levodopa) 
Major anticholinergics (Example: Phenothiazines, Antiparkinson meds) 
Alzheimer’s medications (Aracept, Remeril, Exelon, Namenda) 
TS    
Sleep disorder/apnea or sedative hypnotic the night before TS & Lab    
Had cold meds, alcohol night before; tobacco 4 hr before Lab    
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Date: I I ID:
1. Subject Packet
a. Demographiclnfonnation
b. Older Adults Resource Services Activities of Daily Living
Scale
c. Center for Epidemiological Studies Depression Scale
d. Functional Assessment of Cancer Therapy 
- 
Brain Tumor
e. MD Anderson Syrnptom Inventory 
- 
Brain Tumor
2. InvestigatorPacket
a. Health lnf.orn.ation Form
b. Everyday Cognitions Scale
c. EXIT-25
d. North American Adult Reading Test
e. Trails-Making Test Parts A and B
f. Controlled Word Association Test
g. Hopkins Verbal Leaming Test
h. ArrowFlankerTest
i. Symbol Digit Modaiities Testj. Visual Analog Scale for Subject Raring on Inshument
Difficulfy
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C.1     Subject Packet 
 
 
Instructions for Subject Packet 
The following questionnaires are to be completed by the subject:  
a. Demographic Information Sheet 
b. Older Adults Resource Services Activities of Daily Living Scale 
c. Center for Epidemiological Studies Depression Scale 
d. Functional Assessment of Cancer Therapy – Brain Tumor 
e. MD Anderson Symptom Inventory – Brain Tumor 
 
 
 
Provide a pencil with the forms for the subject. 
Be available to answer any questions. 
When the subject indicates that they are done, review the form to make sure all items are 
answered. 
 The subject may indicate that they prefer to take the forms home to complete.   
 If this is the case, provide them a stamped return envelope. 
  
 Subject decided to completed forms here                 _____ Yes  _____ No 
 Subject opted to take forms with them to return       _____ Yes  _____ No 
      Forms are returned and completed                       _____ Yes  _____ No 
  
Record scores on data collection forms for data entry. 
Check the data collection forms for accuracy. 
File in subject record and store in locked file cabinet. 
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C.1.a.  Demographic Information     
 
DEMOGRAPHIC INFORMATION   
(Carlson, 1999) 
1. Race ______  
 1=Caucasian/white  4=Hispanic 
 2=African American  5=Asian/Pacific islander 
 3=American Indian  6=Other 
  
   
2. Gender (1=male, 2=female) ______  
   
3. How many grades did you complete in school? ______  
(Record highest grade) 
1-12=Grade school/High school   
12=GED/High school diploma 
13=Technical only   15=Graduate School 
 14=Baccalaurean only  16=Doctorate 
 
 
 
 
   
4. What activities best describe what you typically do: ______  
 1=employed, full time 
 2=employed, part time 
 3=retired 
 4=never had a job outside home 
 5=disabled 
 6=other_________________________ 
  
   
5. Marital Status ______  
 1=married, living with spouse 
 2=married, separated 
 3=single, living alone 
 4=single, living with someone 
 5=single, recently widowed (2 years) 
  
   
6. Age (rounded to the nearest year) ______  
   
7. What types of jobs have you had?   
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C.1.b  Older Adults Resource Services Activities of Daily Living Scale   
        
Older Adults Resource Services Activities of Daily Living Scale 
(Fillenbaum, 1978) 
 
Instructions:  The following questions are about some of the activities of daily living 
(ADLs), the things that we all need to do as part of our daily lives.  I would like to know 
if, within the last month, you could do these activities without any help at all, or if you 
needed some help to do them, or if you couldn’t do them at all.  Please write the number 
for the best answer in the space provided. 
 
Physical ADLS  
1. Can you eat . . . ______ 
 2 = without help (able to feed yourself completely),  
 1 = with some help (need help with cutting, etc.), 
 0 = or are you completely unable to feed yourself?  
  
2. Can you dress and undress yourself . . . ______ 
 2 = without help (able to pick out clothes, dress and undress  
  yourself), 
 1 = with some help, 
 0 = or are you completely unable to dress and undress yourself?  
  
3. Can you take care of your own appearance, for example  
 combing your hair or shaving . . . ______ 
 2 = without help, 
 1 = with some help, 
 0 = or are you completely unable to maintain your appearance yourself?  
  
4. Can you walk . . . ______ 
 2 = without help (except for a cane), 
 1 = with some help from a person or using a walker, crutches, etc., 
 0 = or are you completely unable to walk?  
  
5. Can you get in and out of bed . . . ______ 
 2 = without any help (without grabbing hold of the bedstand or aids), 
 1 = with some help (either from a person, grabbing hold of  
  a bedstand or with the aid of some device), 
 0 = or are you totally dependent on someone else to lift you?  
  
6. Can you take a bath or shower . . . ______ 
 2 = without help, 
 1 = with some help (need help getting in and out of the tub,  
  or need special attachment on the tub), 
 0 = or are you completely unable to bathe yourself?  
  
7. Do you ever have trouble getting to the bathroom on time? ______ 
 2 = no 
 1 = yes 
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 If yes, how often do you wet our soil yourself? _____ 
   1 = once or twice a week? 
   0 = three times a week or more? 
  
Independent ADLS  
8. Can you use the telephone . . . ______ 
 2 = without help, including looking up the number and dialing, 
 1 = with some help (could answer phone or dial operator in  
  an emergency, but need a special phone or help), 
 0 = or are you completely unable to use the telephone?  
  
9. Can you get to places out of walking distance . . . ______ 
 2 = without help (travel alone on buses, taxis, or drive your own car), 
 1 = with some help (need someone to help you or be with you when 
                 traveling), 
 0 = or are you unable to travel unless emergency arrangements are  
                made for a specialized vehicle like an ambulance?  
  
10. Can you go shopping for groceries or clothes (assuming you 
 have  transportation) . . . ______ 
 2 = without help (take care of all shopping needs yourself), 
 1 = with some help (need someone to go with you on all  
  shopping trips), 
 0 = or are you completely unable to do any shopping?  
  
11. Can you prepare your own meals . . . ______ 
 2 = without help (plan and cook full meals yourself), 
 1 = with some help (could prepare something but unable to  
  cook full meals yourself), 
 0 = or were you completely unable to prepare your meals?  
  
12. Can you do your housework or yardwork . . . ______ 
 2 = without help (scrub floors, cut grass, etc.), 
 1 = with some help (could do light work but need help with  
  heavy work), 
 0 = or are you completely unable to do any of this type of  
  work?  
  
13. Can you take your own medicine . . . ______ 
 2 = without help (in the right dose, at the right time), 
 1 = with some help (able to take medicine if someone prepares it for you  
                or reminds you to take it), 
 0 = or are you completely unable to take your medicine?  
  
14. Can you handle your own money... ______ 
 2 = without help (write checks, pay bills, etc.), 
 1 = with some help (could manage day-to-day buying but need help with  
                managing your checkbook or paying your bills), 
 0 = were you completely unable to handle money?  
Total Score ______ 
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C.1.c  Center of Epidemiology Screen for Depression       
 
 
 
 
  
During the past week: 
 
Rarely  
(<1 day) 
 
Some of the  
time (1-2 days) 
 
Occasionally 
(3-4 days) 
 
Most of the  
time (5-7 days) 
1. I was bothered by things that usually don’t 
bother me. 
                  
2. I did not feel like eating; my appetite was 
poor.  
 
                  
3. I felt that I could not shake off the blues even 
with help from my family or friends. 
 
                  
4. I felt that I was just as good as other people. 
 
                  
5. I had trouble keeping my mind on what I was 
doing. 
 
                  
6. I felt depressed.                   
7. I felt that everything I did was an effort.                   
8. I felt hopeful about the future.                   
9. I though my life had been a failure.                   
10. I felt fearful.                   
11. My sleep was restless.                   
12. I was happy.                   
13. I talked less than usual.                   
14. I felt lonely.                   
15. People were unfriendly.                   
16. I enjoyed life.                   
17. I had crying spells.                   
18. I felt sad.                   
19. I felt that people disliked me.                   
20. I could not get “going.”                   
        Please indicate how often in the past seven days you have agreed with the following statements 
Mood Screen 
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C.1.d  Functional Assessment of Cancer Therapy – Brain Tumor Module 
 
Instructions 
Below are statements that other people with your illness have said are important.  
Please mark the box that indicates your response as it applies to the past 7 days. 
 
 Not 
at all 
A 
little 
bit 
Some-
what 
Quite 
a bit 
Very 
Much 
Physical Well-being □ □ □ □ □ 
1.  I have a lack of energy □ □ □ □ □ 
2.  I have nausea □ □ □ □ □ 
3.  Because of my physical condition, I have trouble  
     meeting the needs of my family 
□ □ □ □ □ 
4.  I have pain □ □ □ □ □ 
5.  I am bothered by side effects of treatment □ □ □ □ □ 
6.  I feel ill  □ □ □ □ □ 
7.  I a forced to spend time in bed □ □ □ □ □ 
Social/Family Well-Being □ □ □ □ □ 
1.  I feel close to my friends □ □ □ □ □ 
2.  I get emotional support from my family □ □ □ □ □ 
3.  I get support from my friends □ □ □ □ □ 
4.  My family has accepted my illness □ □ □ □ □ 
5.  I am satisfied with family communication about my  
     Illness 
□ □ □ □ □ 
6.  I feel close to my partner (or the person who is my  
     support) 
□ □ □ □ □ 
7.  I am satisfied with my sex life □ □ □ □ □ 
Emotional Well-Being □ □ □ □ □ 
1.  I feel sad □ □ □ □ □ 
2.  I am satisfied with how I am coping with my illness □ □ □ □ □ 
3.  I am losing hope in the fight against my illness □ □ □ □ □ 
4.  I feel nervous □ □ □ □ □ 
5.  I worry about dying □ □ □ □ □ 
6.  I worry that my condition will get worse □ □ □ □ □ 
Functional Well-Being □ □ □ □ □ 
1.  I am able to work (inlcude work at home) □ □ □ □ □ 
2.  My work (include work at home) is fulfilling □ □ □ □ □ 
3.  I am able to enjoy life □ □ □ □ □ 
4.  I have accepted my illness □ □ □ □ □ 
5.  I am sleeping well □ □ □ □ □ 
6.  I am enjoying the things I usually do for fun □ □ □ □ □ 
7. I am content with the quality of my life right now □ □ □ □ □ 
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Additional Concerns Instructions: 
 
Please mark the box that indicates your response as it applies to the past 7 days. 
 
 Not 
at 
all 
A 
little 
bit 
Some-
what 
Quite 
a bit 
Very 
Much 
Additional Concerns □ □ □ □ □ 
1.  I am able to concentrate □ □ □ □ □ 
2. I have had seizures (convulsions) □ □ □ □ □ 
3.  I can remember new things □ □ □ □ □ 
4.  I get frustrated that I cannot do things I 
used to 
□ □ □ □ □ 
5.  I am afraid of having a seizure (convulsion) □ □ □ □ □ 
6.  I have trouble with my eyesight □ □ □ □ □ 
7.  I feel independent □ □ □ □ □ 
8.  I have trouble hearing □ □ □ □ □ 
9.  I am able to find the right word(s) to say 
what I mean 
□ □ □ □ □ 
10. I have difficulty expressing my thoughts □ □ □ □ □ 
11. I am bothered by the change in my 
personality 
□ □ □ □ □ 
12. I am able to make decisions and take 
responsibility 
□ □ □ □ □ 
13. I am bothered by the drop in my 
contribution to the family 
□ □ □ □ □ 
14. I am able to put my thoughts together □ □ □ □ □ 
15. I need help in caring for myself (bathing, 
dressing, eating, etc.) 
□ □ □ □ □ 
16. I am able to put my thoughts into action □ □ □ □ □ 
17. I am able to read like I used to □ □ □ □ □ 
18. I am able to write like I used to □ □ □ □ □ 
19. I am able to drive a vehicle (my car, truck, 
etc.) 
□ □ □ □ □ 
20. I have trouble feeling sensations in my 
arms, hands, or legs 
□ □ □ □ □ 
21. I have weakness in my arms or legs □ □ □ □ □ 
22. I have trouble with coordination □ □ □ □ □ 
23. I get headaches □ □ □ □ □ 
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C. 1.e  MD Anderson Symptom Inventory – Brain Tumor Module 
 
MD Anderson Symptom Inventory-Brain Tumor Module 
Instructions:   
 
Part 1.  How severe are your symptoms? 
 
People with cancer frequently have symptoms that are caused by their ddisease or by 
their treatment.  We ask you to rate how severe the following symptoms have been in the 
last 24 hours.  Please fill in the circle below from 0 (symptom has not been present) to 10 
(the symptom was as bad as you can imagine it could be) for each item.   
 
                                                                                          As Bad As 
Not                                                                                      You Can 
Present                                                                                Imagine 
0 1 2 3 4 5 6 7 8 9 10 
1.  Your pain at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
2.  Your fatigue (tiredness) at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
3.  Your nausea at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
4.  Your disturbed sleep at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
5.  Your feeling of being distressed (upset) at 
its WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
6.  Your shortness of breath at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
7.  Your problem with remembering things at 
its WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
8.  Your problem with lack of appetite at its 
WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
9.  Your feeling drowsy (sleepy) at its 
WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
10. Your having a dry mouth at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
11. Your feeling sad at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
12. Your vomiting at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
13. Your numbness or tingling at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
14. Your weakness on one side of the body at 
its WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
15. Your difficulty understanding at its 
WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
16. Your difficulty speaking (finding the words) 
at its WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
17. Your seizures at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
18. Your difficulty concentrating at its 
WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
19. Your vision at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
20. Your change in appearance at its 
WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
21. Your change in bowel pattern (diarrhea or 
constipation) at its WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
22. Your irritability at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
 □ □ □ □ □ □ □ □ □ □ □ 
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                                                                                                 As Bad As 
Not                                                                                             You Can 
Present                                                                                       Imagine 
0 1 2 3 4 5 6 7 8 9 10 
16. Your difficulty speaking (finding the words) 
at its WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
17. Your seizures at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
18. Your difficulty concentrating at its 
WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
19. Your vision at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
20. Your change in appearance at its 
WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
21. Your change in bowel pattern (diarrhea or 
constipation) at its WORST? 
□ □ □ □ □ □ □ □ □ □ □ 
22. Your irritability at its WORST? □ □ □ □ □ □ □ □ □ □ □ 
 
 
Part 2.  How have your symptoms interfered with your life? 
 
Symptoms frequently interfere with how we feel and function.  How much have your 
symptoms interfered with the following items in the last 24 hours: 
 
 
 Did                                                                           
Not                                                                                    Interfered 
Interfere                                                                         Completely 
0 1 2 3 4 5 6 7 8 9 10 
23. General activity? □ □ □ □ □ □ □ □ □ □ □ 
24. Mood? □ □ □ □ □ □ □ □ □ □ □ 
25. Work (including work around the 
house)? 
□ □ □ □ □ □ □ □ □ □ □ 
26. Relations with other people? □ □ □ □ □ □ □ □ □ □ □ 
27. Walking? □ □ □ □ □ □ □ □ □ □ □ 
28. Enjoyment of life? □ □ □ □ □ □ □ □ □ □ □ 
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C.2  Investigator Packet 
 
 
 
Instructions for Investigator Packet 
The following evaluations are to be completed by the researcher:  
a. Health Information Form 
b. Everyday Cognitions Scale 
c. EXIT-25 
d. North American Adult Reading Test 
e. Trails-Making Test Parts A and B 
f. Controlled Word Association Test 
g. Hopkins Verbal Learning Test 
h. Arrow Flanker Test 
i. Symbol Digit Modalities Test 
j. Visual Analog Scale for Subject Rating on Instrument Difficulty 
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C.2.a  Health Information Form 
 
Health Information  
 
 
I.  Vital Signs 
 
Have the subject sitting comfortably.  Inform the subject that you are going to take their 
vital signs, starting with their blood pressure in their right arm.  Loose any restrictive 
clothing on the right arm (roll up sleeve of shirt if necessary). 
 
 
1.  Place the Dynamap 1846 SX cuff on the right arm and begin the machine. 
2.  Place the Nonin1500 pulse oximeter on the middle finger of the left hand. 
3.  Take oral temperature with the IVAC thermometer. 
4.  Record vital signs below. 
 
 
Heart rate ____ ____ ____ 
Systolic blood pressure ____ ____ ____ 
Diastolic blood pressure ____ ____ ____ 
Respiratory rate ____ ____ 
Oral Temperature to nearest .1 degree Fahrenheit ____ ____.____ 
Oxyhemoglobin saturation: ____ ____ % 
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II.  Key Medical-Related Events 
 
Ask the subject the following: 
“Over the past three months, have you had any of the following?” 
 
 
KEY MEDICAL RELATED EVENTS YES NO 
General:   
 Falls   
 Fainting spells /blacking out   
 Dizziness   
 Numbness/weakness   
 Chills/fever   
 Headaches or migraines   
 Seizures   
 Orthnopnea   
 Shortness of breath   
 Chest pain   
 Tachycardia   
 Leg swelling   
 #Pillows to sleep   
 Numbness/weakness   
 Upper respiratory infection in past week?   
 Coughing   
 Hemoptysis   
 Wheezing   
Shortness of breath in the past week   
 Weakness of any extremity    
 Problems walking   
 Joint problems   
 Difficulty with dexterity (button clothes, etc)   
Self-Report Health Rating:  How would you say that your health at 
this time compares with your health one month ago?  Is it: 
     3=better than 1 month ago 
     2=about the same as 1 month ago 
     1=worse than 1 month ago   
 
______ 
 
 
 
 
 
 
 
 
 
 
 
 
If subject is in the healthy control group, have the subject proceed with the 
Everyday Cognitions Scale. 
 
If subject is in the primary brain tumor group, complete the following set of 
questions below.  Upon completion, proceed to the Everyday Cognitions 
Scale. 
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III.  Primary Brain Tumor Treatment Information 
 
1.      When were you diagnosed with your tumor?  ________________ 
 
2.      What kind of tumor was it?  
_____  astrocytoma   
_____  oligodendroglioma 
            _____  anaplastic astrocytoma  
_____  glioblastoma multiforme   
_____  other: _______________________ 
 
3.       Do you know the location of the tumor?   
  _____ right side  _____ frontal 
  _____ left side  _____ parietal 
      _____ temporal 
      _____ occipital 
      _____ cerebellum 
      _____ brain stem 
 
4.       What kind of surgical procedure did you have when you were diagnosed? 
_____ biopsy   
____   partial surgical resection   
_____  gross total resection 
 
5. Date of surgery or surgeries:  _________   _______ 
     _________ _______ 
    _________ _______ 
 
6.        What kind of treatments did you have for your tumor? 
____ radiation therapy   
____ stereotactic radiosurgery   
____ stereotactic radiotherapy 
 
7.   Date of radiation therapies:  _________   _______ 
     _________ _______ 
     _________ _______ 
 
8.         Did you have chemotherapy?  ______ yes    ______ no 
  If yes, duration _______________ 
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C. 2.b Everyday Cognition Scale 
 
Everyday Cognition Scale 
(Farias, 2007) 
Instructions  
Please rate your ability to perform certain everyday tasks NOW, as compared to your 
ability to do these same tasks 10 years ago.   Try to remember how you were 10 years 
ago and indicate any change you have seen.  Check the box that fits your response to 
the following sentence:  
 
Compared to 10 years ago, I have noticed a change in… 
 
Better or 
no 
change 
Questionable 
or 
occasionally 
worse 
Consistently 
a little worse 
Consistentl
y much 
Worse 
Don’t 
know 
1.   Remembering a few shopping items without a 
list. □ □ □ □ □ 
2.   Remembering things that happened recently 
(such as recent outings, events in the news). □ □ □ □ □ 
3.   Recalling conversations a few days later. □ □ □ □ □ 
4.   Remembering where she/he has placed 
objects. □ □ □ □ □ 
5.   Repeating stories and/or questions. □ □ □ □ □ 
6.   Remembering the current date or day of the 
week. □ □ □ □ □ 
7.   Remembering he/she has already told 
someone something. □ □ □ □ □ 
8.   Remembering appointments, meetings, or 
engagements. □ □ □ □ □ 
9.   Forgetting the names of objects or people. □ □ □ □ □ 
10. Verbally giving instructions to others. □ □ □ □ □ 
11. Finding the right words to use in a 
conversation. □ □ □ □ □ 
12. Communicating thoughts in a conversation. □ □ □ □ □ 
13. Following a story in a book or on TV. □ □ □ □ □ 
14. Understanding the point of what other people 
are trying to say. □ □ □ □ □ 
15. Remembering the meaning of common 
words. □ □ □ □ □ 
16. Describing a program he/she has watched on 
TV. □ □ □ □ □ 
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Better or 
no 
change 
Questionably 
or 
occasionally 
worse 
Consistently 
a little worse 
Consistently 
much worse 
Don’t 
know 
17. Following a map to find a new location. □ □ □ □ □ 
18. Reading a map and helping with directions 
when someone else is driving. □ □ □ □ □ 
19. Finding one’s car in a parking lot. □ □ □ □ □ 
20. Finding the way back to a meeting spot in the 
mall or other location. □ □ □ □ □ 
21. Finding his/her way around a familiar  
neighborhood. □ □ □ □ □ 
22. Finding his/her way around a familiar store. □ □ □ □ □ 
23. Finding his/her way around a house visited 
many times. □ □ □ □ □ 
24. Planning the sequence of stops on a 
shopping trip. 
□ □ □ □ □ 
25. The ability to anticipate weather changes and 
plan accordingly (ie, bring a coat or umbrella). □ □ □ □ □ 
26. Developing a schedule in advance of 
anticipated events. □ □ □ □ □ 
27. Thinking things through before acting. □ □ □ □ □ 
28. Thinking ahead. □ □ □ □ □ 
29. Keeping living and work space organized. □ □ □ □ □ 
30. Balancing the checkbook without error. □ □ □ □ □ 
31. Keeping financial records organized. □ □ □ □ □ 
32. Prioritizing tasks by importance. □ □ □ □ □ 
33. Keeping mail and papers organized. □ □ □ □ □ 
34. Using an organized strategy to manage a 
      medication schedule involving multiple 
medications. 
□ □ □ □ □ 
35. The ability to do two things at once. □ □ □ □ □ 
36. Returning to a task after being interrupted. □ □ □ □ □ 
37. The ability to concentrate on a task without 
being distracted by external things in the 
environment. 
□ □ □ □ □ 
38. Cooking or working and talking at the same 
time. 
□ □ □ □ □ 
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C.2.c  EXIT-25 
     EXIT-25 (Royall, 1995) 
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C.2.d   North American Adult Reading Test 
 
Instructions for Administration of the NAART 
 
Read to the Subject: 
Please read out loud the following words on this list.    
 
Scoring: 
Mark the incorrect pronunciations by using the pronunciation key as the subject 
reads the list out loud.  Have the subject read all the words to the best of their 
ability. 
Answer Key for the NAART 
 
 Word SCORE Pronunciation 
1. DEBT ________ Det 
2. DEBRIS ________ dĕ-brē, dā-brē´, dā-brē 
3. AISLE ________ Īl 
4. REIGN ________ Rān 
5. DEPOT ________ dē-pō,dé pō 
6. SIMILE ________ sim´ ə lē 
7. LINGERIE ________ lan´ zhə rē´, lon´ zhə rā´ 
8. RECIPE ________ res´ ə pē 
9. GOUGE ________ Gauj 
10. HEIR ________ Ār 
11. SUBTLE ________ sət´ əl 
12. CATACOMB ________ kat´ ə kōm 
13. BOUQUET ________ bō kā´, bü kā´ 
14. GAUGE ________ Gāj 
15. COLONEL ________ kərn´ əl 
16. SUBPOENA ________ sə pē´ nə 
17. PLACEBO ________ plə sē´ bō 
18. PROCREATE ________ prō krē āt 
19. PSALM ________ säm, sälm 
20. BANAL ________ bə nål´, bā nal´, bān´ əl 
21. RAREFY ________ rār´ ə fī 
22. GIST ________ Jist 
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23. CORPS ________ kor, korz 
24. HORS D’OEUVRE  ________ or´ dərv(r)´ 
25. SIEVE ________ Siev 
26. HIATUS ________ hī ā təs 
27. GAUCHE ________ Gōsh 
28. ZEALOT ________ zel´ ət 
29. PARADIGM ________ par´ ə dīm, par´ ə dim 
30. FAÇADE ________ fə säd´ 
31. CELLIST ________ chel´ əst 
32. INDICT ________ in dīt´ 
33. DETENTE ________ dā tä(n)t 
34. IMPUGN ________ im pyün´ 
35. CAPON ________ kā´ pən, kā´ pon 
36. RADIX ________ rād´ iks 
37. AEON ________ ē´ ən, e´ an 
38. EPITOME ________ i pit´ ə mē 
39. EQUIVOCAL ________ i kwiv´ ə kəl 
40. REIFY ________ rā´ ə fī, rē´ ə fi 
41. INDICES ________ in´ də sēz 
42. ASSIGNATE ________ as´ ig nāt´ 
43. TOPIARY ________ tō pē er´ ē 
44. CAVEAT ________ kav´ ē at, kāv´ ē at, kā vē at´ 
45. SUPERFLUOUS ________ sů pėr´ flü əs 
46. LEVIATHAN ________ li vī´ thən 
47. PRELATE ________ prel´ ət, prēl āt 
48. QUADRUPED ________ kwäd´ rə ped 
49. SIDEREAL ________ sī dir´ ē al, sə dir´ ē al 
50. ABSTEMIOUS ________ ab stē´ mē əs 
51. BEATIFY ________ bē at´ ə fī 
52. GAOLED ________ Jāld 
53. DEMESNE ________ di mān´, di mēn´ 
54. SYNCOPE ________ sing´ kə pē, sin´ k´rrn pē 
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55. ENNUI ________ an wē´ 
56. DRACHM ________ Dram 
57. CIDEVANT ________ sēd ə vä(n)´ 
58. EPERGNE ________ i pərn´, ā pərn´ 
59. VIVACE ________ vē väch´ ā, vē väch ē 
60. TALIPES ________ tal´ ə pēz 
61. SYNECDOCHE ________ sə nek´ də kē 
 Total Errors: ________  
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C.2.e  Trails-Making Test, Parts A & B 
   
Instructions for Administering the Trails A & B 
Part A 
1. Tell the subject “For this test I want you to work as quickly as possible but try to 
avoid making mistakes.” 
2. Place the example for Trails A in front of the participant, the bottom of the test 
should be about 6 inches from the edge of the table. 
3. Give the participant a pencil and say:  “On this page are some numbers” (Point at 
the numbers).  Begin at number 1 (point to 1) and draw a line from 1-2 (point to 
2), 2 to 3 (point to 3), 3-4 (point to 4) and so on, in order, until you reach the end 
(point to the circle marked ‘end’”  Draw the lines as fast as you can.  Ready—
Begin.” 
4. If the participant completes the sample and shows he/she understands the 
instructions then say:  “Good!  Why don’t you try this next one.” 
5. Turn the page over and give Part A of the test and say: ”On this page are some 
more numbers.  Begin with the number 1 (point to 1) and draw a line from 1 to 2 
(point to 2) and so on, until you reach the end (point to end).  Remember to work 
as fast as you can.”   
Start timing as soon as the subject moves the pencil toward the number 2.  Watch the 
participant closely in order to catch any errors as soon as they are make.  If the 
subject makes any errors, call it to her/his attention immediately, return the subject’s 
pencil to the last correct circle and continue the test from that point.  Do not stop 
timing while correcting the subject’s error. 
6. After the subject completes Part A, take the test sheet and record the time as it is 
shown on the stop watch. 
7. Then say “That’s fine.  Now we’ll try another one.” 
8. Write down the stopwatch time in the upper right hand corner 00:00:00 
 
Part B 
1. Place the sample side of Part B on the table in front of the subject in the same 
position as the sheet for Part A.   
2. Point to the sample and say “On this page are some numbers and letters.  Begin at 
1 (point) and draw a line from 1 to A (point to A), A to 2 (point to 2), 2 to B 
(point to B), B to 3 (point to 3), 3 to C (point to C) and so on, in order, until you 
reach the end.  Ready ---Begin.” 
3. When the subject completes Sample B, say.  On this page are both number and 
letters.  Please do this the same way.  Begin at 1 (point) and draw a line from 1 to 
A (point to A), A to 2 (point to 2), 2 to B (point to B), B to 3 (point to 3), 3 to C 
(point to C) and so on, in order, until you reach the end.  Ready ---Begin.” 
Start timing as soon as the subject moves the pencil toward the letter ‘A’.  Watch the 
participant closely in order to catch any errors as soon as they are make.  If the 
subject makes any errors, call it to her/his attention immediately, return the subject’s 
pencil to the last correct circle and continue the test from that point.  Do not stop 
timing while correcting the subject’s error. 
4. Write down the stopwatch time in the upper right hand corner 00:00:00 
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C.2.f  Controlled Word Association Test 
 
Controlled Oral Word Association 
(Bechtoldt, Benton, & Fogel, 1962; Benton, 1967)  
 
GET OUT STOPWATCH 
 
Instructions to the Subject: 
“I am going to say a letter of the alphabet and I want you to say as quickly as you 
can all the words you can think of which begin with that letter.  You may say any 
word at all except proper names, such as names of people or places or brand 
names.  So you would not say “Raleigh” or “Robert” or “Radioshack.”  Also, do 
not use the same words again with a different ending, such as “eat” and “eating.”  
For example, if I say “S”, you could say “sun, sit, shoe, or slow”.   Can you think 
of other words beginning with the letter “S?” 
 
Wait for the subject to give a work, indicate if the word is correct by saying “That 
is correct, that word begins with “S.”  Can you think of another word?”  Once two 
appropriate words beginning with the demonstration letter are given, say “That is 
fine.  Now I’m going to give you another letter, and again say all the words 
beginning with that letter that you can think of.  Remember, no names of people 
or places, just ordinary words.  Also, if you should draw a blank, I want you keep 
on trying until the time limit is up.  You will have a minute for each one.”   
 
“The first letter is C and 1 minute is allowed.” 
 
Do not interrupt the subject during the minute.  At the end of one minute, stop the 
subject and clarify any answers (e.g. “frank” which could represent a proper 
name).   Then say “The same instructions apply for the second letter.  The 
second letter is “F.”  You have one minute.” 
 
Follow the same rules for the second letter “F”  and the third letter “L.” 
 
Instructions for Responses: 
Version A and Version B use the same procedure (version B is used with the 
alternate letters PRW).  Record subject responses on the numbered record 
sheet.  If the subject is stating words quickly, you may record + on the line for 
correct responses.  Be sure to record all responses verbatim for those that are 
incorrect or need clarification.  Many words have two or more meaning therefore 
a repetition of the word is accepted only in those cases where the subject 
definitely indicates the alternate meaning.  For responses that need clarification, 
do not interrupt the subject during the one-minute interval.  At the end of the 
minute, ask the subject what was meant by the word (example of “frank” above).  
Slang terms are admissible as correct answers, as well as certain foreign words 
(e.g. “lasagna”) as long as these words are listed as standard English.  
Perseverative errors are also scored, even in the case where a word has two or 
more meaning and the subject does not indicate the different meanings (e.g. 
“four” and “for”). 
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First Letter:   Second Letter:    Third Letter: 
  C   or   P        F    or    R        L   or   W 
 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
____________ _____________   _____________ 
 
  1. 
  2. 
  3. 
  4. 
  5. 
  6. 
  7. 
  8. 
  9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
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C.2.g  Hopkins Verbal Learning Test-Revised 
 
Hopkins Verbal Learning Test-Revised 
 
Copyright protected and not reproduceble; available through purchase with licensure of 
Dr. Renee Raynor (neuropsychologist) only.   
Will be purchased and available for subject test battery administration. 
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C.2.h  Arrow Flanker Test (also seen in attached Computerized Tests) 
 
Arrow Flanker Test 
 
Instructions to the Subject 
 
This is a reaction time task, so you should always respond as quickly as possible but it is 
most important to be as accurate as possible, so to avoid making errors. You will press 
the right or left arrow key on the computer screen according to the object’s direction that 
is placed in the center of the screen.  These are examples of something you might see. 
Which direction arrow would you press?  The right arrow or left arrow? 
 
 
 
 
 
The left arrow key would be correct.   
 
As you see, the object in the center is an arrow in the middle of squares.  But you might 
see the same object and have to find the middle direction. 
 
Which direction arrow would you press for this example? 
 
 
 
 
 
The right arrow key would be correct. 
Now try this example.  What is the correct direction? 
 
 
 
 
 
 
 
The right arrow key is again correct.  Are you ready to start the program?  It will only 
take 5 minutes to complete.
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C.2.i  Symbol Digit Modalities Test 
 
Symbol Digit Modalities Test 
(Smith, 1991) 
 
Instructions for administering the Symbol Digit Modalities Test 
 
1. GET OUT STOPWATCH. 
2. Place the test page in front of the subject  
3. “In this task, you will use this key (point), to complete the page of symbols.”  
Point at the key at the top of the page.  “You can see that each box in the upper 
row has a little mark in it.  Now look at the boxes in the row just underneath the 
marks.  Each of the boxes under the marks has a number.  Each of the marks in 
the top row is different, and under each mark in the bottom row is a different 
number.” 
4. Then say “Now look at the rest of the sheet. Notice that the boxes on the top have 
marks, but the boxes underneath are empty.  You are to fill each empty box with 
the number that should go there according to the way they are paired n the key at 
the top of the page.” 
5. Start the sample items by saying “For example if you look at the first mark, and 
then look up at the key, you will see that the number 1 goes in the first empty box.  
So write the number 1 in the first box.”   
6. Make a vertical line to indicate the end of the sample and the start of the test. 
7. Then say, “The boxes here are just practice, why don’t you try it”. 
8. Once the participant finishes the practice set, say  “Now you will have 90 seconds 
to fill out as many boxes as you can on the rest of the sheet.  In other words, when 
you come to the end of the first line, go quickly to the next line without stopping 
and so on.  If you make a mistake, do not erase, just write the correct answer over 
your mistake.  Do not skip any boxes and work as quickly as you can. Start when 
you are ready”. 
9. Start the stopwatch at the first number is being drawn. 
10. Stop the participant after 90 seconds (1 minute, 30 seconds) 
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C.2.j  Visual Analog Scale for Subject Rating of Test Difficulty 
 
Visual Analog Scale for Subject Rating 
 
 
Name of Test 
 
____  Exit-25   ____  NAART  ____  Trails Part A 
____  Trails Part B  ____  COWA   ____  HVLT-R 
____  HVLT-R Delayed ____ Arrow Flanker  ____  SDMT 
 
 
 
Instructions 
 
On the line below, place an X where you feel it indicates how difficult the test was for 
you to complete. 
Very           Very  
Difficult          Easy 
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APPENDIX G: REFERRAL LETTERS
F.1 Referral Protocol and Irtter for Subjects
Instructions fpr Referrine Subiects based on the findines from this,studv
A referral letter must be given to all subjects who atttains:
1. An EXT-25 score of > 20,
2. Trails Making Test B time > 3 minutes,
3. An OARS score of < 20,
4. A CESD score of> 15,
5. A blood pressures over 140 systolic or 90 diastolic,
6. A heart rate > 120 bpm,
7. A low arterial oxygen desaturation of< 907o,
8. Prolonged arxiety or fear duriag testing procedure of > 10 minutes,
All ofthese conditions are serious and the lab director should be notified for adverse
events requiring emergency personnel.
Attached are two major types of study referral letters: one for cognitive impairrnents and
one for vital signs.
Please make sure that a copies ofeach form are on file in the research office under
subiect referrals.
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Date:   March 6, 2011 
 
To: Mr. XXX 
 Address 
 
From:  Deborah Allen 
 Principal Investigator 
 School of Nursing 
 University of North Carolina at Chapel Hill 
 
RE: Results of test here 
 
 
Dear  Mr. XXX, 
 
As one of my study participants, you underwent a battery of health, memory and 
functional tests at the University of North Carolina, School of Nursing Biobehavioral 
Laboratory.  In the process of our evaluation, we found that you are having difficulties 
with ______ and thought that it would be good for you to tell your doctor.   
 
Specifically, you scored below normal on the EXIT-25 Exam.  The EXIT-25 Exam is a 
test of cognitive function.  The average passing score on the Mini-Mental Status Exam is 
35 and you scored a __ on this test.  You may also want to tell your doctor about these 
problems.  Please let you doctor know that I would be happy to talk with him/her about 
the findings of this study.  I can be reached at (919) 883-7002. 
 
 
Sincerely, 
 
 
Deborah Allen 
Principal Investigator 
UNC School of Nursing 
 
[C l i c k  t o  t ype  Un i t  Name ]    C B # 7 4 6 0 ,  C a r r i n g to n  H a l l    Chape l  H i l l ,  NC   27599 -7460  
PHONE:  [PHONE NUMBER]    FAX:  [FAX NUMBER]  
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Date:   January 8, 2009 
 
 
To: Mr. XXX 
 Address 
 
From:  Deborah Allen 
 Principal Investigator 
 School of Nursing 
 University of North Carolina at Chapel Hill 
 
RE: Results of test here 
 
 
Dear  Mr. XXX, 
 
As one of my study participants, you underwent a battery of health, memory and 
functional tests at the University of North Carolina, School of Nursing Biobehavioral 
Laboratory.  In the process of our evaluation, we found that you are having difficulties 
with one of your vital signs and thought that it would be good for you to tell your doctor.   
 
Specifically, you had a blood pressure that was very high.  Your blood pressure was 
______ systolic /______ diastolic.   The average blood pressure is below 120 systolic / 80 
diastolic.  You may also want to tell your doctor about these problems.   
 
Please let you doctor know that I would be happy to talk with him/her about the findings 
of this study.  I can be reached at (919) 883-7002.  
 
 
 
 
Sincerely, 
 
 
Deborah Allen 
Principal Investigator 
UNC School of Nursing 
 
 
 
[C l i c k  t o  t ype  Un i t  Name ]    C B # 7 4 6 0 ,  C a r r i n g to n  H a l l    Chape l  H i l l ,  NC   27599 -7460  
PHONE:  [PHONE NUMBER]    FAX:  [FAX NUMBER]  
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APPENDIX H: BBL SAFETY PLAN
SAFETY-MONTTORING PLAN
Operational Definition of an Adverse Event
An adverse event will be defined as an event that occurs during the course of the study that should
be documented and reported to the director ofthe School ofNursing Biobehavioral Laboratory
(BBL) and Public Health/School of Nursing (SON) IRB. This study does not involve a"n
intervention but does involve individuals with a neurologic impairment trom a primary brain
tumor. Therefore, this safety plan reflects provisions to prevent or rapidly identif, adverse events
that could occur whilc undergoing the three hour study protocol: seizures, CNS cerebrovascular
event, confusion, personality/behavioral alteration, or mood distulbance. The safef'monitoring
protocol and basic laboratory emergency protocol (including 9 I I protocol and phone number of
the medical directot for the study) is posted in the monitoring area of the observation room where
the study protocoi will be performed. Human subject issues such as psychological distress
associated with cognitive testing, subject confidentiality, and incidents that are not directly
associated rvith testing (falls, theft) have been addressed in the IRB application. Although
important, violations of these issues will be reported to the IRB but will not be directly addressed
in this subject safety-monitoring plan.
L Seizures: Unstable seizure disorders can produce alterations in mental status or cognitive
issues. Seizure disorders may present as brief sensory or motor events without altered
consciousness to prolonged generalized seizure states including status epilepticus.
Therefore the telephone screen r's designed to review the seizure history ofthe potential
subject to assure that there is a seizure-free state of6 months and that no recent changes in
anticonvulsants have occurred that could place the potential subject more at risk for
seizures. As there may be a few weeks between the telephone screen and the subject
presenting or consent and study procedures, a laboratory screen will be performed.
Questions include:
a. Changes in medications will be reviewed to assure that changes in anticonvulsant
therapy have not occurred.
b. Occurrence ofany seizures to assure a stable seizure status-
c. No recent use ofcold medicines that could interfere with anticonvulsant therapy serum
levels, placing the subject at risk for seizure occurrence.
d. Studies will be rescheduled if a subject or a member of the study staff reports to the
Iaboratory a cold or flu.
2. Cerebrovascular event: Survivors of primary brain tumors who have undergone surgery,
chemotherapy. and/or radiation therapy are at more risk for the development of stroke.
While telephone screening will eliminate those with a history of prior cerebrovascular
events, the laboratory screen will serve to ask ifthere have been any changes in their health
status which could indicate transient events. In addition, vital signs will be perfomed to
asswe a stable cardiovascular state for study procedures.
3. Confusion, personalityibehavioral alterations, and mood disturbances: While it is not
anticipated that these adverse events may occur at a grade 3 or 4 severities constituting a
medical emergency, study personnel are aware survivors of primary brain tumors may have
frontal lobe damage which could result in extreme changes in mental status, personality,
behaviors, or mood. The subject will be reassured that their perfomance is within
expected parameters. In addition, subjects will be provided regularly scheduled rest
periods and opportunities for nutrition.
Reportins Procedure
The principal investigator will mcnitor the study throughout for adverse events. Primary safety
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measures as described above will be implemented in presence of an adverse event.  While in the 
BBL, the subjects will be monitored continuously for any sign of an adverse event.  In the case of 
an adverse event, regardless of whether the event is identified by the staff or the subject, the PI and 
the BBL director will be notified and the following NCI Common Toxicity Criteria Adverse Event 
version 3 scale will be used to grade its severity: Grade 1 -- no intervention needed/not a problem; 
neuro-oncologist informed of occurrence, Grade 2 -- instituted initial safety protocol and neuro-
oncologist informed of occurrence, Grade 3 or 4 -- initiated safety protocol and called for local 
EMS.  The table below provides the criteria for recording and reporting adverse events.  The 
principal investigator will review all adverse events with study subjects or their family before they 
leave the BBL.  The principal investigator will also review each occurrence with the co-
investigators, BBL director, and subject’s neuro-oncologist.  Serious adverse events (Grades 3 or 
4) will be reported to the IRB.  All adverse events will be compiled to describe common events in 
this small sample size.  
 
Table 1.  Adverse Event Severity Form 
 1 2 3 4 
Seizure None One brief 
generalized 
seizure; seizure 
well controlled 
by 
medications; 
infrequent focal 
motor seizures 
not interfering 
with activities 
of daily living 
(ADL) 
Seizures in 
which 
consciousness is 
altered; poorly 
controlled 
seizure 
disorder, with 
breakthrough 
generalized 
seizures despite 
medical 
intervention 
Seizures of 
any kind 
which are 
prolonged, 
repetitive, or 
difficult to 
control (e.g. 
status 
epilepticus, 
intractable 
epilepsy) 
Cerebrovascular event None Asymptomatic Transient event 
of < 24 hours 
duration 
CVA, 
neurologic 
deficit > 24 
hours duration 
Confusion Transient 
confusion, 
disorientation, or 
alteration deficit 
Confusion or 
delirium not 
interfering with 
activities of 
daily living 
ADL 
Confusion or 
delirium 
interfering with 
ADL (such as 
testing 
procedures) 
Harmful to 
others or self; 
hospitalization 
indicated 
Personality/behavioral 
alterations 
Change, but not 
adversely 
affecting subject 
or family 
Change, 
adversely 
affecting 
subject or 
family 
Mental health 
intervention 
indicated 
Change 
harmful to 
others or self; 
hospitalization 
indicated 
Mood alteration – 
select one: 
 Agitation 
 Anxiety 
 Depression 
 Euphoria 
Mild mood 
alteration not 
interfering with 
function 
Moderate 
mood alteration 
interfering with 
function but 
not interfering 
with ADL 
Severe mood 
alteration 
interfering with 
ADL 
Suicidal 
ideation; 
danger to self 
or others 
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911protocol for BBL 
 
Post in BBL Observation Room 
 
In case of Emergency dial “911” 
 
Tell the Operator: 
 
Hello, my name is _______ and I am calling you from the Biobehavioral Laboratory, Observation 
Room 3,  Carrington Hall, School of Nursing.  I am calling to report a medical emergency: one of our 
research subjects is ____________(symptoms) and _____________is being done to help him/her. 
 
 For a CPR victim say: 
  ●  The person is unresponsive, does not have a pulse, and is not breathing.     
  ●  CPR with AED is being administered.   
 
Where are we?  Our laboratory is located on the ground floor of Carrington Hall, the School of 
Nursing.   The phone number is 966-7598.   
 
STAY ON THE LINE UNTIL YOU ARE TOLD TO HANG UP THE PHONE 
 
Directions to Carrington Hall 
(if asked) 
 
1)  Head south on Airport Road 
2)  Turn right on Cameron and go 
around the Carolina Inn, heading south 
on Pittsboro Road. 
3)  At the intersection with Manning 
Dr. take a right onto Columbia Street. 
4)  Go through one light and stop 
curbside just before the intersection 
with N. Medical Dr. 
5)  The School of Nursing (Carrington 
Hall) is the building on your right 
 
 
 
 
 
 
After Contacting 911 
 
1) Unlock and prop open the BBL Main Door (from the hallway) 
2) LISTEN OUT FOR EMS  
3) Keep your cell phone on for further contact with BBL personnel, EMS, Campus Police 
4) Assist with CPR and AED diagnostics 
5) Contact the lab director and PI of the study 
 
Contact information     Mobile       Home phone 
Dr. Virginia Neelon – Lab Director      (919) 286-3334 
Dr. Barbara Carlson – Faculty Chair   225-4214 (919) 929-1112 
Deborah Allen – PI     883-7002 (919) 542-9933 
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APPENDIX I: FEASIBILILTY STUDY
UNC LTNnegnGER CoMPREHENSIVE CANCER CENTER
ClrNrcar- ONcor-ocv Rpspancri Pnocnarr
Scsoor. or MporcrNp
Ulwpnsrrv op NoRtlr CanouNa ar Criappl Hrr.l
MpruonaNDUM
Principal Investigators: Carlson, MD, Barbara
Oncology lrotocol Review Qommittee
Third Floor Administrative Office
Lineberger Cancer Center, CB# 7295
hfrp : I I cancer.med. unc.edu/research/prc/default. asp
November 03,2008
NUMBER: LCCC0822
TITLE. Pilot Study Of Sensory Information Processing And Motor Processing
Relationship To Executive Control In Adults With Primary Brain Tumors
New Study Application [PRC approvall
This letter is written to notiff you that the protocol application listed above was approved with
on Novemtrer 03r 2008 by the Lineberger Comprehensive Cancer Center Clinical Oncology
Research Program's Protocol Review Committee (PRC).
This application and PRC approval letter may be forwarded to the Behavioral Institutional
Review Board for review. Please note: This letter does not constitute IRB approval for use
of human subjects in clinical trials.
For the purposes of the NCI approved Lineberger Data and Safety Monitoring Plan, this trial has
been assigned a Risk Level of Minimal and a Complexity rating of_O_.
If you have any questions, please contact Micah Sam, PRC Coordinator at 843-6901, email
msam@med.unc.edu, or Lisa Carey,MD, PRC Chair at 966-4431.
cc: IRB Chaiman PRC Chair, GCRC Chairman (if applicable), PRC file, Reg Associate, Reg file
DssrcNerpDA CoMpREHENSTvE CeNcpR CnNrpnByrHE NeuoNal Caucaa
INsrrrurp
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UNC LINEBERGER COMPREHENSIVE CANCER CENTER                                                                                                                                                                                                                   
CLINICAL ONCOLOGY RESEARCH PROGRAM                                                                                                                  
SCHOOL OF MEDICINE                                                                                                                                                               
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 
 
DESIGNATED A COMPREHENSIVE  CANCER  CENTER BY THE  NATIONAL  CANCER  
INSTITUTE 
 
MEMORANDUM 
 
To: Barbara Carlson, PhD., RN. 
From: Data Safety and Monitoring Committee 
Third Floor Administrative Office 
Lineberger Cancer Center, CB# 7295 
Date: January 5, 2010 
Subject: 
 
 
 
IRB #:  08-1888  
LCCC#:  LCCC0822 
Title:  Pilot Study Of Sensory Information Processing And Motor Processing 
Relationship To Executive Control In Adults With Primary Brain Tumors   
RE: DSMC REVIEW- RESULTS AND COMMENTS 
This letter is written to notify you that the Lineberger Comprehensive Cancer Center Clinical 
Oncology Research Program’s Protocol Review Committee (PRC), in compliance with the NCI 
approved UNC Lineberger CCC’s Data and Safety Monitoring Plan, and has reviewed your 
study on December 28, 2009.  As a result of the review, the following comments were generated: 
 A report was received from the PI and the DSMC thanks the PI for the materials 
provided.  
 There were no safety concerns at this time.  As a minimal risk trial with little to no 
risk to patient safety this study is exempt from further DSMC review.  
 Abstentions: None  
 Next scheduled review: Exempt 
If you have any questions please contact Micah Sam, PRC/DSMC Coordinator at 843-6901, 
email msam@med.unc.edu.  
A copy of the UNC Lineberger CCC’s Data and Safety Monitoring Plan may be found at http://cancer.med.unc.edu/research/PRC/.   
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CLINICAL ONCOLOGY RESEARCH PROGRAM                                                                                                                  
SCHOOL OF MEDICINE                                                                                                                                                               
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 
 
DESIGNATED A COMPREHENSIVE  CANCER  CENTER BY THE  NATIONAL  CANCER  
INSTITUTE 
 
MEMORANDUM 
TO: Principal Investigator: Barbara Carlson, PhD., RN. 
FROM: Oncology Protocol Review Committee 
Third Floor Administrative Office 
Lineberger Cancer Center, CB# 7295 
http://cancer.med.unc.edu/research/prc/default.asp 
 
DATE: May 06, 2010 
SUBJECT: 
 
 
 
IRB #: 08-1888 
PROTOCOL#: LCCC0822 
TITLE:  Pilot Study Of Sensory Information Processing And Motor 
Processing Relationship To Executive Control In Adults With Primary Brain 
Tumors   
 
Renewal Application (PRC Approval) 
  
This is to notify you that the protocol application listed above was approved on May 05, 2010 by 
the Lineberger Comprehensive Cancer Center Clinical Oncology Research Program’s Protocol 
Review Committee (PRC).   
The renewal application packet and PRC approval letter may now be forwarded to the Medical 
School Institutional Review Board for review. If you have any questions, please contact Micah 
Sam, PRC Coordinator at 843-6901, email msam@med.unc.edu, or Lisa Carey, MD, PRC Chair 
at 966-4431.  
Please note: This letter does not constitute IRB approval for use of human subjects in 
clinical trials. 
cc: IRB Chairman  
     PRC Chair 
     GCRC Chairman (if applicable) 
     reg/prc files     
      Reg Associate 
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UNC LINEBERGER COMPREHENSIVE CANCER CENTER                                                                                                                                                                                                                   
CLINICAL ONCOLOGY RESEARCH PROGRAM                                                                                                                  
SCHOOL OF MEDICINE                                                                                                                                                               
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 
 
DESIGNATED A COMPREHENSIVE  CANCER  CENTER BY THE  NATIONAL  CANCER  
INSTITUTE 
 
MEMORANDUM 
TO: Principal Investigator: Barbara Carlson, MD 
FROM: Oncology Protocol Review Committee 
Third Floor Administrative Office 
Lineberger Cancer Center, CB# 7295 
http://cancer.med.unc.edu/research/prc/default.asp 
 
DATE: June 9, 2011 
  
SUBJECT: 
 
 
 
IRB #: 08-1888 
PROTOCOL#: LCCC0822 
TITLE:  Pilot Study Of Sensory Information Processing And Motor Processing 
Relationship To Executive Control In Adults With Primary Brain Tumors  
Renewal Application (PRC Approval) 
  
This is to notify you that the protocol application listed above was approved on June 8, 2011 by 
the Lineberger Comprehensive Cancer Center Clinical Oncology Research Program’s Protocol 
Review Committee (PRC).   
The renewal application packet and PRC approval letter may now be forwarded to the Medical 
School Institutional Review Board for review. If you have any questions, please contact Micah 
Sam, PRC Coordinator at 843-6901, email msam@med.unc.edu, or Lisa Carey, MD, PRC Chair 
at 966-4431.  
Please note: This letter does not constitute IRB approval for use of human subjects in 
clinical trials. 
cc: IRB Chairman  
     PRC Chair 
     GCRC Chairman (if applicable) 
     reg/prc files     
      Reg Associate 
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UNC LINEBERGER COMPREHENSIVE CANCER CENTER                                                                                                                                                                                                                   
CLINICAL ONCOLOGY RESEARCH PROGRAM                                                                                                                  
SCHOOL OF MEDICINE                                                                                                                                                               
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 
 
DESIGNATED A COMPREHENSIVE  CANCER  CENTER BY THE  NATIONAL  CANCER  
INSTITUTE 
 
May 05, 2010 
 
Barbara Carlson, PhD., RN  
5105 Carrington Hall 
UNC Chapel Hill 
Chapel Hill, NC 27599 
CB#7460 
 
RE: LCCC0822– UNC  
 
Dear Dr. Carlson, 
 
Thank you for your participation in the March 26, 2010 audit of the Lineberger Comprehensive 
Cancer Center studies. 
 
During our audit of study number LCCC0822 for site UNC patients E.B.-. Sequence# 0822002 
and F.A. – Sequence# 0822005 were audited: 
 
The audit for this site was acceptable and requires no response at this time.  
 
Sincerely, 
 
 
 
Young E. Whang, MD 
Chair, LCCC Audit Committee 
 
cc:   Joy Ostroff, RN, BSN, OCN, Facility Director, Clinical Protocol Office 
       Micah Sam, Audit Committee Coordinator, PRC Coordinator, DSMC Coordinator 
       Mary O’Dwyer, Assoc. Director for Regulatory and Admin Services, CPO 
       Deborah Allen, RN, Protocol Coordinator  
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University of North Carolina-Chapel Hill 
Consent to Participate in a Research Study  
Adult Participants  
Social Behavioral Form 
________________________________________________________________ 
 
IRB Study # 08-1888 
Consent Form Version Date:  February 9, 2009  
 
Title of Study: Pilot Study of Sensory Information Processing and Motor 
Processing: Relationship to Executive Control in Adults with Primary Brain 
Tumors 
 
Principal Investigator: Deborah Allen, RN, MSN 
Faculty Advisor:  Barbara Waag Carlson RN, Ph.D. 
UNC-Chapel Hill Department:  School of Nursing  
UNC-Chapel Hill Phone number: 919-966-9416 
Email Address: allendd@email.unc.edu 
Co-Investigators:  Barbara Waag Carlson RN, Ph.D. 
Virginia J. Neelon RN, Ph.D. 
    Merle Mishel, RN, Ph.D. 
    Mark A. Tommerdahl, Ph.D. 
   Matthew Ewend, MD 
Funding Source: American Cancer Society Doctoral Scholarship in Nursing and 
the UNC-Ch School of Nursing Speight Scholarship Foundation 
 
Study Contact telephone number: 919-883-7002 
Study Contact email:  allendd@email.unc.edu 
_________________________________________________________________ 
 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is 
voluntary. You may refuse to join, or you may withdraw your consent to be in the 
study, for any reason, without penalty.  
 
Research studies are designed to obtain new knowledge. This new information 
may help people in the future.   You may not receive any direct benefit from being 
in the research study. There also may be risks to being in research studies. 
 
Page 1 of 6 
258
   
Details about this study are discussed below.  It is important that you understand 
this information so that you can make an informed choice about being in this 
research study.  You will be given a copy of this consent form.  You should ask the 
researchers named above, or staff members who may assist them, any questions 
you have about this study at any time. 
 
What is the purpose of this study?  
The major purpose of this research study is to compare how the ability to perceive 
touch as well as the ability to initiate and sustain movements differs in persons 
who have and have not undergone treatment for primary brain tumor.  Studies have 
shown that the brain’s ability to perceive touch and initiate and maintain 
movements may be affected first in persons following treatment for primary brain 
tumor.  With this information, we may be able to design better methods to detect 
cognitive changes and design interventions to decrease the risk of further cognitive 
decline.  You are being asked to be in the study because you are in good health and 
do not have any problems taking care of yourself.   
 
Are there any reasons you should not be in this study? 
You should not be in this study if you have had any seizures in the past six months 
requiring medication changes, any known neurodegenerative disorder or taking 
medications for a similar disorder such as Parkinson’s disease, multiple sclerosis, 
Alzheimer’s Disease or other dementias, psychiatric disorders such as 
schizophrenia, mania, or bipolar disorder, known problems feeling touch or 
vibration, problems moving your arms or legs, problems speaking clearly, 
problems with sleep such as sleep apnea, or history of stroke, HIV, herpes, 
tuberculosis, syphilis, or hepatitis.  You should not participate if you have been 
treating a cold with over-the-counter medications in the past two weeks, drank 
alcoholic beverages or recreational drugs in the past 24 hours, or took sleeping 
medicines last night which you do not routinely take every night, or smoked 
tobacco products within four hours prior to testing procedures.   
 
How many people will take part in this study? 
If you decide to be in this study, you will be one of approximately 11 adults with 
primary brain tumors and 11 healthy adults in this research study. 
 
How long will your part in this study last?  
The study will take no more than 3 hours to complete.   
 
Page 2 of 6 
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What will happen if you take part in the study? 
After you review this consent form and have opportunity to ask questions about the 
testing procedures, you will have your vital signs measured (heart rate, blood 
pressure, blood oxygen levels in your finger)  Next you will be asked to complete a 
questionnaire about depression and a second questionnaire about your ability to 
take care of yourself.  You will then be asked to take a brief neurological test.  This 
test will be videotaped so that a reviewer will independently score the results.  The 
video camera will include your face.  The video recordings will be kept in a locked 
cabinet.  You may opt not to allow the video taping without any affect on 
participation in the study.  Please check the line that best matches your choice: 
_____ OK to record me during the study 
_____ Not OK to record me during the study 
Afterwards you will undergo the test that will measures your ability to perceive 
touch.  In this test, you will place your hand under two plastic tips that touch or 
vibrate on the back of your hand.  You will be asked to use the computer mouse 
with your left hand to indicate when you felt the touch, which tip you felt first, or 
which tip had the stronger pressure.  In the last test, we will ask you to connect 
consecutive numbers or letters in alternating order.  In this test we will be 
measuring how fast and how accurate you are in connecting the dots.  You will be 
provided opportunities during all the testing procedures to have breaks for food 
and bathroom use.  Upon completion of the study, we will provide you another 
snack.  We will ask you to provide feedback to us regarding the tests, testing 
format, procedures, and breaks.  You will be provided another snack and you may 
go home.   
 
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge.  You may not 
benefit personally from being in this research study. 
 
What are the possible risks or discomforts involved from being in this study? 
There are no major risks to you as a subject in this study.  It is possible that you 
may feel uncomfortable with some of the tasks that we ask you to do.  For 
example, the memory test may make you feel anxious because some of the answers 
will be very easy and some will be very hard.  We do not expect you to know all 
the answers.  Please do not hesitate to ask any member of the research team any 
question, and we want you tell us about any problems you may be having.   
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Because we are taking a lot of measurements, we may find people who may have a 
condition that requires medical attention.  Examples of conditions that require 
medical attention include findings like a high pulse rate, high or low blood 
pressure, below normal measures on a memory test, or the inability to perceive 
certain kinds of tactile stimulation.  If this is detected, Ms. Allen or Dr. Carlson 
will talk to you directly.  In this case, you will be given a form that (1) tells you 
what the test measures, (2) tells you what results we got, and (3) tells you to share 
this information with your doctor.  Lastly, there may be uncommon or previously 
unknown risks.  You should report any problems to the researcher. 
 
How will your privacy be protected? 
Every effort will be taken to protect your identity.  Only Ms. Allen, Dr. Carlson, 
the other study investigators, and their research assistants will have access to your 
data.  All data (paper forms and compact discs) will be kept under lock and key at 
the School of Nursing.  The videotape will be kept in a locked file cabinet until 
completion of the study.  Once the study is completed and the videotape has been 
scored, the videotape will be destroyed. 
 
Participants will not be identified in any report or publication about this study. 
Although every effort will be made to keep research records private, there may be 
times when federal or state law requires the disclosure of such records, including 
personal information.  This is very unlikely, but if disclosure is ever required, 
UNC-Chapel Hill will take steps allowable by law to protect the privacy of 
personal information.  In some cases, your information in this research study could 
be reviewed by representatives of the University, research sponsors, or government 
agencies for purposes such as quality control or safety. 
 
What will happen if you are injured by this research? 
All research involves a chance that something bad might happen to you.  This may 
include the risk of personal injury. In spite of all safety measures, you might 
develop a reaction or injury from being in this study.  If such problems occur, the 
researchers will help you get medical care, but any costs for the medical care will 
be billed to you and/or your insurance company. The University of North Carolina 
at Chapel Hill has not set aside funds to pay you for any such reactions or injuries, 
or for the related medical care. However, by signing this form, you do not give up 
any of your legal rights. 
 
 
Page 4 of 6 
261
   
 
Will you receive anything for being in this study? 
You will be receiving $25.00 for taking part and completing the procedures in this 
study.  You will also receive a parking voucher. 
 
Will it cost you anything to be in this study? 
There will be no costs for being in the study 
 
What if you are a UNC student? 
You may choose not to be in the study or to stop being in the study before it is over 
at any time.  This will not affect your class standing or grades at UNC-Chapel Hill.  
You will not be offered or receive any special consideration if you take part in this 
research. 
 
What if you are a UNC employee? 
Taking part in this research is not a part of your University duties, and refusing 
will not affect your job.  You will not be offered or receive any special job-related 
consideration if you take part in this research.   
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about 
this research. If you have questions, or concerns, you should contact the 
researchers listed on the first page of this form. 
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect 
your rights and welfare.  If you have questions or concerns about your rights as a 
research subject you may contact, anonymously if you wish, the Institutional 
Review Board at 919-966-3113 or by email to IRB_subjects@unc.edu. 
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
Title of Study: Pilot Study of Sensory Information Processing and Motor 
Processing:  Relationship to Executive Control in Adults with Primary Brain 
Tumors 
 
Principal Investigator: Deborah Allen. RN, MSN 
 
Participant’s Agreement:  
 
I have read the information provided above.  I have asked all the questions I have 
at this time.  I voluntarily agree to participate in this research study. 
 
________________________________________ _________________ 
Signature of Research Participant Date 
 
________________________________________ 
Printed Name of Research Participant 
 
 
________________________________________ _________________ 
Signature of Person Obtaining Consent Date 
 
________________________________________ 
Printed Name of Person Obtaining Consent 
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Appendix A.1        
 
TELEPHONE SCREENING INSTRUMENT 
 
 
 
I.  PHONE RECRUITMENT SCRIPT 
 
A.  Introductory Remarks: 
 
“Hello, this is Debbie Allen, from the University of North Carolina School of Nursing.  I 
understand that you would like to learn more about participating in a research study 
involving your ability to feel touch or vibration and your movements in drawing as it 
relates to thinking and memory.  Is this a good time to talk?”  If not, ask the potential 
participant “when is a good time to call you?” 
 
 If we need to call again, date/time agreed upon: _______________ 
 
 
B.  Brief Description of the Study 
 
“I thank you for your interest and calling us to discuss this study more.    The purpose of 
this research is to compare the ability to perceive touch as well as the ability to initiate 
and sustain movements as it differs in persons who have undergone treatment for a 
primary brain tumor as to persons who have not had a brain tumor.” 
   
“We will ask you questions about your health, how well you think, measure your writing 
ability, and your sense of touch.  It is our aim to use this information to design better 
methods to detect early changes in cognition and design interventions to decrease the risk 
of further decline.  We are testing this only in adults with primary brain tumors and 
healthy adults.  The total time to complete the study will be around three hours and we 
will compensate you for your time and travel with $25.00 cash.  Does this sound like 
something you might be interested in?” 
 
 
 
   
 
 
 
 
 
 
 
 
   
Response:             Yes                          No 
 
If they say yes, go to the Mini-Consent for Telephone Screening. 
 
If they say no, thank them for their time and interest in speaking with you. 
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C.  Mini-Consent for the Telephone Screen 
 
After the respondent tells you that they are interested in participating, ask them 
“Is it okay to ask you a few questions about your health and the medications you take?  It 
should take no more than 15 minutes.” 
 
  
   
If they say yes, go to Health Screening Questionnaire. 
 
If they need to reschedule, ask them for preference of contact phone numbers 
and a date/time to call.  
   Phone number 1:   (____) _____- ________ 
   Phone number 2:   (____) _____- ________ 
   Date & Time: _____________ , _________ AM/PM  
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II.  RESPONDENT TELEPHONE SCREENING  
 
A.  Tracking Information 
 
Date participant called us: ____/____/____  
Date call was returned: ____/____/____  
 
B.  Group Assessment 
 
1.  Have you had a brain tumor? 
 
  
 
 
 
 
 
 
 
 
     a.   Have you had surgery, chemotherapy, or radiation therapy as treatment for your   
brain tumor?    Yes                No 
 i.    Date of surgery      _____/_____/_____   or     NA 
 ii.   Date of chemotherapy    _____/_____/_____    or     NA 
 iii.  Date of radiation therapy   _____/_____/_____    or     NA 
 
 
 
 
 
 
 That means that it has been _______ months/years since your last treatment. 
 
 
  
 
 
      
 
 
 
 
b.  Do you have any problems with movement, speech or touch?     Yes        No 
  
 
 
   
If they say yes, they are assigned to the brain tumor subject group. 
Proceed to ask questions a and b below. 
 
If they say no, they are assigned to the control group. 
Proceed to question 2.   
If YES, stop interview here and go to NOT ELIGIBLE section on the last page 
   
Subtract date of last procedure from the current date:  ___/____/____ - ___/___/____ 
   
If > 12 months (1 year), proceed with question b below. 
 
If < 12 months (1 year), stop interview and go to NOT ELIGIBLE section on the 
last page. 
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2.  Medications 
Are you taking medications (including prescription & over-the-
counter)? 
Yes No  
 
 
 
 
 
 
 
 
Record below: 
 
Medication Name Reason for taking 
1.        
2.         
3.         
4.         
5.         
6.         
7.         
8.       
9.   
10.   
11.   
12.   
 
Compare the list of medications to the Medication Exclusion Card.  Exclude the subject if 
she or he is taking any of the medications listed on the Medication Exclusion Card.  Put a 
check next to the name of any drug that excludes the subject from participating.   
 
MEDICATION EXCLUSION    
   Changes in seizure medications in the last six months YES NO 
   Dopaminergics YES NO 
   Major anticholinergics YES NO 
   Alzheimer’s drugs YES NO 
   Cold medications, sedative hypnotics in past 48 hours? YES NO 
 
 
Medication Exclusion: 
  
      Taking a medication on the Medication Exclusion Card? Yes No 
  
 If YES, STOP interview here.   
 Go to Not Eligible section on last page. 
  
   
If they say yes, ask “What medications are you taking?” 
 
If they do not know, ask them to read all medication bottles to you that they 
have. 
Proceed to questions   
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3.  Neurological Conditions 
I’m now going to read a list to you.  Please wait until I have read the entire list, and 
then say ‘yes’ if you have been diagnosed with any of these conditions, or say ‘no’ if 
you have not.  
a. Alzheimer’s Disease 
b. Dementia 
c. Parkinson’s Diseases 
d. Schizophrenia 
e. Mania 
f. Bipolar Disorder 
g. Unstable Seizure Disorder requiring antiepileptic changes in the last six months 
h. Any problems with numbness or tingling in your arms or legs 
i. Any problems moving your arms or legs 
j. Had any surgery requiring general anesthesia in the last two weeks 
 
Neurological Disease Exclusion:   
Answer of “Yes” to any of the neurological conditions? Yes No 
 If YES, STOP interview here.   
 Go to “Not-Eligible” section on last page. 
  
 
4.  Other Neuroimmune Disorders 
For this next list, again, please wait until I have read the entire list, and then say ‘yes’ 
if you have been diagnosed with any of these conditions, or say ‘no’ if you have not.  
a. Tuberculosis 
b. Hepatitis 
c. HIV or AIDS 
d. Herpes 
e. Syphilis 
 
Neuroimmune Disorder Exclusion:   
Answer of “Yes” to any of the neuroimmune disorders? Yes No 
 If YES, STOP interview here.   
 Go to “Not-Eligible” section on last page. 
  
 
5.  Cerebrovascular Events 
For this next list, please wait until I have read the entire list, and then say ‘yes’ if you 
have had any of these conditions in the past 6 months or say ‘no’ if you have not.  
a. Stroke or Transient Ischemic Attack 
b. Hit your head and lost consciousness  
 
 
Cerebrovascular Event Exclusion:   
Answer of “Yes” to any of the cerebrovascular events? Yes No 
 
 If YES, STOP interview here.   
 Go to “Not-Eligible” section on last page. 
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6.  Sleep-Related Symptoms 
After I have read the next list, please say ‘yes’ if you have had any of the following 
problems in the past month, or say ‘no’ if you have not. 
  
a. Pain so bad it keeps you awake 
b. Having to get up and urinate 3 or more times a night 
c. Being easily awakened by sounds  
d. Having difficulty sleeping when away from home 
e. Walking in your sleep 
f. Falling out of bed 
g. Waking from sleep violent or confused 
 
Sleep-Related Exclusions:   
Answer of “Yes” to any of the sleep-related symptoms  
questions? 
Yes No 
 If YES, STOP interview here.   
 Go to “Not-Eligible” section on last page. 
  
 
7.  Alcohol & Drug Exclusions  
These next questions are about alcohol and illegal drugs.  Please wait until I have read 
the entire list, and then just say ‘yes’ if you do any of the following or ‘no’ if you do 
not: 
 
a. Have more than 3 cans of beer on more than 3 nights/week 
b. Have more than 3 glasses of wine on more than 3 nights/week 
c. Have more than 3 shots of distilled liquor on more than 3 nights/week 
d. Currently smoke marijuana or use illegal drugs 
 
Alcohol and Drug Exclusion:   
Answer of “Yes” to any of the alcohol/drug questions? Yes No 
 If YES, STOP interview here.   
 Go to “Not-Eligible” section on last page. 
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8.   What is your date of birth    ____/_____/_____   
 
 
 
 
“Then that would mean that you are:  ____ ____ years old. 
 
Age exclusion:   
      Age < 30 years     OR                Age > 55 years Yes No 
 If YES, STOP interview here.   
 Go to “Not-Eligible” section below. 
  
 
 
 
 
 
 
   
Subtract date of last procedure from the current date:  ___/____/____ - ___/___/____ 
Not-Eligible Section 
If the subject is deemed ineligible for study, state: 
 
“Thank you for you time today.  We appreciate your interest.   However some health 
conditions or medications may interfere with the results with the study tests.  We are 
not able to enroll you in the study, but greatly appreciate your time and effort.”   
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COMPLETION OF PHONE ELIGIBILITY 
 
Script 
Thank you for answering all of these questions.  You may enroll to participate in the 
study by completing more study questions that will be done at the UNC School of 
Nursing.  What days of the week are you able to come to the School of Nursing? 
 
 
 
 
 
 
 
 
 
 
Instructions to the Participant 
You will receive a subject information packet that provides a letter telling you the 
scheduled study date and time, instructions for transportation and parking with a map, an 
overview of the study and things you will need to do the night before the study.  I want 
you to read over all these instructions when you received them in the mail and call me if 
you have any questions. 
 
 
 
 
 
 
 
 
It is expected that you will be with us for three to four hours depending on your needs.  
While you are with us, you will be provided some nourishing refreshments.  Please bring 
any medications that you need to take during those times with you.  Would you like to 
have a reminder call the day before you come in for the research study?   
 
 
 
 
 
 
 
 
 
We thank you for your interest in this study and your willingness to participate.  I look 
forward to working with you in this research study at the UNC School of Nursing. 
 
   Date 1:  ____/____/______   Time: ___:____ 
 
   Date 2: ____/____/______   Time: ___:____ 
 
Enter these dates to schedule the study procedures to check for availability 
with the UNC SON BBL calendar on the Scheduling Form, next page. 
     Yes               No 
 
If yes, ask them for two phone numbers of their choice to contact them. 
 Contact 1:  (_____) ______ - ________ 
 Contact 2:  (_____) ______ - ________ 
What address would you like for us to mail this information packet to? 
Street or Box:  ________________________________________ 
  ________________________________________ 
City:     ________________________________________ 
State:  _____________ Zip:___________________ 
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A.2  Subject Information Packet 
 
 
 
SUBJECT INFORMATION PACKET 
 
 
Instructions for sending the Subject Information Packet 
 
1.  After consulting with the UNC SON Biobehavioral Laboratory calendar to schedule 
the subject, you will send the Subject Information Packet to the subject.   
 
This packet contains: 
1.  Letter to subject with their scheduled study date and time 
2.  Instructions sheet labeled “What they should do now” 
3.  Instructions sheet labeled “Overview of the study” 
4.  Instruction sheet labeled “Directions” 
5.  Map of the UNC Campus 
 
 
2.  Be sure to address the letter to the subject. 
 
3.  Be sure to insert in the letter (Item #1) the scheduled date and time. 
 
4.  Make a copy of the letter to be retained in the subject file which will be kept in the 
locked cabinet. 
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 April 12, 2014 
«Title» «First» «MidI»  «Last» 
«Street_1» 
«City», «State» «Zip5»«Zip9» 
 
 
Dear «Title» «Last»: 
 
Thank you again for participating in our research study titled “Pilot Study of 
Sensory Information Processing and Motor Processing: Relationship to Executive 
Control in Adults with Primary Brain Tumors.”  We’re very excited that you called 
us about this important study and we’re looking forward to seeing you for your 
scheduled appointment in the University of North Carolina School of Nursing 
Biobehavioral Laboratory.  We presently have you scheduled to come in as 
follows: 
 
 Date:  «BDay1», «BDate1», at 
 Time:  «BTime2» 
 
I have enclosed materials that provide more detailed information that I hope you 
will find helpful.  Please pay special attention to the page entitled, “What you 
should do now.” 
I will call you the day before your study to make sure you’ve received this packet 
and to answer any questions you may have.  Please bring this packet with you 
when you come for your study, because you will be receiving other information 
that you may want to keep together.  In the meantime, please feel free to phone me 
(919-883-7002) with any questions or concerns you might have.  We’ll look 
forward to seeing you then! 
 
Sincerely, 
 
 
Deborah H. Allen, RN, MSN, FNP-BC, AOCNP 
Predoctoral Student, School of Nursing 
University of North Carolina at Chapel Hill 
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What You Should Do Now 
 
1.  Please let us know if you have any food allergies or other dietary requirements 
of which we might not already be aware.  You may call us at (919) 883-7002 to so 
advise. 
 
2.  Please let us know if you plan to drive so that we can reserve a parking space 
for you.  You may reach us by telephone at (919) 883-7002.  Parking is limited to 
the Bell Tower parking lot, which is located down the hill from the School of 
Nursing.  If you choose to drive, one of my research assistants will meet you at the 
Bell Tower parking lot entrance to give you the permit and assist you with gaining 
access to the parking area (see the directions on the following page).   
 
If you would prefer not to drive, you may ride one of the Chapel Hill Transit 
busses free of charge.  There is a bus stop located directly in front of the School 
of Nursing.  If you are having difficulty in arranging for transportation, please 
call so that we may help.  If you would like for us to do this, please call us as 
soon as possible (919-883-7002) so we may have enough time to make plans 
for your transportation. 
 
 
 
 
 
 
 
 
 
 
 
A MAP AND DIRECTIONS TO THE PARKING AREA  
ARE INCLUDED LATER IN THE PACKET. 
 
On the day of your appointment: 
If you are going to be late or need to cancel your study,  
Please call Deborah Allen directly.   
At phone number 919-883-7002. 
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OVERVIEW OF THE STUDY PROTOCOL 
 
The study will be conducted at the Biobehavioral Laboratory (Room 10) at the 
UNC School of Nursing, located in Carrington Hall.  We will ask that you report to 
the lab at the scheduled time of _______ as indicated in your letter.  The study will 
take 3 hours.  You will be given time for breaks, as well as snacks and drinks.  You 
may opt to bring in food, drinks, or items like pillows to make sitting more 
comfortable.  Let us know if you have any allergies, require special foods or 
drinks, or have special needs that we should know; you may call us at 919-883-
7002.   
 
 WHAT YOU SHOULD KNOW BEFORE COMING IN FOR YOUR STUDY 
 
1.  On the day before the study, you should do the things that you would regularly 
do.  This includes going to bed and getting up at your usual times, eating what you 
usually eat, and taking your medications as prescribed by your doctor.  (The 
exceptions to this are listed below under the heading “What we ask you to avoid.”) 
 
2.  If you have been taking cold medicines the week before the study, please call us 
to discuss rescheduling the study procedures.   
 
3.  Do not to bring any valuables (large amounts of money or jewelry) that could 
be stolen.  Although this is unlikely to occur, it is better to be safe than sorry. 
 
4.  Your family or friends may come with you to see the laboratory.   
 
What We Ask You To Avoid 
 
We would ask that you avoid the following so we get the best recordings possible: 
 
a. Any alcoholic beverages after dinner (including wine and beer) on the 
night before coming in for your study, 
 
b. Medications that help you sleep or cold medications for 24 hours before 
coming in for your study, and 
 
c. Do not smoke any tobacco products for 4 hours before coming in for 
your study. 
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Directions to the Bell Tower Parking Lot/School of Nursing 
 
1. North on 15-501 Bypass (from Burlington/Carrboro): Take the Chapel Hill-
Pittsboro exit.  At the stoplight, make a left onto South Columbia Street.  Follow 
the road up the hill and go through the intersection of South Columbia and 
Manning Drive.  Start to get into the right lane.  After you pass the School of 
Nursing (which will be located on your right), make a right turn at the next 
stoplight (which is at South Road).  Stay to the right again and make a right-hand 
turn at the next stop light, which is Bell Tower Drive (this will take you into the 
Bell Tower parking area).   
 
2. South on 15-501 Bypass (from University Mall/Durham):  From University 
Mall, get ready to make a right turn at the Highway 54 exit (as you head into 
campus this becomes South Road).  At the first stoplight at the top of the hill you 
will see the Institute of Law to your left.  Continue going straight on South Road.  
At the second stoplight you will see Fetzer Gymnasium to your left and Raleigh 
Road to your right.  You’ll next see Student Stores on your right, followed by 
Stadium Drive and the Bell Tower on your left.  Continue to the next stoplight and 
make a left turn onto Bell Tower Drive (this will take you into the Bell Tower 
parking area).   
 
3. From Highway 54 (RTP or Raleigh): Take Highway 54 toward campus, go 
under the 15-501 bypass, and continue up the hill (as you head into campus, Hwy 
54 becomes South Road).  At the first stoplight at the top of the hill you will see 
the Institute of Law to your left.  Continue going straight on South Road.  At the 
second stoplight you will see Fetzer Gymnasium to your left and Raleigh Road to 
your right.  You’ll next see Student Stores on your right, followed by Stadium 
Drive and the Bell Tower on your left.  Continue to the next stoplight and make a 
left turn onto Bell Tower Drive (this will take you into the Bell Tower parking 
area).   
 
4. From Downtown Chapel Hill (Coming from Franklin Street):  From the 
intersection of Franklin and South Columbia Streets (Spanky’s is on this corner), 
take South Columbia into campus.  At the second stop light, make a right onto 
Cameron Avenue and get into the left lane.  At the next stoplight, make a left onto 
Pittsboro Street.  Then make a left again at the next stop light, which will be at 
McCauley Street.  Cross South Columbia Street (at this point McCauley Street 
becomes South Road).  Make a right at the next stop light, which is Bell Tower 
Drive (which will take you into the Bell Tower parking area).   
 
PLEASE REFER TO THE MAP ON THE NEXT PAGE. 
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A.3   Scheduling Form 
 
 
    SCHEDULING FORM 
 
INSTRUCTIONS TO RECRUITER: 
Add new participant name to this form when recruiting.  After completing this form and 
confirming the schedule with the SON BBL, file in the Scheduling Folder and keep 
stored in locked file cabinet. 
 
Adults with Primary Brain Tumors: 
 
Subject Name Age Gender Study Date 1 Study Date 2 
1.     
2.     
3.     
4.     
5.     
6.     
7.     
8.     
9.     
10.     
11.     
 
 
 
Healthy Adult Controls 
 
Subject Name Age Gender Study Date 1 Study Date 2 
1.     
2.     
3.     
4.     
5.     
6.     
7.     
8.     
9.     
10.     
11.     
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A.4 Laboratory Intake Screen & Mini-Consent     
 
LABORATORY INTAKE SCREEN 
 
Subject Preparation 
 
Give the subject a tour of the BBL including the test area, bathroom, and nourishment 
station.  Offer them something to drink and have them seated in the testing interview 
area.  Make sure the door is closed to the BBL and the interview room prior to 
proceeding with the Laboratory Intake Screen. 
 
Mini Consent 
 
Ask them: 
 “Before we start, I’d like to ask you a few questions and would like to perform a brief 
exam on your ability to process and think.  This is to make sure that you have had not 
changes in your health status since we spoke on the telephone.   There are some health 
conditions or problems with thinking that may keep you from participating in the study.  
If you are not eligible to be involved in the study, I will shred all of the information that 
you have given me over the phone and what we have done today and you will not receive 
the $25 for your time and travel. Is it okay to proceed with the questions and test now?” 
 
 
 
 
 
 
 
Adjunct to Pre-Study Instrument 
 
“Since we’ve last talked have you had any of the following: 
 
1. Surgical procedures requiring general anesthesia?   Yes  No 
 
2. Please tell me about any new medicine you are taking.   
 List the medications:  ___________________________ 
 _____________________________________________ 
 
Are any of these drugs a sedative hypnotic or cold medication?    Yes  No 
 
3. Have you had alcohol in the last 24 hours?   Yes  No 
 
4. Have you smoked in the last 4 hours?    Yes  No 
 
 
 
 
 
If yes, proceed with the four questions below. 
 
If no, stop the interview and thank the subject for coming.   
Escort the subject and ask if they need directions back to their parking area. 
If yes to any of the question, reschedule the research study time. 
 Date: _____/_____/_________ Time:  ____:____ 
 
If no, proceed to the Mini-Mental Status Examination, next page.   
Escort the subject and ask if they need directions back to their parking area. 
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A.5  Mini-Mental Status Examination     
 
The Mini-Mental State Examination 
(Folstein et al., 1975) 
 
Instructions to Patient: “Now I’d like you to answer some questions and follow some 
Instructions.  Do your best to respond to each question or instruction.  Some will seem 
very simple and some will be more difficult.” 
 
Code in margin any question that patient refuses to answer (9) or is physically unable to answer (8). 
Do not include the 8’s and 9’s in the total score, but do indicate reason code was used (where applicable). 
   
 
Orientation 
Points 
Avail. 
Points 
Earned 
1. Ask first:  “What is the day, date and season?” 
 If information is omitted, ask as needed: 
  
  Year 1   ______ 
  Season? 1   ______ 
  Date? 1 ______ 
  Day?  1   ______ 
  Month? 1   ______ 
   
  If patient can’t answer three of these correctly ask,  
  “What part of the day is this?” (morning, afternoon, evening, night).  
  Code response at end of MMSE total (see item #13) 
  
   
2. Ask:  “What is the name of this place and where is it located?” 
 If information is omitted, ask as needed: 
  
  State? 1   ______ 
  County? 1   ______ 
  Town or City? 1 ______ 
  Building? 1   ______ 
  Floor? 1   ______ 
   
   
Registration   
3. Name three objects, taking one second to say each.  
“I am going to give you a list of 3 words.  I want you to listen carefully then 
repeat them back to me. The words are book, house, candle. Please tell me 
the three words.” 
  
  Book 1   ______ 
  House 1   ______ 
  Candle 1 ______ 
  (Score responses on first try.  Then repeat objects until all are learned.)   
Tell patient, “Try to remember those objects because I’m going to ask you   
to repeat them from memory later.”   
 
Attention and Calculation   
4. Serial Sevens.  Give one point for each correct answer.     
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 “I want you to start with the number 100, subtract 7, and tell me 
 your answer.  So how much is 7 from 100?  _____  (93) 
 Now keep subtracting seven until I tell you to stop.” 
  (Stop after five answers; you may prompt after each answer.) 
  Record responses:   _____   _____   _____   _____   _____ 
  Correct Responses:    93        86          79           72             65 5   ______ 
   
 If patient missed any calculation, then ask the following:   
           “Now I am going to spell a word forward and I want you to spell  
 it backwards.  The word is ‘world,’ W-O-R-L-D.  Spell ‘world’  
 backwards.”  
  (Answer: D-L-R-O-W; repeat if necessary but not after spelling starts.   )
  Record responses:  _____   _____   _____   _____   _____ 
  
   
Recall   
5. Ask for the names of the three objects learned in Question 3.  
 (Give 1 point for each correct answer.) 
  
 (book, house, candle)  :  __________   __________   __________ 3 ______ 
   
Language   
6. Point to a pencil & a watch.  Have patient name them as you point.   
 “What do you call this?”   “What is this?” 2 ______ 
   
7. Have the patient repeat: “No ifs, ands, or buts.” 1 ______ 
 (Stress s’s when you say it, s’s must be repeated back for a correct response.)   
   
8. Have the patient follow a three-step command (using next page):   
 “Take this paper in your right hand, fold the paper in half with  
 both hands, and put the paper on the bed (floor, etc.).” 3 ______ 
   
9. Have the patient read and obey the following from the next page:   
      “CLOSE YOUR EYES.”   1 ______ 
   
10. Have the patient write a simple sentence of his or her choice. 1 ______ 
 (The sentence should contain a subject and a verb and should make sense. 
 Ignore spelling errors when scoring.). 
  
   
11. Put the Bender Gestalt design before patient and ask patient to,    
 “Copy this shape.” 1 ______ 
 (Give one point if all sides and angles are preserved and if the intersecting  
 sides form a quadrangle.). 
  
   
12. Total Score (sum 0’s & 1’s). 30 ______ 
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Close your eyes. 
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A.6   Subject Eligibility Form      
    SUBJECT ELIGIBILITY FORM 
 
Eligibility Criteria for Adults Subject with Primary 
Brain Tumor 
Screen 
TS/Lab 
YES NO N/A 
Age 30 to 55 years old TS    
Primary Brain Tumor treated with chemotherapy or 
radiation therapy  (completed therapy at least one year 
prior to enrollment) 
TS    
Read and write English language TS    
Stable seizure status for last six months with no 
antiepileptic medication changes in the last six months 
TS    
MMSE > 24 points Lab    
Signed informed consent Lab    
Exclusion Criteria     
General anesthesia within the last six months TS    
Paresis or Aphasia TS    
Unstable seizure disorder requiring antiepleptic 
medication adjustments 
TS    
Known neuro disorders listed in Appendix A.1     
(Example:  Parkinson’s disease, multiple sclerosis, 
Alzheimer’s disease, CVA, immune disorders) 
TS    
Sleep disorder/apnea or sedative hypnotic the night before TS & Lab    
Had cold meds, alcohol night before; tobacco 4 hr before Lab    
Exclude subject if yes to any of these exclusions.     TS=telephone screen 
 
Eligibility Criteria for Healthy Control Subjects Screen 
TS/Lab 
YES NO N/A 
Age 30 to 55 years old TS    
No seizures TS    
Read and write English language TS    
MMSE > 24 points Lab    
Signed informed consent Lab    
Exclusion Criteria     
General anesthesia within the last six months TS    
Paresis or Aphasia TS    
Unstable seizure disorder requiring antiepleptic medication 
adjustments 
TS    
Known neuro disorders listed in Appendix A.1     
(Example:  Parkinson’s disease, multiple sclerosis, 
Alzheimer’s disease, CVA, immune disorders) 
TS    
Sleep disorder/apnea or sedative hypnotic the night before TS & Lab    
Had cold meds, alcohol night before; tobacco 4 hr before Lab    
Exclude subject if yes to any of these exclusions.   TS=telephone screen
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Appendix B:    Informed Consent 
1. Informed Consent Protocol  
2. Informed Consent for the study 
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B.1.  Informed Consent Protocol Checklist    
 
 
    Informed Consent Protocol 
 
 
Informed Consent: 
  
 1.  Allow subject to read consent or read it to them 
 2.  Allow subject time to ask questions 
 3.  Review the three hour schedule 
 4.  Have subject sign the consent and researcher cosign the consent  
 5.  Make a copy for subject, place original in file 
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Appendix C:    Evaluations 
1. Subject Packet 
a. Demographic Information 
b. Older Adults Resource Services Activities of Daily Living 
Scale 
c. Center for Epidemiological Studies Depression Scale 
2. Investigator Packet 
a. Health Information Form 
b. EXIT-25 
c. Quantitative Sensory Test 
d. Trails-Making Test B on the OASIS Digitizer Writing Tablet 
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C.1     Subject Packet 
 
 
Instructions for Subject Packet 
The following questionnaires are to be completed by the subject:  
 Demographic Information Sheet 
Older Adults Resource Services Activities of Daily Living Scale 
Center for Epidemiological Studies Depression Scale 
 
 
Provide a pencil with the forms for the subject. 
Be available to answer any questions. 
When the subject indicates that they are done, review the form to make sure all items are 
answered. 
Record scores on data collection forms for data entry. 
Check the data collection forms for accuracy. 
File in subject record and store in locked file cabinet. 
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C.1.a.  Demographic Information     
 
DEMOGRAPHIC INFORMATION   
(Carlson, 1999) 
1. Race ______  
 1=Caucasian/white  4=Hispanic 
 2=African American  5=Asian/Pacific islander 
 3=American Indian  6=Other 
  
   
2. Gender (1=male, 2=female) ______  
   
3. How many grades did you complete in school? ______  
(Record highest grade) 
1-12=Grade school/High school   
12=GED/High school diploma 
13=Technical only   15=Graduate School 
 14=Baccalaurean only  16=Doctorate 
 
 
 
 
   
4. What activities best describe what you typically do: ______  
 1=employed, full time 
 2=employed, part time 
 3=retired 
 4=never had a job outside home 
 5=disabled 
 6=other_________________________ 
  
   
5. Marital Status ______  
 1=married, living with spouse 
 2=married, separated 
 3=single, living alone 
 4=single, living with someone 
 5=single, recently widowed (2 years) 
  
   
6. Age (rounded to the nearest year) ______  
   
7. What types of jobs have you had?   
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C.1.b  Older Adults Resource Services Activities of Daily Living Scale   
        
Older Adults Resource Services Activities of Daily Living Scale 
(Fillenbaum, 1978) 
 
Instructions:  The following questions are about some of the activities of daily living 
(ADLs), the things that we all need to do as part of our daily lives.  I would like to know 
if, within the last month, you could do these activities without any help at all, or if you 
needed some help to do them, or if you couldn’t do them at all.  Please write the number 
for the best answer in the space provided. 
 
Physical ADLS   
1. Can you eat . . . ______  
 2 = without help (able to feed yourself completely),  
 1 = with some help (need help with cutting, etc.), 
 0 = or are you completely unable to feed yourself?  
 
   
2. Can you dress and undress yourself . . . ______  
 2 = without help (able to pick out clothes, dress and undress  
  yourself), 
 1 = with some help, 
 0 = or are you completely unable to dress and undress  
  yourself?  
 
   
3. Can you take care of your own appearance, for example  
 combing your hair or shaving . . . ______ 
 
 2 = without help, 
 1 = with some help, 
 0 = or are you completely unable to maintain your  
  appearance yourself?  
 
   
4. Can you walk . . . ______  
 2 = without help (except for a cane), 
 1 = with some help from a person or using a walker, crutches, etc., 
 0 = or are you completely unable to walk?  
 
   
5. Can you get in and out of bed . . . ______  
 2 = without any help (without grabbing hold of the bedstand or aids), 
 1 = with some help (either from a person, grabbing hold of  
  a bedstand or with the aid of some device), 
 0 = or are you totally dependent on someone else to lift you?  
 
   
6. Can you take a bath or shower . . . ______  
 2 = without help, 
 1 = with some help (need help getting in and out of the tub,  
  or need special attachment on the tub), 
 0 = or are you completely unable to bathe yourself?  
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7. Do you ever have trouble getting to the bathroom on time? ______  
 2 = no 
 1 = yes 
  
 a.  If yes, how often do you wet our soil yourself? _____ 
   1 = once or twice a week? 
   0 = three times a week or more?  
 
   
Independent ADLS   
8. Can you use the telephone . . . ______  
 2 = without help, including looking up the number and  
  dialing, 
 1 = with some help (could answer phone or dial operator in  
  an emergency, but need a special phone or help), 
 0 = or are you completely unable to use the telephone?  
 
   
9. Can you get to places out of walking distance . . . ______  
 2 = without help (travel alone on buses, taxis, or drive your  
  own car), 
 1 = with some help (need someone to help you or be with  
  you when traveling), 
 0 = or are you unable to travel unless emergency  
  arrangements are made for a specialized vehicle like an  
  ambulance?  
 
   
10. Can you go shopping for groceries or clothes (assuming you 
 have  transportation) . . . ______ 
 
 2 = without help (take care of all shopping needs yourself), 
 1 = with some help (need someone to go with you on all  
  shopping trips), 
 0 = or are you completely unable to do any shopping?  
 
   
11. Can you prepare your own meals . . . ______  
 2 = without help (plan and cook full meals yourself), 
 1 = with some help (could prepare something but unable to  
  cook full meals yourself), 
 0 = or were you completely unable to prepare your meals?  
 
   
12. Can you do your housework or yardwork . . . ______  
 2 = without help (scrub floors, cut grass, etc.), 
 1 = with some help (could do light work but need help with  
  heavy work), 
 0 = or are you completely unable to do any of this type of  
  work?  
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13. Can you take your own medicine . . . ______  
 2 = without help (in the right dose, at the right time), 
 1 = with some help (able to take medicine if someone  
  prepares it for you or reminds you to take it), 
 0 = or are you completely unable to take your medicine?  
 
   
14. Can you handle your own money... ______  
 2 = without help (write checks, pay bills, etc.), 
 1 = with some help (could manage day-to-day buying but  
  need help with managing your checkbook or paying  
  your bills), 
 0 = were you completely unable to handle money?  
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C.1.c  Center of Epidemiology Screen for Depression       
 
 
 
 
  
During the past week: 
 
Rarely  
(<1 day) 
 
Some of the  
time (1-2 days) 
 
Occasionally 
(3-4 days) 
 
Most of the  
time (5-7 days) 
1. I was bothered by things that usually don’t 
bother me. 
                  
2. I did not feel like eating; my appetite was 
poor.  
 
                  
3. I felt that I could not shake off the blues even 
with help from my family or friends. 
 
                  
4. I felt that I was just as good as other people. 
 
                  
5. I had trouble keeping my mind on what I was 
doing. 
 
                  
6. I felt depressed.                   
7. I felt that everything I did was an effort.                   
8. I felt hopeful about the future.                   
9. I though my life had been a failure.                   
10. I felt fearful.                   
11. My sleep was restless.                   
12. I was happy.                   
13. I talked less than usual.                   
14. I felt lonely.                   
15. People were unfriendly.                   
16. I enjoyed life.                   
17. I had crying spells.                   
18. I felt sad.                   
19. I felt that people disliked me.                   
20. I could not get “going.”                   
        Please indicate how often in the past seven days you have agreed with the following statements 
Mood Screen 
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C.2  Investigator Packet 
 
 
 
Instructions for Investigator Packet 
The following evaluations are to be completed by the researcher:  
Health Information Form 
EXIT-25 
Quantitative Sensory Test 
Trails-Making Test B on the OASIS Digitizer Writing Tablet 
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C.2.a  Health Information Form 
 
Health Information  
 
 
I.  Vital Signs 
 
Have the subject sitting comfortably.  Inform the subject that you are going to take their 
vital signs, starting with their blood pressure in their right arm.  Loose any restrictive 
clothing on the right arm (roll up sleeve of shirt if necessary). 
 
 
1.  Place the Dynamap 1846 SX cuff on the right arm and begin the machine. 
2.  Place the Nonin1500 pulse oximeter on the middle finger of the left hand. 
3.  Take oral temperature with the IVAC thermometer. 
4.  Record vital signs below. 
 
 
Heart rate ____ ____ ____ 
Systolic blood pressure ____ ____ ____ 
Diastolic blood pressure ____ ____ ____ 
Respiratory rate ____ ____ 
Oral Temperature to nearest .1 degree Fahrenheit ____ ____.____ 
Oxyhemoglobin saturation: ____ ____ % 
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II.  Key Medical-Related Events 
 
Ask the subject the following: 
“Over the past three months, have you had any of the following?” 
 
 
KEY MEDICAL RELATED EVENTS YES NO 
General:   
 Falls   
 Fainting spells /blacking out   
 Dizziness   
 Numbness/weakness   
 Chills/fever   
 Headaches or migraines   
 Seizures   
 Orthnopnea   
 Shortness of breath   
 Chest pain   
 Tachycardia   
 Leg swelling   
 #Pillows to sleep   
 Numbness/weakness   
 Upper respiratory infection in past week?   
 Coughing   
 Hemoptysis   
 Wheezing   
Shortness of breath in the past week   
 Weakness of any extremity    
 Problems walking   
 Joint problems   
 Difficulty with dexterity (button clothes, etc)   
Self-Report Health Rating:  How would you say that your health at 
this time compares with your health one month ago?  Is it: 
     3=better than 1 month ago 
     2=about the same as 1 month ago 
     1=worse than 1 month ago   
 
______ 
 
 
 
 
 
 
 
 
 
 
 
 
If subject is in the healthy control group, begin the EXIT-25 examination. 
 
If subject is in the primary brain tumor group, complete the following set of 
questions below.  Upon completion, proceed to the EXIT-25 examination. 
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III.  Primary Brain Tumor Treatment Information 
 
1.      When were you diagnosed with your tumor?  ________________ 
 
2.      What kind of tumor was it?  
_____  astrocytoma   
_____  oligodendroglioma 
            _____  anaplastic astrocytoma  
_____  glioblastoma multiforme   
_____  other: _______________________ 
 
3.       Do you know the location of the tumor?   
  _____ right side  _____ frontal 
  _____ left side  _____ parietal 
      _____ temporal 
      _____ occipital 
      _____ cerebellum 
      _____ brain stem 
 
4.       What kind of surgical procedure did you have when you were diagnosed? 
_____ biopsy   
____   partial surgical resection   
_____  gross total resection 
 
5. Date of surgery or surgeries:  _________   _______ 
     _________ _______ 
    _________ _______ 
 
6.        What kind of treatments did you have for your tumor? 
____ radiation therapy   
____ stereotactic radiosurgery   
____ stereotactic radiotherapy 
 
7.   Date of radiation therapies:  _________   _______ 
     _________ _______ 
     _________ _______ 
 
8.         Did you have chemotherapy?  ______ yes    ______ no 
  If yes, duration _______________ 
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C.2.b  EXIT-25 
     EXIT-25 (Royall, 1995) 
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C.2.c   Quantitative Sensory Testing (QST) Protocol 
 
Instrument Prep (prior to subject arrival) 
1. Turn on the computer 
2. Make sure the cables from the QST to the computer is intact 
3. Turn on the QST 
4. Locate the QST program icon on the laptop screen 
5. Double click to enter into the program 
6. On the left side of the screen find the calibration program, highlight and click 
7. Observe the tips beginning to move, place your finger tips (second and third tips) 
over the finger tip holes and feel the tips touch; once completed the machine is 
calibrated. 
8. Find the SON program on the right side of the program options, highlight it and 
click. 
9. Enter subject number and date into the program  
10. Click on UL D2D3 for the stimulus location 
11. Save this program and exit out until ready for subject to begin the study 
 
Initiation of the Trial  
1. To begin study, find subject data 
2. Click on SON program, UL D2D3 
3. Have subject sit comfortably in a chair in front of the computer scan 
4. Show the subject the device and the 2 finger tip holes 
5. Offer the bean bag on top of the device in order to rest their wrist 
6. Show them the two button mouse which they will use with their left hand to 
indicate their choices 
7. Ask them if they are ready for a demonstration 
8. Press GO 
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Subject Instructions 
1. Get the subject to place their arm on the device with their wrist on the top of the 
device and the fingertips over the applicator holes.  Say to the subject “Place your 
finger tips against the holes.  Do not press too hard against the holes as the device is 
sensitive to the pressure.  Be sure to relax your arm and wrist.” 
 
Practice Session 
2. Prepare to begin the demonstration program and say “This first test is one that is a 
reaction time test so as soon as you feel the tip against your finger, press the right 
button here with your left hand.” 
3. Start the program and as the applicators extend to make contact the subject say “Do 
you feel it?” 
4. As the subject indicates that they successfully felt the applicator, say “Good.  Are you 
ready to start the first program?” 
5. As the subject indicates that they are ready, press start and say “Let’s start the training 
session.” 
6. Stay with the subject as they are completing the first series in case they have 
questions or to troubleshoot any technical difficulties with the equipment.  At the end 
of the program, say “Now you can relax.”  Point to the computer screen and explain it 
to the subject by saying “This screen shows your reaction times when you felt the tip 
against your finger.  The average is 150 milliseconds.” 
 
Series One 
7. To prepare for the first study series, explain to the subject “This next test is a little 
different.  The touch that you will feel will be on either finger, the right one or the left 
one.  You will need to indicate where you feel it by pressing the right or left button 
here with your left hand.  There is a training here with 3 tries.  So let’s start that to see 
if you have questions.” 
8. Make sure that their arm is back in position.  Press GO to start the training session. 
9. As they are completing the training, ask “Did you feel that?  How was it to press the 
right or the left button.”  Listen to their comments to see if they need a more 
comfortable seat, hand position, different mouse for their left hand. 
10. When they are finished responding to you, ask “Are you ready to start the session on 
this test?”  As they indicate that they are ready, press GO. 
11. Stay with the subject as they are completing the first series in case they have 
questions or to troubleshoot any technical difficulties with the equipment.  At the end 
of the program, say “Now you can relax.”  Point to the computer screen and explain it 
to the subject by saying “This screen shows your reaction times again and it does take 
longer for you to distinguish between right and left.  That is normal.” 
 
Series Two 
12. To prepare the subject for the second series, explain to them “This next test is again 
different.  You will feel 2 taps and you need to determine which one is first.  The 
point of this test is to be correct with where you felt it first, not how fast you are.  
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There will be a ‘choose’ screen after the taps have been done and that is when you 
press the right or the left button.  Are you ready?” 
13. As they have their fingers in position and their arm rested on top of the device, press 
GO. 
14. At the end of the program, state “You can relax your arm now.  This shows your 
tracking with the tap.  The taps did occur faster and that makes it more difficult to 
judge where you felt them.” 
 
Series Three 
15. Prepare the subject for the third series, and say “This next test is using vibration 
instead of the light touch or tap.  You will feel the vibration on both fingertips.  You 
will need to indicate where you feel the strongest vibration. There is training with this 
one so let’s begin that with three test trials.  Ready?”   
16. As they indicate that they are ready, check their arm positioning and make sure the 
arm is relaxed.  Press GO. 
17. At the end of the program, say “You can relax now.  How are you doing?  Are you 
ready for the next one?” 
 
Series Four 
18. Continue to make sure that the subject is comfortable.  Say “For this fourth test, it is 
similar to the last one but you will feel the vibration on one finger.  Ignore this 
vibration.  There will be a short interval and then you will feel vibration on both 
fingertips.  You will need to pick which vibration is stronger.  You will have the 
CHOOSE screen come up when it is time for you to make your choice.  Are you 
ready?  Good.” 
19. As they indicate that they are ready, press GO. 
20. At the end of the program, make sure they relax their position “You can relax now.”   
 
Series Five 
21. For the last test, say “This last test is similar.  There is a short delay in between the 
vibrations.  One will be weak and one will be strong.  Press the button when they feel 
the same to you.  Ready?” 
22. When the subject is ready, press GO. 
23. As the program ends, reassure them that they are now completed with this session.  
“You can relax your arm now and get up to move around if you prefer.  You have 
completed the tests with this instrument.  Do you have any questions?  It is now time 
for a break.” 
 
Instructions to end the program 
After the subject has completed the test, press end to save the data to the hard drive.  Do 
not turn off the computer as you will need to copy and back up the data after the subject 
has left the lab. 
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C.2.d  Writing Board/Trails Making Test B Protocol 
 
 
Instrument Prep  (prior to subject arrival) 
a. Review the purpose of the instrument with the subject  
b. Show the subject the conventional Trails Making Test paper and pen 
c. Show the subject the OASIS digital writing tablet 
i. Place the Trails Making Test A sample on the digital writing tablet on the 
board and turn on the magnetization to keep the paper secured 
ii. Demonstrate how the pen writes on the paper 
iii. Do not start the computerized program 
d. Review the Trails Making Test B by removing sample A from the board and placing 
sample B on the board 
i. Review the instructions of sample B 
ii. Have them perform the sample B on the writing board 
iii. Do not start the computerized program 
e. Ask if they have any questions 
f. Remove sample B and place test B on the board, magnetize 
g. Begin the subject’s computerized program 
i. Read the instructions to the subject 
ii. Start the computerized program when they are ready to start drawing 
iii. Stop the computerized program when they stop the drawing process at 
number 13 
iv. Record total time on the data collection form 
v. Save the subject data and close the program 
vi. Leave the computer on so that at completion of this session and subject has 
left, the PI can go back in to the program to record the data on the data 
collection forms and save to a CD 
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C.2.d  Trails-Making Test, Parts A & B 
   
Instructions for Administering the Trails A & B 
Part A 
1. Tell the subject “For this test I want you to work as quickly as possible but try to 
avoid making mistakes.” 
2. Place the example for Trails A in front of the participant, the bottom of the test 
should be about 6 inches from the edge of the table. 
3. Give the participant a pencil and say:  “On this page are some numbers” (Point at 
the numbers).  Begin at number 1 (point to 1) and draw a line from 1-2 (point to 
2), 2 to 3 (point to 3), 3-4 (point to 4) and so on, in order, until you reach the end 
(point to the circle marked ‘end’”  Draw the lines as fast as you can.  Ready—
Begin.” 
4. If the participant completes the sample and shows he/she understands the 
instructions then say:  “Good!  Why don’t you try this next one.” 
5. Turn the page over and give Part A of the test and say: ”On this page are some 
more numbers.  Begin with the number 1 (point to 1) and draw a line from 1 to 2 
(point to 2) and so on, until you reach the end (point to end).  Remember to work 
as fast as you can.”   
Start timing as soon as the subject moves the pencil toward the number 2.  Watch the 
participant closely in order to catch any errors as soon as they are make.  If the 
subject makes any errors, call it to her/his attention immediately, return the subject’s 
pencil to the last correct circle and continue the test from that point.  Do not stop 
timing while correcting the subject’s error. 
6. After the subject completes Part A, take the test sheet and record the time as it is 
shown on the stop watch. 
7. Then say “That’s fine.  Now we’ll try another one.” 
8. Write down the stopwatch time in the upper right hand corner 00:00:00 
 
Part B 
1. Place the sample side of Part B on the table in front of the subject in the same 
position as the sheet for Part A.   
2. Point to the sample and say “On this page are some numbers and letters.  Begin at 
1 (point) and draw a line from 1 to A (point to A), A to 2 (point to 2), 2 to B 
(point to B), B to 3 (point to 3), 3 to C (point to C) and so on, in order, until you 
reach the end.  Ready ---Begin.” 
3. When the subject completes Sample B, say.  On this page are both number and 
letters.  Please do this the same way.  Begin at 1 (point) and draw a line from 1 to 
A (point to A), A to 2 (point to 2), 2 to B (point to B), B to 3 (point to 3), 3 to C 
(point to C) and so on, in order, until you reach the end.  Ready ---Begin.” 
Start timing as soon as the subject moves the pencil toward the letter ‘A’.  Watch the 
participant closely in order to catch any errors as soon as they are make.  If the 
subject makes any errors, call it to her/his attention immediately, return the subject’s 
pencil to the last correct circle and continue the test from that point.  Do not stop 
timing while correcting the subject’s error. 
4. Write down the stopwatch time in the upper right hand corner 00:00:00 
316
Date: _____/_____/______  ID: _________ 
   
 
317
Date: _____/_____/______  ID: _________ 
   
318
Date: _____/_____/______  ID: _________ 
   
 
319
Date: _____/_____/______  ID: _________ 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix D:    Subject Debriefing 
1. Qualitative Assessment Questionnaire 
2. Participation Packet 
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D.1  Qualitative Assessment Questionnaire     
 
 
QUALITATIVE ASSESSMENT QUESTIONNAIRE 
 
 
1.  Please tell me about today’s testing experience? 
 May need to ask more specifically to start them talking by discussing or asking --- 
 Were there specifics tests or questionnaires that you did like?   
What did you like about them?  What did you not like?  Tell me more about that. 
 
 
 
 
2.  Did you get enough rest and food breaks today?   
What would you suggest to improve it? 
 
 
 
 
 
 
3.  Did any of the tests or questionnaires make you feel uncomfortable?    
Were you surprised by any of the tests, for instance, did a description of the test 
make you think it was going to be something different? 
 
 
 
 
4.  Are there any of the tests that you would not want to do again?  Why? 
Are there any of the test that you would do again?  and why? 
 
 
 
 
5.  Is there anything else that you would like to tell me that I haven’t asked you regarding 
the testing procedure that you have done today? 
 
 
 
 
Thank you for your participation today.  You may contact me at any time if you have any 
further questions that you may want to ask or any other forms of feedback about these 
tests that you would like to suggest. 
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D.2  Debriefing Protocol Checklist 
 
 
 
 
Instructions for the final debriefing prior to subject departure 
 
1.  Perform Qualitative Assessment Questionnaire 
2.  Thank subject for their participation, time, travel. 
3.  Offer more nourishment. 
4.  Make sure they have their copy of the consent, card for future questions. 
5.  Provide them their cash for participation. 
6.  Have the subject sign a receipt. 
7.  Escort the subject to the door and make sure they have directions for their parking 
area. 
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Appendix E:    Additional Materials 
1. Referral Protocol and Letters for Subjects 
2. Recruitment Flyers 
a. Tear-off Flyer 
b. Handout Flyer 
3.  Recruitment Email 
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E.1   Referral Protocol and Letter for Subjects 
 
Instructions for Referring Subjects based on the findings from this study 
 
A referral letter must be given to all subjects who atttains: 
1. a MMSE score < 24 points, 
2. an EXIT-25 score of > 20,  
3. Trails Making Test B time > 3 minutes, 
4. an OARS score of < 20, 
5. a CESD score of > 15, 
6. a blood pressures over 140 systolic or 90 diastolic, 
7. has a heart rate > 120 bpm, 
8. a low arterial oxygen desaturation of < 90%, 
9. prolonged anxiety or fear during testing procedure of > 10 minutes. 
 
All of these conditions are serious and the lab director should be notified for adverse 
events requiring emergency personnel.     
 
Attached are two major types of study referral letters: one for cognitive impairments and 
one for vital signs.   
Please make sure that a copies of each form are on file in the research office under 
subject referrals. 
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Date:   January 8, 2009 
 
To: Mr. XXX 
 Address 
 
From:  Deborah Allen 
 Principal Investigator 
 School of Nursing 
 University of North Carolina at Chapel Hill 
 
RE: Results of test here 
 
 
Dear  Mr. XXX, 
 
As one of my study participants, you underwent a battery of health, memory and 
functional tests at the University of North Carolina, School of Nursing Biobehavioral 
Laboratory.  In the process of our evaluation, we found that you are having difficulties 
with ______ and thought that it would be good for you to tell your doctor.   
 
Specifically, you scored below normal on the Mini-Mental Status Exam.  The Mini-
Mental Status Exam is a test of overall cognitive function.  The average passing score on 
the Mini-Mental Status Exam is 24 and you scored a __ on this test.  You may also want 
to tell your doctor about these problems.  Please let you doctor know that I would be 
happy to talk with him/her about the findings of this study.  I can be reached at (919) 
883-7002. 
 
 
Sincerely, 
 
 
Deborah Allen 
Principal Investigator 
UNC School of Nursing 
 
 
[C l i ck  to  t ype  U n i t  Name ]    CB#7460 ,  Ca r r i ng ton  Ha l l    Chape l  H i l l ,  NC   27599 -7 4 6 0  
P HONE:  [P HONE NU M BER]    F AX :  [F AX  NU M BER]  
325
Date: _____/_____/______  ID: _________ 
   
 
 
Date:   January 8, 2009 
 
 
To: Mr. XXX 
 Address 
 
From:  Deborah Allen 
 Principal Investigator 
 School of Nursing 
 University of North Carolina at Chapel Hill 
 
RE: Results of test here 
 
 
Dear  Mr. XXX, 
 
As one of my study participants, you underwent a battery of health, memory and 
functional tests at the University of North Carolina, School of Nursing Biobehavioral 
Laboratory.  In the process of our evaluation, we found that you are having difficulties 
with one of your vital signs and thought that it would be good for you to tell your doctor.   
 
Specifically, you had a blood pressure that was very high.  Your blood pressure was 
______ systolic /______ diastolic.   The average blood pressure is below 120 systolic / 80 
diastolic.  You may also want to tell your doctor about these problems.   
 
Please let you doctor know that I would be happy to talk with him/her about the findings 
of this study.  I can be reached at (919) 883-7002.  
 
 
 
 
Sincerely, 
 
 
Deborah Allen 
Principal Investigator 
UNC School of Nursing 
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ARE YOU A SURVIVOR OF A BRAIN TUMOR  
and Interested in Participating in Research? 
 
If you are between 30 & 55 years of age and have 
undergone treatment for a primary brain tumor, you may be 
eligible to participate in a research study that is examining 
in tactile perception and motor control in survivors of 
primary brain tumors. 
        
If you chose to participate, you will come to the 
School of Nursing in the morning to early 
afternoon.  While there, you will complete: 
 Questionnaires about your health and ability to care 
for yourself, 
 Heart rate, blood pressure, oxygen level measured, 
 Tests that will measure your ability to think, sense 
different types of touch, and ability to connect 
numbers and letters on a digital writing board, 
 
We will provide you with free parking and $25 for your 
time upon completion of testing procedures.   
There are no needles or blood draws!!!! 
For more information, please call… 
Deborah Allen, RN, MSN at 919-883-7002 
Supported by the Biobehavioral Laboratory at  
The School of Nursing, The University of North Carolina at Chapel Hill 
This study has been reviewed and approved by the UNC-Chapel Hill IRB (IRB# 08-1888 
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ARE YOU A HEALTHY ADULT  
and Interested in Participating in Research? 
If you are between 30 & 55 years of age and have no 
neurological disorders, you may be eligible to participate in 
a research study that is examining tactile perception and 
motor control in relationship to cognitive processing. 
        
If you chose to participate, you will come to the 
School of Nursing in the morning to early 
afternoon.  While there, you will complete: 
 Questionnaires about your health and ability to care 
for yourself, 
 Heart rate, blood pressure, oxygen level measured, 
 Tests that will measure your ability to think, sense 
different types of touch, and ability to connect 
numbers and letters on a digital writing board, 
 
We will provide you with free parking and $25 for your 
time upon completion of testing procedures. 
There are no needles or blood draws!!!! 
For more information, please call… 
Deborah Allen, RN, MSN at 919-883-7002 
Supported by the Biobehavioral Laboratory at  
The School of Nursing, The University of North Carolina at Chapel Hill 
This study has been reviewed and approved by the UNC-Chapel Hill IRB (IRB# 08-1888) 
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Date: _____/_____/______  ID: _________ 
   
Are You Interested in Participating in a 
Research Study? 
E.3  Information flyer -- handout 
If you are 30-55 years of age and have undergone treatment 
for a primary brain tumor OR 30-55 years of age with no 
known neurological disorder and willing to serve as a 
healthy adult control, then you may be eligible to 
participate in a research study that is examining touch and 
motor control in survivors of primary brain tumors.        
 
If you chose to participate, you will come to the School of 
Nursing in the morning to early afternoon.  While there, 
you will complete: 
 Questionnaires about your health and ability to 
care for yourself, 
 Heart rate, blood pressure, oxygen level 
measured, 
 Tests that will measure your ability to think, 
sense different types of touch, and ability to 
connect numbers and letters on a digital writing 
board, 
 
We will provide you with free parking and $25 for your time 
upon completion of the testing procedures. 
There are no needles or blood draws!!!! 
For more information, please call… 
Deborah Allen, RN, MSN at 919-883-7002 
This study has been reviewed and approved by the UNC-Chapel Hill IRB (IRB# 08-1888) 
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Date: _____/_____/______  ID: _________ 
   
E.4    Email Information Flyer 
Subject:  INFORMATIONAL:  Interested in research on touch or motor control? 
 
From:  Deborah Allen, Principal Investigator 
 
If you are between 30 & 55 years of age and have undergone treatment for a primary 
brain tumor OR if you are between 30 and 55 years of age and have no known 
neurological disorder and willing to serve as a healthy adult control then you may be 
eligible to participate in a research study that is examining in tactile perception and motor 
control in survivors of primary brain tumors.        
 
If you chose to participate, you will come to the School of Nursing in the 
morning to early afternoon.  While there, you will complete: (1) Questionnaires 
about your health and ability to care for yourself, (2) Heart rate, blood pressure, 
oxygen level measured, and (3) Tests that will measure your ability to think, 
sense different types of touch, and ability to connect numbers and letters on a 
digital writing board.  There are no needles or blood draws!!!! 
 
All participants will be provided with free parking and $25 for your time upon 
completion of the testing procedures.  For more information, please call 
Deborah Allen, RN, MSN at 919-883-7002. 
 
This study has been reviewed and approved by the UNC-Chapel Hill IRB (IRB# 08-
1888) 
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APPENDIX J:  PROXIES OF COGNITIVE RESERVE 
 
 
Premorbid intelligence (IQ), educational achievement, and occupational attainment are 
the most commonly used proxies of cognitive reserve in subjects with dementia, traumatic brain 
injury, psychiatric disorders, and healthy aging.  However, these proxies have not previously 
been explored for use with survivors or primary brain tumors.  Thus, the measures for the CR 
proxies were first examined for suitability as a proxy of cognitive reserve in this sample. 
Premorbid intelligence: the North American Adult Reading Test (NAART). 
Premorbid intelligence was estimated by calculating the Full Scale Intelligence Quotient 
(FSIQ) from performance scores on the North American Adult Reading Test ([NAART]; Blair & 
Spreen, 1987, 1989).   The NAART is reading test of 61 words that do not follow normal 
pronunciation procedures and requires previous exposure for its correct pronunciation.  
Population-based FSIQ scores for an average intelligence ranges from 90 to 110 with higher 
scores indicating higher IQ.   
This sample had correct pronunciations on the NAART that ranged from 5 to 59 words 
for a median of 40.5 words (M 38.4, SD 12.7).  Using the correct scores then produced FSIQ 
estimations of premorbid intelligence that ranged from 84.1, or slightly below average 
intelligence, to 126.2, or slightly above average intelligence.  The sample mean was 110.0 (SD 
9.8) reflecting average intelligence.   
Age, t(39)=-20.45, p<.001, and education, t(39)=-9.10, p<.001, were associated with 
lower NAART performance scores.  Thus, subjects who were older or had less education were 
more likely to have lower performance scores on the NAART.  Those with longer survival times 
since diagnosis were more likely to have lower NAART performance scores, t(39)=8.05, p<.001.  
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There were no significant effects observed from tumor-related variables on NAART 
performance.   
Spreen and Strauss (2006) recommend using two determinations to ensure that the FSIQ 
estimation of premorbid intelligence is reliable in samples containing subjects with extensive 
neuropathology:  (1) use of cutpoint score of 15 calculated from the difference between actual 
NAART performance and expected performance using age and education-based normative data, 
and (2) use of a cutpoint score of 28 for correct pronunciations.   
The difference between actual and estimated NAART performance scores in this sample 
ranged from -33.7 to 16.1 and averaged -2.1 (SD 12.1).  Eight subjects (20%) performed > 15 
points below the estimated NAART scores based on the education and age-adjusted calculations.  
All 8 subjects also performed > 28 correct pronunciations.  There were a total of 9 subjects 
(22.5%) who had actual NAART performance scores of less than 28 as observed on Figure AJ.1.   
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Figure AJ.1.  Bland-Altman Difference Plot of Actual & Estimated NAART Performance Scores (n=40). 
  
 
The magnitude of the difference scores in relationship to actual performance on the 
NAART is demonstrated on the Bland-Altman plot, Figure 1.  For every correctly pronounced 
word on the NAART, the difference between expected and actual performance improves by 0.97 
(R2=0.94, p<.001).  While the majority of subjects performed within acceptable parameters 
according to Spreen and Strauss, the bias plot shows that half of the subjects in this sample 
performed below expected ranges based on their age and education.  In addition, the magnitude 
of those performing below their expected scores is greater than those performing well. 
 To further describe differences observed in performances on the NAART, two groups 
were formed using the NAART difference cutpoint of >15, Table 1.  Subjects with more 
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education and held more professional job categories, as measured by the Hollingshead Index, 
were more likely to perform better on the NAART, t(38)=2.64, p=.01.   
Table AJ.1.    
Subject characteristics by difference scores between actual and expected NAART performance (n=40). 
 
Characteristics 
 Difference < -15 
(n=8) 
Difference > -15  
(n=32) 
Group Comparisons 
t-test or χ2  
Age in years 54.5 (7.4) 49.0 (9.9) t(38)=1.45, p=.16 
Education in years 14.5 (1.4) 15.3 (2.0) t(38)=-1.02, p=.32 
Hollingshead Index 40.8 (8.9) 29.5 (11.2) t(38)=2.64, p=.01* 
Time since diagnosed,  
in years 
126.0 (83.5) 95.0 (79.6) t(38)=0.98, p=.36 
WHO Grade 
   Low Grade  
   High Grade    
 
1 (12.5%) 
7 (88.5%) 
 
  9 (28.0%) 
23 (72.0%) 
Fisher’s exact p=.65 
Tumor stability 
   No recurrence 
   Any recurrence 
 
7 (88.5%) 
1 (12.5%) 
 
20 (62.5%) 
12 (37.5%) 
Fisher’s exact p=.24 
Tumor Hemisphere 
   Right 
   Left 
 
5 (62.5%) 
3 (37.5%) 
 
15 (47.0%) 
17 (43.0%) 
χ2(1)=0.63, p=.43 
Tumor Location 
   Frontal 
   All other locations 
 
1 (12.5%) 
7 (88.5%) 
 
18 (75.0%) 
14 (25.0%) 
Fisher’s exact p=.05* 
* Statistically significant difference between groups p<.05 
 
 
Educational and Occupational Attainment: the Hollingshead 2-Factor Index. 
The Hollingshead 2-Factor Index of Social Position ([Hollingshead Index]; Hollingshead, 
1957) uses educational and occupational attainment to derive a solitary score for CR.   Scores 
may range from 11-77 points.  Lower scores on the Hollingshead Index indicate higher levels of 
education and occupational attainment, and thus, would reflect higher CR.   
The Hollingshead Index ranged from 11 to 51 points in this sample, with a median of 
29.5 points and mean of 31.75 (SD 11.56) points.  These scores approach the midpoint of 33 on 
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the Hollingshead Index.  Those with higher CR were more likely to live longer after diagnosis, 
t(39)=-5.53, p<.001.   No other subject or tumor-related factors were significantly associated 
with the Hollingshead Index.  
Figure 2 illustrates a curvilinear relationship between the Hollingshead Index and 
NAART performance.  Those with higher educational and occupational attainment (lower 
Hollingshead Index scores) had higher NAART performance, and thus higher premorbid 
intelligence.  Likewise, those with average educational and occupational attainment (higher 
Hollingshead Index scores) tended to have lower NAART performance.  Estimated premorbid 
intelligence was significantly associated with the Hollingshead Index, r= -.52, p<.001.    
 
Figure AJ.2.   
Scatterplot of Actual NAART Performance Scores and Hollingshead Index (n=40).   
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To further examine differences in NAART performance as it relates to CR, the NAART 
cutoff score of 28 was used to distinguish normal and low performance while the Hollingshead 
Index mean of 31.75 for the sample was used to distinguish high and low CR, Figure 2.  These 
two cutpoints established four quadrants, or groups, within the scatterplot.  This permitted the 
subjects within the cells to be further described:  1) Group A has low CR and low NAART 
performance; 2) Group B has low CR and normal NAART performance; 3) Group C has high 
CR and low NAART performance; and 4) Group D has high CR and normal NAART 
performance.     
The majority of subjects (n=20, 50%) comprised the group with high CR and normal 
NAART performance, Group D.   There are fewer subjects in the cells for lower NAART 
performance (n=9), Groups A and C, than those with overall normal NAART performance 
(n=31), Groups B and D.  There is only one subject with high CR with low NAART 
performance, Group C, as compared to the 8 subjects with low CR and low NAART 
performance, Group A.  Subject characteristics were similar across the four groups, Table AJ.2, 
thus no significant differences were observed using Kruskal-Wallis procedures.    
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Table 2.   
Subject characteristics by Hollingshead Index and NAART performance groupings (n=40). 
 
 
Characteristics 
 Group A 
Low CR-Low P 
(n=8) 
Group B 
Low CR-Normal P 
(n=11) 
Group C 
High CR-Low P 
(n=1) 
Group D 
High CR-Normal P 
(n=20) 
Age in years  51.3 (9.2) 46.0 (9.3) 62 51.4 (9.8) 
Education in years 14.0 (1.5) 13.5 (0.9) 16 16.4 (1.4) 
Hollingshead Index 42.6 (5.1) 42.3 (5.4) 22 22.0 (5.5) 
Time since diagnosed,  
in months 
113.8 (89.4) 109.0 (62.4) 132 90.4 (89.1) 
WHO Grade 
   Low Grade  
   High Grade    
 
1 (13%) 
7 (87%) 
 
4 (36%) 
7 (64%) 
 
0 
1 
 
  5 (25%) 
15 (75%) 
Tumor stability 
   No recurrence 
   Any recurrence 
 
6 (75%) 
2 (25%) 
 
4 (40%) 
6 (60%) 
 
1 
0 
 
15 (75%) 
  5 (25%) 
Tumor Hemisphere 
   Right 
   Left 
 
4 (50%) 
4 (50%) 
 
6 (60%) 
4 (40%) 
 
1 
0 
 
  9 (45%) 
11 (55%) 
Tumor Location 
   Frontal 
   All other locations 
 
2 (25%) 
6 (75%) 
 
5 (50%) 
5 (50%) 
 
0 
1 
 
12 (60%) 
  8 (40%) 
  CR=cognitive reserve; P=NAART performance 
  
Summary on Proxies of Cognitive Reserve 
These findings suggest that caution may be warranted when using NAART estimations of 
premorbid intelligence in this sample of survivors with PBT.  The relationship between lower 
occupational and educational attainment (higher Hollingshead Index) and lower than expected 
NAART performance suggests that that Hollingshead Index may serve as a useful proxy for CR 
when limitations in using the NAART exist.   Thus, for the purposes of this study, the 
Hollingshead Index was used to explore Specific Aim 4.  The sample mean of 31.75 was used to 
differentiate between high and low CR.   
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